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 Introduction Chapter I.
Arboviruses: An Emerging Public Health Threat 
New and emerging viruses pose an immense public health risk to the world 
population,
1, 2
 due in large part to a lack of effective vaccines and treatments, although 
inadequate public health responses may also play a significant role.
3
 Mosquito-borne 
viruses, collectively called arboviruses (arthropod-borne viruses), constitute a large 
portion of this risk because of the ubiquity of mosquitoes and the potential for mosquito-
human transmission.
4-6
 Increasing urbanization and mosquito range expansion further 
complicates the threat of potential arboviral pandemic.
4-6
 Among emerging New World 
arboviruses, the equine encephalitis viruses (EEVs) (Western, Eastern, and Venezuelan) 
are of particular interest, and are listed as category B agents of biodefense concern due in 
part to their potential use in bioterrorism.
7-9
  
EEVs are neurotropic arboviruses that infect the central nervous system (CNS) of 
vertebrates, causing debilitating inflammation and damage to the brain.
10-12
 They are 
members of the genus Alphavirus of the Group IV family Togaviridae,
13
 of which more 
than ten members cause significant disease in humans, and all are arboviruses.
1
 They are 
also RNA viruses, and their emerging status may be attributed to this characteristic,
2
 
largely due to poor genome replication fidelity and high mutation rates common to RNA 
viruses.
14
  In nature, EEV existence is maintained by a cycle between passerine birds and 
the mosquitoes that prey exclusively on them (Figure 1).
15, 16
 Infection in humans and 
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animals occurs when other mosquitoes, the so-called bridging vectors, pass the virus 
along from birds.
17
 The natural infection rate in humans, while underreported, is 
nonetheless low: since 1964, only 639 cases of Western equine encephalitis virus 
(WEEV)
18
 and 220 cases of Eastern equine encephalitis virus (EEEV) infection have 
been confirmed.
19
 Still, the clinical manifestations of infection can be severe. For victims 
of WEEV, the fatality rates may be as low as 3%,
20
 but neural sequelae may persist well 
after infection.
21
 Young children exhibit seizures and paralysis,
22-24
 for example, and 
upwards of 60% continue to do so for months or years after the virus has disappeared.
25
 
Adults, too, may experience persistent disease-associated impairment.
24
 Of greater 
concern is EEEV, which boasts a mortality rate in excess of 30-40%, and even as high as 
70% among some strains,
19
 and is also likely to cause permanent neurological damage in 
survivors.
26-28
 On the other hand, Venezuelan equine encephalitis virus (VEEV), while 
least likely to cause debilitating symptoms in humans,
29-31
 may have high agricultural 
costs associated with infection as equine mortality rates have been observed to exceed 
80-90% during epizootic pandemics. Furthermore, unlike with WEEV and EEEV 
infections, horses and humans are not dead-end hosts and may continue to spread the 
virus.
16
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Figure 1. Equine Encephalitis Virus Maintenance Cycle.  
Passerine birds serve as reservoirs for many of the New World alphaviruses, but all 
alphaviruses are transmitted to humans and susceptible animals by arthropods. 
 
 
After World War II, many of the early developers of biological warfare found that 
the equine encephalitis viruses and related alphaviruses were highly amenable to 
weaponization.
9, 16, 32
 As stated from a report by the US Army Medical Research Institute 
for Infectious Diseases, “Few [viruses] possess as many of the required characteristics for 
strategic or tactical weapon development as the alphaviruses.”16 The reasons are simple: 
they can be produced in large quantities, they are stable and many are infectious as 
aerosols, many are fatal (or at the very least, incapacitating), they are relatively simple to 
engineer (and make more lethal), and defensive vaccine development is hindered by the 
existence of multiple serotypes. Many nations have long since shut down their offensive 
bioweapon programs (the United States in 1969), but today there is a growing threat from 
small groups of bioterrorists.
9, 16, 33
 
There currently exist vaccines for WEEV
34
 and a few of the other alphaviruses,
35, 
36
 but they require multiple shots, confer little immunoprotection, and are available only 
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to researchers.
15, 16, 35
 It has also been demonstrated that potential vaccines against one 
alphavirus may interfere with vaccination against other alphaviruses.
37-39
 From a public 
health perspective, this underlines the need for an effective antiviral, but there are no 
therapeutics available for treating infection once the virus has colonized the CNS.
15, 40
 
Therefore, the focus of our research is the development of new, novel compounds for the 
pharmacological intervention of CNS infection by alphaviruses. 
 
Neurotropic Alphavirus Virus Biology 
The reproductive life cycle of neurotropic alphaviruses is among the most simple 
of viruses, and is largely localized to the cytoplasm of the host cell.
13
 As shown in Figure 
2, the first step (step 1) of reproduction involves binding of the virion to specific host 
receptors displayed on the exterior of the cell membrane, and receptor-mediated 
endocytosis draws the virion into the cell. Upon acidification of the vesicle, the virion is 
uncoated and released into the cellular environment (step 2), where it may release its 
simple positive-sense single-stranded RNA ((+)ssRNA) genome (step 3.) The genome 
may be directly translated upon cellular entry by cytoplasmic ribosomes to produce 
protein and enzyme products that facilitate amplification of the genome (step 4), or it 
may be transcribed to produce many copies of the original genome (step 5). The copies 
may be involved in further translation, or they may be packaged in the capsid of new 
virion particles (steps 5, 9, and 10.) Some copies are involved in the translation of 
membrane-bound proteins in the secretory pathway, where they will be involved in 
recruitment of capsid proteins and assembly of new virion particles, and will ultimately 
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form the viral envelope (steps 6 through 8). Finally, budding occurs and the mature virion 
is released (step 11.)
13, 41-45
 
 
 
Figure 2. Alphavirus Single-Cell Reproductive Cycle. 
Overview of the alphavirus life cycle. Our research focuses on the development of 
inhibitors of replication (step 5). 
 
 
 Mosquitoes transmit EEVs to hosts upon biting, causing a localized infection that 
may escalate to observable viremia after several days.
46-48
 The mechanism of invasion of 
the CNS is a contentious subject, with some evidence suggesting that the olfactory nerves 
are the major route as opposed to the direct crossing of the blood-brain-barrier (BBB).
49-
54
 Nevertheless, once the virus is established in the CNS, the recruitment of 
immunological cells is responsible for encephalitis, but the majority of serious brain 
destruction is caused by the induction of neuronal cell death.
43, 55
 Other cell types are 
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susceptible as well, but form of death is not uniform: glial cells chiefly undergo 
apoptosis, whereas neuronal cells usually die via necrotic pathways.
55-59
  
 
Project History 
High-Throughput Discovery. In search of potential antiviral leads, the David 
Miller lab executed a high-throughput screen (HTS) of a >50,000-compound library at 
the University of Michigan Center for Chemical Genomics (CCG).
60
 Central to the screen 
was a cell-based assay that utilized WEEV replicon plasmids encoding the firefly 
luciferase reporter gene.  
 
 
Figure 3. Natural WEEV Genome and WEEV Replicon. 
Structural genes were excised and replaced with the reporter gene fLUC, coding for 
firefly luciferase. In this way, the WEEV replicon is incapable of producing infectious 
virus and may be used without special precautions. 
 
WEEV Replicon Assay. Inhibitory concentrations (IC50 values) were determined 
using a WEEV replicon assay developed by our collaborators in the lab of Prof. David 
Miller.
60
 BSR-T7/C3 cells were transfected with a complementary plasmid (pWR-LUC) 
encoding a majority of the WEEV genome (Figure 3); however, most of the structural 
genes are replaced with the reporter gene firefly luciferase.
61
 In this way, the replicon 
cannot produce infectious virus and thus requires less stringent biosafety containment 
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measures. BSR cells constitutively express bacteriophage T7 RNA polymerase, for which 
promoters and terminators exist in the plasmid to maintain high levels of transcription of 
the WEEV replicon. Therefore, control cells will produce a baseline luminescence while 
cells treated with active inhibitors will show a marked decrease from baseline, from 
which an IC50 can be calculated.  
MTT Reduction Assay. Cytotoxic concentrations (CC50 values) were established 
using a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide 
(MTT) assay in BSR cells used in the WEEV replicon assay by the lab of Prof. David 
Miller.
60, 62
 In this classical measure of cellular viability, the tetrazolium compound MTT 
is reduced to a dark purple formazan dye by oxidoreductase enzymes in living cells. Cells 
stressed or killed by cytotoxic compounds exhibit diminished metabolic activity and, as a 
result, are less or not at all capable of reducing the MTT to the colorful dye. Therefore, 
CC50 values are calculated from the drop in absorbance relative to a healthy baseline 
control. 
HTS Triage. Because luciferase served as a marker for disruption of genome 
replication, those compounds with the lowest IC50 values in the initial HTS were 
submitted to secondary and tertiary validation assays. The secondary assay utilized 
replicons containing the SEAP reporter gene to indicate transcriptional activity and 
confirm that activity was not an artificial construct of luciferase inhibition,
63
 and the 
tertiary assay screened for compounds with selectivity indices (CC50/IC50) greater than 
five. One compound, CCG-32091, possessed favorable potency and selectivity, and its 
activity was further verified in cultured human neurons in the presence of the live 
alphaviruses SINV (Sindbis virus) and FMV (Fort Morgan Virus), which are surrogates 
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for WEEV that require lower level biosafety containment facilities. Limited structure-
activity relationships (SAR) among commercial thienopyrroles related to CCG-32091 
showed promising activities and selectivity ratios, as well as a clearly defined SAR 
spanning two orders of magnitude potency,
60
 so the compound was selected for further 
optimization.  
 
 
Figure 4. HTS Discovery Hit CCG-32091 and Initial Development. 
The thienopyrrole was substituted with bioisosteric indole (blue), and the known 
metabolism-prone furan was replaced with benzyl functionality (red). 
 
Initial SAR. The initial approach was replacement of the thienopyrrole core of 
CCG-32091 with an indole core (Figure 4).
64
 This was undertaken for several reasons: 
indoles are generally more metabolically stable than thienopyrroles,
65
 are cheaper and 
synthetically more robust, and phenyl and thiophene are well established bioisosteres.
66, 67
 
CCG-102516, synthesized by Kyle Bolduc, was developed from this rationale. It 
contains an indole core, a more lipophilic chloro-substituted N-benzyl group, and a 
benzylamide predicted to be more metabolically stable relative to the furylmethylamide 
of CCG-32091.
68, 69
 This initial strategy was successful, as CCG-102516 proved to be 
nearly twice as potent as CCG-32091. 
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 Reduction of Polar Surface Area Chapter II.
Rationale 
The Blood-Brain Barrier. Neurotropic alphaviruses replicate to high titer within 
the CNS,
70
 necessitating development of CNS-penetrant antiviral agents. This is 
especially important because clinical manifestations may appear well after the systemic 
virus titer has dropped to immeasurable levels, days after initial transmission.
71-73
 This 
places an enhanced emphasis upon retaining physical properties predictive of both good 
pharmacokinetics and CNS penetration while optimizing both in vitro and in vivo 
activity. The most challenging barrier to CNS entry is the blood-brain barrier (BBB).
74-77
 
The BBB is structurally distinct from other membrane obstacles; due to diminished 
pinocytosis and the presence of tight-junctions, most drugs must cross the BBB via 
transcellular passive diffusion alone.
74, 77
 However, there are a number of common 
features among successful CNS-active drugs that enhance passive BBB transit, including 
low molecular weight (< 400-450), low topological polar surface area (< 60–70 Å2), and 
positive logD (~1-3).
74-76, 78, 79
  
MDR1 Recognition Assays. Transporter-mediated efflux is a major hurdle to a 
CNS drug’s biological activity in vivo.80, 81In its protective role, the blood-brain barrier 
(BBB) has a number of efflux transporters to facilitate removal of xenobiotics from the 
CNS, of which MDR1 is generally the most important.
80, 82
 Neurotropic alphaviruses 
replicate to high titer in the CNS, thereby necessitating the development of transporter-
10 
 
evasive inhibitors to elicit the greatest antiviral effect. It is therefore important to generate 
analogs with little to no affinity for MDR1 early in the drug development process.  
Over the course of the project, two recognition assays were employed to evaluate 
MDR1 recognition of WEEV inhibitors in the lab of Prof. Richard Keep.
83
 Initially, our 
collaborators utilized a simple experiment that measured the impact of our analogs on the 
efflux of tritiated (
3
H) vinblastine, a known MDR1 substrate, from MDCK cells that 
expressed human MDR1 (MDR1-MDCKII cells).
83, 84
 This specific assay was employed 
in early evaluations of WEEV inhibitor MDR1 interactions, such as those reported for 
low topological polar surface area (TPSA) analogs in this chapter, but later the 
Rhodamine 123 uptake assay was employed (see Chapter III). In the
 3
H-vinblastine 
uptake assay, if the test compound of interest has no interaction with MDR1, the 
3
H-
vinblastine concentration inside the cell will drop as the substrate is pumped out. If the 
test compound does interact with MDR1, the measured 
3
H-vinblastine concentration will 
be higher within the cell. However, due to the nature of the experiment, it cannot be said 
whether or not analogs are simple blockers of MDR1 or actual substrates. Regardless, the 
data are useful for identifying compounds with low recognition by MDR1 (and thus 
potential for efflux) and was used for the prioritization of compounds for further 
development. 
Initially, we were most interested in maximizing potential for achieving CNS 
penetration by reducing the TPSA of the inhibitors. TPSA is a measure of the surface 
area of all polar atoms in a molecule, predominately heteroatoms like oxygen and 
nitrogen.
79, 85, 86
 Additionally, polar substituents possess high desolvation penalties and 
reduce passive permeability due to repulsive interactions with highly nonpolar lipid 
11 
 
membranes.
87, 88
 High TPSA is also associated with greater recognition by efflux 
transporters.
89, 90
 The total heteroatom contribution to the TPSA of CCG-102516 is 
presented in Figure 5; it is evident that heteroatoms with electrons engaged in resonance 
have little impact, whereas heteroatoms with a complement of free electrons contribute 
more to the TPSA.  
 
Figure 5. Polar Surface Area Contribution per Heteroatom. 
Total TPSA and individual contributions were calculated using ChemDraw’s chemical 
properties calculator.
 
 
BBB-PAMPA Assay. Due to the importance of BBB penetration to our 
compounds, and the role of TPSA in enhancing this property, we estimated the passive 
membrane permeability for select compounds using BBB-PAMPA (blood-brain barrier 
parallel artificial membrane permeability assay) from pION, Inc.,
91, 92
 and utilized a 
cosolvent system due to the poor aqueous solubility of early compounds.
93
 The traditional 
PAMPA assay was developed as a useful low-cost tool for assessing potential passive 
membrane permeability for drug-like compounds in the gut, and was found to correlate 
well with higher-cost cellular assays.
94, 95
 However, the BBB is structurally and 
compositionally distinct from other membranes, causing PAMPA to often report false 
positives; for this reason, BBB-PAMPA was developed and was found to possess 
12 
 
superior correlation with BBB passive permeability.
96
 It is also an important complement 
to the MDR1 recognition assay because the MDR1 assay correlates poorly with BBB 
passive permeability – due to the different lipid composition of the cells – but contains 
efflux transporters not present in BBB-PAMPA.
97
 
While the TPSA of CCG-102516 is within the range of successful CNS drugs, 
which have TPSAs significantly lower than other drug classes,
74
 it is on the higher end of 
that range, and we felt it was important to identify low TPSA features that could serve as 
new templates throughout other aspects of the SAR campaign in order to maintain 
optimal properties predictive of BBB-penetration. Furthermore, it was important to 
determine whether TPSA could be reduced with maintenance of anti-viral activity. 
  
SAR 
Initial analogs were based on CCG-203880, the equipotent N-4-fluorobenzyl 
analog of CCG-102516 (Figure 6) because of its lower molecular weight (see Chapter 
III). A general feature of these analogs was the replacement of the right-hand secondary 
amide with alternative linkers. 
 
Figure 6. Lead Compounds. 
 
CCG-102516 and its equipotent fluoro analog CCG-203880. 
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Table 1. WEEV Replicon Data for Alicyclic Low TPSA Analogs. 
 
CCG No. X R 
IC
50 
(µM)a 
CC
50
 
(µM)b 
MDR1 
(% vinblastine 
uptake)c 
TPSAd 
203880† F  15 ± 2 >100 1,495 53 
203941 F  >100 >100 --- 27 
205421 F  14 ± 1 24 ± 1 --- 44 
205475 F  >100 >100 --- 41 
203945 F  23 ± 2 >100 --- 44 
204055 F  12 ± 1 96 821 27 
205476 Cl  10 ± 2 38 --- 27 
aInhibition of luciferase expression in WEEV replicon assay. bCell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
dTPSA was predicted using ChemDraw’s chemical properties calculator. †Synthesized by 
Janice Sindac. 
 
Alicyclic Low TPSA SAR. As seen in Table 1, we were able to demonstrate that 
TPSA could be reduced substantially in some cases without impacting activity or toxicity 
(e.g. alicyclic analogs CCG-203945 and 204055). Aromatic rings are capable of 
engaging in numerous types of bonding interactions – like ring-stacking or weak CH 
14 
 
hydrogen bonding – not available to alicycles. That the active low TPSA analogs bear 
non-aromatic heterocycles and carbocycles suggests that the binding in this region may 
be largely dependent on hydrophobic interactions between the ring and lipophilic 
residues in the unknown binding site. Also of interest is the difference in activities 
between CCG-205421 and CCG-205475. Both compounds are hydrogen bond acceptors, 
but only CCG-205421 is also a hydrogen bond donor, perhaps forming a key contact 
with an acceptor in the binding site. CCG-205421 is also tetrahedral about the sp
3
 
alcohol carbon, unlike the sp
2
 carbonyl carbon in CCG-205475. This could indicate that 
CCG-205421 has geometry that enhances interactions with unknown binding site 
contacts. 
Aromatic Low TPSA SAR. As seen in Table 2, like the alicyclic analogs, we 
found TPSA could be halved in the aromatic analogs while maintaining favorable 
potency and toxicity profiles (e.g. aromatic analogs CCG-203942 and CCG-203945), 
placing WEEV inhibitor properties well within the range of successful CNS drugs. 
Intriguingly, the SAR of ketone CCG-203943 and alcohol CCG-204056 matched that of 
their alicyclic counterparts CCG-205475 and CCG-205421, respectively (Table 1). We 
also noted that benzylamine CCG-205420 was substantially more potent than its 
benzylether analog CCG-203944, but this result may be an artificial product of its high 
toxicity. Curiously, benzyl piperazine analogs (e.g. CCG-203942) were eqipotent with 
the lead, in contrast to the inactive cyclohexylmethyl piperazine CCG-203941 (Table 1). 
This challenged the assumption that lipophilicity was the most important factor for 
binding in this region of molecule.  
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Table 2. WEEV Replicon Data for Aromatic Low TPSA Analogs. 
 
CCG No. X R 
IC
50 
(µM)a 
CC
50
 
(µM)b 
MDR1 
(% vinblastine 
uptake)c 
TPSAd 
203880† F  15 ± 2 >100 1,495 53 
203943 F  >100 >100 --- 41 
204056 F  15 ± 0.4 40 --- 44 
204020 F  >100 >100 --- 27 
205420 F  22 ± 3 39 --- 36 
203944 F  >100 >100 --- 33 
203942 F 
 
12 ± 1 >100 764 27 
206372 Cl 
 
12 ± 1 >100 --- 27 
211827 Cl 
 
7.2 >100 --- 27 
211826 Cl 
 
12.4 >100 --- 39 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments.
 
†Synthesized by Janice Sindac. dTPSA was predicted using ChemDraw’s chemical 
properties calculator. 
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Table 3. MDR1 Recognition Data for Indole and Thienopyrrole leads. 
 
CCG No. R 
MDR1 Recognition (% 
vinblastine uptake)
a
 
102516† 
 
534.0 
203880† 
 
1495.6 
203881† 
 
433.3 
32088* 
 
694.1 
a
MDR1 recognition was assessed by measuring uptake 
3
H-vinblastine at 30 µM of test 
anti-viral or vehicle. †Synthesized by Janice Sindac. *Synthesized by Bryan 
Yestrepsky. 
 
MDR1 Recognition. It was hoped that the best low TPSA candidates from this 
assay may serve as new templates for further development. After our initial survey of the 
activity of these analogs was complete, CCG-204055 and CCG-203942 were graduated 
to the MDR1/vinblastine assay because they showed promising inhibition and low 
cytotoxicity. Both of these compounds were found to possess improved MDR1-efflux 
results over CCG-203880 (which may be attributed to their lower TPSA compared to 
their amide counterparts), and were therefore considered potential new leads. However, 
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initial trends among other scaffolds suggested that chloro-substituted compounds may be 
more MDR1-evasive than their fluoro-substituted counterparts (Table 3), prompting us to 
prepare and evaluate chloro-substituted analogs of some of the better fluoro-substituted 
compounds (e.g. CCG-205476 and CCG-206372, Table 1 and Table 2, respectively). 
These compounds were found to be equipotent to their fluoro-substituted cousins. 
Unfortunately, these compounds were never submitted to the MDR1 recognition assay 
due to the discovery of the significantly more potent 4-pyridylethylamide inhibitor class, 
described briefly below and in detail in Chapter III. 
TPSA Analog Length-Activity Dependence. While many of the TPSA analogs 
feature low polar surface area with retention of activity, it was apparent that there was 
still room for potency optimization. Janice Sindac, working on other aspects of the 
WEEV project, had established that the right-hand portion of the template must be of a 
specific length, where the intervening alkyl chain between the amide and the aromatic is 
optimally 2-carbons long (Figure 7).
83
 Interestingly, propyl linkers abolished activity 
entirely. The low TPSA compounds in Table 1 and Table 2 were significantly truncated, 
so longer analogs were investigated. Interestingly, analogs with ethyl and propyl linkers 
did not perform significantly better than their shorter counterparts (e.g. CCG-206372 
compared to CCG-211827, Table 2), nor were they worse. Even CCG-211826, which 
bears a 4-pyridylethyl substituent crucial to the activity of later analogs (see Chapter 
III), merely maintained activity. This suggested that either important structural features 
were not present among the low TPSA analogs or that they were not binding in the same 
way as the amide leads. Indeed, later work established the importance of the right-hand 
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secondary amide to activity (see Chapter IV) which is lacking in the low TPSA inhibitor 
class. 
 
Figure 7. Right-Hand Chain Length-Dependence. 
Chain-length dependence of the right-hand region “R” was found to decrease in activity 
such that n=2>1>>3, where n is an intervening number of methylene units. 
 
 
Secondary Amine Analog SAR. The low TPSA analogs are highly lipophilic. 
While this aids in BBB permeation, it decreases water solubility such that aqueous 
delivery of compound is impeded. Interestingly, analogs containing ionizable 
functionalities, such as amines, exhibited the greatest activity (e.g. piperazine-containing 
analogs CCG-203942 and CCG-204055), perhaps because of improved aqueous 
solubility. Alternatively, the analogs may simply possess improved permeability, as very 
lipophilic compounds may be retained by the membrane, inhibiting their ability to 
penetrate the cell. In an effort to exploit this trend, a new generation of right-hand amine-
bearing analogs was prepared (Table 4), but these proved to be quite toxic, especially 
those containing secondary amines (e.g. CCG-206486 and CCG-206500), perhaps via 
detergent activity (disruption of cellular membranes). On the other hand, tertiary amines 
(e.g. CCG-206502 and CCG-206503) were better tolerated but displayed markedly 
decreased activity. All of the analogs possessed lower CC50 values than those seen in 
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their amide counterparts, and there was no significant activity improvement. For these 
reasons, the amine-containing series was discontinued early. This did not undermine 
development efforts of the low TPSA WEEV inhibitor class; overall, we demonstrated 
that activity could be maintained with reduced TPSA and – potentially – increased 
hydrophilicity. 
 
Table 4. WEEV Replicon Data for Amine Analogs. 
 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
203880† 
  
14.8 ± 2.1 >100 
206486 
  
6.1 ± 0.7 9 
206499 
  
>100 >100 
206500 
  
6.5 ± 0.3 12 
206501 
  
8.9 ± 0.4 16 
206502 
  
40.6 ± 0.5 96 
206503 
  
25.1 ± 1.9 85 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell 
viability determined by the MTT reduction assay. Values are mean 
of at least n=3 independent experiments.
 †Synthesized by Janice 
Sindac. 
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Synthesis 
Low TPSA analogs were generally prepared through the alkylation of ethyl 2-
indolecarboxylate 1 with either 4-chloro- or fluorobenzyl chloride 2a or 2b. The N-
alkylated ethyl ester intermediate 3a,b was then saponified to the corresponding 
carboxylic acid 4a,b and coupled with the desired amine to give the general structure 
5a,b (Scheme 1).  
 
Scheme 1. General Preparation of Low TPSA Analogs.
a
 
 
a
Reagents and conditions: (a) K2CO3, DMF, 60 °C, 20 h, 70%; (b) 7 M aq. NaOH, EtOH, 
50 °C, 3 h, 97%; (c) HNR1R2, EDC, HOBt, DIPEA, DMF, rt, ~ 24 h. 
 
 
Many amines R1R2NH had to be prepared due to commercial unavailability. The 
1-(piperidin-4-ylmethyl)piperidine portion of the analogs CCG-204055 and CCG-
205476 was first accessed through the Boc-protection and Swern oxidation of 
piperidinyl-4-methanol 6. This provided the aldehyde 8 that underwent reductive 
amination with piperidine to give the boc-protected amine 9, and this was subsequently 
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deprotected to reveal the amine as a trifluoroacetate salt and coupled with the 
appropriately halogenated indole carboxylic acid to yield the desired analogs (Scheme 2). 
 
Scheme 2. Preparation of CCG-204055 and CCG-205476.
a
 
 
a
Reagents and conditions: (a) Boc2O, Na2CO3, H2O, THF, reflux, 2 h, 87%; (b) DMSO, 
(COCl)2, -78  °C, 30 min; then TEA, -78 °C→0 °C, 3 h, 89%; (c) piperidine, NaCNBH3, 
TFE, 3 Å MS, RT, 20 h, 72%; (d) TFA, DCM, RT; (e) 4a or 4b, EDCHCl, HOBT, 
DIPEA, DMF, RT, 15-24 h, 54-63%. 
 
 
 
The alicyclic analogs CCG-205421 and CCG-205475 were accessed through a 
single linear route in which the latter was a direct synthetic derivative of the former 
(Scheme 3). In this fashion, the aldehyde 8 was treated with cyclohexylmagnesium 
bromide and the resulting Grignard reaction adduct 10 was deprotected to reveal the 
secondary amine, which was then coupled with the indole carboxylic acid to afford the 
first analog, hydroxyl-containing CCG-205421, which was contaminated with ester from 
competing O-acylation. The desired amide was separated from the ester side-product and 
confirmed by IR spectroscopy. CCG-205475 was then prepared by simply oxidizing the 
alcohol to the ketone under Swern conditions. 
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Scheme 3. Preparation of CCG-205421 and CCG-205475.
a
 
 
a
Reagents and conditions: (a) cyclohexyl-MgBr, Et2O, RT, 2 h, 85%; (b) TFA, DCM, 
RT, 15 h; (c) 1-(4-fluorobenzyl)-1H-indole-2-carboxylic acid, EDCHCl, HOBT, DIPEA, 
DMF, rt, 24 h, 60%; (d) (COCl)2, DMSO, DCM, -78 °C, 30 min; then TEA, -78 °→RT, 
30 min, 58%. 
 
 
 
Scheme 4. Preparation of CCG-204020 and CCG-205420.
a
 
 
a
Reagents and conditions: (a) BnBr, Na2CO3, H2O, DCM, reflux, 3 h, 87%; (b) TFA, 
DCM, RT, 18 h; ; (c) 1-(4-fluorobenzyl)-1H-indole-2-carboxylic acid, EDCHCl, HOBT, 
DIPEA, DMF, rt, 30 h, 52%; (d) Pd(OH)2, H2, HCl, EtOH, THF, RT, 1 h, 77%. 
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The benzylated amine analogs CCG-204020 and CCG-205420 were prepared in 
a synthetically distinct, albeit similarly linear fashion, to the previous two compounds 
(Scheme 4). The protected 4-aminopiperidine 12 was doubly benzylated with benzyl 
bromide and deprotected with TFA to afford the amine salt 14. Coupling with the indole 
carboxlic acid 4b gave CCG-204020, and time-sensitive selective mono-debenzylation 
provided the singly substituted benzyl amine CCG-205420. 
The synthesis of piperazine analog CCG-211826 required prior preparation of a 
suitable alkylation partner (Scheme 5) by displacement of alcohol 15 under forcing 
conditions with refluxing hydrobromic acid. 1-Boc-piperazine was then alkylated with 
the resulting bromo compound 16, deprotected under acidic conditions, and coupled with 
the indole carboxylic acid 4a to provide the desired final analog.  
 
 
Scheme 5. Preparation of CCG-211826.
a
 
 
a
Reagents and conditions: (a) conc. HBr, 130 °C, 2 h, 40%; (b) t-butyl piperazine-1-
carboxylate, NaH, DMF, RT, 19 h, 66%; (c) HCl, 1,4-dioxane, RT, 15 min, 100%; (d) 1-
(4-Chlorobenzyl)-1H-indole-2-carboxylic acid, TEA, EDCHCl, HOBT, DCM, RT, 14 h, 
63%. 
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Secondary amine analogs were generally prepared through the coupling of the 
indole carboxylic acid 4b and piperidine-4-methanol 19 (Scheme 6). The resulting 
alcohol adduct was then oxidized under Swern conditions to the aldehyde 20, which 
could undergo reductive amination with various amines to provide the desired diversity 
of structural type 21. 
 
 
Scheme 6. General Preparation of Secondary Amine Analogs. 
 
a
Reagents and conditions: (a) EDCHCl, HOBT, DIPEA, DMF, 94%; (b) DMSO, 
(COCl)2, DCM, -78 °C; then TEA, -78 °C→0 °C, 66%; (c) NHR1R2, Na(CN)BH3, 
AcOH, THF, EtOH. 
 
 
 
 
Conclusion 
The primary goal of this chapter was reduction of topological polar surface area. To 
this end, we succeeded in halving the TPSA while maintaining potency, bringing our 
compounds well within the optimal range of successful CNS drugs. This work also 
identified useful structural modifications (e.g. piperidine-to-piperazine substitutions) and 
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underlined the need to avoid secondary amine functionality due to cytotoxicity issues. 
Notably, reduction of TPSA appeared to enhance MDR1 evasion, an important feature 
for CNS-active drugs.  
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Reduction of Molecular Weight Chapter III.
Rationale 
Janice Sindac, working on other aspects of the WEEV project, had identified 
CCG-205432 as a viable new lead due to its substantially improved potency and 
solubility over the earlier lead CCG-102516 (Figure 8).
83
 However, it was clear that 
some properties of CCG-205432 required optimization due to its increased molecular 
weight (MW) and TPSA, features associated with diminished passive permeability and 
thus reduced activity. Due to the rather flat SAR associated with the low TPSA analogs 
(see Chapter II), we elected to focus on molecular weight reduction as an alternative 
course of action for correcting the physicochemical properties of CCG-205432. 
 
 
Figure 8. Development of Lead CCG-205432. 
 
 
Molecular weight (MW) is a property of extreme importance for CNS-acting 
drugs, which tend to be of low molecular weight (<450).
74, 98
 This is crucial, as reduction 
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of molecular weight promotes passive permeability into membranes non-linearly;
99
 even 
a small change in molecular weight can have a large impact on membrane penetration. 
Furthermore, reduced molecular weight is associated with lower recognition by efflux 
transporters like MDR1,
79, 80, 100, 101
 an attribute we considered essential for our WEEV 
inhibitors.  
MDR1 Rho123 Uptake Assay. Our collaborators in the lab of Prof. Richard 
Keep discovered that the 
3
H-vinblastine uptake assay suffered from poor reproducibility 
due to complications in acquiring the specific MDR1-MDCKII cell line used in previous 
work (see Chapter II). Fortunately, they found that the Rhodamine 123 (Rho123) uptake 
assay
102
 was a superior substitute to the 
3
H-vinblastine uptake assay, and this was utilized 
for the reduced molecular weight analog class. Not only did the Rho123 assay feature 
improved reproducibility, but Rho123 is a simple dye whose concentration may be 
measured by absorbance and avoids those complications associated with radioactivity. 
Both of these assays operate in the same manner; if the test compound of interest has no 
interaction with MDR1, the 
3
H-vinblastine or Rho123 concentration inside the cell will 
drop as the substrate is pumped out. If the test compound does interact with MDR1, the 
measured 
3
H-vinblastine or Rho123 concentration will be higher within the cell. Results 
for selected analogs are reported as percent effect on Rho123 intracellular concentration 
relative to tariquidar, where lower values indicate lesser interaction with MDR1 and 
therefore less potential for efflux. Moreover, the Rho123 assay was controlled by 
comparing WEEV inhibitors to the efflux of the known MDR1 inhibitor tariquidar. 
We were also interested in undertaking MDR1 SAR studies in order to define an 
MDR1-recognition pharmacophore, but such work is not always trivial.
89
 MDR1 binds 
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many different substrates, and traditional SAR, which focuses on biomolecules that bind 
specific substrates, is not always up to the task. Further complications arise when MDR1 
binds only a few compounds from a class of analogs. There are very general SAR trends 
associated with the transporter, but most individual chemotypes must typically be 
optimized on a case-by-case basis. 
Mouse Liver Microsome Metabolic Stability Assay. Metabolic stability is one 
of the most crucial aspects of early drug development, and instability is a potential killer 
of lead series.
81
 It is therefore necessary to improve the stability of a compound to 
maximize its potential for in vivo efficacy, especially as half-life is related to a 
compound’s biological availability. (See Chapter V for more information regarding 
metabolic stability in drug development.) To this end, the half-lives of compounds were 
determined by incubating in the presence of Balb/C mouse liver microsomes containing 
cytochrome p450 (CYP) enzymes and monitoring the decrease in parent compound 
concentration over time. Compounds more susceptible to CYP-mediated metabolism will 
decrease more rapidly than those that are more stable. Concentration was measured using 
an LC/MS/MS method developed specifically to maximize throughput, and all values 
were controlled against a known concentration of a structurally-related internal standard. 
The assay and analytical protocols were developed in our lab specifically to fit the needs 
of the WEEV project, and details appear in the experimental section.  
Kinetic Solubility Assay. The kinetic solubility is a measure of the metastable 
solution equilibrium of a compound (pre-dissolved in a solvent like DMSO and added to 
aqueous media) that begins to precipitate as its concentration exceeds its ability to 
dissolve.
79, 103
 This can be observed by measuring the absorbance of the sample. The 
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concentration at which the compound precipitates is reported as the kinetic solubility, and 
is a useful measure of aqueous solubility that allows for prioritization of compounds of 
interest. 
 
SAR 
The average CNS drug has a molecular weight of about 319, but the lead 
compounds CCG-102516 and CCG-205432 (Figure 8) were much higher than that. We 
were therefore interested in exploring the indole and piperidine cores as potential sites for 
molecular weight reduction (Figure 9), largely due to the lack of attention these regions 
had received until this point. A number of analogs featuring monocyclic heterocycles 
lacking the fused phenyl ring of indole, such as pyrroles and imidazoles, were prepared 
(Table 5). Azetidine-containing analogs of the piperidine core were also synthesized and 
evaluated. 
 
 
Figure 9. Sites for Molecular Weight Reduction. 
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 Heterocyclic Monocycle SAR. The imidazole analogs (CCG-206586 and CCG-
208916) were completely inactive, presumably due to the enhanced ionizability and 
diminished lipophilicity arising from the presence of two azine nitrogens (Table 5). 
These properties would be expected to impede passive membrane permeability. 
Gratifyingly, the pyrrole analog CCG-206381 was nearly equipotent with indole CCG-
205432, and boasted improved aqueous solubility and a 50 Da improvement in molecular 
weight (Table 5). Attempts to reduce molecular weight of CCG-206381 further, by 
replacing the central piperidine with azetidine, returned significantly less active 
compounds (Table 5). This may be attributed to the length-activity dependence discussed 
in Chapter II, as the small 4-membered ring is much smaller and shorter than the larger 
6-membered piperidine. Curiously, the pyrrole analog of CCG-102516 (CCG-204054) 
was substantially less active than its lead.  
Potential for BBB Penetration. Passive permeability is an excellent predictor of 
successful BBB penetration, and high permeability may also overcome the effect of 
efflux transporters.
79
 Therefore, compounds with good BBB permeability are of central 
importance to our development of CNS active inhibitors, and the pyrrole and imidazole 
analogs were evaluated for their potential to permeate the BBB. The notion that the 
significantly diminished activity of the imidazole analogs was related to increased 
ionizability and lipophobicity was supported by the high aqueous solubility and low 
BBB-PAMPA permeability of CCG-208916 seen in Table 5 (compounds with log Peff > 
4.7 are considered to be highly permeable, whereas those with log Peff  6 are 
considered poorly permeable). CCG-206381, as expected, possessed improved aqueous 
solubility (Table 5), but appeared to have reduced permeability as measured by the BBB-
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PAMPA assay. It is important to note that PAMPA assays are not perfect models of 
membranes because of reduced surface area and the presence of multiple (>100) lipid 
layers. Therefore, it could not be confidently concluded that CCG-206381 was in fact 
less permeable than CCG-205432. 
 Recognition by efflux transporters is highly correlated with diminished BBB 
permeation, so selected analogs were tested for recognition by MDR1 in the Rho123 
assay, using the known MDR1 substrate tariquidar as a control (Table 5). Significantly, 
CCG-205432 interacted with MDR1 to an extent equal to 30% that of tariquidar, whereas 
CCG-206381 had virtually no detectable interaction with the transporter. This indicated 
that CCG-206381 could potentially evade MDR1 and thus achieve a higher in vivo brain 
concentration than CCG-205432. 
 Antiviral Activity. Due to its improved aqueous solubility and reduced molecular 
weight, CCG-206381 was advanced into live virus studies and compared to CCG-
205432. In these assays, cells were infected with live WEEV and the number of plaques – 
often visually distinct zones caused by infection – were counted and used to extrapolate 
viral concentration after treatment with varying concentrations of test compound. 
Viability was determined by measuring the number of living cells with the MTT assay. 
CCG-205432 reduced viral titer by over two log units, and CCG-206381 was able to 
successfully reduce viral titer by about one log unit (Figure 10A). Both compounds also 
comparably conferred protection to infected cells (Figure 10B). Together, these results 
indicated that, while only modestly less active, pyrrole could serve as a viable reduced 
molecular weight alternative to indole.  
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Figure 10. WEEV Antiviral Activity for CCG-205432 and CCG-206381. 
 
(A) HEK293 cells were infected with WEEV at a multiplicity of infection (MOI) of 1 and 
simultaneously treated with decreasing concentrations of the indicated compound.  Virus 
titers in cell culture supernatants were determined at 24 hpi by plaque assay. Calculated 
IC50 values for CCG-205432 and CCG-206381 were 1.8 ± 0.1 and 13.9 ± 6.9, 
respectively. (B) Assay utilized the alphavirus WEEV. Infections were done in cultured 
human BE(2)-C neuronal cells.  Viability was measure using an MTT assay, and viral 
titers were measured using a plaque assay.  Values are mean ± SEM of n = 3-4 
independent experiments.  P value <0.05
*
 or 0.005
**
 compared to DMSO control.   
 
In Vivo Pharmacokinetic Properties. Despite its reduced molecular weight, 
CCG-206381 was less permeable in the BBB-PAMPA assay (Table 5) than its indole 
analog CCG-205432. However, while lead CCG-205432 could not achieve a measurable 
brain concentration in mouse pharmacokinetic studies, CCG-206381 did register brain 
permeation at the early time points (Figure 11). This confirmed our prediction that 
reduction of molecular weight would enhance BBB permeability; due to significantly 
reduced MDR1 recognition, we can credit CCG-206381’s BBB penetration with 
enhanced evasion of efflux transporters despite its worse BBB-PAMPA permeability. 
35 
 
However, the instability of CCG-206381 towards CYP-mediated metabolism compared 
to CCG-205432 in the mouse liver microsomal (MLM) assay (see Chapter V for more 
information) was reflected in its pharmacokinetic profile (Figure 11). CCG-205432 had 
an MLM half-life of 11.5 minutes and was measurable in rat plasma for over 20 hours, 
whereas CCG-206381 had an MLM half-life of 2.9 minutes and was measurable in rat 
plasma or brain samples only up to one hour. Overall, this data indicated that reduction of 
molecular weight was a viable tactic in achieving brain penetration and, therefore, in vivo 
efficacy. 
 
Figure 11. In Vivo Pharmacokinetic Data for CCG-205432 and CCG-206381. 
  
CCG-205432 and CCG-206381 possess different pharmacokinetic profiles. Balb/C mice 
were dosed and sacked at various time points (David Irani lab). Compound 
concentrations in plasma and brain samples were evaluated via LC/MS/MS by the lab of 
Prof. Duxin Sun.  
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Table 6. WEEV Replicon Data for Acyclic Low MW Analogs. 
 
No. R 
IC50 
(µM)
a 
CC50 
(µM)
b MW 
206381 --- 0.68 ± 0.04 >100 451 
208825 
 
60.2 ± 4.6 >100 401 
208827 
 
40.9 ± 5 >100 415 
208848 
 
>100 >100 386 
208846 
 
>100 >100 400 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell 
viability determined by the MTT reduction assay. Values are mean of 
at least n=3 independent experiments.
 
 
 
 
Acyclic Analog SAR. Having established that a smaller scaffold than indole 
could retain antiviral activity and improve BBB permeability, a variety of additional 
analogs was synthesized (Table 6) that featured complete excision of the left-hand 
heterocycle. Many of these analogs possess molecular weights in the low 400 to high 300 
g/mol range, bringing these values substantially closer to successful CNS drugs than any 
WEEV inhibitor synthesized to this point. However, while the pyrrole analogs indicated 
that the indole left-hand core was not a necessary component of the SAR, it was 
immediately evident that complete removal of the heterocycle eliminated activity. Only 
ureas CCG-208825 and CCG-208827 retained any activity in the WEEV replicon assay, 
and those were greatly diminished relative to pyrrole CCG-206381.  Amides 208848 and 
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208846 were completely inactive.  These results suggested that some degree of rigidity is 
likely necessary to retain good antiviral activity.  
 
Table 7. WEEV Replicon Data for Pyrrolidine Analogs. 
 
No. X 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
MW 
206381 --- 0.68 ± 0.04 >100 451 
(S)-211758 CH2 13.5 ± 2 91.6 455 
(R)-211757 CH2 53.5  ± 12 >100 455 
(S)-211754 CO >100 >100 467 
(R)-211756 CO >100 >100 467 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell 
viability determined by the MTT reduction assay. Values are mean 
of at least n=3 independent experiments.
 
 
 
 
Pyrrolidine Analog SAR. We therefore turned our attention to cyclic, but non-
aromatic, pyrrolidine analogs (Table 7). Our rationale was that the saturated heterocycles 
would possess greater stability towards oxidation than pyrrole, yet provide the rigidity 
that was apparently required. While significantly less active than pyrrole CCG-206381, 
N-benzyl pyrrolidines CCG-211758 and CCG-211757 still retain some activity. Worth 
noting is the small but significant chiral preference for the S-enantiomer, which is four 
times more potent than the R-enantiomer. This was consistent with our previous 
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observation that the unknown molecular target for this series of antiviral compounds 
possesses some degree of enantiospecificity.
64, 83
 N-benzoyl pyrrolidines CCG-211754 
and CCG-211756 by contrast were completely inactive. This could suggest a need for a 
basic nitrogen in the linker, but more likely reflects an unfavorable conformational bias 
induced by the planar nature of the amide. 
 Arene Monocycle SAR. We then synthesized and evaluated a series of arene 
derivatives (Table 8) to more closely mimic the pyrrole scaffold but with greater 
predicted stability to oxidative metabolism. Several of these compounds possessed low 
micromolar activity in the replicon assay, including salicylamide CCG-212392 and 
anthranilamide CCG-211824. We anticipated that the aniline moiety might be the most 
suitable bioisosteric replacement for pyrrole based on its electronic similarity, and indeed 
CCG-211824 was only two-fold less potent than CCG-206381. The benzyl aniline 
homologue CCG-222660 proved to be equipotent with the lead (compound CCG-
206381), while further homologation of the anthranilamide (analog CCG-222983) 
resulted in a diminishment of activity. This observation of an optimal length is consistent 
with what we observed while developing CCG-205432
83
 and suggests either a well-
defined limit to the size of the unknown binding site, or simply reflects an excessive loss 
of entropy needed for binding a long acyclic substituent. Removal of the chloride 
(intended to improve metabolic stability by reducing lipophilicity) resulted in compounds 
(CCG-222981 and CCG-222982) with greatly reduced potency. Replacement of the 
aniline nitrogen of CCG-211824 with oxygen (ether analog CCG-212392) resulted in a 
modest loss of activity, while replacement with methylene (benzyl analog CCG-222821) 
provided an equipotent analogue.  
39 
 
T
a
b
le
 8
. 
W
E
E
V
 R
ep
li
co
n
 a
n
d
 I
n
 V
it
ro
 A
D
M
E
 D
a
ta
 f
o
r 
A
re
n
e 
A
n
a
lo
g
s.
 
 
 
M
W
 
5
0
1
 
4
5
1
 
4
6
4
 
4
6
3
 
4
2
9
 
S
o
l 
(µ
g
/m
L
)f
 
3
1
-6
3
 
1
2
5
-2
5
0
 
  
>
2
5
0
 
M
L
M
 
T
1
/2
 
(m
in
)e
 
9
 
3
 
1
8
 
1
9
 
--
- 
M
D
R
1
 
R
ec
o
g
n
it
io
n
 
(%
 R
h
o
1
2
3
 
u
p
ta
k
e)
d
 
3
0
.9
 ±
 1
.0
 
-1
.2
 ±
 0
.6
 
9
.3
 ±
 3
.2
 
4
7
.7
 ±
 7
.2
 
1
0
.9
 ±
 1
.7
 
B
B
B
-
P
A
M
P
A
 (
lo
g
 
P
ef
f)
c  
-4
.1
8
 ±
 0
.0
6
 
-5
.0
1
 ±
 0
.0
3
 
-4
.6
8
 ±
 0
.0
9
 
-4
.4
5
 ±
 0
.1
1
 
-4
.7
5
 ±
 0
.0
2
 
C
C
5
0
 
(µ
M
)b
 
4
9
.9
 
>
1
0
0
 
5
6
.0
 
>
1
0
0
 
>
1
0
0
 
IC
5
0
 
(µ
M
)a
 
0
.5
3
 ±
 0
.0
8
 
0
.6
8
 ±
 0
.0
4
 
6
.1
 ±
 0
.8
 
1
.6
 ±
 0
.2
 
2
8
.8
 ±
 5
.2
 
G
 
--
- 
--
- 
  
 
N
o
. 
2
0
5
4
3
2
 
2
0
6
3
8
1
 
2
1
2
3
9
2
 
2
1
1
8
2
4
 
2
2
2
9
8
1
 
 
40 
 
T
a
b
le
 8
. 
C
o
n
ti
n
u
ed
. 
 
M
W
 
4
7
7
 
4
7
7
 
4
4
3
 
4
9
1
 
4
7
6
 
4
6
2
 
S
o
l 
(µ
g
/m
L
)f
 
>
2
5
0
 
 
>
2
5
0
 
>
2
5
0
 
  
M
L
M
 
T
1
/2
 
(m
in
)e
 
--
- 
1
5
 
--
- 
--
- 
--
- 3
 
M
D
R
1
 
R
ec
o
g
n
it
io
n
 
(%
 R
h
o
1
2
3
 
u
p
ta
k
e)
d
 
3
.9
 ±
 1
.5
 
5
9
.6
 ±
 7
.5
 
2
.5
 ±
 0
.3
 
3
0
.7
 ±
 4
.7
 
1
.8
 ±
 1
.3
 
2
2
.6
 ±
 2
.7
 
B
B
B
-
P
A
M
P
A
 (
lo
g
 
P
ef
f)
c  
-4
.7
1
 ±
 0
.0
9
 
-4
.3
9
 ±
 0
.0
5
 
-4
.9
3
 ±
 0
.0
3
 
-4
.4
9
 ±
 0
.3
5
 
-5
.0
8
 ±
 0
.0
2
 
-4
.4
0
 ±
 0
.0
6
 
C
C
5
0
 
(µ
M
)b
 
>
1
0
0
 
7
5
.2
 
9
2
.2
 
8
6
.0
 
>
5
0
 
7
0
.7
 
IC
5
0
 
(µ
M
)a
 
1
5
.4
 ±
 2
.8
 
0
.5
6
 ±
 0
.0
8
 
1
9
.0
 ±
 1
.7
 
3
.4
9
 ±
 0
.1
 
>
5
0
 
1
.4
6
 ±
 0
.0
9
 
G
 
  
 
 
  
N
o
. 
2
1
2
3
9
3
 
2
2
2
6
6
0
 
2
2
2
9
8
2
 
2
2
2
9
8
3
 
2
1
2
3
9
1
 
2
2
2
8
2
1
 
41 
 
T
a
b
le
 8
. 
C
o
n
ti
n
u
ed
. 
 
a I
n
h
ib
it
io
n
 o
f 
lu
ci
fe
ra
se
 e
x
p
re
ss
io
n
 i
n
 W
E
E
V
 r
ep
li
co
n
 a
ss
ay
. 
b
C
el
l 
v
ia
b
il
it
y
 d
et
er
m
in
ed
 b
y
 t
h
e 
M
T
T
 r
ed
u
ct
io
n
 a
ss
ay
. 
V
al
u
es
 a
re
 
m
ea
n
 o
f 
at
 l
ea
st
 n
=
3
 i
n
d
ep
en
d
en
t 
ex
p
er
im
en
ts
. c
L
o
g
 o
f 
ef
fe
ct
iv
e 
p
er
m
ea
b
il
it
y
 (
cm
/s
) 
d
et
er
m
in
ed
 u
si
n
g
 P
A
M
P
A
 E
x
p
lo
re
r 
(p
IO
N
) 
w
it
h
 B
B
B
 l
ip
id
 m
ix
tu
re
 m
ea
su
re
d
 a
t 
p
H
 =
 7
.4
. 
d
R
h
o
d
am
in
e 
1
2
3
 u
p
ta
k
e 
w
as
 m
ea
su
re
d
 i
n
 M
D
R
1
-M
D
C
K
II
 c
el
ls
 u
ti
li
zi
n
g
 
G
lo
m
ax
 M
u
lt
i 
D
et
ec
ti
o
n
 S
y
st
em
 (
P
ro
m
eg
a)
. 
‘M
D
R
1
 r
ec
o
g
n
it
io
n
’ 
w
as
 a
ss
es
se
d
 b
y
 m
ea
su
ri
n
g
 u
p
ta
k
e 
o
f 
R
h
o
d
am
in
e 
1
2
3
 i
n
 t
h
e 
p
re
se
n
ce
 o
f 
M
D
R
 i
n
h
ib
it
o
r,
 t
ar
iq
u
id
ar
 (
5
 µ
M
),
 3
0
 µ
M
 o
f 
te
st
 a
n
ti
-v
ir
al
 o
r 
v
eh
ic
le
, 
an
d
 c
al
cu
la
ti
n
g
: 
(C
av
 –
 C
v
eh
)*
1
0
0
/(
C
ta
r-
C
v
eh
),
 
w
h
er
e 
C
av
 =
 c
o
n
ce
n
tr
at
io
n
 o
f 
rh
o
d
am
in
e 
1
2
3
 i
n
 t
h
e 
p
re
se
n
ce
 o
f 
an
ti
-v
ir
al
, 
C
v
eh
 =
 c
o
n
ce
n
tr
at
io
n
 i
n
 t
h
e 
p
re
se
n
ce
 o
f 
v
eh
ic
le
, 
C
ta
r 
=
 
co
n
ce
n
tr
at
io
n
 o
f 
rh
o
d
am
in
e 
1
2
3
 i
n
 t
h
e 
p
re
se
n
ce
 o
f 
ta
ri
q
u
id
ar
. 
In
 t
h
e 
p
re
se
n
ce
 o
f 
ta
ri
q
u
id
ar
, 
rh
o
d
am
in
e 
1
2
3
 u
p
ta
k
e 
w
as
 1
1
2
3
 ±
 
5
4
%
 o
f 
v
eh
ic
le
 c
o
n
tr
o
ls
 (
n
=
4
4
) 
. 
e H
al
f-
li
fe
 i
n
 B
A
L
B
/c
 m
o
u
se
 l
iv
er
 m
ic
ro
so
m
e 
in
cu
b
at
io
n
. 
V
al
u
es
 a
re
 h
al
f-
li
v
es
 c
al
cu
la
te
d
 f
ro
m
 
th
e 
eq
u
at
io
n
 T
1
/2
=
ln
(2
)/
sl
o
p
e,
 w
h
er
e 
th
e 
sl
o
p
e 
w
as
 l
n
(%
 d
et
ec
te
d
) 
ag
ai
n
st
 t
im
e,
 p
lo
tt
ed
 f
ro
m
 t
h
e 
m
ea
n
 o
f 
at
 l
ea
st
 n
=
3
 
in
d
ep
en
d
en
t 
ex
p
er
im
en
ts
. 
 f
K
in
et
ic
 s
o
lu
b
il
it
y
 m
ea
su
re
d
 u
si
n
g
 t
h
e 
sa
m
e 
as
sa
y
 m
ed
ia
 a
s 
W
E
E
V
 r
ep
li
co
n
 a
ss
ay
, 
ex
ce
p
t 
w
it
h
 1
0
%
 
fe
ta
l 
b
o
v
in
e 
se
ru
m
. 
S
ee
 E
x
p
er
im
en
ta
l 
S
ec
ti
o
n
 f
o
r 
d
et
ai
le
d
 m
et
h
o
d
s 
an
d
 s
y
n
th
et
ic
 p
ro
ce
d
u
re
s.
 
 
 
42 
 
Interestingly, the N-methylated analogue CCG-212393 was ten times less active 
than its parent anthranilamide CCG-211824, suggesting that the aniline nitrogen may be 
engaged in internal hydrogen bonding with the ortho carbonyl oxygen, resulting in a 
specific conformation favorable for activity. Further evidence for this conformational 
hypothesis is provided by comparing benzylbenzamide analogue CCG-222821, with 
inactive benzoylbenzamide CCG-212391.  The latter would not be expected to be able to 
achieve a conformation similar to the internally hydrogen bonded conformation of CCG-
211824.  
 
Figure 12. Conformational Restriction Plan for Arene Analogs. 
Analogs were designed to tether the arene rings (red, carbazole derivatives) or tie the 
amide to the aniline nitrogen (blue, quinolone derivatives).  
 
 
Conformational Restriction. Several rigid analogues were designed to evaluate 
our conformational hypothesis (Figure 12 and Table 9). Carbazole derivatives (CCG-
222824 and CCG-222825) were intended to tether the two arenes in the molecule and 
prevent rotation around the two C-N bonds. Surprisingly, these compounds were 
remarkably less active than their more flexible parent, which may indicate that the 
putative internal NH hydrogen bond is not sufficient for achieving the biologically active 
43 
 
conformation and that in fact the two tethered aromatic rings need to be orthogonal rather 
than planar. It is also possible that tight binding to the unknown molecular target entails 
induced fit, which the rigid carbazole cannot accommodate. The quinolone derivatives 
(CCG-222823 and CCG-222822), on the other hand, were designed to freeze rotation 
about the aniline-amide C-C bond. Their poor activity, however, indicates either a poor 
match for the biologically active conformation, or a key role for the benzamide carbonyl 
of CCG-211824 that has been disrupted.   
 
 
Table 9. WEEV Replicon Date for Rigid Arene Analogs. 
 
No. G IC50 (µM)
a
 CC50 (µM)
b
 
222824 
 
59.2 ± 6.5 >100 
222825 
 
18.7 ± 5.4 66.1 
222823 
 
88.3 ± 11.7 >100 
222822 
 
10.9 ± 2.0 34.1 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined by the MTT reduction assay. 
Values are mean of at least n=3 independent experiments.
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Potential for CNS Penetration. To measure the potential for MDR1 recognition 
of the arene analogs, we used the Rho123 assay.
83
  In Table 8, replacement of the pyrrole 
of CCG-206381 with phenyl (CCG-211824) markedly increased recognition by MDR1. 
Surprisingly, simple N-methylation of CCG-211824 (CCG-212393) almost completely 
abated MDR1 recognition.  Reductions in MDR1 recognition were also observed upon 
replacement of the NH of CCG-211824 with O, C=O, or CH2 (CCG-212393, CCG-
212391 and CCG-222821, respectively) suggesting that the NH may be a key factor for 
recognition.  This is supported by the strong MDR1 recognition of NH homologs CCG-
222660 and CCG-222983.  However, it is notable that simple removal of the aromatic 
chloro group strongly attenuated MDR1 recognition (CCG-222981 and CCG-222982), 
indicating that overall lipophilicity may also be a factor.  
Permeability is an excellent predictor of potential BBB penetration, so selected 
compounds were evaluated using pION’s BBB-PAMPA assay and PAMPA Explorer 
program as previously described.
83
 Compounds with log Peff > 4.7 are considered to be 
highly permeable, whereas those with log Peff  6 are considered poorly permeable. In 
general, our compounds exhibit moderate to high BBB permeability, and all but one 
(CCG-212391) possess modestly better permeability than pyrrole lead CCG-206381 
(Table 8).  
In vitro Metabolic Stability. Based on their WEEV replicon activities, selected 
compounds were advanced into the mouse liver microsome (MLM) assay to assess their 
stabilities towards Phase I oxidative metabolism (Table 8). (See Chapter V for more 
information regarding metabolism.) The stability of aniline CCG-211824 was improved 
with a half-life of 19 minutes, a six-fold improvement over the slightly more electron-rich 
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pyrrole CCG-206381 (3 minutes) and a two-fold improvement over the indole CCG-
205432 (9 minutes). The chlorobenzyl homologue CCG-222660 was slightly less stable 
towards metabolism than CCG-211824, perhaps because of the introduction of a benzylic 
carbon and increased lipophilicity. Phenolic ether CCG-212392 was as stable towards 
microsomal metabolism as aniline CCG-211824. Interestingly, replacement of the NH of 
CCG-211824 with CH2 (CCG-222821) markedly attenuated metabolic stability, due 
either to increased lipophilicity or the creation of an additional site for oxidation. 
 
Table 10. Antiviral Data for Select Analogues
a 
  FMV  WEEV  
CCG No. Conc. (µM) 
Titer (x 10
6
 
pfu/ml) 
Viability (% 
uninfected control) 
 Titer (x 10
4
 
pfu/ml) 
 
DMSO NA 30.7 ± 9.0 35.6 ± 4.7  37.3 ± 7.3  
205432 25 ND 69.5 ± 10.0
*
  1.1 ± 0.1
**
  
211824 25 3.7 ± 1.4
*
 58.1 ± 9.0  3.2 ± 2.2
*
  
 5 10.6 ± 4.1 54.6 ± 9.2  49.2 ± 19.4  
222660 25 3.2 ± 1.0
**
 66.6 ± 9.5
*
  1.6 ± 0.5
**
  
 5 9.4 ± 5.6
*
 73.3 ± 9.1
*
  11.7 ± 3.6
*
  
a
Assay utilized the alphaviruses Fort Morgan Virus (FMV) and western equine 
encephalitis virus (WEEV).  Infections were done in cultured human BE(2)-C neuronal 
cells.  Viability was measure using an MTT assay, and viral titers were measured using a 
plaque assay.  Values are mean ± SEM of n = 3-4 independent experiments.  P value 
<0.05
*
 or 0.005
**
 compared to DMSO control.  NA, not applicable.  ND, not determined. 
Data from the David Miller lab. 
 
Antiviral Activity. Based on their WEEV replicon potencies, CCG-211824 and 
CCG-222660 were advanced into assays to evaluate their ability to inhibit cellular 
replication of infectious live virus. Our collaborators used two parallel assays to measure 
activity against infectious virus: reduction in cytopathic effect (CPE) and extracellular 
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virus titers, and examined activity against both WEEV and Fort Morgan Virus (FMV), a 
WEEV-serogroup alphavirus that can be used safely under reduced biosafety level 
conditions compared to WEEV. Against FMV, both CCG-211824 and CCG-222660 
reduced virus titers by ten-fold when used at 25 µM, and also reduced FMV-induced CPE 
similar to previous lead CCG-205432 (Table 10).  Furthermore, both CCG-211824 and 
CCG-222660 also reduced WEEV titers by at least 10-fold when used at 25 µM.  
Although we did not do full titration curves with these experiments, CCG-222660 
maintained antiviral activity against both FMV and WEEV when used at 5 µM, whereas 
CCG-211824 had reduced activity at this lower concentration (Table 10).  
 
Figure 13. Spectrum Antiviral Data for Selected Analogues. 
CCG-211824 and CCG-222660 have potent and broad spectrum antiviral activity.  (A) 
HEK293 cells were infected with FMV at an MOI of 1 and simultaneously treated with 
decreasing concentrations of the indicated compound.  Virus titers in cell culture 
supernatants were determined at 24 hpi by plaque assay.  The horizontal dashed line 
indicates FMV titers in cells treated with control DMSO.  Calculated IC50 values for 
CCG-205432, CCG-211824, and CCG-222660 were 1.0 ± 0.5, 5.2 ± 1.0, and 2.3 ± 1.2 
µM, respectively.  (B) HEK293 cells were infected with the indicated viruses at an MOI 
of 0.1, simultaneously treated with the indicated compound at 25 µM, and virus titers in 
tissue culture supernatants were determined by plaque assay at 24 hpi.  P <0.05* or 
0.005** compared to DMSO-treated controls. Data from the David Miller Lab. 
 
47 
 
To further evaluate the antiviral potency and breadth of activity for CCG-211824 
and CCG-222660, we completed both full titration studies with FMV in HEK293 cells 
(Figure 13A) and examined their inhibitory activity against viruses derived from three 
different families: Venezuelan equine encephalitis virus (VEEV, TC-83 vaccine strain; 
Togaviridae), California encephalitis virus (CEV; Bunyaviridae), and 
encephalomyocarditis virus (EMCV; Picornaviridae) (Figure 13B).  Both CCG-211824 
and CCG-222660 had dose-dependent antiviral activity against FMV, where CCG-
222660 had an IC50 similar to previous lead CCG-205432  (Figure 13A).  In addition, 
both CCG-211824 and CCG-222660 had demonstrable antiviral activity against VEEV, 
CEV, and EMCV in cultured cells, with an approximate 10-fold reduction in infectious 
virus titers for all three pathogens, similar to previous lead CCG-205432  (Figure 13B). 
Mechanism of Action Studies. The use of the WEEV replicon assay, a 
phenotypic cell-based assay, increases the probability of selecting compounds having a 
cellular rather than a viral target for antiviral activity. There are several advantages of 
targeting host factors over viral proteins. The most significant advantage is a decreased 
probability of the targeted virus developing resistance to therapeutics.
105
 Our 
collaborator’s studies with the lead CCG-205432 and related carboxamide analogs 
indicated that the mechanism of action for their antiviral activity is through the 
modulation of cellular cap-dependent translation.
104
 To examine whether our monocyclic 
analogs used a similar mechanism, we evaluated the ability of CCG-211824 and CCG-  
222660 to modulate cellular cap-dependent translation (Figure 14A).  For these 
experiments, we used BSR-T7 cells and two reporter plasmids: pSV40-LUC, which 
produces a capped mRNA through nuclear transcription and export, and pCITE-LUC, 
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which produces an uncapped mRNA containing a cap-independent translational element 
(CITE) through cytoplasmic transcription that is driven by a T7 promoter (Figure 
14B).
106
  Similar to lead CCG-205432 and  previous generation compounds, both CCG-
211824 and CCG-222660 had no effect upon cap-independent translation, but potently 
inhibited cellular cap-dependent translation of transcripts produced by the pSV40-LUC 
reporter plasmid (Figure 14B). These results suggest that the anthranilamide analogs 
CCG-211824 and CCG-222660 also function as antiviral compounds, in part, through 
suppression of host cell cap-dependent translation. 
 
Figure 14. Effect of Selected Analogs on Transfected Gene Expression in BSR-T7 
Cells.
a
 
9a and 11a modulate cellular gene expression.  BSR-T7 cells were transfected with the 
expression plasmids pSV40-LUC (circles) or pT7/CITE-LUC (triangles), treated with 
decreasing concentrations of the indicated compound, and fLUC activity was measured 
20 h later.  Calculated IC50 values for suppression of pSV40-LUC activity for 9a and 11a 
were 2.2 ± 0.2 and 1.0 ± 0.1 µM, respectively.  1 has an IC50 value of 0.1 µM in this 
assay.
104
 N=3 or 4 for all data, and results are the mean ± SEM. Data from the David 
Miller lab. 
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Synthesis 
The piperidine-containing pyrrole analogs CCG-204054, CCG-206381, and 
CCG-208914 and the imidazole analogs CCG-206586, CCG-208913, and CCG-208916 
were first prepared by alkylating the appropriate azole with 4-chlorobenzyl chloride to 
provide the methyl ester. Saponification of this ester and amide coupling with ethyl 
isonipecotate gave the intermediate. This ethyl ester was then hydrolyzed and coupled 
with the appropriate amine (Scheme 7). 
 
Scheme 7. Preparation of Pyrrole and Imidazole Analogs. 
 
Reagents and conditions: (a) p-chlorobenzyl chloride, K2CO3, DMF, 60 °C, 36 h; (b) 7M 
NaOH, EtOH, 70 °C, 4 h; (c) 26, EDCHCl, HOBt, DIPEA, DMF, rt, 24 h; (d) 7M 
NaOH, EtOH, 60 °C, 8 h; (e) 27, EDCHCl, HOBt, DIPEA, DMF, rt, 24 h. 
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Scheme 8. Preparation of Azetidine Analogs.
a
 
a
Reagents and conditions: (a) methyl 4-azetidinecarboxylate hydrochloride, EDC, HOBT, 
DIPEA, DCM, rt; (b) 10% aq. NaOH, EtOH; (c) R-NH2, EDC, HOBT, TEA, DCM, rt. 
 
 
The azetidine-containing pyrroles CCG-208793, CCG-208829, and CCG-
208915 were prepared through the union of N-benzyl pyrrole 28 and methyl azetidine-3-
carboxylate, followed by base hydrolysis and amidation with the appropriate amine 
(Scheme 8). Urea analogs CCG-208825, CCG-208826, CCG-208827, and CCG-
208828 were synthesized by the addition of ethyl isonipecotate 26 to isocyanates 30a,b, 
followed by hydrolysis and amidation with the appropriate amine (Scheme 9). The 
acyclic amides CCG-208846, CCG-208847, CCG-208848, and CCG-208849 were 
synthesized from the amide coupling of the appropriate carboxylic acid 32a,b and ethyl 
isonipecotate 26, followed by hydrolysis/amidation with the appropriate amine similar to 
the previous syntheses (Scheme 9). 
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Scheme 9. Preparation of Acyclic Amide and Urea Analogs.
a
 
 
a
Reagents and conditions: (a) 26, DCM, rt; (b) 10% aq. NaOH, EtOH, rt; (c) R-NH2, 
EDC, HOBT, TEA, DCM, rt; (d) 26, EDCHCl, HOBT, TEA, DCM, RT. 
 
 
The right-hand portion of the pyridine-bearing analogs, N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide dihydrochloride 36 (Scheme 10), was assembled by 
first boc-protecting ethyl isonipecotate 26. The protected ethyl ester was then hydrolyzed 
to the carboxylic acid and coupled with 4-(2-aminoethyl)pyridine 27. The protecting 
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group was then removed under dry acidic conditions to yield the dihydrochloride salt 36 
of the desired amine.  
 
Scheme 10. Preparation of the Right-Hand Amine Dihydrochloride 36.
a
 
 
a
Reagents and conditions: (a) Boc2O, Na2CO3, H2O, THF, reflux; (b) NaOH, H2O, EtOH, 
RT; (c) 4-(2-aminoethyl)pyridine, EDCHCl, HOBT, DCM, RT; (d) HCl, dioxane, RT. 
 
N-benzylpyrrolidine enantiomers CCG-211757 and CCG-211758 were prepared 
through base-catalyzed alkylation of proline with 4-chlorobenzylchloride to protect 
stereochemical integrity via the carboxylate anion,
107
 followed by amide coupling with 
amine dihydrochloride 36
83
 to yield the appropriate (R)- and (S)- analogs (Scheme 11). 
Pyridine-bearing enantiomers CCG-211754 and CCG-211756, and indane-bearing 
enantiomers CCG-211753 and CCG-211755, were synthesized in similar fashion, first 
by acylating proline under classical Schotten-Baumann conditions
108, 109
 followed by 
amide coupling with ethyl isonipecotate 26 (Scheme 11). Hydrolysis of the ethyl ester 
(R)- or (S)-40 through a non-racemizing protocol
110
 provided the carboxylic acid, and 
amidation with amine 27 gave the desired (R)- and (S)- benzoyl analogs.  
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Scheme 11. Preparation of N-Benzyl and N-Benzoyl Pyrrolidine Analogs.
a
 
a
Reagents and conditions: (a) 2a, KOH, IPA, 40 °C; (b) 36, HATU, TEA, DCM, RT; (c) 
4-chlorobenzoylchloride, IPA, KOH, H2O, 0 °C; (d) 26, HATU, TEA, DCM, RT; (e) 9:1 
DCM:MeOH, NaOH, rt; (f) 27, HATU, TEA, DCM, RT. 
 
 
Salicylamide analogue CCG-212392 was prepared from the Chan-Lam 
coupling
111
 of methyl salicylate 41 and 4-chlorophenyl boronic acid, providing the ether 
intermediate 42 in low yield, followed by ester hydrolysis and amidation (Scheme 12). 
Secondary phenyl anthranilamides CCG-211824 and CCG-222981 were assembled from 
Buchwald amination
112, 113
 of triflated methyl salicylate and the appropriate aniline, 
followed by saponification/amidation. The N-methyl anthranilamide derivative CCG-
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212393 was accessed through methylation of coupling intermediate 43a, followed by the 
usual saponification and amide coupling.  
 
 
Scheme 12. Preparation of Anthranilamide and Salicylamide Analogues.
a
 
a
Reagents and conditions: (a) Cu(OAc)2, 4-chlorophenylboronic acid, TEA, pyridine, 
DCM, rt; (b) 10% aq. NaOH, EtOH, RT; (c) 36, EDC, HOBT, TEA, DCM, RT; (d) 
PhN(Tf)2, TEA, DMF, RT; (e) 4-chloroaniline or aniline, Pd(OAc)2, DPPP, Cs2CO3, 
toluene, reflux; (f) ethyl isonipecotate, EDC, HOBT, TEA, DCM, RT; (g) 4-(2-
aminoethyl)pyridine, EDC, HOBT, TEA, DCM, rt; (h) MeI, Cs2CO3, DMF, RT. 
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Benzyl anthranilamides CCG-222660 and CCG-222982 were obtained from the 
alkylation of methyl 2-aminobenzoate 46 and the corresponding benzyl halide, followed 
by the base hydrolysis and amidation (Scheme 13).  
Phenethyl anthranilamide CCG-222983 could not be prepared through direct N-
alkylation of methyl 2-aminobenzoate because the electrophile was highly prone to 
elimination. Conveniently, the transformation could be achieved through a Jourdan-
Ulmann coupling
114
 of 2-bromobenzoic acid 48 and 1-(2-aminoethyl)-4-chlorophenyl 
amine in ethylene glycol dimethyl ether (Scheme 14). Base hydrolysis and amidation 
then provided the desired analog. 
 
Scheme 13. Preparation of Benzyl Anthranilamide Analogues.
a
 
 
a
Reagents and conditions: (a) 4-chlorobenzyl chloride or benzyl bromide, tBuOK or 
Cs2CO3, DMF; (b) 10% aq. NaOH, EtOH, rt; (c) 36, EDC, HOBT, TEA, DCM, rt. 
 
 
Scheme 14. Preparation of Phenethyl Anthranilamide Analogue CCG-222983.
a
 
 
a
Reagents and conditions: (a) 1-(2-aminoethyl)-4-chlorophenyl amine, Cu2O, Cu
0
, 
K2CO3, EDME, 130 °C; (b) 36, EDC, HOBT, TEA, DCM, rt. 
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Scheme 15. Preparation of Benzyl and Benzoyl Benzoate Analogues.
a
 
 
a
Reagents and conditions: (a) AlCl3, PhCl, reflux; (b) 36, EDC, HOBT, TEA, DCM, rt; 
(c) Zn
0
, CuSO45H2O, 28% aq. NH3, reflux.  
   
 
The preparation of benzyl- and benzoyl benzamide derivatives (CCG-222821 and 
CCG-212391 respectively) entailed the known Friedel-Crafts acylation of chlorobenzene 
with phthalic anhydride, 
115
 which delivered ketone intermediate 51 from which a simple 
amidation with 36 provided the benzoylbenzamide analogue CCG-212391 (Scheme 15). 
The related benzylbenzamide analogue CCG-222821 was accessed through a dissolving 
metal reduction of the ketone intermediate 51
116, 117
 to afford benzyl benzoic acid 52, 
which was followed by amidation with amine 36. Interestingly, the ketone could not be 
reduced without concomitant reduction of the chloride under several heterogenous 
hydrogenation conditions.
115, 118
 Also, attempts to reduce the ketone to the respective 
alcohol with NaBH4 failed,
119
 even with excess borohydride and vigorous conditions. 
Thionation with Lawesson’s Reagent and subsequent Raney-Ni reduction also could be 
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used to generate the desired benzyl intermediate 52, but the dissolving metal reduction in 
Scheme 15 was found to be more direct and efficient.  
 
Scheme 16. Preparation of Carbazole Analogues.
a
 
 
a
Reagents and conditions: (a) pyrrolidine, 37% aq. HCHO, EtOH, reflux; (b) s-BuLi, 
THF, CO2(g), then 1 M aq. HCl, reflux; (c) sat. methanolic HCl, reflux; (d) SO2Cl2, DCM, 
0 °C; (e) 10% aq. NaOH, EtOH, THF, rt; (f) 36, EDC, HOBT, TEA, DCM, rt. 
 
  
Carbazole analogues were synthesized as shown in Scheme 16.  Ortho-directed 
lithiation of carbazole 53 followed by carboxylation with carbon dioxide in a manner 
similar to that reported by Katritzky provided key intermediate 54.
120
 Direct coupling 
with amine 36 provided analogue CCG-222824. The carbazole carboxylic acid 54 could 
not be chlorinated with NCS under a variety of conditions,
121, 122
 while the methyl ester 
yielded a complex mixture of variously chlorinated carbazoles. Ultimately, sulfuryl 
chloride
123
 gave clean regioselective conversion to chloro-substituted carbazole ester 55 
as confirmed by 
1
HNMR. This ester was then hydrolyzed to the corresponding carboxylic 
acid and coupled with amine 36 to give the desired analogue CCG-222825. 
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Scheme 17. Preparation of Quinolone Analogues.
a
 
a
Reagents and conditions: (a) 6 M aq. HCl, 1,4-dioxane, reflux; (b) ethyl isonipecotate, 
NaI, Na2CO3, DMF; 80 °C; (c) 4-chlorophenylboronic acid, Cu(OAc)2, TEA, pyridine, 
DCM, rt; (d) 10% aq. NaOH, EtOH, THF, rt; (e) 4-(2-aminoethyl)pyridine, EDC, HOBT, 
TEA, DCM, rt; (f) 4-chlorobenzyl chloride, KOtBu, DMF, 0 °C to rt. 
  
Finally, quinolone analogues were accessed as shown in Scheme 17. Hydrolysis 
of 2,4-dichloroquinoline 56
124, 125
 and subsequent addition/elimination with ethyl 
isonipecotate 26 gave intermediate 57 which subsequently could be N-arylated via a 
Chan-Lam coupling,
126
 then saponified and coupled with amine 27 to give 
phenylquinolone CCG-222823. Conversely, 57 could be alkylated with 4-chlorobenzyl 
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chloride 2a, hydrolyzed and coupled under similar conditions to the phenylquinolone to 
provide the benzylquinolone CCG-222822. 
 
Conclusion 
The primary goal of this chapter was the reduction of molecular weight, as low MW 
is associated with improved BBB-permeability and is a feature of successful CNS drugs. 
To this end, we successfully developed a novel MDR1-evasive pyrrole compound (CCG-
206381) with sub-micromolar potency and demonstrable in vivo CNS penetration. This 
marks the first successful alphavirus antiviral with measurable CNS exposure, and 
confirmed our predictions that reduction of MW was a viable tactic in achieving 
favorable CNS permeability. However, this compound was remarkably susceptible to 
CYP-mediated metabolism; therefore, an additional goal was improvement of metabolic 
stability, and we identified the aniline moiety as a suitable substitute for pyrrole. We 
unveiled phenylaniline CCG-211824 and benzylaniline CCG-222660 as low-to-sub-
micromolar inhibitors with MLM half-lives twice that of the original indole lead CCG-
205432 and five-to-six times that of the pyrrole lead CCG-206381. Importantly, these 
aniline compounds demonstrated excellent activity (almost two-fold titer reduction) 
against live viruses from three different families. This is an important step towards the 
development of antivirals that are both potent and bioavailable. 
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 Conformational Restriction Chapter IV.
Rationale 
Potency is important for many aspects of drug delivery; potent compounds are 
generally more amenable to oral administration because they require less material to 
achieve the desired therapeutic effect, and they are less prone to off-target effects 
(toxicity) because of the low doses required.
79
 Therefore, as with any drug, a high 
therapeutic index, representing high potency and low toxicity, is a major goal for WEEV 
inhibitors. Potency is also especially important for the successful action of many CNS-
active drugs; due to the brain-blood barrier (BBB), very little of the available drug will 
actually penetrate the brain, as described later. 
 An important task in potency optimization is the identification of the bioactive 
conformation of the inhibitors.
127-130
 In the absence of structural information, this can 
only be accomplished by synthesizing and evaluating rigid analogs.
131, 132
 Of the multiple 
conformations that a drug can adopt, only a small subset will have maximal activity if the 
binding site is well defined and not highly flexible.
128, 133
 It is therefore informative to 
lock out or freeze certain conformations and observe their effect on activity in an effort to 
pinpoint the active one, especially when the binding site is unknown.
134
 It is also a very 
useful strategy for improving selectivity versus off-target effects.
135-137
 When designing 
such analogs, it is important to minimize the number of additional atoms used in locking 
a conformation because adding molecular weight or introducing new interactions with the 
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binding site may have their own effects on activity, thereby confounding interpretation of 
the actual impact of conformational restriction. Rigid analogs may be prepared utilizing 
several approaches to restricting rotatable bonds: a) substituting small functionality with 
sterically demanding functionality; b) bridging nonadjacent atoms; and c) restricting ring 
conformations.  
 
Figure 15. Steric Approach to Conformational Restriction. 
 
  
Installation of sterically restricting functionality is most often the simplest 
approach of the three tactics and retains some degree of flexibility. In the case of lead 
CCG-102516, the N-benzyl encounters minimal resistance to rotation from the small 
indole hydrogens and would be expected to adopt a configuration that minimizes steric 
clashes with the amide carbonyl (Figure 15 A). On the other hand, methylation of the 
indole 7-position hinders its ability to rotate over this region and would be expected to 
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greatly limit the available conformers, inducing a conformation (63) that is distinct from 
61 (Figure 15 B).  
 
  
Figure 16. Tethering Approach to Conformational Restriction. 
 
The second tactic, bridging of nonadjacent atoms, is a much more restrictive 
approach. For example, the distal amide of CCG-102516 is free to rotate about 
piperidine-amide C-C bind (Figure 16), but inclusion of a bridging methylene between 
the piperidine 3-position and the amide nitrogen provides a compound with an 
immobilized carboxamide conformer.  
 
Figure 17. Ring-Locking Approach to Conformational Restriction. 
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The third approach, the locking or steric restriction of ring conformers, is similar 
to that of the previous tactic in that it most frequently involves bridging of nonadjacent 
and (often) transannular atoms (Figure 17). The lead compound CCG-102516 features a 
1,4-disubstituted piperidine, and due to the meso C2 symmetry about the ring, there 
predominantly exist two major conformers: equatorial-equatorial (66) and axial-
equatorial (67). Either of these can be conveniently locked. An ethylene bridge across the 
piperidine 2- and 6-positions can only axial-axial (68), resulting in a locked equatorial-
equatorial relationship between the piperidine substituents. Similarly, preparation of the 
fused cyclopropane/pyrrolidine (69) allows access to the axial-equatorial analog, with 
minimal impact on molecular weight. 
 
 
 
SAR 
Initial SAR focused on the restricting the indole and benzamide portions of the 
lead CCG-102516. Biological results for indole core analogs appear in Table 11. 
Utilizing the steric approach to conformational restriction, two compounds were designed 
on the notion that strategically placed methyl groups would impede bond rotations of 
interest while only contributing a small increase in molecular weight. Both the 7-
methylindole CCG-206447 and the 3-methylindole CCG-205431 possessed substantially 
reduced potency, indicating that the methyl groups may in fact be blocking access to the 
active conformations.  
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Table 11. WEEV Replicon Data for Methylindole Analogs. 
 
CCG No. L M-R IC50 (µM)
a
 CC50 (µM)
b
 
102516† 
  
15.6 ± 1.8 >100 
205431 
  
>100 >100 
206447 
  
61 ± 39 >100 
206485 
  
17.1 ± 1.3 >100 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments.
 
†Synthesized by Janice Sindac. 
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Table 12. WEEV Replicon Data for Rigid Benzamide Analogs. 
 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
102516† 
 
15.6 ±1.8 >100 
205470 
 
>100 >100 
205471 
 
>100 >100 
205472 
 
>100 >100 
205473 
 
>100 >100 
205474 
 
>100 >100 
206328 
 
>100 >100 
206382 
 
0.53 ± 0.04 >100 
206549 
 
1.7 ± 0.1 >100 
206550 
 
7.1 ± 0.9 >100 
206397† 
 
15.2 ± 4.7 62 ± 13  
206587 
 
>100 >50 
206382 
  
0.53 ±0.04 >100 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments.
 
†Synthesized by Janice Sindac. 
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Restricted of the Terminal Carboxamide. We then synthesized and evaluated 
analogs of the benzamide featuring phenylpyrrolidines, isoindolines, indolines, and 
indane substructures (Table 12) and a bicyclic compound CCG-206485 (Table 11), but 
the majority of analogs exhibited no activity, which was not entirely undesirable. 
Uniformly active compounds would indicate a non-selective binding site – one to which 
binding optimization would be difficult. Excitingly, one compound (CCG-206382) 
possessed significantly better activity than others in this series, and constituted the most 
active compound in the analog arsenal at that time. This result was most likely not the 
product of increased lipophilicity or chain extension because analogs of similar logP 
(CCG-206550) and length (CCG-206587) have higher IC50 values (Table 12). 
Interestingly, the racemic methyl analog of CCG-206382 (CCG-206549) was also 
active, though just over two-fold less so than its more potent relative. Curiously, CCG-
206550 was similarly active to the lead CCG-102516, but CCG-205472 was completely 
inactive despite being shorter by only a single methylene unit. Overall, the results in 
Table 12 suggest that the amide binding pocket of the unknown molecular target is very 
well defined and discriminating. 
Indane SAR. Due to the superb in vitro potency of CCG-206382 in the WEEV 
replicon assay, the indane moiety was incorporated into other WEEV inhibitor analogs, 
including those of the low molecular weight class (Chapter III). As previously discussed 
in that chapter, Janice Sindac had discovered the equally potent compound CCG-205432 
bearing a pyridine in place of the indane. Curiously, related analogs differing only by the 
indane or pyridine functionality did not possess similar activities (Table 13); in some 
cases, the IC50 values differed in excess of one hundred-fold (e.g. CCG-206381 
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compared to CCG-208914, and CCG-209021 compared to CCG-209020.)  The indane 
compounds also behaved differently than their pyridine counterparts in the replicon 
assay. For example, an IC50 value for CCG-209793 could not be deduced because the 
concentration-inhibition plot was uncharacteristically linear, and more than one 
compound’s plot oddly plateaued in a manner inconsistent with every other analog and 
class synthesized to-date. These results questioned the validity of CCG-206382’s 
activity, but our collaborators found no evidence of direct luciferase inhibition. The 
compound was consequently promoted for further studies to evaluate its true efficacy 
against live virus. 
Table 13. WEEV Replicon Data Comparisons of Analogs Based on CCG-205432 
and CCG-206382. 
 CCG # R IC50 (µM)
a
 CC50 (µM)
b
 
 
205432† 
 
0.53 ± 0.08 65.0 
206382 
 
0.53 ± 0.04 >100 
 
206381 
 
0.68 ± 0.04 >100 
208914 
 
61.8
c
 70.3 
 
208916 
 
>100 >100 
208913 
 
>100 >100 
 
208915 
 
22.0 ± 8 >100 
208793 
 
CNBD
d
 >100 
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Table 13. Continued.     
 CCG # R IC50 (µM)
a
 CC50 (µM)
b
 
 
209021 
 
0.93 ± 0.2 8.0 
209020 
 
>100 >100 
 
211756 
 
>100 >100 
211753 
 
>100 >100 
 
211754 
 
>100 >100 
211755 
 
>100 >100 
 
208825 
 
60 ± 5 >100 
208826 
 
>100 >100 
 
208827 
 
41 ± 5 >100 
208828 
 
>100 >100 
 
208846 
 
>100 >100 
208847 
 
>100 >100 
 
208848 
 
>100 >100 
208849 
 
33 ± 15 >100 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
c
Value is n=1 experiment. 
d
Could not be determined.
  †Synthesized by Janice Sindac. 
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Antiviral Activity. When cells infected with WEEV or NSV (neuro-adapted 
sinbis virus) were treated with the pyridine analog CCG-205432, viral titer was reduced 
by nearly two log units, and cell viability was significantly improved (Figure 18). 
However, the indane analog CCG-206382 (despite being equipotent in the WEEV 
replicon assay) neither decreased viral titer nor improved cell viability relative to the 
negative control, suggesting that the compound was truly not active. Analogs featuring 
the indane moiety were subsequently dropped.  
 
 
 Figure 18. Activity of Various Analogs Against Live Virus. 
Data from the David Miller Lab. 
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Piperidine Amide SAR. Having determined the terminal carboxamide portion of 
the analogs to be a challenging site for conformational restriction, our attention was 
turned towards the central piperidine ring. As in Chapter III (low molecular weight 
series), CCG-205432 was employed as the lead due to its potency and demonstrable 
activity against live virus, and thus this series features the right-hand pyridylethyl amide. 
Biological results appear in Table 14. In Chapter II (reduced TPSA series), it was noted 
that there appeared to be a limited tolerance for TPSA reduction, perhaps because certain 
structure-activity requirements were not met. It was noted that compounds like CCG-
211826 (Table 2), despite being structurally similar to potent leads, lacked the right-hand 
secondary amide. To evaluate the postulated importance of this functionality, four 
compounds were prepared (Table 14). Activities of the inverse amide CCG-2120532 and 
the shifted amide CCG-224001 are over 30-fold less than CCG-205432, confirming that 
the amide is important to the unknown pharmacophore. In particular, both of these 
analogs retain the amide carbonyl in the same relative location, but differ in the location 
of the amide nitrogen, which indicates that the position of the carbonyl is apparently 
more important than the NH. The amide carbonyl may be engaged as a hydrogen-bond 
acceptor, and, due to the dependence on the acceptor-donor angle, translocation of the 
carbonyl by one methylene unit may be sufficient to deprive the molecule of a productive 
hydrogen bond in the unknown target, accounting for the diminished activity. 
Furthermore, complete excision of the amide (e.g. E- and Z-alkenes CCG-211823 and 
CCG-211825) returned analogs with no activity, complementing this hypothesis.  
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Table 14. WEEV Replicon Data for Central Piperidine Analogs. 
 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
205432† 
 
0.53 ± 0.08 65.0 
212052 
 
17.6
c
 66.7
c
 
224001 
 
24.7 ± 3.5 77.3 
211823 
 
>50 >50 
211825 
 
>50 >50 
212390 
 
24.4 ± 4.0 78.0 
211822 
 
3.9 ± 0.4 74.2 
211829 
 
>50 >50 
211761† 
 
1.3 ± 0.4 63.2 
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Table 14. Continued. 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
212394 
 
24.4 ± 6.3 61.0 
222980 
 
24.6 ± 1.6 >100 
224000 
 
0.96 ± 0.06 50.9 
224220 
 
10.9 ± 0.6 56.5 
224002 
 
73.1 ± 29.1 88.1 
222661 
 
0.49 ± 0.09 41.1 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
c
Value is n=1 experiment.
  †Synthesized by Janice Sindac. 
 
 
Core Piperidine SAR. The significantly reduced activity of the urea analog 
CCG-212390 and eneamide CCG-211822 are also consistent with the postulated 
importance of the secondary amide (Table 14). Both analogs were built to rigidify and 
flatten the core ring, and such modifications may have changed the projection of the 
amide carbonyl. The bicyclic analog CCG-212394 may display the amide in a similarly 
nonproductive manner, especially in light of the better activity of the very similar (but 
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less restricted) analog CCG-211761. The α-methyl analog CCG-211829 was much less 
active, presumably because the methyl was either impeding favorable chair 
conformations or occluding the amide carbonyl. The exo-bicycle CCG-222980 was also 
less potent than the lead. Interestingly, the ethylene-bridged piperidine CCG-224000 was 
a mere two-fold less potent than CCG-205432, suggesting that the locked equatorial-
equatorial relationship between the 1- and 4-substituents may be indicative of the 
unknown bioactive conformation. 
 The importance of length to the activity of WEEV inhibitors was discussed in 
Chapter II and Chapter III, and, unsurprisingly, the azetidine-containing CCG-224002 
was less active than its piperidine-containing counterpart CCG-205432 (Table 14). To 
determine the effect of larger rings on activity, the azapane analog CGG-222661 was 
synthesized and tested. Interestingly, this compound was equally potent with the lead 
despite being less rigid and possessing an offset right-hand amide. Furthermore, the 
active enantiomer could potentially be two-fold more active than the racemate, marking 
this compound as the most active to-date in the WEEV replicon assay.  
  
 
Synthesis 
Restricted analogs based upon the benzylamide lead CCG-102516 were generally 
prepared through amide coupling of various amines with the core carboxylic acid 71, 
which was itself accessed via coupling of the indole-2-carboxylic acid 4a with ethyl 
isonipecotate 26 followed by saponification (Scheme 18). 
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Scheme 18. General Preparation of Rigid Benzamide Analogs.
a
 
 
a
Reagents and conditions:  (a) 26, EDC∙HCl, HOBT, TEA, DCM, RT; (b) 10% aq. 
NaOH, EtOH, RT; (c) HNR1R2, EDC∙HCl, HOBT, TEA, DCM, RT. 
 
 
Scheme 19. Preparation of 2-(aminomethyl)indane 75.
a
  
 
a
Reagents and conditions: (a) HMDS, HATU, DIPEA, DMF, rt, 20 h; (b) LiAlH4, THF, 
RT, 8 h. 
 
 
2-(Aminomethyl)indane 75 (Scheme 19, for the synthesis of CCG-206382) was 
accessed  first through amidation with the 2-indane carboxylic acid 73 and HMDS, after 
which aqueous workup conditions resulted in hydrolytic degradation of the silyl 
functionality to reveal the primary carboxamide 74. This procedure was found to be more 
efficient than direct aminolysis of the carboxylic acid. Reduction of the carboxamide with 
LAH provided the desired amine 75, which was coupled with indole carboxylic acid 71 
as described in Scheme 18. Racemic 2-(2-aminoethyl)indane 78 was prepared first 
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through double displacement of dibromoxylene 76 with acetylacetate followed by 
reductive amination of the ketone 77 (Scheme 20). 
 
 
Scheme 20. Preparation of Racemic 2-(2-Aminoethyl)indane.
a
 
 
a
Reagents and conditions: (a) ACAC, NaH, DMF; (b) 7 M NH3/MeOH, NaBH4, RT, 20 
h. 
 
 
 
The 7- and 3-methyl indole analogs were generally prepared through classical 
Fischer indolization (Scheme 21 and Scheme 22).  The appropriate anilines (o-toluidine 
79 and aniline 84) were transformed into their respective diazonium salts and reduced to 
hydrazines through the action of tin(II) chloride.
138
 The hydrazines were then allowed to 
undergo Fischer indolization with the necessary β-ketoester 80 or 85, but only the 7-
methyl indole required a transition metal Lewis acid catalyst to facilitate cyclization to 
indole 81. Overall, this route was found to be more expedient than the reported two-step 
Japp-Klingemann/Fischer indolization approach
139
 to the indole scaffold. Alkylation of 
the indole N1-position with 4-chlorobenzyl chloride 2a was found to be slow for the 7-
methyl analog 81, presumably due to steric hindrance of the nucleophile. Subsequent 
saponification and amide coupling with benzylamine yielded the desired methyl indole 
analogs CCG-205431 and CCG-206447.  
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Scheme 21. Preparation of 7-Methylindole CCG-206447.
a
  
 
a
Reagents and conditions: (a) 79, NaNO2, conc. HCl, 0 °C, 30 min; then SnCl2, 4 °C, 11 
h, 56%; (b) 80, ZnCl2, TsOH, EtOH, reflux, 8 h; (c) 2a, K2CO3, DMF, 60 °C, 3 d, 46%; 
(d) 10% aq. KOH, EtOH, 70 °C, 4 h, 94%; (e) N-benzylpiperidine-4-carboxamide, 
EDCHCl, HOBT, DIPEA, DMF, RT, 18 h, 47%. 
 
 
 
Scheme 22. Preparation of 3-Methylindole CCG-205431.
a
 
 
a
Reagents and conditions: (a) PhNH2, NaNO2, conc. HCl, 0 °C, 15 min; then SnCl2, 0 °C, 
24 h; then 85, EtOH, TsOH, reflux, 12 h, 65%; (b) 2a, K2CO3, DMF, 60 °C, 12 h, 72%; 
(c) THF, 5 M aq. NaOH, 55 °C, 18 h, 96%; (d) N-benzylpiperidine-4-carboxamide 
hydrochloride, HATU, DIPEA, DMF, RT, 20 h, 51%. 
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The pyrrolopiperidine analogs CCG-206485 and CCG-212394 were accessed 
first through the partial reduction of the imide 88 to the amide 89 as reported by Dugar et 
al.
140
 Presumably, selectivity arises from chelation-directed reduction of the carbonyl 
situated on the same side of the molecule as the azine nitrogen.
141
 Complete reduction of 
the pyridine gave the piperidine 90, and amidation with this and the indole carboxylic 
acid 4a provided intermediate 91, which was alkylated with the requisite electrophiles 
(Scheme 23).  
 
Scheme 23. Preparation of pyrrolidopiperidine Analogs CCG-206485 and CCG-
212394.
a
 
 
a
Reagents and conditions: (a) Zn
0
, AcOH, 6 h, 115 °C, 38%; (b) PtO2, 50 psi H2, AcOH, 
RT, 2 d; (c) 4a, EDCHCl, HOBT, DIPEA, DCM, RT, 12 h, 56%; (d) Ar(CH2)nBr, NaH, 
DMF, RT, 18 h, 72%. 
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Scheme 24. Preparation of Inverse Amide CCG-212052.
a
 
 
a
Reagents and conditions: (a) EDCHCl, HOBT, TEA, DCM, RT, 30 h, 71%; (b) HCl, 
dioxane, RT, 1 h, 100%; (c) 4a, EDCHCl, HOBT, TEA, DCM, RT, 22 h, 61%. 
 
 
Scheme 25. Preparation of Shifted Amide CCG-224001.
a
 
 
a
Reagents and conditions: (a) EDCHCl, HOBT, TEA, DCM, RT; (b) KOH, H2O, EtOH, 
RT; (c) 4-(aminomethyl)pyridine, EDCHCl, HOBT, TEA, DCM, RT. 
 
 
The inverse amide CCG-212052 was prepared through the amide coupling of N1-
protected 4-aminopiperidine 92 and 3-(4-pyridyl)propanoic acid 93. Subsequent 
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deprotection and coupling with indole carboxylic acid 4a furnished the desired inverse 
amide CCG-212052 (Scheme 24).  
To prepare the shifted amide analog CCG-224001, the commercially available 
amino ester 95 was first coupled with the indole carboxylic acid 4a. The ester of the 
resulting intermediate was then hydrolyzed and coupled with 4-(aminomethyl)pyridine to 
provide the final compound (Scheme 25). 
It was anticipated that a Wittig reaction would ultimately provide the key (Z)-
alkene feature of analog CCG-211829, so the requisite phosphonium bromide 98 was 
prepared from 4-(3-hydroxypropyl)pyridine 97.
142
 This was then deprotonated by nBuLi 
to provide the ylide, which was subsequently permitted to react with the piperdinyl 
aldehyde 8 to provide the desired alkene 99a with >50 Z:E selectivity. Deprotection and 
subsequent coupling with the indole carboxylic acid 4a gave the (Z)-alkene analog CCG-
211829 (Scheme 26). 
A large number of highly E-selective olefinations exist,
143
 but because the 
phosphonium bromide salt was already in hand, the Schlosser modification of the Wittig 
reaction was employed in order to access (E)-alkene analog CCG-211822 (Scheme 26). 
In this procedure, the intermediate oxaphosphetane is deprotonated by PhLi – uniquely 
suited to deprotontion of sterically shielded protons
144
 – and allowed to equilibrate to the 
more thermodynamically favorable trans-betaine carbanion before being quenched with 
tBuOH. In this way, the desired E stereochemistry was quickly accessed to provide the 
(E)-alkene 99b. Deprotection and amide coupling with indole carboxylic acid 4a yielded 
the desired (E)-alkene analog CCG-211822. 
80 
 
Scheme 26. Preparation of (E)- and (Z)-alkene Analogs.
a
 
 
a
Reagents and conditions: (a) Conc. HBr, PPh3, tol, reflux, 11 h, 34%; (b) n-BuLi, THF, 
RT; then 8, RT, 12 h, 52%; (c) 4 M HCl/1,4-dioxane, RT, 1 h; (d) 1-(4-chlorobenzyl)-
1H-indole-2-carboxylic acid, EDCHCl, HOBT, TEA, DCM, RT, 14 h, 56% (2 steps); (e) 
PhLi, LiBr, THF, RT, 20 min; then 8, THF, -78 °C, 30 min; then PhLi, -78 °C, 30 min; 
then t-BuOH, THF, -78 °CRT, 36 h, 41%; (f) 4 M HCl/1,4-dioxane, RT, 1 h; (g) 1-(4-
chlorobenzyl)-1H-indole-2-carboxylic acid, EDCHCl, HOBT, TEA, DCM, RT, 14 h, 
60% (2 steps). 
 
The piperazinyl urea analog CCG-212390 was prepared by treating boc-
piperazine 100 with phosgene and 4-(2-aminoethyl)pyridine 27 (Scheme 27). Order of 
addition was critical; if 27 was treated with phosgene, the intermediate N-acyl chloride 
would rapidly react with the pyridine nitrogen and no productive chemistry would arise. 
Thus, the boc-piperazine 100 was treated first with phosgene, and the pyridyl amine 27 
was added last. Once the urea was in hand, deprotection and coupling with indole 
carboxylic acid 4a provided the desired urea analog CCG-212390.  
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Scheme 27. Preparation of Urea Analog CCG-212390.
a
 
 
a
Reagents and conditions: (a) COCl2, TEA, tol, DCM, 0 °C, 1 h, 81%; (b) HCl, dioxane, 
RT, 1 h, 100%; (c) 4a, EDCHCl, HOBT, TEA, DCM, RT,  
 
 
 
Initial attempts to access the tetrahydropyridine core of CCG-211823 proceeded 
through the partial reduction of the formyl pyridinium salt of ethyl isonicotinate with 
NaBH4,
145, 146
 but this method was found to be poor yielding and complicated by side 
products. The selenoxide elimination was then identified as a viable alternative, shown in 
Scheme 28.
147, 148
 Treatment of protected ethyl isonipecotate 102 with LDA and 
subsequent addition of phenylselenyl chloride provided the phenylselenide 103. The 
compound could undergo the oxidation-elimination at this point, but it was found that 
carrying the selenyl functionality through the first amidation aided purification efforts. In 
this way, phenylselenide intermediate 105 was oxidized with mCPBA under cold 
conditions and basified to prevent Bronsted-acid catalyzed hydrolytic decomposition via 
a seleno-Pummerer pathway,
149
 and the resulting tetrahydropyridine ethyl ester 106 was 
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saponified then amidated with 4-(2-aminoethyl)pyridine to give the desired analog CCG-
211823. 
 
Scheme 28. Preparation of Tetrahydropyridine Analog CCG-211823.
a
 
 
a
Reagents and conditions: (a) Boc2O, Na2CO3, THF, H2O, reflux, 86%; (b) n-BuLi, 
DIPA, -78 °C, 15 min; then PhSeCl, THF, -78 °CRT, 3 h, 58%; (c) 4 M HCl/1,4-
dioxane, RT, 2 d, 100%; (d) 4a, EDCHCl, HOBT, TEA, DCM, RT, overnight, 63%; (e) 
mCPBA, DCM, -78 °C, 30 min; then TEA, DCM, -78 °C; then -78 °CRT, 1 h, 82%; (f) 
10% aq. NaOH, EtOH, RT, 95%; (g) 27, EDCHCl, HOBT, TEA, DCM, RT, 91%. 
 
 
In a manner similar to the preparation of the tetrahydropyridine analog CCG-
211823, Boc-protected ethyl isonipecotate 102 was alkylated with methyl iodide after 
treatment with LDA to provide the methylpiperidine 107. This piperidine was 
deprotected and coupled with indole carboxylic acid 4a, and the ethyl ester 109 was 
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saponified and coupled with 27 to give the desired methyl analog CCG-211829 (Scheme 
29). 
 
Scheme 29. Preparation of Methylpiperidine Analog CCG-211829.
a
 
 
a
Reagents and conditions: (a) nBuLi, DIPA, THF, -78 °C; then MeI, THF, -78 °C; (b) 4 
M HCl, dioxane, RT, 1 h; (c) 4a, EDC∙HCl, HOBT, TEA, DCM, RT; (d) 27, EDC∙HCl, 
HOBT, TEA, DCM, RT. 
 
 
 The key cyclopropane of the exo-bicyclic analog CCG-222980 was installed by a 
method previously reported.
150, 151
 An electron-deficient carbenoid was generated from 
ethyl diazoacetate and treated with Cbz-protected 2,5-dihydropyrrole 111 over several 
days. This yielded a mixture of unreacted starting material and two diastereomers of the 
product 112, enriched in the exo-isomer, which was taken forward after tedious 
separation and deprotected via hydrogenolysis and coupled with the indole carboxylic 
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acid 4a. Treatment with KOTMS hydrolyzed the ester to the potassium salt, which was 
subsequently coupled with amine 27 to yield the final analog (Scheme 30). 
 
 
Scheme 30. Preparation of Exo Bicyclic Analog CCG-222980.
a
 
 
a
Reagents and conditions: (a) N2CHCO2Et, Rh2(OAc)4, DCM, reflux, 72 h, 3:1 dr; (b) 
Pd/C, H2, EtOH, HCl, RT; (c) 4a, EDC∙HCl, HOBT, TEA, DCM, RT; (d) KOTMS, THF, 
RT; (e) 27, EDC∙HCl, HOBT, TEA, DCM, RT. 
 
 
 
 
Scheme 31. Preparation of Bridged Analog CCG-224000.
a
 
 
a
Reagents and conditions: (a) KOTMS, THF, RT, 12 h; (b) 27, EDC∙HCl, HOBT, TEA, 
DCM, RT; (c) HCl, dioxane, RT; (d) 4a, EDC∙HCl, HOBT, TEA, DCM, RT. 
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The ethylene-bridged piperidine analog CCG-224000 was first constructed by 
hydrolyzing the commercially available protected amino ester 114 and coupling the 
resulting acid with amine 27 to provide the latent right-hand half 115 of the analog. 
Deprotection under acidic conditions followed by amide coupling with the indole 
carboxylic acid 4a provided the desired analog (Scheme 31). 
 
Scheme 32. Preparation of the Spiro Analog CCG-224220.
a
 
 
a
Reagents and conditions: (a) PhCHO, tol, reflux, 2 h, 85%; (b) diethyl malonate, NaH, 
DMF, reflux, 12 h, 84%; (c) Pd/C, H2, MeOH, RT, 6 d, 98%; (d) MsCl, TEA, DCM, RT, 
3 h; (e) TsNH2, K2CO3, DMSO, 90 °C, 5 h, 48% (2 steps); (f) NaOH, H2O, EtOH, reflux, 
2 h, 91%; (g) pyridine, reflux, 12 h, 92%; (h) 4-pyridylethylamine, EDCHCl, HOBT, 
TEA, DCM, RT, 12 h, 80%; (i) Na
0
, naphthalene, THF, RT, 5 min; (j) 4a, EDCHCl, 
HOBT, TEA, DCM, RT, 14 h, 61% (2 steps). 
 
 The spiro core of CCG-224220 was assembled in manner similar to that reported 
(Scheme 32).
152, 153
 The diol 117 was protected as an acetal,
154
 and the bromides were 
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doubly displaced by diethylmalonate under basic conditions to give the diester 119. The 
acetal was removed to reveal the alcohols of 120, which were subsequently mesylated 
and displaced by tosylamide to give the cyclized spiro product 121. Ester hydrolysis and 
thermal decarboxylation furnished the mono-carboxylic acid 122 in good yield, and this 
was coupled with amine 27 to give the latent right-hand half 123 of the desired final 
compound. Cleavage of the tosyl proved to be a substantial challenge, however. Various 
conditions with samarium (II) iodide either failed to remove the tosyl, or reduced and 
cleaved the amide preferentially.
155, 156
 Other reported methods of tosyl deprotection were 
employed with no success
157, 158
 until sodium napthalenide was used,
159
 which quickly 
and cleanly cleaved the S-N bond to reveal the amine 124, which was then coupled with 
the indole carboxylic acid 4a to afford the desired analog CCG-224220. 
 
 
Scheme 33. Preparation of Azetidine-Containing CCG-224002.
a
 
 
a
Reagents and conditions: (a) methyl 4-azetidinecarboxylate hydrochloride, EDC, HOBT, 
DIPEA, DCM, rt; (b) 10% aq. NaOH, EtOH; (c) 27, EDC, HOBT, TEA, DCM, rt. 
 
87 
 
The azetidine-containing analog CCG-224002 (Scheme 33)  
 
Scheme 33was assembled in a manner similar to that used for construction of the 
azetidine-containing pyrrole analogs. The indole carboxylic acid 4a was coupled with the 
azetidine methyl ester, and the intermediate 125 was saponified and coupled with 4-(2-
aminoethyl)pyridine to give the final analog. 
 
Scheme 34. Preparation of Azapane Analog CCG-222661.
a
 
 
a
Reagents and conditions: (a) N2CHCO2Et, BF3OEt2, Et2O, -78 °CRT, 1h; (b) NaBH4, 
EtOH, 0 °CRT, 2h; (c) MsCl, TEA, DCM, 0 °CRT, 6 h; (d) DBU, THF, 80 °C, 1 h; (e) 
Pd/C, 50 psi H2, EtOH, HCl, RT, 24 h; (f) ) 4a, EDCHCl, HOBT, TEA, DCM, RT, 16 h; 
(g) 10% aq. NaOH, EtOH; (h) 27, EDCHCl, HOBT, TEA, DCM, RT. 
 
 
The core azapane of CCG-222661 was first accessed by way of ring expansion of 
N-protected 4-piperidone 126 with ethyl diazoacetate and the strong Lewis acid BF3 
(Scheme 34).
160
 The resulting racemic γ-ketoester 127 was reduced with NaBH4 to the γ-
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hydroxy ester and mesylated. The mesylate 129 was then easily eliminated under mild 
heating with DBU, and the ene ester 130 was exposed to heterogenous reduction 
conditions to both reduce the alkene and the Cbz protecting group. The product amine 
131 was then coupled with indole carboxylic acid 4a, saponified, and then coupled with 
amine 27 to give the azapane analog CCG-222661.   
 
 
Conclusion 
 The primary goal of this chapter was the identification of the unknown inhibitor 
pharmacophore. To achieve this, conformationally-restricted analogs were prepared and 
evaluated in the WEEV replicon assay. While the majority of compounds possessed 
substantially reduced potency, the data pointed towards the importance of the distal 
amide carbonyl to activity and a potential equatorial-equatorial relationship between the 
1,4-substituents of the core piperidine ring. Intriguingly, the azapane CCG-222661 was 
identified as our most potent compound to-date, with an IC50 = 0.49 ± 0.09 for the 
racemate, and with an expected IC50 up to two-fold better for the active enantiomer. It is 
hoped this data may be useful for the generation of a computational 3-D pharmacophore 
model that may be applied to the identification of new alphavirus inhibitor templates via 
in silico screening methods.  
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 Metabolic Stability Chapter V.
Rationale 
Metabolism is the enzymatic modification of compounds so that an organism may 
enhance clearance, and is a crucial detoxification mechanism for removing reactive or 
toxic xenobiotics.
161
 Unfortunately, even drugs considered safe may undergo this process. 
Metabolism dictates the overall biological availability of a compound, and those 
compounds that undergo rapid metabolism may be depleted before reaching their 
intended biological target.  Metabolic stability is one of the most crucial aspects of early 
drug development, and instability is a potential killer of lead series.
81
  
The majority of metabolism occurs in the liver, where a battery of metabolic 
enzymes resides, although metabolism may occur elsewhere as well (blood, epithelial 
intestinal cells, etc.)
162, 163
 These enzymes largely consist of a class called the cytochrome 
p450s, or CYPs, that are responsible for Phase I metabolism, whose purpose is the 
installation of polar functional groups to improve aqueous solubility to enhance clearance 
and to provide handles for further Phase II metabolic pathways.
79, 164
  
Potential sites of metabolism can be easily predicted using computational models 
like that shown in Figure 19.
165-169
 However, while likely, empirical methods are 
required to confirm such predictions because properties like atom accessibility and 
overall lipophilicity are important factors. To this end, it was necessary for us to develop 
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an in-house metabolic stability assay to facilitate our ability to rapidly identify labile 
functionalities and design them out of future analogs.  
 
 
Figure 19. Predicted Sites of Metabolism in CCG-205432, Rank Ordered. 
Predicted sites of metabolism are rank ordered where 1 = most likely, 2 = next most 
likely, etc. Predictions calculated using smartCYP v.2.4.2.
165, 166
 
 
 
The assay utilized commercially-available mouse liver microsomes harvested 
from Balb/C mice, though the line of mice used by our collaborators in the lab of Prof. 
David Irani for in vivo testing were C57 BL/6, and we found that the results were 
translatable. Compounds were incubated in the presence of microsomes over 15 minutes, 
and aliquots were removed and quenched over this time at specific time points. We also 
developed an LC/MS/MS method to maximize throughput and detection sensitivity so 
that parent compound concentration could be quickly assessed at concentrations as low as 
single-digit nanomolar, or less than one percent of starting incubation concentration. 
 
 
SAR 
As discussed in Chapter I, avoidance of predicted metabolic instability led to the 
replacement of the early thienopyrrole scaffold with indole. However, it remained 
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necessary to demonstrate empirically that we had gained stability through this 
substitution, so we established a mouse liver microsome-based metabolic stability assay 
and a corresponding LC/MS/MS analytical method for our lab.  
 
Table 15. MLM Metabolic Stabilities for Thienopyrrole and Indole Leads. 
CCG 
No. 
Structure 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
MLM 
T1/2 
(min)
c
 
ClogP 
203881 
 
11.1 ± 1.3 >100 1.7 ± 1.7 4.4 
102516† 
 
15.6 ± 1.8 >100 7.3 ± 3.9 4.5 
203926† 
 
6.8 ± 1.0 >100 31 ± 7.1 4.9 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
c
Half-life in BALB/c mouse liver microsome incubation. Values are half-lives calculated 
from the equation T1/2=ln(2)/slope, where the slope was ln(% detected) against time, 
plotted from the mean of at least n=3 independent experiments. Values are mean ± SEM 
of n = 3 independent experiments. †Synthesized by Janice Sindac. 
 
 
Our newly developed protocol allowed for convenient in-house metabolic 
stability analysis and was able to differentiate the short half-lives of our leads (Table 15). 
Key to this was optimizing the concentration of microsomes, as the compounds were so 
92 
 
unstable as to be not differentiable under the conditions originally employed. Ultimately, 
we found that quartering the amount relative to established protocols worked well. In the 
assay, we discovered that the indole CCG-102516 had a half-life of 7.3 ± 3.9 minutes, 
whereas the thienopyrrole CCG-203881 had a half-life of only 1.7 ± 1.7 minutes, 
supporting our original stability hypothesis and validating our thienopyrrole/indole 
switch. Despite this, CCG-102516 was still quite metabolically unstable. Interestingly, 
CCG-203926, which differs by only a methyl group from CCG-102516, had 
dramatically improved stability, with a half-life of 31 ± 7.1 minutes. This was 
presumably due to steric hindrance of the potentially labile benzylic site.  
Table 16 shows the activities of the lead indole compound CCG-205432, its 
pyrrole-substituted analog CCG-206381, and the best compound from Table 15, 
CCG-203926. Note that the stability of CCG-203926 (2.3 ± 0.1 minutes) does not match 
its stability in Table 15 (31 ± 7.1 minutes); this was mostly likely due to the fresher, 
more active microsomes used in the former study. However, the relative stabilities are not 
affected, and we can confidently conclude that CCG-206381 (3.7 ± 1.3 minutes) and 
CCG-205432 (16.7 ± 1.7 minutes) are substantially more stable than CCG-203926 in the 
assay. This information suggests that the right-hand benzyl functionality may be a major 
site of metabolism, since stability is significantly improved by replacement of the benzyl 
amide with pyridylethyl substitution, although overall reduction in ClogP might also be a 
factor. The data also indicate that pyrroles are far more metabolically labile than indoles 
in this template. Detail regarding the application of these data appears in Chapter III. 
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Table 16. MLM Metabolic Stabilities For Indole and Pyrrole Analogs. 
CCG 
No. 
Structure 
IC50  
(µM)
a
 
CC50 
(µM)
b
 
MLM T1/2 
(min)
c
 
ClogP 
205432† 
 
0.53 ± 0.1 65 16.7 ± 1.7 3.1 
206381 
 
0.68 ± 0.04 >100 3.7 ± 1.3 1.7 
203926† 
 
6.8 ± 1.0 >100 2.3 ± 0.1 4.9 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
c
Half-life in BALB/c mouse liver microsome incubation. Values are half-lives calculated 
from the equation T1/2=ln(2)/slope, where the slope was ln(% detected) against time, 
plotted from the mean of at least n=3 independent experiments. Values are mean ± SEM 
of n = 3 independent experiments. †Synthesized by Janice Sindac. 
 
 
With the metabolic stability knowledge gained from Table 15 and Table 16, a 
variety of proposed metabolically stable compounds were prepared and evaluated. 
Pyridine CCG-212090 was over ten-fold more stable towards metabolism than CCG-
203926 (Table 17). ClogP is highly correlated with CYP metabolism,
170, 171
 thus CCG-
212090’s stability may be attributed to its ten-fold lower ClogP relative to CCG-203926. 
Alternatively, this could suggest that the benzyl ring is a potential site of metabolism, as 
pyridines are known to be less susceptible due to their electron-deficiency and 
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polarity.
172, 173
 While imidazoles are expected to be more stable than pyrroles by virtue of 
the electron-withdrawing property of the azine nitrogen, the improved half-life of CCG-
206582 is more likely indicative of CYP inhibition, as the imidazole moiety is known to 
bind to heme iron, a crucial component of CYP enzyme function.
174-176
 
 
 
Table 17. MLM Stability and WEEV Replicon Data for Select Analogs. 
 
 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
MLM T1/2 
(min)
c
 
ClogP 
205432† 
 
0.53 ± 0.1 65 11.5 ± 0.7 3.1 
203926† 
 
6.8 ± 1.0 >100 1.8 ± 0.5 4.9 
206582† 
 
4.9 ± 2.6 >100 17.0 ± 2.7 2.7 
212090† 
 
0.6 ± 0.3 92 23.4 ± 4.0 3.4 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
c
Half-life in BALB/c mouse liver microsome incubation. Values are half-lives 
calculated from the equation T1/2=ln(2)/slope, where the slope was ln(% detected) 
against time, plotted from the mean of at least n=2 independent experiments. Values are 
mean ± SEM of n = 2 independent experiments. †Synthesized by Janice Sindac. 
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Table 18. MLM Stability and WEEV Replicon Data for Select Analogs. 
 
 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
MLM T1/2 
(min)
c
 
ClogP 
205432† 
 
0.53 ± 0.1 65 11.5 ± 0.7 3.1 
206381 
 
0.68 ± 0.04 >100 2.9 ± 0.1 1.7 
211751 
 
4.4 ± 0.5 >100 9.1 ± 3.0 1.9 
209023 † 
 
1.6 ± 0.5 46 77.9 ± 20.4 2.4 
206565† 
 
4.1 ± 0.1 75 43.0 ± 1.5 2.3 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability determined 
by the MTT reduction assay. Values are mean of at least n=3 independent experiments. 
c
Half-life in BALB/c mouse liver microsome incubation. Values are half-lives 
calculated from the equation T1/2=ln(2)/slope, where the slope was ln(% detected) 
against time, plotted from the mean of at least n=2 independent experiments. Values 
are mean ± SEM of n = 2 independent experiments. †Synthesized by Janice Sindac. 
 
 
Azaindole CCG-211751 was prepared in an effort to silence possible sites of 
metabolism in the indole phenyl ring, but its lack of improved stability indicates that the 
phenyl portion of the indole may only be a minor site of metabolism (Table 18). 
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Conversely, benzimidazole CCG-206565 was markedly more stable than the 
corresponding indole CCG-205432, due either to stabilization of the pyrrole ring, or 
simply reduced ClogP. Intriguingly, replacement of chlorine with hydrogen upon the N-
benzyl substituent of the template (CCG-209023) resulted in a dramatic half-life 
improvement. This may simply be the result of lower ClogP, as compounds with high 
logP are known to be susceptible to CYP450 enzymes. Furthermore, it suggests that 
metabolism of the indole N-benzyl is not a major pathway. Despite having less activity 
than the lead CCG-205432, this information allowed us to move CCG-209023 into 
mouse studies, on the basis that enhanced metabolic stability would translate into 
improved bioavailability. Gratifyingly, a ten mouse preliminary study demonstrated a 
40% survival rate when infected mice were treated with the compound, marking CCG-
209023 as our most efficacious compound to-date.   
Several fluorinated analogs (fluoropyrroles CCG-209020 and CCG-209021, and 
Janice Sindac’s fluoroindoles CCG-208918 and CCG-208919) were synthesized to 
probe potential metabolic soft spots around the pyrrole and indole rings (Table 19). 
Incorporation of fluorine into compounds is a well-known and powerful tactic for 
improving stability towards Phase I metabolism as fluorine is similar in size to hydrogen 
(classical isostere) but is less reactive due to the strength of the C-F bond.
177-179
 
Interestingly, these analogs, while active in the WEEV replicon assay, were also 
surprisingly toxic and were therefore not promoted to MLM stability studies.  
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Table 19. WEEV Replicon Data for Fluorinated Analogs. 
 
CCG No. R IC50 (µM)
a
 CC50 (µM)
b
 
205432† 
 
0.53 ± 0.1 65 
206381 
 
0.68 ± 0.04 >100 
209021 
 
0.93 ± 0.02 8.0 
208918† 
 
0.73 ± 0.05 24 
208919† 
 
0.92 ± 0.05 52 
a
Inhibition of luciferase expression in WEEV replicon assay. 
b
Cell viability 
determined by the MTT reduction assay. Values are mean of at least n=3 independent 
experiments. †Synthesized by Janice Sindac. 
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Synthesis 
Scheme 35. Preparation of 4-Fluoropyrrole Analogs.
a
 
 
a
Reagents and conditions: (a) TEMPO, TCCA, DCM, 0 °CRT, 20 min, 99%; (b) DAST, 
DCM, -78 °CRT, 12, h, 86%; (c) 4 M HCl/1,4-dioxane, THF, RT, 4 h, 100%; (d) MnO2, 
THF, reflux, 3 h, 20%; (e) 4-chlorobenzyl chloride, K2CO3, DMF, 60 °C, 30 h, 83%; (f) 
10% aq. NaOH, EtOH, RT, 18 h, 78%; (g) ) NH2R1, EDCHCl, HOBT, TEA, DCM, rt, 
15 h, 52%. 
 
Fluoropyrroles CCG-209020 and CCG-209021 were prepared in a manner 
similar to that previously described (Scheme 35).
180
 The 4-hydroxyproline 133 was 
oxidized to 4-ketoproline 134 under TEMPO catalysis, and this was subsequently 
fluorinated with DAST to provide the germinal fluoroproline 135. After acid-mediated 
deprotection, the resulting 1H-proline was aromatized to the 4-fluoropyrrole 127 with 
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MnO2.
181
 Alkylation with 4-chlorobenzyl choride gave the N-benzyl intermediate, which 
was saponified and coupled with the appropriate amine.  
 
Scheme 36. Preparation of 6-Azaindole Analog CCG-211751.
a
 
 
a
Reagents and conditions: (a) TFAA, 0 °C, 2 h; then Fum. HNO3, RT, 12 h; then 
Na2S2O5, H2O, RT, 24 h, 9%; (b) Na
0
, diethyl oxalate, EtOH, tol, RT, overnight, 40%; (c) 
Pt/C, 1 ATM H2, EtOH, AcOH, RT, 24 h; (d) EtOH, K2CO3, RT, 18 h, 51% (2 steps); (e) 
2a, t-BuOK, DMF, RT, 14 h, 65%; (f) 10% aq. NaOH, EtOH, RT, 24 h, 84%; (g) 36, 
EDCHCl, HOBT, TEA, DCM, RT, 20 h, 55%. 
 
 
Azaindole analog CCG-211751 was prepared using largely known procedures 
(Scheme 36).
182
 First, 4-picoline was nitrated under inefficient but mild conditions as 
reported by Katritzky.
183
 The resulting 3-nitro-4-picoline 141 was then treated with 
sodium in EtOH to form the anion, which was subsequently treated with diethyloxalate to 
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give the β-ketoester 142. The nitro was then fully reduced to the amine under 
heterogeneous catalysis, and, upon introduction of basic conditions, this cyclized via 
addition/elimination to yield the desired 6-azaindole core 143. Alkylation with 2a was 
accomplished by fully deprotonating the azole nitrogren with tBuOK before addition of 
the electrophile. Weaker bases, such as alkali metal carbonates (e.g. Cs2CO3) returned 
mostly pyridinium salts. Saponification of the ester 144 and amidation with the amine 
dihydrochloride 36 provided the desired azaindole analog CCG-211751. 
 
Conclusion 
 The primary goal of this chapter was the development of a mouse-liver 
microsome assay and LC/MS/MS protocol suitable for prioritizing compounds based 
upon their stability towards Phase I metabolism. To this end, we designed a relatively 
high-throughput MLM method that was successful in assessing and identifying 
compound stabilities, and that correlated well with in vivo pharmacokinetic data. 
Moreover, it facilitated identification of important modifications (e.g. pyrrole-to-aniline 
substitution and chlorine-to-hydrogen substitution) that significantly improved stability, 
leading to the discovery of our most stable compound to-date (CCG-209023). 
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 Future Directions Chapter VI.
Overall, our design and development of inhibitors of neurotropic alphavirus 
replication has been successful in identifying and optimizing potent compounds both in 
vitro and in vivo against a broad spectrum of alphaviruses. Furthermore, we have 
successfully improved physicochemical properties both predictive and demonstrable of 
enhanced bioavailability and BBB-penetration. This is a significant step towards the 
development of a successful antiviral for neurotropic alphaviruses, as there are no known 
antivirals that possess CNS-permeability that are also therapeutically useful in the 
treatment of these viruses.
15, 40
  
Furthermore, the general mechanism of action is unique as there are few known 
antivirals that target host machinery. Classically, such targets were avoided due to 
assumed toxicity issues, but the low toxicity of our compounds places them firmly within 
a small promising class of new host-targeting antivirals, and the only ones specific for 
alphaviruses.
184-187
 The advantages of such a compound include enhanced broad-
spectrum activity and – more importantly – significantly reduced incidence of resistance. 
Due to relatively rapid viral replication and poor fidelity, resistance-conferring mutations 
in viral proteins may arise after treatment with viral-targeting drugs, which places a large 
emphasis on the development of new drugs. On the other hand, due to the relatively low 
turnover of host cells, resistance-conferring mutations are expected to occur much more 
slowly, if at all, with host-targeting antivirals.  
102 
 
However, an important aspect of medicinal chemistry is the establishment of a 
pharmacophore model – the collection of structural and electronic features requisite for 
engaging with binding site contacts and maximizing activity. Importantly, such a model 
facilitates the design and development of future analogs, including those based on 
fundamentally different scaffolds. Over the course of the WEEV inhibitor project, we 
identified multiple attributes critical to activity, such as the potency-length dependence 
(Chapter II) and the disposition of the right-hand secondary amide (Chapter IV). With 
the aid of our collaborator Paul Kirchhoff, we have attempted to computationally develop 
a three-dimensional pharmacophore model of our compounds and apply such a model to 
an in silico high-throughput screen to discover new chemical templates. Unfortunately, 
we have been unable to generate a predictive pharmacophore model; models built from 
diverse WEEV inhibitor training sets could not discriminate between known active and 
inactive compounds. Moving forward, we would like to direct studies toward 
identification of the pharmacophore through the design, synthesis, and evaluation of new 
analogs.   
Related to pharmacophore identification, we have also noted conformation-
dependent recognition by MDR1 in this project. Despite the magnitude of on-going work 
in the field of medicinal chemistry, this observation has been noted only rarely in the 
literature. Historically, tremendous efforts have been expended by medicinal chemists in 
identifying structure-activity relationships for small molecule interactions with MDR1, 
but the SAR is still largely undefined due to the promiscuity of the transporter. Therefore, 
research regarding conformation-activity relationships could significantly enhance the 
design of transporter-evasive compounds.  
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Another important aspect of drug development is the identification of the biological 
target, and by extension, the mechanism of action through which the compounds exert 
their pharmacological effect. Our collaborators have made tremendous strides towards 
this end,
104
 and Janice Sindac has developed several photo-affinity probes to assist in 
target identification. In contrast to the phenotype-based approach to analog design 
employed throughout the project, such information could facilitate a target-based avenue 
to future drug development. In this way, knowledge of the target could lead to models of 
the binding site (e.g. homology) that could allow us to predict and incorporate structural 
features tailored specifically to engage with potential binding site contacts. Also, because 
toxicity is often a product of off-target binding to structurally similar biological 
macromolecules, this could also allow us to improve the toxicity profile of our analogs, 
especially in light of their host-based mechanism of action. Therefore, the continued 
design and development of probes – no trivial endeavor – is an important aspect of the 
project’s future. 
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 Experimental Data Chapter VII.
 
All reagents were used as received from commercial sources unless otherwise noted. 
1
H 
and 
13
C spectra were obtained in DMSO-d6 or CDCl3 at room temperature, unless 
otherwise noted, on a Varian Inova 400 MHz, Varian Inova 500 MHz, or Bruker Avance 
DRX 500 instruments. Chemical shifts for the 
1
H NMR and 
13
C NMR spectra were 
recorded in parts per million (ppm) on the δ scale from an internal standard of residual 
tetramethylsilane (0 ppm). Rotamers are described as a ratio of rotamer A and B if 
possible. Otherwise, if the rotamers cannot be distinguished, the NMR peaks are 
described as multiplets. Mass spectroscopy data were obtained on a Waters Corporation 
LCT. HPLC retention times were recorded in minutes (min) using an Agilent 1100 series 
with an Agilent Zorbax Eclipse Plus–C18 column with the gradient 10% ACN/water (1 
min), 10–90% ACN/water (6 min), and 90% ACN/water (2 min).  
 
Reagent abbreviations and acronyms: ACAC (acetylacetone), AcOH (acetic acid), Ac2O 
(acetic anhydride), AlCl3 (aluminum chloride), Ar (argon), BnBr (benzyl bromide), 
Boc2O (di-tert-butyl dicarbonate), Cs2CO3 (cesium carbonate), Cu
0
 (elemental copper), 
Cu2O (copper (I) oxide), DAST (diethylaminosulfur trifluoride), DCM 
(dichloromethane), DIPA (diisopropylamine), DIPEA (N,N-diisopropylethylamine, 
Hünig’s base), DMF (N,N-dimethylformamide), DPPP (1,3-
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bis(diphenylphosphino)propane, EDCHCl (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride), EGDME (ethylene glycol dimethyl 
ether), Et2O (diethyl ether), EtOAc (ethyl acetate), EtOH (ethanol), H2 (hydrogen), 
HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate), H2O (water), HBr (hydrobromic acid), HCl (hydrogen chloride or 
hydrochloric acid), Hex (hexanes), HMDS (hexamethyldisilazane), HOBT (1-
hydroxybenzotriazole), ind (indane), IPA (isopropanol), K2CO3 (potassium carbonate), 
KOH (potassium hydroxide), LiAlH4 (lithium aluminum hydride), LiBr (lithium 
bromide), m-CPBA (meta-chloroperoxybenzoic acid), MeCN (acetonitrile), MeI (methyl 
iodide), MeOH (methanol), MgCl2 (magnesium chloride), MgSO4 (magnesium sulfate), 
MnO2 (manganese (IV) oxide), N2 (nitrogen), Na
0
 (elemental sodium), NaBH4 (sodium 
borohydride), NaBH3CN (sodium cyanoborohydride), NaBH(OAc)3 (triacetoxy sodium 
borohydride), Na2CO3 (sodium carbonate), Na2SO4 (sodium sulfate), NAPDH 
(nicotinamide adenine dinucleotide phosphate), NaH (sodium hydride), NaHCO3 (sodium 
bicarbonate), NaNO2 (sodium nitrite), NaOH (sodium hydroxide), Na2S2O5 (sodium 
metabisulfite), NH3 (ammonia), n-BuLi (n-butyl lithium), Pd/C (palladium on carbon), 
PhCl (chlorobenzene), PhLi (phenyllithium), PhNH2 (aniline), PhN(Tf)2 (N,N-
bis(trifluoromethylsulfonyl)anilie, PhSeCl (phenylselenyl chloride), PPh3 
(triphenylphosphine), Pt/C (platinum on carbon), PtO2 (platinum (IV) oxide), pyr 
(pyridine), s-BuLi (sec-butyl lithium), SmI2 (samarium (II) iodide), SnCl2 (tin (II) 
chloride), t-BuOH (tert-butanol), t-BuOK (potassium tert-butoxide), TCCA 
(trichloroisocyanuric acid), TEA (triethylamine), TEMPO ((2,2,6,6-tetramethylpiperidin-
1-yl)oxy), TFA (trifluoracetic acid), TFE (trifluoroethanol), TFFA (trifluoroacetic 
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anhydride), TFE (2,2,2-trifluoroethanol); THF (tetrahydrofuran), tol (toluene), TsOH 
(toluenesulfonic acid), Zn
0
 (elemental zinc), ZnCl2 (zinc chloride). 
 
Condition abbreviations and acronyms: ATM (atmosphere), aq. (aqueous), conc. 
(concentrated), d (days), fum. (fuming), g (grams), h (hours), M (molar), mg 
(milligrams), mL (milliliters), µL (microliters), mM (millimolar), min (minutes), psi 
(pressure per square inch), RT (room temperature), wt. (weight). 
 
Biology 
Mouse Microsomal Metabolic Stability Procedure. Balb-C mouse liver 
microsomes were purchased from Invitrogen. MgCl2 and NADPH were obtained from 
Sigma. Solvents were of HPLC grade or better. The HPLC-MS/MS system consisted of a 
ThermoElectron Finnigan TSQ Quantum Ultra AM. 
Microsomal incubations were done in triplicate. Incubation mixtures contained 2 
µL of 20mg/mL microsomes (approximately 0.04 mg microsomal protein), 4 µL of 100 
µM DMSO-dissolved substrate (1.0 µM final), in 475 µL potassium phosphate buffer 
(0.1 M, pH 7.5, containing 3.3 mM MgCl2.) The incubation mixture was allowed to shake 
at 37 °C for 5 min, and a T=0 aliquot was removed. Reaction was initiated by the 
addition of 20 µL of NaDPH (22 mM under the same buffer conditions) and the mixture 
was allowed to shake at 37 °C until the final aliquot was removed. 30 µL aliquots were 
taken after 0 minutes, 5 minutes, and 15 minutes. All aliquots were quenched by dilution 
in 90 µL MeCN containing an internal standard and the precipitate was pelleted via 
centrifugation. 20 µL of supernatant was injected onto the HPLC-MS/MS. Mobile phase 
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A was 95:5 H2O:MeCN with 0.1% formic acid, and mobile phase B was MeCN with 
0.1% formic acid. Column used was a Luna C18(2) 4.6 X 30 mm column with 3µM 
particle size. The flow rate was 2 mL/min and a gradient mobile phase composition was 
used: isocratic hold for 1 min at 90% A (10% B), 1 min gradient to 10% A (90% B), 1 
min gradient back to 90% A (10% B), and 1 min isocratic hold at 90% A (10% B.) 
Ionization method consisted of positive electrospray. Source parameters were optimized 
for each individual substrate. Substrates and internal standards were followed by selected 
reaction monitoring. Substrate/internal standard area ratios were determined and 
converted into percent substrate remaining. The natural log of the percent remaining was 
plotted against time, the slope of the linear regression was determined, and the equation 
T1/2 = – ln(2)/k was used to calculate half-life.  
 
Chemistry 
Ethyl 1-(4-chlorobenzyl)-1H-indole-2-carboxylate (3a). Ethyl 1H-indole-2-
carboxylate 1 (4.50 g, 23.78 mmol) was dissolved in anhydrous DMF (60 mL) under N2 
at RT, then cooled to -10 °C. Granular t-BuOK (2.94 g, 26.20 mmol) was added to the 
solution, eliciting a slight yellow color. 4-Chlorobenzyl chloride 2a (4.02 g, 24.97 mmol) 
– pre-dissolved in anhydrous DMF (5 mL) – was added via syringe pump at 0.1 mL/min 
at -10 °C. After this time, was allowed to stir at RT for 12 h. The reaction was then 
diluted with 1:1 EtOAc:Hex and quenched by the addition of sat. aq. NaHCO3. The 
organic phase was then washed with H2O (10 X) and brine (1X), dried (MgSO4), and 
concentrated to give the pure compound as a white solid that was subsequently washed 
thoroughly with hexanes. Yield: 6.80 g, 21.67 mmol, 91%. 
1
H NMR (500 MHz, 
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Chloroform-d) δ 7.78 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.38 – 7.34 (m, 2H), 
7.25 (ddd, J = 15.1, 8.4, 2.8 Hz, 3H), 7.07 – 7.01 (m, 2H), 5.83 (s, 2H), 4.39 (qd, J = 7.1, 
1.6 Hz, 2H), 1.42 (td, J = 7.1, 1.6 Hz, 3H). 
 
Ethyl 1-(4-fluorobenzyl)-1H-indole-2-carboxylate (3b). Ethyl 1H-indole-2-
carboxylate 1 (500 mg, 2.64 mmol) was dissolved in anhydrous DMF (8 ml), followed by 
1-(chloromethyl)-4-fluorobenzene 2b (0.380 ml, 3.17 mmol) and the addition of solid 
K2CO3 (730 mg, 5.29 mmol). This was stirred at 60 °C for 20 h, at which time the 
reaction was allowed to cool to room temperature. Precipitate formed upon the addition 
of water (40 mL), was isolated over a filter, and dried under high vacuum overnight to 
give 550 mg of the title compound as a white solid which was recrystallized from Et2O. 
Yield: 550 mg, 1.850 mmol, 70%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.72 (d, J = 7.9 
Hz, 1H), 7.40 (s, 1H), 7.37 – 7.31 (m, 2H), 7.18 (ddd, J = 7.7, 6.5, 1.3 Hz, 1H), 7.05 (dd, 
J = 8.4, 5.3 Hz, 2H), 6.94 (t, J = 8.5 Hz, 2H), 5.81 (s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 1.38 
(t, J = 7.1 Hz, 3H). 
 
1-(4-Chlorobenzyl)-1H-indole-2-carboxylic acid (4a). Ethyl 1-(4-chlorobenzyl)-
1H-indole-2-carboxylate 3a (5.95 g, 18.96 mmol) was added to a mixture of 10% aq. 
NaOH (13.7 mL, 37.9 mmol), EtOH (15 mL), and THF (15 mL), but did not completely 
dissolve. This suspension stirred at RT for 14 h, over which time all material dissolved 
and the reaction proceeded to completion. Solvent was stripped off in vacuo, the residue 
was taken up in H2O and acidified to pH<1 with conc. HCl at 0 °C. The resulting 
precipitate was collected over a filter and washed with cold 1 M HCl, air-dried, then 
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dried thoroughly under high vacuum to give a white powder. No further purification 
necessary. Yield: 5.20 g, 18.20 mmol, 96%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.76 
(d, J = 8.1 Hz, 1H), 7.56 (s, 1H), 7.40 – 7.31 (m, 2H), 7.27 – 7.16 (m, 3H), 7.00 (d, J = 
8.2 Hz, 2H), 5.81 (s, 2H). 
 
1-(4-Fluorobenzyl)-1H-indole-2-carboxylic acid (4b). Ethyl 1-(4-fluorobenzyl)-
1H-indole-2-carboxylate 3b (409 mg, 1.376 mmol) was suspended in ethanol (5 mL) and 
7M NaOH (5 mL) and stirred at 50 °C for 3 h. Ethanol content was reduced in vacuo. 
The solution was then acidified to pH 2 and the precipitate was collected over a filter, 
washed with a small amount of ice cold-water, air dried on the filter, and then finally 
vacuum dried to give the title compound as a fine, white powder. Yield: 360 mg, 1.337 
mmol, 97%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.41 (d, J = 5.8 Hz, 1H), 7.81 – 7.71 
(m, 4H), 7.70 – 7.60 (m, 3H), 7.18 (d, J = 5.7 Hz, 1H), 5.90 (d, J = 5.5 Hz, 2H). 
 
Tert-Butyl 4-(hydroxymethyl)piperidine-1-carboxylate (7). Piperidine-4-methanol 
6 (3.74 g, 32.5 mmol) and Boc2O (8.5 g, 38.9 mmol) were added to THF (50 mL) at RT, 
followed by Na2CO3 (6.88 g, 64.9 mmol) and H2O (30 mL). Addition was mildly 
exothermic. The reaction was refluxed at 100 °C for 2 h, after which it was allowed to 
cool to RT. The reaction was then extracted with EtOAc, and the extract was washed 
with brine (1X), dried (MgSO4), and concentrated. The residue was purified by silica 
flash chromatography (150 g silica, 50% EtOAc:Hex). Concentration provided a white 
solid. Yield: 6.09 g, 28.3 mmol, 87%. 
1
H NMR (500 MHz, Chloroform-d) δ 4.10 (s, 2H), 
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3.47 (t, J = 5.2 Hz, 1H), 2.69 (s, 2H), 1.70 (d, J = 13.2 Hz, 2H), 1.62 (ddp, J = 15.2, 6.7, 
4.0 Hz, 1H), 1.44 (s, 9H), 1.12 (qd, J = 12.5, 4.4 Hz, 2H). 
 
Tert-Butyl 4-formylpiperidine-1-carboxylate (8). Tert-butyl 4-
(hydroxymethyl)piperidine-1-carboxylate 7 (1.50 g, 6.97 mmol) and anhydrous DMSO 
(1.24 mL, 17.42 mmol) were dissolved in DCM (100 mL) at RT, then cooled to -78 °C. 
(COCl)2 (1.22 mL, 13.93 mmol) was then added dropwise under N2 and the reaction was 
allowed to stir for 30 min at -78 °C. Still at this temperature, TEA (4.86 mL, 34.8 mmol) 
was added dropwise and a slight yellow color change was observed. The reaction was 
allowed to stir for 30 min at -78 °C, then 3 h at 0 °C. After this time, the reaction was 
quenched by the addition of 0.1 M HCl and material was extracted with EtOAc. The 
extract was washed with 0.1 M HCl (2X), H2O (3X), and brine (1X), then dried (MgSO4) 
and concentrated in vacuo. This was immediately purified via silica flash 
chromatography (100 g silica, 40% EtOAc:Hex) to provide the desired product as a white 
crystal after removal of solvent. Yield: 1.32 g, 6.19 mmol, 89%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 9.58 (s, 1H), 3.99 – 3.82 (m, 2H), 2.85 (t, J = 11.9 Hz, 2H), 2.35 (dt, J = 
10.5, 6.0 Hz, 1H), 1.82 (d, J = 12.4 Hz, 2H), 1.52 – 1.44 (m, 2H), 1.37 (s, 9H). 
 
Tert-Butyl 4-(piperidin-1-ylmethyl)piperidine-1-carboxylate (9). Piperidine (1.2 
mL, 11.73 mmol) was dissolved in TFE (10 mL) over 3 Å MS, then a drop of glacial 
AcOH (~ 50 µL) was added. Tert-butyl 4-formylpiperidine-1-carboxylate 8 (500 mg, 
2.35 mmol) was added slowly with stirring at RT. NaCNBH3 (192 mg, 4.69 mmol) was 
added and the reaction was stirred at RT for 19 h. After this time, the reaction was diluted 
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with EtOAc and washed with 10% aq. Na2CO3 (3X), dried (MgSO4), concentrated under 
high vacuum. The residue was then purified by silica flash chromatography (60 g silica, 
70% to 100% EtOAc:Hex). Yield: 477 mg, 1.69 mmol, 72%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 4.03 (bs, 2H), 2.64 (bs, 2H), 2.28 (bs, 3H), 2.08 (d, J = 6.4 Hz, 2H), 
1.71 – 1.45 (m, 10H), 1.42 (s, 9H), 1.03 (m, 2H). 
 
Tert-Butyl 4-(cyclohexyl(hydroxy)methyl)piperidine-1-carboxylate (10). Tert-
butyl 4-formylpiperidine-1-carboxylate 8 (250 mg, 1.172 mmol) was dissolved in 
anhydrous Et2O (20 mL) and a 2 M solution of cyclohexylmagnesium chloride (0.62 mL, 
1.23 mmol) in Et2O was added dropwise to this under N2. The reaction was allowed to 
stir at RT for 2 h, after which time the reaction was quenched by the addition of EtOH 
then sat. aq. NaHCO3. Material was extracted with EtOAc, and the extract was dried 
(MgSO4) and concentrated to give the desired alcohol as a solid, which was used directly 
in the subsequent reaction without purification. Yield: 296 mg, 0.20 mmol, 85%.  
 
Tert-Butyl 4-(dibenzylamino)piperidine-1-carboxylate (13). Tert-butyl 4-
aminopiperidine-1-carboxylate 12 (200 mg, 1.00 mmol) was dissolved in DCM (3 mL), 
followed by the addition of H2O (1.5 mL) and granular Na2CO3 (318 mg, 3.00 mmol), 
and finally benzyl bromide (0.30 mL, 2.50 mmol). The reaction was stirred at reflux (55 
°C) for 3 h, after which H2O (10 mL) was added and the material was extracted with 
EtOAc. The extract was dried (MgSO4) and concentrated, and the resulting residue was 
purified by silica flash chromatography (20 g silica, 5% EtOAc:Hex) to give the desired 
amine as a white solid. Yield: 330 mg, 0.87 mmol, 87%. 
1
H NMR (500 MHz, 
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Chloroform-d) δ 7.40 (d, J = 7.2 Hz, 4H), 7.33 (t, J = 8.2, Hz, 4H), 7.29 – 7.23 (m, 2H), 
4.18 (s, 2H), 3.67 (s, 4H), 2.69 (tt, J = 11.8, 3.5 Hz, 1H), 2.59 (bs, 2H), 1.84 (d, J = 12.4 
Hz, 2H), 1.63 – 1.52 (m, 2H), 1.52 – 1.46 (m, 9H). 
 
4-(3-Bromopropyl)pyridine (16). 3-(Pyridin-4-yl)propan-1-ol (500 mg, 3.64 
mmol) was dissolved in conc. HBr (1 mL) in a pressure vessel stirred at 130 °C for 2h, 
after which the reaction was allowed to cool. The reaction was then basified to pH>14 
with 10% aq. NaOH at 0 °C and extracted with EtOAc (3X). The combined extracts were 
dried (MgSO4) and concentrated. The residue was then purified on a silica plug (20 g 
silica, 100% EtOAc) to give a crude oil that was taken into the next reaction without 
further purification. Yield: 292 mg, 1.46 mmol, 40%. ). TOF ES+ MS: (M + H, Br
79
) 
200.0, (M + H, Br
81
) 202.0. 
 
Tert-Butyl 4-(3-(pyridin-4-yl)propyl)piperazine-1-carboxylate (17). t-Butyl 
piperazine-1-carboxylate (186 mg, 1.00 mmol) was dissolved in anhydrous DMF (10 
mL) under N2, and a 60% oil suspension of NaH (120 mg, 3.00 mmol) was added. After 
stirring at RT under N2 for 1 h, 4-(3-bromopropyl)pyridine (200 mg, 1.00 mmol) was 
added and the reaction was allowed to stir for 19 h. After this time, the reaction was 
quenched with sat. aq. NaHCO3 then diluted with EtOAc and washed with H2O (3X), 
10% aq. Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. The residue 
was purified by silica flash chromatography (25 g silica, 1% to 10% methanolic 
ammonia:EtOAc). Yield: 201 mg, 0.660 mmol, 66%. 
1
H NMR (500 MHz, Chloroform-d) 
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δ 8.49 (d, J = 5.9 Hz, 2H), 7.11 (d, J = 5.8 Hz, 2H), 3.45 – 3.39 (m, 4H), 2.65 (t, J = 7.7 
Hz, 2H), 2.42 – 2.31 (m, 6H), 1.83 (p, J = 7.6 Hz, 2H), 1.46 (s, 9H). 
 
(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone 
(CCG-206462). The following was added sequentially to DMF (10 mL): 1-(4-
fluorobenzyl)-1H-indole-2-carboxylic acid (1.175 g, 4.36 mmol), DIPEA (2.29 mL, 
13.09 mmol), EDCHCl (1.00 g, 5.24 mmol), and HOBT (802 mg, 5.24 mmol). This 
solution was allowed to stir at RT for 1.5 h, at which time 4-piperidinemethanol (754 mg, 
6.55 mmol) was added. Stirring continued for 22 h at RT, at which time the solution was 
partitioned between H2O and 1:1 solution of EtOAc:Et2O. The organic extract was then 
washed with saturated aq. Na2CO3, dried with MgSO4, and concentrated in vacuo. 
Purification was accomplished via silica flash chromatography (100 g silica, 80% 
EtOAc/Hexanes.) Resulting residue was crystallized via Et2O:Hex trituration to give the 
title compound as a white solid. Yield: 1.51 g, 4.11 mmol, 94%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 7.63 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.29 – 7.22 (m, 1H), 
7.14 (t, J = 7.5 Hz, 1H), 7.10 – 7.04 (m, 2H), 6.91 (t, J = 8.2 Hz, 2H), 6.60 (s, 1H), 5.46 
(s, 2H), 4.64 (bs, 1H), 4.14 (bs, 1H), 3.42 (t, J = 5.1 Hz, 2H), 2.76 (s, 2H), 1.44 (t, J = 5.0 
Hz, 1H), 1.05 (bs, 1H), 0.71 (bs, 1H). 
 
1-(1-(4-Fluorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carbaldehyde (20). (1-
(4-fluorobenzyl)-1H-indol-2-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone (762 mg, 
2.08 mmol) was dissolved in DCM (80 mL) in dry glassware under N2. The solution was 
chilled to -78 °C and anhydrous DMSO (0.37 mL, 5.20 mmol) and (COCl)2 (0.36 mL, 
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4.16 mmol) were added. The reaction was allowed to stir for 30 min, after which TEA 
(1.45 mL, 10.40 mmol) was added dropwise and stirring continued for 1 h, after which 
the temperature was elevated to 0 °C and stirring continued for 30 min. At this time, the 
solution was taken up in EtOAc while still cold and immediately washed with 0.1 M HCl 
(2X), dried (MgSO4), and concentrated to give a white solid. Yield: 527 mg, 1.46 mmol, 
70%. 
1
H NMR (500 MHz, Chloroform-d) δ 9.61 (s, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.40 
(d, J = 8.2 Hz, 1H), 7.32 – 7.26 (m, 1H), 7.19 – 7.14 (m, 1H), 7.12 – 7.06 (m, 2H), 6.93 
(t, J = 8.6 Hz, 2H), 6.63 (s, 1H), 5.48 (s, 2H), 4.55 (bs, 1H), 4.07 (s, 1H), 2.50 – 2.41 (m, 
1H), 2.16 – 1.93 (m, 2H), 1.84 – 1.47 (m, 4H). 
 
Methyl 1-(4-chlorobenzyl)-1H-pyrrole-2-carboxylate (23a). Methyl 1H-pyrrole-2-
carboxylate (2.77 g, 22.14 mmol) was dissolved in anhydrous DMF (15 mL). Granular 
K2CO3 (1.94 g, 26.6 mmol) was added, followed by the addition of 4-chlorobenzyl 
chloride (1.80 mL, 26.6 mmol). The reaction was permitted to stir at 60 °C for 24 h, then 
again 90 °C for 48 h. Cs2CO3 (21.6 g, 66.4 mmol) was then added, and the reaction was 
allowed to stir at 90 °C for 24 h, then NaI (332 mg, 2.214 mmol) was added and stirring 
continued at 90 °C for 24 h. At this time, the reaction was allowed to cool to RT, diluted 
with EtOAc, and washed with brine (3×). The organic phase was then dried (MgSO4), 
concentrated in vacuo, and purified by silica flash chromatography (150 g silica, 5% 
EtOAc:Hex) to provide methyl 1-(4-chlorobenzyl)-1H-pyrrole-2-carboxylate as colorless 
crystals. Yield: 4.91 g (89%). 
1
H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 4.7 Hz, 1H), 
7.26 (d, J = 3.5 Hz, 1H), 7.05–6.98 (m, 3H), 6.92–6.86 (m, 1H), 6.20 (dd, J = 3.9, 2.6 Hz, 
1H), 5.52 (s, 2H), 3.76 (s, 3H). 
115 
 
 
Ethyl 1-(4-chlorobenzyl)-1H-imidazole-2-carboxylate (23b). Ethyl 1H-imidazole-
2-carboxylate (4 g, 28.5 mmol), 4-chlorobenzyl chloride (4.38 mL, 34.3 mmol), and 
Na2CO3 (3.63 g, 34.3 mmol), was dissolved in anhydrous DMF (8 mL). The solution was 
stirred at RT for 24 h, at which time H2O was added and material was extracted with 
EtOAc. The organic phase was collected, dried over MgSO4, and decanted. Purification 
accomplished via silica flash chromatography (150 g silica, 10% EtOAc/Hexanes to 80% 
EtOAc/Hex.) The title compound was obtained as a clear, yellow-tinted oil. Yield: 7.28 g, 
27.5 mmol, 96%. 
1
H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 0.9 
Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 0.9 Hz, 1H), 5.59 (s, 2H), 4.37 (q, J = 7.2 
Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H). 
 
Ethyl 1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-carboxylate 
(24a). To methyl 1-(4-chlorobenzyl)-1H-pyrrole-2-carboxylate (4.5 g, 18.02 mmol) was 
added to EtOH (50 mL) and 10% aq. NaOH (20 mL) and stirred overnight at RT, then 
again overnight at 50 °C to give completion. The EtOH was stripped by rotary 
evaporation until material began to precipitate, at which point the aqueous mixture was 
cooled in an ice bath and acidified with conc. HCl, which elicited further precipitation. 
The precipitate was collected over a filter and washed with a small amount of cold 1 M 
HCl and Hex. The material was then dried under high vacuum to provide the carboxylic 
acid as a white powder. Yield: 4.20 g, (99%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.34 
(d, J = 8.2 Hz, 2H), 7.19 (s, 1H), 7.06 (d, J = 8.2 Hz, 2H), 6.82 (s, 1H), 6.16–6.08 (m, 
1H), 5.53 (s, 2H). 
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The following were added sequentially to anhydrous DMF (20 mL), 1-(4-
chlorobenzyl)-1H-pyrrole-2-carboxylic acid (2.0 g, 8.5 mmol), DIEA (4.45 mL, 25.5 
mmol), EDCI (1.79 g, 9.34 mmol), and HOBt (1.43 g, 9.34 mmol), and this solution was 
allowed to stir at RT for 30 min. Finally, ethyl isonipecotate (1.44 mL, 9.34 mmol) was 
added and the reaction was permitted to stir at RT for 24 h. At this time, DCM was 
removed in vacuo and the residue was dissolved in ethyl acetate, which was subsequently 
washed with 1 M HCl (3X), H2O (2X), 10% aq. Na2CO3 (2X), and at last brine (1X). The 
organic layer was then dried (MgSO4) and concentrated in vacuo. The residue was 
crystallized from EtOAc:Hex via the slow evaporation of solvent at RT to give ethyl 1-
(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-carboxylate as large translucent 
crystals. Yield: 2.16 g (68%). 
1HNMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.4 Hz, 2H), 
7.03 (d, J = 8.4 Hz, 2H), 6.84−6.74 (m, 1H), 6.31 (dd, J = 3.7, 1.5 Hz, 1H), 6.18−6.06 (m, 
1H), 5.27 (s, 2H), 4.21 (d, J = 11.5 Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H), 2.94 (t, J = 11.5 Hz, 
2H), 2.46 (tt, J = 10.7, 4.0 Hz, 1H), 1.79 (d, J = 12.7 Hz, 2H), 1.56−1.30 (m, 2H), 1.25 (t, 
J = 7.1 Hz, 3H). 
 
1-(1-(4-Fluorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-carboxylic acid (25a). 
Ethyl 1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-carboxylate (700 mg, 
1.867 mmol) was dissolved in EtOH (60 mL) and H2O (20 mL). Granular LiOH (134 mg, 
5.60 mmol) was added to this, and the reaction was allowed to stir at RT for 24 h. After 
this time, most of the solvent was removed in vacuo, and the remaining aqueous solution 
was chilled to 0 °C and acidiﬁed by concentrated HCl, which elicited a thick, sticky 
precipitate that adhered to the ﬂask. The aqueous solution was decanted, and a small 
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amount of 1 N HCl was added, and the material sonicated. The aqueous solution was 
again decanted, and a small amount of ice-cold water was added, mixed, and decanted. 
Remaining water and HCl was then removed by rotary evaporation, followed by high-
vacuum drying to afford the title compound as a white powder. Yield: 620 mg (96%). 
1
HNMR (400 MHz, DMSO-d6) δ 7.33 (dd, J = 9.0, 2.7 Hz, 2H), 7.14−6.97 (m, 2H), 6.27 
(dd, J = 3.6, 1.5 Hz, 1H), 6.10−5.94 (m, 1H), 5.25 (s, 2H), 3.98 (d, J = 11.0 Hz, 2H), 
3.03−2.80 (m, 2H), 2.35−2.19 (m, 1H), 1.64 (d, J = 11.1 Hz, 2H), 1.24 (d, J = 11.5 Hz, 
2H). 
 
Methyl 1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)azetidine-3-carboxylate 
(29).  1-(4-chlorobenzyl)-1H-pyrrole-2-carboxylic acid (500 mg, 2.12 mmol) was added 
to DCM (20 mL), followed sequentially by DIPEA (1.1 mL, 6.36 mmol), EDCHCl (447 
mg, 2.33 mmol), HOBT (357 mg, 2.33 mmol), and methyl azetidine-3-carboxylate 
hydrochloride (387 mg, 2.55 mmol). The reaction was allowed to stir at rt for 18 h, at 
which time the DCM was removed in vacuo and the residue was taken up in 2:1 
EtOAc:Et2O and washed with 1 M aq. HCl (5X), H2O (5X), 10% aq. Na2CO3 (5X), and 
brine (1X), then dried (MgSO4) and concentrated. The resulting residue was purified by 
silica flash chromatography (25 g silica, 5% to 30% EtOAc/Hex) to give the desired 
compound as a clear, slightly yellow oil. Yield: 508 mg, 1.53 mmol, 72%. 
1
H NMR (500 
MHz, Chloroform-d) δ 7.25 (d, J = 8.3 Hz, 2H), 7.04 (d, J = 8.2 Hz, 2H), 6.81 (s, 1H), 
6.58 – 6.44 (m, 1H), 6.20 – 6.13 (m, 1H), 5.52 (s, 2H), 4.36 (bs, 4H), 3.75 (s, 3H), 3.43 
(p, J = 7.5 Hz, 1H). 
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Ethyl 1-((4-chlorobenzyl)carbamoyl)piperidine-4-carboxylate (31a). (4-
chlorobenzyl)isocyanate (0.30 mL, 2.26 mmol) was dissolved in DCM (10 mL) at RT, 
then ethyl isonipecotate 26 (0.38 mL, 2.49 mmol) was added dropwise with stirring, 
resulting in precipitation and discoloration. This slurry was allowed to stir at RT for 1 h, 
at which time the precipitate was collected over a filter and dried via aspirator to afford 
an off-white granular solid. No further purification was necessary. Yield: 690 mg, 2.13 
mmol, 94%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.30 – 7.25 (m, 2H), 7.25 – 7.20 (m, 
2H), 4.84 (s, 1H), 4.37 (d, J = 5.6 Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H), 3.87 (dt, J = 13.3, 
3.7 Hz, 2H), 2.96 – 2.87 (m, 2H), 2.46 (ddd, J = 14.6, 10.7, 3.8 Hz, 1H), 1.91 (dd, J = 
13.4, 3.1 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H). 
 
Ethyl 1-((4-chlorophenethyl)carbamoyl)piperidine-4-carboxylate (31b). 1-
Chloro-4-(2-isocyanatoethyl)benzene 19 (0.45 mL, 2.94 mmol) was dissolved in DCM 
(10 mL) at RT. Ethyl isonipecotate 26 was then added dropwise, which elicited 
precipitation. The slurry was allowed to stir at RT for 1 h, at which time the precipitate 
was collected and dried over a filter to afford ethyl 1-((4-chlorophenethyl)-
carbamoyl)piperidine-4-carboxylate as an off-white granular solid. This material was 
taken into the next reaction in this crude form. Yield: 916 mg (92%). 
1
H NMR (500 
MHz, Chloroform-d) δ 7.26 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 8.3 Hz, 2H), 4.52 (t, J = 5.3 
Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.79 (dt, J = 13.4, 3.8 Hz, 2H), 3.44 (q, J = 6.7 Hz, 
2H), 2.90 – 2.80 (m, 2H), 2.78 (t, J = 6.9 Hz, 2H), 2.44 (tt, J = 10.8, 3.9 Hz, 1H), 1.92 – 
1.83 (m, 2H), 1.62 (qd, J = 11.2, 4.1 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H). 
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Ethyl 1-(2-(4-chlorophenyl)acetyl)piperidine-4-carboxylate (33a). 4-
chlorophenylacetic acid (900 mg, 5.28 mmol) was dissolved in DCM (20 mL), followed 
by the sequential addition of TEA (2.21 mL, 15.83 mmol), EDCHCl (1110 mg, 5.80 
mmol), HOBT (889 mg, 5.80 mmol), and ethyl isonipecotate (0.894 mL, 5.80 mmol). 
The reaction was stirred at RT for 28 h, after which time the DCM was evaporated off. 
The residue was taken up in EtOAc and washed with 1M HCl (3X), H2O (5X), 10% aq. 
Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. The residue was 
then purified through a plug of silica (30 g silica, 5% EtOAc:Hex). Yield: 1.31 g, 4.22 
mmol, 80%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.29 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 
8.2 Hz, 2H), 4.40 (dt, J = 12.5, 4.0 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.79 (dt, J = 13.5, 
3.7 Hz, 1H), 3.69 (s, 2H), 3.12 – 3.05 (m, 1H), 2.89 – 2.82 (m, 1H), 2.52 – 2.45 (m, 1H), 
1.96 – 1.87 (m, 2H), 1.83 – 1.77 (m, 1H), 1.61 – 1.57 (m, 1H), 1.49 (ddd, J = 24.1, 10.9, 
3.8 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H).  
 
Ethyl 1-(3-(4-chlorophenyl)propanoyl)piperidine-4-carboxylate (33b). 3-(4-
chlorophenyl)propionic acid (0.90 g, 4.87 mmol) was dissolved in DCM (20 mL), 
followed by TEA (2.04 mL, 14.62 mmol), EDCHCl (1.03 g, 5.36 mmol), HOBT (0.82 g, 
5.36 mmol), and ethyl isonipecotate (0.83 mL, 5.36 mmol). The solution was stirred at 
RT for 28 h, after which time the DCM was removed in vacuo and the residue was 
dissolved in 2:1 EtOAc:Et2O and washed with 1 M aq. HCl (3X), H2O (2X), 10% aq. 
Na2SO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. The residue was 
then purified by silica flash chromatography (100 g silica, 5% to 50% EtOAc:Hex). 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.20 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 4.41 
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– 4.34 (m, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.71 (d, J = 13.7 Hz, 1H), 3.04 – 2.96 (m, 1H), 
2.89 (t, J = 7.8 Hz, 2H), 2.80 – 2.72 (m, 1H), 2.58 – 2.53 (m, 2H), 2.46 (tt, J = 10.7, 4.0 
Hz, 1H), 1.90 – 1.80 (m, 2H), 1.54 (ddd, J = 24.1, 13.3, 3.5 Hz, 2H), 1.22 (t, J = 7.1 Hz, 
3H). 
 
1-Tert-Butyl 4-ethyl piperidine-1,4-dicarboxylate (34). Ethyl isonipecotate 26 
(3.53 mL, 22.91 mmol), Boc2O (6.0 g, 27.50 mmol), and Na2CO3 (4.86 g, 45.80 mmol) 
were added to a mixture of H2O (8 mL) and THF (20 mL) at RT (mild exotherms). This 
was subsequently refluxed at 80 °C for 2 h, over which time the reaction proceeded from 
a white suspension to a clear biphasic solution. The reaction was allowed to cool and was 
extracted with EtOAc (2X) with no dilution of the aqueous phase. The organic extracts 
were combined, dried (MgSO4), and concentrated in vacuo. The clear residue was then 
purified by silica flash chromatography (150 g, 10% EtOAc:Hex) to give a thin, clear, 
colorless liquid. Yield: 5.07 g, 19.70 mmol, 86%. 
1
H NMR (500 MHz, Chloroform-d) δ 
4.12 (q, J = 7.1 Hz, 2H), 3.99 (s, 2H), 2.81 (t, J = 11.4 Hz, 2H), 2.41 (tt, J = 11.0, 3.6 Hz, 
1H), 1.85 (d, J = 12.3 Hz, 2H), 1.60 (qd, J = 12.6, 12.1, 4.4 Hz, 2H), 1.43 (s, 9H), 1.23 (t, 
J = 6.8 Hz, 3H). 
 
Tert-Butyl 4-((2-(pyridin-4-yl)ethyl)carbamoyl)piperidine-1-carboxylate (35). The 
boc-protected ethyl isonipecotate 34 (3.00 g, 11.66 mmol) was dissolved in EtOH (20 
mL) and 10% aq. NaOH (10 mL) and stirred at RT for 4 h, after which time the EtOH 
was stripped off in vacuo and the solution neutralized with conc. HCl at 0 ºC as quickly 
as possible, and the resulting precipitate was collected over a filter and washed with cold 
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H2O, then dried via aspirator, and finally high vacuum to provide the desired carboxylic 
acid as a white powder. Yield: 2.43 g, 10.60 mmol, 91%. 
The following was added to DCM: 1-(tert-butoxycarbonyl)piperidine-4-
carboxylic acid (600 mg, 2.62 mmol), DIPEA (1.37 mL, 7.85 mmol), EDC (552 mg, 2.88 
mL), HOBT (441 mg, 2.88 mmol), and pyridylethylamine (0.34 mL, 2.88 mL). The 
solution was stirred at RT for 17 h, at which time the DCM was stripped off and 10% aq. 
sodium carbonate was added. Material was extracted out with EtOAc (3X). The organic 
extractions were pooled, dried over magnesium sulfate, and concentrated in vacuo. The 
residue was taken up in a small amount of EtOAc and diethyl ether was added. The 
precipitate was collected over a filter and washed with diethyl ether to give the title 
compound as an off-white solid. Yield: 634 mg, 1.9 mmol, 73%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 8.49 (d, J = 5.9 Hz, 2H), 7.09 (d, J = 5.9 Hz, 2H), 5.59 (t, J = 5.3 Hz, 
1H), 4.22 – 3.95 (m, 2H), 3.52 (q, J = 6.8 Hz, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.68 (t, J = 
12.5 Hz, 2H), 2.14 (tt, J = 11.6, 3.8 Hz, 1H), 1.77 – 1.65 (m, 2H), 1.56 (qd, J = 12.1, 4.3 
Hz, 2H), 1.43 (s, 9H). 
 
N-(2-(Pyridin-4-yl)ethyl)piperidine-4-carboxamide dihydrochloride (36). The 
Boc-protected 35 (575 mg, 1.72 mmol) was suspended in Et2O at RT, and 4M HCl in 
dioxane (6 mL, 24 mmol) was added. The mixture was stirred at RT for 30 min, at which 
time the organic solution was decanted off and the solid material collected and dried in 
vacuo. The title compound was thus obtained as a tan powder. Yield: 448 mg, 1.6 mmol, 
97%. 
1
H NMR (400 MHz, DMSO-d6) δ 9.22 (bs, 1H), 8.91 (bs, 1H), 8.79 (d, J = 6.4 Hz, 
2H), 8.18 (t, J = 5.6 Hz, 1H), 7.89 (d, J = 6.3 Hz, 2H), 3.40 (q, J = 6.2 Hz, 2H), 3.15 (d, J 
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= 12.6 Hz, 2H), 3.00 (t, J = 6.4 Hz, 2H), 2.83 – 2.69 (m, 2H), 2.39 – 2.26 (m, 1H), 1.80 – 
1.59 (m, 4H). TOF ES+ MS: (M + H) 234.1, (M + Na) 256.1. 
 
(R)-1-(4-Chlorobenzyl)pyrrolidine-2-carboxylic acid (R-38). L-proline (500 mg, 
4.34 mmol) was dissolved in IPA (20 mL) in a dry flask, followed by the addition of 
KOH pellets (730 mg, 13.03 mmol). Reaction was stirred at 40 °C while an IPA (5 mL) 
solution of 4-chlorobenzyl chloride (770 mg, 4.78 mmol) was added via syringe pump 
over 3 h. Reaction was allowed to stir an additional 6 h, after which time the reaction was 
allowed to cool to RT. The solution was then acidified to pH 5 and DCM was added and 
the reaction stirred for 16 hours at RT. After this time, the precipitate was filtered off and 
washed with DCM (2X), and the combined organic filtrate extracts were concentrated to 
provide a light yellow solid. Dried under high vacuum. Yield: 956 mg, 3.77 mmol, 87%. 
1
H NMR (400 MHz, Chloroform-d) δ 10.24 (s, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.35 (s, 
4H), 6.62 (s, 2H), 4.75 (s, 4H), 1.58 (s, 2H). TOF ES– MS: (M – H) 238.1. 
 
(S)-1-(4-Chlorobenzyl)pyrrolidine-2-carboxylic acid (S-38). D-proline (500 mg, 
4.34 mmol) was dissolved in IPA (20 mL) in a dry flask, followed by the addition of 
KOH pellets (730 mg, 13.03 mmol). Reaction was stirred at 40 °C while an IPA (5 mL) 
solution of 4-chlorobenzyl chloride (770 mg, 4.78 mmol) was added via syringe pump 
over 3 h. Reaction was allowed to stir an additional 6 h, after which time the reaction was 
allowed to cool to RT. The solution was then acidified to pH 5 and DCM was added and 
the reaction stirred for 16 hours at RT. After this time, the precipitate was filtered off and 
washed with DCM (2X), and the combined organic filtrate extracts were concentrated to 
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provide a light yellow solid. Taken directly into the subsequent step without further 
characterization. Yield: 923 mg, 3.64 mmol, 84%. TOF ES– MS: (M – H) 238.1. 
 
(R)-1-(4-Chlorobenzoyl)pyrrolidine-2-carboxylic acid (R-39). L-proline (800 mg, 
6.95 mmol) was dissolved in IPA (30 mL) in a dry flask, followed by the addition of 
KOH pellets (1.17 g, 20.85 mmol). Reaction was stirred at RT while an IPA solution of 
4-chlorobenzoyl chloride (1.34 g, 7.64 mmol) was added via syringe pump over 1 h. 
Reaction was allowed to stir an additional 1 h, after which time the reaction was cooled 
to 0°C. The solution was then acidified to pH 5, DCM was added, and the reaction stirred 
for 12 hours at RT. After this time, the precipitate was filtered off and washed with DCM 
(2X), and the combined organic filtrate extracts were concentrated to provide an off-
white solid without further purification. Taken directly into the subsequent step without 
further characterization. Yield: 1.58 g, 6.23 mmol, 90%. TOF ES– MS: (M – H) 252.0. 
 
(S)-1-(4-Chlorobenzoyl)pyrrolidine-2-carboxylic acid (S-39). D-proline (800 mg, 
6.95 mmol) was dissolved in IPA (30 mL) in a dry flask, followed by the addition of 
KOH pellets (1.17 g, 20.85 mmol). Reaction was stirred at RT while an IPA solution of 
4-chlorobenzoyl chloride (1.34 g, 7.64 mmol) was added via syringe pump over 1 h. 
Reaction was allowed to stir an additional 1 h, after which time the reaction was cooled 
to 0°C. The solution was then acidified to pH 5, DCM was added, and the reaction stirred 
for 13 hours at RT. After this time, the precipitate was filtered off and washed with DCM 
(2X), and the combined organic filtrate extracts were concentrated to provide an off-
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white solid without further purification. Taken directly into the subsequent step without 
further characterization. Yield: 1.62 g, 6.39 mmol, 92%. TOF ES– MS: (M – H) 252.0. 
 
(R)-Ethyl 1-(1-(4-chlorobenzoyl)pyrrolidine-2-carbonyl)piperidine-4-carboxylate 
(R-40). (R)-1-(4-chlorobenzoyl)pyrrolidine-2-carboxylic acid (430 mg, 1.79 mmol) and 
TEA (750 µL, 5.38 mmol) were dissolved in DCM (10 mL) followed by HATU (720 mg, 
1.88 mmol), ethyl isonipecotate (290 µL, 1.88 mmol), and 3Å MS. The reaction was 
allowed to stir at RT for 17 h, at which time the DCM was removed and the residue taken 
up in a 1:1 solution of EtOAc:Et2O and washed with 0.5 M aq. HCl (2X), H2O (1X), 10% 
aq. Na2CO3 (3X), and brine (1X). The solution was then dried (MgSO4) and 
concentrated, and the residue was purified via silica flash chromatography (100 g silica, 
50% to 100% EtOAc:Hex) to give the desired product as a clear oil. Yield: 420 mg, 1.11 
mmol, 62%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.52 (d, J = 8.1 Hz, 2H), 7.35 – 7.30 
(m, 2H), 5.04 (dt, J = 14.6, 7.4 Hz, 1H), 4.50 – 4.44 (m, 1H), 4.40 (m, 0.5H), 4.27 (dd, J 
= 9.6, 3.9 Hz, 0.5H), 4.17 – 4.09 (m, 2H), 4.04 (d, J = 13.6 Hz, 0.5H), 3.94 (d, J = 13.7 
Hz, 0.5H), 3.80 (tt, J = 11.5, 5.9 Hz, 0.5H), 3.67 (q, J = 7.8 Hz, 1H), 3.50 (ddd, J = 10.5, 
7.2, 4.1 Hz, 1H), 3.41 – 3.30 (m, 0.5H), 3.17 (dt, J = 13.8, 6.9 Hz, 0.5H), 3.05 – 2.95 (m, 
0.5H), 2.90 – 2.76 (m, 0.5H), 2.62 – 2.48 (m, 1H), 2.22 (ddt, J = 22.4, 15.3, 7.9 Hz, 1H), 
2.06 – 1.81 (m, 7H), 1.64 (ddd, J = 27.7, 15.2, 8.6 Hz, 2H), 1.27 – 1.21 (m, 3H). 
 
(S)-Ethyl 1-(1-(4-chlorobenzoyl)pyrrolidine-2-carbonyl)piperidine-4-carboxylate 
(S-40). (S)-1-(4-chlorobenzoyl)pyrrolidine-2-carboxylic acid (490 mg, 2.05 mmol) and 
TEA (860 µL, 6.15 mmol) were dissolved in DCM (10 mL) followed by HATU (820 mg, 
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2.15 mmol), ethyl isonipecotate (330 µL, 2.15 mmol), and 3Å MS. The reaction was 
allowed to stir at RT for 16 h, at which time the DCM was removed and the residue taken 
up in a 1:1 solution of EtOAc:Et2O and washed with 0.5 M aq. HCl (2X), H2O (1X), 10% 
aq. Na2CO3 (3X), and brine (1X). The solution was then dried (MgSO4) and 
concentrated, and the residue was purified via silica flash chromatography (100 g silica, 
50% to 100% EtOAc:Hex) to give the desired product as a clear oil. Yield: 340 mg, 0.91 
mmol, 44%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.52 (d, J = 8.1 Hz, 2H), 7.33 (m, 2H), 
5.04 (dt, J = 14.6, 7.4 Hz, 1H), 4.49 – 4.40 (m, 1H), 4.27 (d, J = 9.6 Hz, 0.5H), 4.13 (dp, 
J = 13.9, 7.4 Hz, 2H), 4.04 (d, J = 13.6 Hz, 0.5H), 3.94 (d, J = 13.7 Hz, 0.5H), 3.80 (tt, J 
= 11.5, 5.9 Hz, 0.5H), 3.67 (q, J = 7.8 Hz, 1H), 3.50 (ddd, J = 10.5, 7.2, 4.1 Hz, 1H), 3.39 
– 3.29 (m, 0.5H), 3.17 (dt, J = 13.8, 6.9 Hz, 0.5H), 3.05 – 2.94 (m, 0.5H), 2.88 – 2.80 (m, 
0.5H), 2.61 – 2.48 (m, 1H), 2.22 (ddt, J = 22.4, 15.3, 7.9 Hz, 1H), 2.10 – 1.80 (m, 4H), 
1.64 (m, 2H), 1.30 – 1.19 (m, 3H). 
 
Methyl 2-(4-chlorophenoxy)benzoate (42). Methyl salicylate (0.40 mL, 3.86 
mmol), pyridine (0.75 mL, 9.26 mmol), (4-chlorophenyl)boronic acid (531 mg, 3.40 
mmol), and Cu(OAc)2 (617 mg, 3.40 mmol) were added to MeOH (10 mL) with 4Å MS 
and allowed to stir at RT for 5 d. After this time, the reaction mixture was filtered over 
celite and the filtrate was concentrated. The resulting residue was taken up in EtOAc and 
washed with 5% aq. NaOH (3X) to remove residual copper, then H2O (3X), 1 M aq. HCl 
(3X), and brine (1X), then the organic phase as dried (MgSO4) and concentrated, and the 
resulting residue was purified via silica flash chromatography (1% to 10% EtOAc:Hex) 
to provide the desired ether as colorless clear oil. Yield: 233 mg, 0.89 mmol, 23%. 
1
H 
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NMR (500 MHz, Chloroform-d) δ 7.90 (dd, J = 7.8, 1.6 Hz, 1H), 7.46 (ddd, J = 9.0, 7.9, 
1.7 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.23 – 7.17 (m, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.92 – 
6.84 (m, 2H), 3.94 (s, 3H).  
 
Methyl 2-((4-chlorophenyl)amino)benzoate (43a). Methyl salicylate (1.50 mL, 
11.57 mmol), N,N-Bis(triflyl)aniline (4.76 g, 13.31 mmol), and DIPEA (6.06 mL, 34.70 
mmol) were dissolved into anhydrous DMF (20 mL) in dry glassware under N2 at RT. 
The solution was stirred for 18 h at RT, at which time the reaction was diluted with 2:1 
EtOAc:Et2O and washed with H2O (5X) and brine (1X), then dried (MgSO4) and 
concentrated. The residue was purified via silica flash chromatography (80 g silica, 5% 
EtOAc:Hex) to give methyl 2-(((trifluoromethyl)sulfonyl)oxy)benzoate as a clear, 
colorless oil. Yield: 2.76 g, 9.72 mmol, 84%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.09 
(d, J = 7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.3 Hz, 
1H), 3.97 (s, 3H). 
A Schlenck flask was filled with toluene (60 mL, not anhydrous) and then 
charged sequentially with the following reagents: methyl 2-
(((trifluoromethyl)sulfonyl)oxy)benzoate (900 mg, 3.17 mmol), 4-chloroaniline (485 mg, 
3.80 mmol), Cs2CO3 (1444 mg, 4.43 mmol), Pd(OAc)2 (36 mg, 0.16 mmol), and DPPP 
(104 mg, 0.25 mmol). The mixture was then thoroughly sparged with argon, and the flask 
was fitted with a condenser and then purged and filled with an argon atmosphere. The 
reaction was stirred at reflux under argon for 6 h, then allowed to cool to RT and stir for 
12 h. At this time, the reaction was diluted with EtOAc and washed with 1M aq. HCl 
(3X) and brine (1X), dried (MgSO4), and concentrated. The residue was purified via 
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silica flash chromatography (40 g silica, 1% to 5% EtOAc:Hex gradient) to yield the 
desired compound as a clear, vaguely yellow oil. Yield: 710 mg, 2.71 mmol, 86%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 9.46 (s, 1H), 7.98 (d, J = 9.0 Hz, 1H), 7.37 – 7.26 (m, 
3H), 7.24 – 7.16 (m, 3H), 6.77 (t, J = 7.6 Hz, 1H), 3.92 (d, J = 1.1 Hz, 3H). 
 
Methyl 2-(phenylamino)benzoate (43b). Methyl salicylate (1.50 mL, 11.57 
mmol), N,N-Bis(triflyl)aniline (4.76 g, 13.31 mmol), and DIPEA (6.06 mL, 34.70 mmol) 
were dissolved into anhydrous DMF (20 mL) in dry glassware under N2 at RT. The 
solution was stirred for 18 h at RT, at which time the reaction was diluted with 2:1 
EtOAc:Et2O and washed with H2O (5X) and brine (1X), then dried (MgSO4) and 
concentrated. The residue was purified via silica flash chromatography (80 g silica, 5% 
EtOAc:Hex) to give methyl 2-(((trifluoromethyl)sulfonyl)oxy)benzoate as a clear, 
colorless oil. Yield: 2.76 g, 9.72 mmol, 84%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.09 
(d, J = 7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.3 Hz, 
1H), 3.97 (s, 3H). 
A Schlenck flask was filled with toluene (30 mL, not anhydrous) and then 
charged sequentially with the following reagents: methyl 2-
(((trifluoromethyl)sulfonyl)oxy)benzoate (440 mg, 1.63 mmol), aniline (178 µL, 1.94 
mmol), Cs2CO3 (743 mg, 2.28 mmol), Pd(OAc)2 (18 mg, 0.08 mmol), and DPPP (67 mg, 
0.16 mmol). The mixture was then thoroughly sparged with argon, and the flask was 
fitted with a condenser and then purged and filled with an argon atmosphere. The 
reaction was stirred at reflux under argon for 6 h, then allowed to cool to RT and stir for 
12 h. At this time, the reaction was diluted with EtOAc and washed with 1M aq. HCl 
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(3X) and brine (1X), dried (MgSO4), and concentrated. The residue was purified via 
silica flash chromatography (40 g silica, 1% to 5% EtOAc:Hex gradient) to yield the 
desired compound as a clear, somewhat yellow oil. Yield: 377 mg, 1.66 mmol, 57%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 9.47 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 
16.2, 7.3 Hz, 3H), 7.26 (d, J = 7.8 Hz, 3H), 7.10 (t, J = 7.3 Hz, 1H), 6.74 (t, J = 7.5 Hz, 
1H), 3.91 (s, 3H). 
 
Ethyl 1-(2-((4-chlorophenyl)amino)benzoyl)piperidine-4-carboxylate (44a). 
Methyl 2-((4-chlorophenyl)amino)benzoate (650 mg, 2.48 mmol) was dissolved in 200 
proof EtOH (15 mL) at RT and 10% aq. NaOH (6 mL) was added. The reaction was 
allowed to stir at RT for 5 h, at which time the solvent was stripped off in vacuo and 1M 
aq. HCl was added to the residue. The solution was then chilled in an ice bath and 
acidified to pH 1, and the resulting white precipitate was collected over a filter, washed 
with 1M aq. HCl, and dried via aspirator and high vacuum to yield a white powder. No 
further purification necessary. Yield: 581 mg, 2.35 mmol, 94%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 9.27 (s, 1H), 8.06 (dd, J = 8.1, 1.5 Hz, 1H), 7.38 (ddd, J = 8.6, 7.1, 1.6 
Hz, 1H), 7.35 – 7.31 (m, 2H), 7.23 – 7.19 (m, 2H), 7.17 (d, J = 8.5 Hz, 1H), 6.79 (t, J = 
7.5 Hz, 1H). 
2-((4-chlorophenyl)amino)benzoic acid (370 mg, 1.49 mmol) was then dissolved 
in DCM (15 mL), followed by ethyl isonipecotate (253 µL, 1.64 mmol), TEA (625 µL, 
4.48 mmol), EDCHCl (315 mg, 1.64 mmol), and HOBT (252 mg, 1.64 mmol). The 
reaction was stirred at RT for 16 h, at which time the reaction was diluted with 2:1 
EtOAc:Et2O and washed with 1 M aq. HCl (2X), 10% aq. Na2CO3 (3X), and brine (1X), 
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dried (MgSO4) and concentrated. The residue was purified via silica flash 
chromatography (12 g silica, 5% to 20% EtOAc:Hex) to provide the product as a yellow 
oil. Yield: 129 mg, 0.333 mmol, 22%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.32 (d, J = 
8.2 Hz, 1H), 7.25 – 7.15 (m, 4H), 7.02 (d, J = 8.7 Hz, 2H), 6.89 (t, J = 7.4 Hz, 1H), 4.30 
(bs, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.09 (t, J = 11.1 Hz, 2H), 2.56 (tt, J = 10.6, 4.0 Hz, 
1H), 1.95 (bs, 2H), 1.75 – 1.67 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H).  
 
Methyl 2-((4-chlorophenyl)(methyl)amino)benzoate (45). Methyl 2-((4-
chlorophenyl)amino)benzoate (150 mg, 0.57 mmol) was dissolved in anhydrous DMF (8 
mL) under N2. The solution was then charged with granular K2CO3 (158 mg, 1.15 mmol). 
MeI (40 µL, 0.63 mmol), dissolved in 1 mL anhydrous DMF, was added dropwise to the 
solution at RT under N2, and the reaction was allowed to stir for 12 h at RT. After this 
time, the reaction was diluted in 2:1 EtOAc:Et2O and washed with H2O (3X), 10% aq. 
Na2S2O3 (1X), and brine (1X), then dried (MgSO4) and concentrated. The residue was 
purified via silica flash chromatography (25 g silica, 1% to 10% EtOAc:Hex) to afford 
the desired compound as a colorless oil taken crude into the next reaction. Yield: 139 mg, 
0.50 mmol, 88%. TOF ES+ MS: (M + H) 276.1 
 
Methyl 2-((4-chlorobenzyl)amino)benzoate (47a). Methyl 2-aminobenzoate (500 
mg, 3.31 mmol) was dissolved in anhydrous DMF (15 mL) at RT under N2. Tert-BuOK 
(408 mg, 3.64 mmol) was then added and the solution became yellow, and this was 
allowed to stir at RT for 30 min, at which point 4-chlorobenzyl chloride (0.45 mL, 3.47 
mmol) was added, and the solution lost color. The reaction was allowed to stir for 18 h 
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under N2, at which time the reaction was diluted in EtOAc and washed with 10% aq. 
NaHCO3 (1X), H2O (5X), and brine (1X), then dried (MgSO4) and concentrated. The 
residue was purified by silica flash chromatography (40 g silica, 1% to 30% EtOAc:Hex) 
to provide the desired compound as a colorless oil. Yield: 1.37 g, 2.88 mmol, 87%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 8.20 (t, J = 5.7 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.31 
(q, J = 7.8, 7.1 Hz, 5H), 6.63 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.5 Hz, 1H), 4.43 (d, J = 5.7 
Hz, 2H), 3.88 (s, 3H). TOF ES+ MS: (M + H) 276.1. 
 
Methyl 2-(benzylamino)benzoate (47b). To anhydrous DMF in dry glassware was 
added methyl 2-aminobenzoate (280 mg, 1.85 mmol), benzyl bromide (330 mg, 1.94 
mmol), and Cs2CO3 (1.50 g, 4.62 mmol). The reaction was stirred at 85 °C for 5 days, 
after which time the reaction was cooled to RT and diluted with 1:1 EtOAc:Et2O and 
washed with H2O (3X) and brine (1X), then dried (MgSO4) and concentrated. The 
residue was purified via silica flash chromatography (5% EtOAc:Hex isochratic) to 
separate product from unreacted starting material. Yield: 138 mg, 0.57 mmol, 31%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 8.18 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.40 – 7.25 (m, 
6H), 6.65 (d, J = 8.5 Hz, 1H), 6.61 (t, J = 7.6 Hz, 1H), 4.46 (d, J = 5.6 Hz, 2H), 3.87 (s, 
3H). 
 
2-((4-Chlorophenethyl)amino)benzoic acid (49). 2-Bromobenzoate (200 mg, 1.00 
mmol), 2-(4-chlorophenyl)ethanamine (290 mg, 1.86 mmol), K2CO3 (260 mg, 1.86 
mmol), copper powder (12 mg, 0.19 mmol), and copper (I) oxide (13 mg, 0.09 mmol) 
were added to ethylene glycol dimethyl ether (5 mL) in a dry pressure tube. The mixture 
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was sparged and the headspace purged with argon, and the reaction was stirred at 130 °C 
for 24 h. After cooling to RT, the reaction was diluted with EtOAc and H2O and filtered 
through celite. The filtrate was acidified with conc. HCl and material was extracted with 
EtOAc (3X). The combined extracts were dried (MgSO4) and concentrated. Purification 
of the resulting residue was accomplished via silica flash chromatography (25 g silica, 
10% EtOAc:Hex with 1% formic acid) to give a white powder. Yield: 120 mg, 0.44 
mmol, 44%.
 1
H NMR (500 MHz, Chloroform-d) δ 8.06 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 
8.0 Hz, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.2 Hz, 2H), 
6.71 (d, J = 8.5 Hz, 1H), 6.64 (t, J = 7.5 Hz, 1H), 3.47 (t, J = 7.1 Hz, 2H), 2.97 (t, J = 7.0 
Hz, 2H). 
 
2-(4-Chlorobenzoyl)benzoic acid (51). Aluminum chloride (9.0 g, 67.5 mmol) 
was carefully added at RT to chlorobenzene (50 mL) in dry glassware with a water 
separator for dense solvents, followed by phthalic anhydride (5.0 g, 33.8 mmol). The 
reaction was then refluxed under N2 for 1.5 h, over which time it took on a deep red 
color. Note: longer reaction times result in rapid accumulation of a second, internal 
acylation. The reaction was then allowed to cool to RT over 1 h and was quenched by the 
slow and careful addition of 1 M aq. HCl and allowed to stir another 1 h, over which time 
color was lost and a white precipitate formed. The reaction was then taken up in EtOAc 
and washed with 1M aq. HCl (1X), then the solvent was removed in vacuo. The residue 
was then dissolved in 10% aq. NaOH, the resulting precipitate was filtered off, and the 
filtrate was washed with EtOAc (2X) before being chilled in an ice bath and acidified to 
pH 1 with conc. HCl. The resulting precipitate was collected over a filter to give the 
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desired product as a white powder. No further purification necessary. Yield: 6.34 g, 24.31 
mmol, 72%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 7.8 Hz, 1H), 7.70 – 7.61 
(m, 3H), 7.58 (tt, J = 7.7, 1.2 Hz, 1H), 7.36 (dd, J = 12.2, 7.9 Hz, 3H). TOF ES– MS: (M 
– H) 259.0. 
 
2-(4-Chlorobenzyl)benzoic acid (52). 2-(4-chlorobenzoyl)benzoic acid 51 (200 
mg, 0.77 mmol) was added to 28% aq. ammonia (10 mL), followed by zinc (600 mg, 
9.21 mmol) and CuSO45H2O (80 mg, 0.31 mmol). This mixture was stirred at reflux for 
48 h, with 2 mL recharges of 28% aq. ammonia every 6 h, barring 12 h at night. After 
this time, the reaction was allowed to cool to RT and the solution was decanted off the 
solid precipitate and concentrated in vacuo. The residue was taken up in H2O and 
acidified to pH < 1 by conc. HCl, then extracted 1X with EtOAc. The extract was dried 
(MgSO4) and concentrated, and the residue was crystallized from EtOAc to give tan 
crystals that were used immediately in the subsequent reaction. Yield: 62 mg, 0.25 mmol, 
33%. TOF ES– MS: (M – H) 245.0. 
 
Methyl 6-chloro-9H-carbazole-1-carboxylate (55). 9H-carbazole-1-carboxylic 
acid 54 (200 mg, 0.95 mmol) – prepared in a manner similar to that reported120 – was 
stirred in refluxing sat. methanolic HCl for 1 h. The reaction was then allowed to cool 
and was concentrated. The residue was dissolved in EtOAc and washed with sat. aq. 
Na2CO3 (1X), then dried (MgSO4), and concentrated. The residue was then purified by 
silica flash chromatography (10 g silica, 10% EtOAc/Hex) to give a white powder. Yield: 
196 mg, 0.87 mmol, 92%. 
1
H NMR (500 MHz, Chloroform-d) δ 9.94 (s, 1H), 8.26 (d, J = 
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7.6 Hz, 1H), 8.14 – 8.04 (m, 2H), 7.57 – 7.46 (m, 2H), 7.34 – 7.28 (m, 1H), 7.26 (t, J = 
7.7 Hz, 1H), 4.03 (s, 3H). 
Methyl 9H-carbazole-1-carboxylate (90 mg, 0.40 mmol) was stirred in DCM (15 
mL) at 0 °C under N2 while SO2Cl2 was added dropwise. The reaction was allowed to stir 
at 0 °C for 4 h. At this time, the reaction was diluted with DCM and washed with 10% 
aq. Na2CO3 (2X) and brine (1X), then dried (Na2SO4) and concentrated. The residue was 
purified via silica flash chromatography (10 g silica, 10 to 30% EtOAc/Hex) to give a 
white powder. Yield: 75 mg, 0.29 mmol, 72%. 
1
H NMR (500 MHz, Chloroform-d) δ 9.93 
(s, 1H), 8.21 (d, J = 7.7 Hz, 1H), 8.10 (d, J = 7.6 Hz, 1H), 8.04 (s, 1H), 7.44 – 7.41 (m, 
2H), 7.27 (t, J = 7.7 Hz, 1H), 4.03 (s, 3H). 
1
H NMR (500 MHz, Benzene-d6) δ 9.70 (s, 
1H), 8.03 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 1.9 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.17 (dd, 
J = 8.6, 2.0 Hz, 1H), 6.92 (t, J = 7.7 Hz, 1H), 6.46 (d, J = 8.6 Hz, 1H), 3.48 (s, 3H). 
 
Ethyl 1-(2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-carboxylate (57). 4-
chloroquinolin-2(1H)-one was prepared according to literature precedent.
124, 125
 4-
chloroquinolin-2(1H)-one (500 mg, 2.78 mmol), ethyl isonipecotate 26 (0.52 mL), NaI 
(420 mg, 2.78 mmol), and Na2CO3 (885 mg, 8.35 mmol) were added to DMF (10 mL) at 
RT under N2 and stirred at 80 °C for 48 h. The reaction was then cooled to RT, at which 
time it was diluted in 1:1 EtOAc:Et2O and washed with 1 M HCl (3X), H2O (3X), 10% 
aq. Na2CO3 (3X), and brine (1X). The organic phase was dried (MgSO4) and 
concentrated. The residue was purified by silica flash chromatography (45 g silica, 20 to 
80% EtOAc/Hex) to give a white microcrystalline solid. Yield: 567 mg, 1.89 mmol, 68%. 
1
H NMR (500 MHz, Chloroform-d) δ 12.43 (s, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.48 – 7.40 
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(m, 2H), 7.17 (t, J = 7.2 Hz, 1H), 6.13 (s, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.54 (d, J = 12.4 
Hz, 2H), 2.82 (t, J = 10.8 Hz, 2H), 2.54 (ddd, J = 15.0, 10.8, 4.1 Hz, 1H), 2.13 – 2.07 (m, 
2H), 2.06 – 1.98 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H). 
 
Ethyl 1-(1-(4-chlorophenyl)-2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-
carboxylate (58). Ethyl 1-(2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-carboxylate 57 
(490 mg, 1.64 mmol) was dissolved in DCM (10 mL) with 4 Å MS, followed by the 
addition of 4-chlorophenylboronic acid (510 mg, 3.27 mmol), pyridine (0.26 mL, 3.27 
mmol), TEA (0.46 mL, 3.27 mmol), and Cu(OAc)2 (590 mg, 3.27 mmol). The reaction 
was stirred at RT for 4 d, over which time the reaction became increasingly green with 
precipitate. After this time, the reaction was diluted with more DCM and washed with 
10% aq. NaOH (3X), 10% aq. NaHCO3 (1X), and brine (1X), then dried (MgSO4) and 
concentrated. The resulting residue was purified by silica flash chromatography (25 g, 5 
to 50% EtOAc/Hex) to give a white solid. Yield: 480 mg, 1.18 mmol, 72%. 
1
H NMR 
(500 MHz, Chloroform-d) δ 7.79 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.32 (t, J = 
7.8 Hz, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 
6.21 (s, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.55 (d, J = 12.2 Hz, 2H), 2.84 (t, J = 11.5 Hz, 2H), 
2.57 (ddd, J = 15.1, 10.9, 4.1 Hz, 1H), 2.16 – 2.09 (m, 2H), 2.09 – 1.96 (m, 2H), 1.31 (t, J 
= 7.1 Hz, 3H). 
 
Ethyl 1-(1-(4-chlorobenzyl)-2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-
carboxylate (59). Ethyl 1-(2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-carboxylate 58 
(95 mg, 0.32 mmol) was dissolved in anhydrous DMF (5 mL) under nitrogen and cooled 
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to 0 °C. KOtBu (43 mg, 0.38 mmol) was added, which elicited a slight color change. 4-
chlorobenzyl chloride 4a (49 µL, 0.38 mmol) was then added and the reaction was 
allowed to stir at RT for 15 h. At this time, the reaction was diluted with 2:1 EtOAc:Et2O 
and washed with 1M aq. HCl (3X), H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), 
then dried (MgSO4) and concentrated. Residue was purified via silica flash 
chromatography (10 g silica, 1% to 30% EtOAc:Hex). Yield: 117 mg, 0.28 mmol, 87%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.79 (d, J = 7.9 Hz, 1H), 7.40 (t, J = 7.7 Hz, 1H), 
7.28 – 7.23 (m, 2H), 7.17 (dd, J = 13.3, 8.2 Hz, 4H), 6.24 (s, 1H), 5.48 (s, 2H), 4.20 (q, J 
= 7.3 Hz, 2H), 3.52 (d, J = 12.4 Hz, 2H), 2.82 (t, J = 11.8 Hz, 2H), 2.55 (tt, J = 11.0, 8.8, 
4.0 Hz, 1H), 2.06 (ddd, J = 31.9, 19.5, 6.8 Hz, 4H), 1.30 (t, J = 7.4 Hz, 3H). 
 
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylate (70). 
The indole carboxylic acid 4a (982 mg, 3.44 mmol) was added to DCM (15 mL), 
followed by ethyl isonipecotate 26 (0.80 mL, 5.16 mmol), DIPEA (1.80 mL, 10.31 
mmol), EDCHCl (800 mg, 4.12 mmol), and HOBT (630 mg, 4.12 mmol). The reaction 
was allowed to stir at RT for 24 h, after which time it was diluted with 1:1 EtOAc:Et2O 
and washed with 1M HCl (5X), H2O (5X), 10% aq. Na2CO3 (5X) and brine (1X), then 
dried (MgSO4) and concentrated. The residue can then be crystallized from a two-phase 
organic solution of EtOAc and Hex to give crystals. Yield: 1.22 g, 2.88 mmol, 83%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.66 (d, J = 9.1 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.30 
– 7.27 (m, 1H), 7.25 – 7.20 (m, 2H), 7.19 – 7.14 (m, 1H), 7.08 – 6.97 (m, 2H), 6.68 – 
6.61 (m, 1H), 5.49 (d, J = 2.5 Hz, 2H), 4.49 (bs, 2H), 4.17 (qd, J = 7.1, 2.5 Hz, 2H), 3.08 
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– 2.95 (m, 2H), 2.51 (tq, J = 9.4, 3.6 Hz, 1H), 1.97 – 1.55 (m, 4H), 1.28 (td, J = 7.2, 2.5 
Hz, 3H). 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (71). 
The ethyl ester 70 (1.22 g, 2.88 mmol) was dissolved in EtOH (20 mL) and 5M aq. 
NaOH (20 mL) and stirred at 50 °C for 48 h. Most of the solvent was then removed in 
vacuo and the remaining aqueous solution was washed with Et2O (1X), then acidified to 
pH<1 at 0 °C with conc. HCl. The material was extracted with 1:1 EtOAc:Et2O (3X), and 
the combined extracts were dried (MgSO4) and concentrated. The resulting residue was 
dissolved in EtOAc and triturated with Hex, collected over a filter, and dried to give the 
desired carboxylic acid as white, fluffy microcrystals. Yield: 1.03 g, 2.59 mmol, 90%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.59 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.3 Hz, 1H), 7.28 
– 7.23 (m, 1H), 7.19 – 7.11 (m, 3H), 6.99 (d, J = 8.0 Hz, 2H), 6.59 (s, 1H), 5.42 (s, 2H), 
4.38 (bs, 1H), 4.08 (bs, 1H), 2.87 (bs, 2H), 2.38 (bs, J = 11.0 Hz, 1H), 1.90 – 1.37 (m, 
4H). 
 
2,3-Dihydro-1H-indene-2-carboxamide (74). 2-indancarboxylic acid 73 (1.4 g, 
8.63 mmol) was dissolved in anhydrous DMF (20 mL), and the following was added 
sequentially: DIPEA (3.02 mL, 17.26 mmol), HATU (3.94 g, 10.36 mmol), and HMDS 
(2.17 mL, 10.36 mmol) after 30 min of stirring at RT. After stirring for 20 h at RT, the 
solution was taken up in EtOAc and washed with 0.5 M HCl (3X), H2O (3X), and 10% 
aq. Na2CO3 (3X). The organic phase was collected and dried over MgSO4s, and 
concentrated in vacuo. The solid residue was recrystallized from EtOH to afford the title 
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compound as sharp, colorless crystals. Yield: 861 mg, 5.06 mmol, 59%. 
1
H NMR (400 
MHz, DMSO-d6) δ 7.40 (bs, 1H), 7.22 – 7.15 (m, 2H), 7.14 – 7.09 (m, 2H), 6.86 (bs, 
1H), 3.19 – 3.10 (m, 1H), 3.06 – 3.02 (m, 4H). 
 
(2,3-Dihydro-1H-inden-2-yl)methanamine (75). 2,3-dihydro-1H-indene-2-
carboxamide 74 (55 mg, 0.341 mmol) was added to anhydrous THF (8 mL), and cooled 
in an ice bath under nitrogen. LAH (0.34 mL, 0.341 mmol, 1M THF soln) was added 
under nitrogen, and the reaction was allowed to warm to rt and stir for 7 h. At this time, 
the reaction was quenched by the Fieser method and the precipitate removed over a filter. 
The filtrate was collected and concentrated in vacuo, and then taken up in a small amount 
of THF. 4M HCl/dioxane was added, the solvent removed in vacuo, and the residue 
sonicated in Et2O to afford the easily handled hydrochloride salt. Yield: 
1
H NMR (400 
MHz, Chloroform-d) δ 7.22 – 7.16 (m, 2H), 7.16 – 7.10 (m, 2H), 3.08 (dd, J = 15.6, 8.0 
Hz, 2H), 2.80 (d, J = 7.1 Hz, 2H), 2.66 (dd, J = 15.6, 7.0 Hz, 2H), 2.54 (p, J = 7.4 Hz, 
1H). TOF ES+ MS: (M + H) 148.1, (M + Na) 170.1.  
 
1-(2,3-Dihydro-1H-inden-2-yl)ethanone (77). Acetylacetate (97 µL, 0.95 mmol) 
was dissolved in anhydrous DMF under N2, followed by the addition of 60% oil-
suspended NaH (95 mg, 2.37 mmol). This was allowed to stir for 30 min, at which time 
1,2-bis(bromoethyl)benzene 76 (250 mg, 0.95 mmol) was added. The reaction was 
allowed to stir for 1 h at RT, then 8 h at 100 °C, then allowed to cool to RT. The reaction 
was quenched with sat. aq. NH4Cl, diluted with EtOAc, and washed with 10% aq. 
NaHCO3 (3X) and brine (1X), then dried (MgSO4) and concentrated. The residue was 
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then purified via silica flash chromatography (50 g silica, 1% to 5% EtOAc:Hex) to give 
a very greasy solid invisible to electrospray MS. Yield: 
1
H NMR (400 MHz, Chloroform-
d) δ 7.21 – 7.17 (m, 2H), 7.17 – 7.12 (m, 2H), 3.47 – 3.37 (m, 1H), 3.20 – 3.11 (m, 4H), 
2.22 (d, J = 2.6 Hz, 3H). 
 
1-(2,3-Dihydro-1H-inden-2-yl)ethanamine (78). 1-(2,3-dihydro-1H-inden-2-
yl)ethanone 77 (44 mg, 0.275 mmol) was dissolved in methanol (2 mL), and 7 M 
methanolic ammonia was added (1 mL, 7 mmol). This was allowed to stir at RT for 4 h, 
at which time NaBH4 (31 mg, 0.824 mmol) and a catalytic drop of glacial AcOH was 
added. Stirring continued for 14 h at RT, after which time the solvent was removed in 
vacuo. The residue was taken up in EtOAc and washed with a small amount of 10% aq. 
Na2CO3, dried with MgSO4, and concentrated. The residue was then taken on in 
subsequent reactions without further purification or characterization. TOF ES+ MS: (M + 
H) 162.2. 
 
Ethyl 7-methyl-1H-indole-2-carboxylate (81). To a 0 °C flask charged with 
crushed ice (~10 g) was added o-toluidine 79 (6.00 mL, 55.4 mmol), followed by conc. 
HCl (10 mL) which elicited the precipitation of the hydrochloride salt. Dissolved in H2O 
(30 mL), NaNO2 (3.82 g, 55.4 mmol) was added dropwise slowly to the flask, and more 
ice was added as needed. The reaction was allowed to stir at 0 °C for 30 min, after which 
~15 g of crushed ice and a 0 °C slurry of SnCl2 (32 g, 166.0 mmol) in conc. HCl (10 mL) 
was added. The reaction was then allowed to sit in a fridge (4 °C) for 11 h, after which 
time the precipitate was filtered off and collected, and washed with cold brine and 
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hexanes. The resulting precipitate was collected over a filter and washed with cold brine 
and 1:1 EtOAc:Hex. Unlike other reports, no attempt was made to basify, wash, and re-
convert the hydrazine to the hydrazine hydrochloride salt (due to observed stability 
issues). The white solid was dried thoroughly under high vacuum. Yield: 4.92 g, 31.02 
mmol, 56%. 
Ethyl pyruvate 80 (1.17 mL, 10.51 mmol), o-tolylhydrazine hydrochloride (1.5 g, 
9.46 mmol), ZnCl2 (7.16 g, 52.55 mmol) and TsOH (9.05 g, 52.55 mmol) were dissolved 
in anhydrous EtOH (15 mL) at RT in dry glassware. The reaction was refluxed for 8 h, 
after which the reaction was allowed to cool to RT and the resulting precipitate was 
filtered off and washed with EtOH. The filtrate was concentrated to give a residue that 
was dissolved in 1:1 EtOAc:Et2O and washed with 10% aq. Na2CO3 (2X), dried 
(MgSO4), and concentrated. The residue was then purified by silica flash chromatography 
(100 g silica, 20% EtOAc:Hex) to give the desired indole as a foul-smelling oil. Yield: 
1.37 g, 6.72 mmol, 71%. 
1
H NMR (400 MHz, Chloroform-d) δ 8.88 (bs, 1H), 7.53 (d, J = 
8.0 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.14 – 7.02 (m, 2H), 4.42 (qd, J = 7.1, 1.3 Hz, 2H), 
2.52 (s, 3H), 1.42 (td, J = 7.1, 1.3 Hz, 3H). 
 
Ethyl 1-(4-chlorobenzyl)-7-methyl-1H-indole-2-carboxylate (82). Ethyl 7-methyl-
1H-indole-2-carboxylate 81 (500 mg, 2.46 mmol) was dissolved in anhydrous DMF (20 
mL) and granular K2CO3 (425 mg, 3.08 mmol) and 4-chlorobenzyl chloride (0.39 mL, 
3.08 mmol) were added. The mixture was stirred for 3 d at 60 °C, after which time the 
incomplete reaction was terminated by dilution with EtOAc and subsequent washing with 
brine (3X). The organic phase was dried over MgSO4, concentrated, and purified vial 
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silica flash chromatography (80 g silica, 40% EtOAc:Hex) to provide the title compound 
as white crystals. Yield: 390 mg, 1.19 mmol, 46%. 
1
H NMR (400 MHz, Chloroform-d) δ 
7.59 – 7.53 (m, 1H), 7.43 – 7.40 (m, 1H), 7.20 (d, J = 8.4 Hz, 2H), 7.06 – 6.97 (m, 2H), 
6.78 (d, J = 8.2 Hz, 2H), 6.08 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 2.54 (s, 3H), 1.33 (t, J = 
7.1 Hz, 3H). 
 
1-(4-Chlorobenzyl)-7-methyl-1H-indole-2-carboxylic acid (83). Ethyl 1-(4-
chlorobenzyl)-7-methyl-1H-indole-2-carboxylate 82 (212 mg, 0.647 mmol) was 
dissolved in EtOH (10 mL) and 10% aq. KOH (10 mL) was added. The reaction stirred 
for 4 h at 70 °C, after which time as much solvent was stripped off as possible in vacuo. 
The mostly aqueous mixture was cooled in an ice bath and acidified with conc. HCl to 
obtain a precipitate that was collected over a filter and washed with 1 M HCl and cold 
H2O. No further purification necessary. Yield: 182 mg, 0.607 mmol, 94%. 
1
H NMR (400 
MHz, DMSO-d6) δ 12.94 (s, 1H), 7.36 – 7.24 (m, 4H), 7.01 – 6.95 (m, 2H), 6.76 (d, J = 
8.1 Hz, 2H), 6.08 (s, 2H), 2.44 (s, 3H). 
 
Ethyl 3-methyl-1H-indole-2-carboxylate (86). Phenylhydrazine was prepared in a 
manner similar to that reported.
138
 Ethyl 2-oxobutanoate 85 (500 mg, 4.90 mmol), 
phenylhydrazine (0.44 mL, 4.41 mmol), and TsOH (2.3 g, 12.24 mmol) were dissolved in 
anhydrous EtOH (15 mL) at RT in dry glassware. The reaction was refluxed for 12 h, 
over which time it took on a dark hue. After the reaction time, the reaction was allowed 
to cool to RT and the resulting precipitate was filtered off and washed with EtOH. The 
combined filtrate was concentrated to give a residue that was dissolved in 1:1 
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EtOAc:Et2O and washed with 10% aq. Na2CO3 (2X), dried (MgSO4), and concentrated. 
The residue was then purified by silica flash chromatography (45 g silica, 20% 
EtOAc:Hex) to give the desired indole as a foul-smelling oil. Yield: 646 mg, 3.18 mmol, 
65%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.83 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.39 
(d, J = 8.3 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.16 (t, J = 7.4 Hz, 1H), 4.45 (qd, J = 7.1, 
1.1 Hz, 2H), 2.64 (d, J = 1.1 Hz, 3H), 1.46 (td, J = 7.2, 1.1 Hz, 3H). 
 
Ethyl 1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylate (87). Anhydrous 
DMF (12 mL) in dry glassware was charged with ethyl 3-methyl-1H-indole-2-
carboxylate 86 (646 mg, 3.18 mmol), 4-chlorobenzyl chloride (0.50 mL, 3.97 mmol), and 
granular K2CO3, and the mixture was stirred at 60 °C for 14 h, allowed to cool for 1 h, 
then diluted in 1:1 EtOAc:Et2O and washed with 10% aq. Na2CO3 (3X), dried (MgSO4), 
and concentrated. The residue was purified by silica flash chromatography ( 40 g 
silica, 20% EtOAc:Hex) to give the desired compound as an oil. Yield: 750 mg, 2.29 
mmol, 72%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.71 (dd, J = 8.1, 1.1 Hz, 1H), 7.33 – 
7.23 (m, 2H), 7.22 – 7.12 (m, 3H), 6.99 – 6.90 (m, 2H), 5.73 (s, 2H), 4.34 (qd, J = 7.2, 
1.1 Hz, 2H), 2.62 (d, J = 1.1 Hz, 3H), 1.35 (td, J = 7.1, 1.1 Hz, 3H). 
 
5-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)octahydro-1H-pyrrolo[3,4-
c]pyridin-1-one (91). The following were added sequentially to DMF (10 mL): 1-(4-
chlorobenzyl)-1H-indole-2-carboxylic acid 4a (250 mg, 0.875 mmol), DIPEA (0.46 mL, 
2.64 mmol), EDCHCl (202 mg, 1.050 mmol), and HOBT (162 mg, 1.050 mmol). This 
solution was allowed to stir at RT for 1 h, at which time crude octahydro-1H-pyrrolo[3,4-
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c]pyridin-1-one 90 (123 mg, 0.875 mmol) was added, having been prepared through the 
known route.
140
 Stirring continued for 12 h at RT, at which time the solution was 
partitioned between water and 1:1 solution of EtOAc:Et2O. The organic extract was then 
washed with water (1X) and saturated aq. Na2CO3 (1X), dried with MgSO4, and 
concentrated in vacuo. Purification was accomplished via silica flash chromatography 
(100 g silica, 100% EtOAc.) Resulting residue was crystallized from the in vacuo 
removal of DCM to give the title compound as a slightly pink solid. Yield: 200 mg, 0.49 
mmol, 56%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 7.9 Hz, 1H), 7.37 – 7.24 
(m, 4H), 7.19 (t, J = 7.4 Hz, 1H), 7.14 (d, J = 8.1 Hz, 2H), 6.93 (s, 1H), 6.31 (bs, 1H), 
5.51 (s, 2H), 4.57 (d, J = 13.2 Hz, 1H), 4.18 (bs, 1H), 3.56 – 3.46 (m, 1H), 3.39 (dd, J = 
13.7, 5.1 Hz, 1H), 3.05 (d, J = 8.6 Hz, 1H), 2.63 (s, 1H), 2.50 (s, 1H), 1.96 – 1.73 (m, 
2H), 1.54 (bs, 1H). 
 
Tert-Butyl 4-(3-(pyridin-4-yl)propanamido)piperidine-1-carboxylate (94). t-Butyl 
4-aminopiperidine-1-carboxylate (500 mg, 2.50 mmol), 3-(pyridin-4-yl)propanoic acid 
(377 mg, 2.50 mmol), TEA (1.04 mL, 7.49 mmol), EDCHCl (574 mg, 3.00 mmol), and 
HOBT (459 mg, 3.00 mmol) were all dissolved in DCM (30 mL) and stirred at RT for 30 
h, after which time the DCM was removed in vacuo and the residue was taken up in 
EtOAc and washed with H2O (1X), 10% Na2CO3 (3X), and brine (1X), then dried 
(MgSO4) and concentrated. The resulting residue was purified via silica flash 
chromatography (40 g silica, 1% to 10%  methanolic ammonia:EtOAc) to provide a white 
solid. Yield: 591 mg, 1.773 mmol, 71%. 
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Ethyl 2-(1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidin-4-yl)acetate (96). 
Indole carboxylic acid 4a (520 mg, 1.82 mmol), ethyl 2-(piperidin-4-yl)acetate 95 (345 
mg, 1.65 mmol), TEA (1.15 mL, 8.27 mmol), EDCHCl (380 mg, 1.98 mmol), and 
HOBT (304 mg, 1.98 mmol) were all dissolved in DCM (50 mL) and stirred at RT for 24 
h, after which time the DCM was removed in vacuo and the residue was taken up in 
EtOAc and washed with 10% aq. citric acid (3X), H2O (2X), 10% Na2CO3 (3X), and 
brine (1X), then dried (MgSO4) and concentrated. The resulting residue was purified via 
silica flash chromatography (40 g silica, 10% to 50% EtOAc:Hex) to provide a white 
powder. Yield: 460 mg, 1.05 mmol, 63%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.67 – 
7.62 (m, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.29 – 7.25 (m, 1H), 7.24 – 7.20 (m, 2H), 7.18 – 
7.13 (m, 1H), 7.06 – 7.01 (m, 2H), 6.62 (s, 1H), 5.48 (s, 2H), 4.63 (bs, 1H), 4.13 (q, J = 
7.2 Hz, 3H), 2.88 (bs, 1H), 2.74 (bs, 1H), 2.18 (d, J = 7.0 Hz, 2H), 1.98 (ttt, J = 11.0, 7.1, 
3.7 Hz, 1H), 1.75 (bs, 1H), 1.57 (bs, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.11 (bs, 1H), 0.65 (bs, 
1H). 
 
4-(3-(Triphenylphosphoranyl)propyl)pyridine bromide (98). 4-(3-
hydroxypropyl)pyridine 97 (1.42 g, 10.35 mmol) and PPh3 (4.07 g, 15.53 mmol) were 
dissolved in conc. HBr (8 mL) in a pressure vessel. The reaction was sealed and the 
suspension as stirred at 135 °C for 2 h, over which time a homogenous solution was 
achieved. After this time, the reaction was allowed to cool to RT, eliciting precipitation. 
The reaction was taken up in toluene and transferred to a flask equipped with a Dean-
Stark apparatus and water condenser, and H2O was removed with heating of 150 °C for 3 
h, at which time more conc. HBr (8 mL) was added. H2O was again removed at 150 °C 
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for 6 h. Once sufficient water had been removed, a precipitate began to appear and the 
reaction was allowed to cool to RT, at which point it was diluted with H2O (50 mL) and 
washed with Et2O (5X). The pH was raised to pH 7 by the addition of 10% aq. NaOH, 
and the resulting solution was washed with Et2O to remove PPh3 which caused 
significant precipitation of product. The aqueous slurry was then washed with Et2O (3X) 
and cooled in a fridge for 2 h, after which time the precipitate was collected over a filter 
and washed with cold H2O and Et2O. The highly hygroscopic crystalline material was 
dried under high vacuum for 1 d and stored in a desiccator. No further purification 
necessary. Off-white crystalline solid. Yield: 1.601 g, 3.46 mmol, 34%. 
1
H NMR (500 
MHz, Chloroform-d) δ 8.41 (d, J = 5.9 Hz, 2H), 7.82 – 7.74 (m, 9H), 7.70 – 7.64 (m, 
6H), 7.17 (d, J = 5.9 Hz, 2H), 3.98 – 3.90 (m, 2H), 3.11 (t, J = 7.4 Hz, 2H), 1.93 (dq, J = 
15.7, 7.8 Hz, 2H). TOF ES+ MS: (M+) 382.2. 
 
(Z)-tert-Butyl 4-(4-(pyridin-4-yl)but-1-en-1-yl)piperidine-1-carboxylate (99a). 
Due to the poor ethereal solubility of the phosphonium bromide, the reaction was 
conducted at RT. 4-(3-(bromotriphenylphosphoranyl)propyl)pyridine 98 (330 mg, 0.714 
mmol) was added to anhydrous THF in a flame-dried flask under N2 at RT. To the 
suspension, n-BuLi (2.5 M in hexane) was added dropwise at RT until a light yellow 
color persisted, at which point a full equivalent was added (285 µL, 0.714 mmol) to give 
a red solution. The reaction then stirred for 10 min at RT under N2 to allow for ylide 
dissolution. Predissolved in anhydrous THF (10 mL), t-butyl 4-formylpiperidine-1-
carboxylate 8 (138 mg, 0.649 mmol) was added dropwise at RT to the reaction, and the 
reaction was allowed to stir at RT under N2 for 14 h, at which time the reaction was 
145 
 
quenched with sat. NH4Cl and extracted with a 1:1 solution of EtOAc:Et2O . This extract 
was then washed with 10% aq. Na2CO3 (1X) and brine (1X), dried (MgSO4) and 
concentrated. The residue was purified via silica flash chromatography (12 g silica, 
isocratic 60% EtOAc:Hex) to give a clear, colorless oil, >50:1 Z:E. Yield: 117 mg, 0.370 
mmol, 57%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.47 (d, J = 4.9 Hz, 2H), 7.08 (d, J = 
5.1 Hz, 2H), 5.38 (t, J = 6.1 Hz, 1H), 5.36 (d, J = 5.9 Hz, 1H), 4.04 (s, 2H), 2.67 (q, J = 
10.3, 7.7 Hz, 4H), 2.31 (q, J = 7.1 Hz, 2H), 2.08 – 1.97 (m, 1H), 1.64 – 1.55 (m, 2H), 
1.45 (s, 9H), 1.19 (tt, J = 13.2, 5.9 Hz, 2H). TOF ES+ MS: (M + H, no Boc) 217.2. 
 
(E)-tert-Butyl 4-(4-(pyridin-4-yl)but-1-en-1-yl)piperidine-1-carboxylate (99b). 
LiBr (340 mg, 3.92 mmol) was dried by flame-heating a 2-neck flask under high vacuum 
until the molten salt ceased bubbling. The flask was then purged with N2 and a stir bar 
was added (so the bar would not char during the flame-dry) and the flask was allowed to 
cool to RT. The flask was then charged with anhydrous THF (40 mL) and 4-(3-
(triphenylphosphoranyl)propyl)pyridine bromide 98 (823 mg, 1.78 mmol) under N2. 
Without cooling – due to the poor ethereal solubility of the phosphonium bromide – 2 M 
PhLi in (Bu)2O was added at RT until a slight yellow color persisted, at which point a full 
1.1 equivalent of PhLi (0.98 mL, 1.96 mmol) was added, and the suspension gave way to 
mostly homogenous red solution after 20 min of RT stirring. This solution was then 
chilled to -78 °C, and t-butyl 4-formylpiperidine-1-carboxylate 8 (380 mg, 1.78 mmol) – 
pre-dissolved in anhydrous THF (10 mL) – was added dropwise to the solution, causing a 
loss of color. The light yellow solution was allowed to stir at -78 °C for 30 min, at which 
time the second equivalent of PhLi (0.98 mL, 1.96 mmol) was added dropwise, resulting 
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in the solution becoming a very dark cherry-red color. The cooling bath was then 
removed, and the reaction was allowed to stir for 30 min as it approached RT. The 
reaction was then re-chilled to -78 °C and t-BuOH (0.204 mL, 2.14 mmol) – predissolved 
in anhydrous THF (5 mL) – was added dropwise, eliciting precipitation and 
decolorization. The reaction was allowed to warm to RT and stir for 36 h, after which 
time the reaction was quenched with a small amount of sat. aq. NH4Cl and diluted with a 
2:1 EtOAc:Et2O solution and washed with 10% aq. Na2CO3 (1X) and brine (1X), dried 
(MgSO4), and concentrated in vacuo. Purification accomplished by silica flash 
chromatography (40 g silica, 50% to 80% EtOAc:Hex) to provide the desired olefin as a 
clear colorless oil, ~5:1 E:Z. Yield: 231 mg, 0.730 mmol, 41%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 8.43 (d, J = 4.4 Hz, 2H), 7.06 (d, J = 4.5 Hz, 2H), 5.25 (t, J = 8.9 Hz, 
1H), 5.16 (t, J = 10.0 Hz, 1H), 3.98 (s, 2H), 2.67 – 2.55 (m, 4H), 2.34 (q, J = 7.3 Hz, 2H), 
2.27 – 2.12 (m, 1H), 1.40 (s, 9H), 1.30 (s, 2H), 1.13 (d, J = 11.8 Hz, 2H). TOF ES+ MS: 
(M + H, no Boc) 217.2, (M + Na, no Boc) 239.2. 
 
Tert-Butyl 4-((2-(pyridin-4-yl)ethyl)carbamoyl)piperazine-1-carboxylate (101). t-
Butyl piperazine-1-carboxylate (400 mg, 2.15 mmol) was dissolved in DCM (15 mL) at 
RT under N2 and cooled to 0 °C. 15% wt. phosgene (360 µL, 0.50 mmol) in toluene was 
added to the solution dropwise, followed by the dropwise addition of TEA (0.90 mL, 6.44 
mmol), and then the dropwise addition of 4-(2-aminoethyl)pyridine (565 µL, 4.72 mmol). 
The reaction was allowed to stir for 1 h at 0 °C, at which point it was diluted with EtOAc 
and washed with 10% aq. NaOH (1X), H2O (3X), and brine (1X), dried (MgSO4), and 
concentrated. The residue was then purified via silica flash chromatography (40 g silica, 
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1% to 20% methanolic ammonia:EtOAc) to give a white solid after concentration. Yield: 
582 mg, 1.74 mmol, 81%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.44 (d, J = 5.6 Hz, 2H), 
7.09 (d, J = 5.4 Hz, 2H), 4.92 (t, J = 5.8 Hz, 1H), 3.47 (q, J = 6.7 Hz, 2H), 3.39 – 3.34 
(m, 5H), 3.30 – 3.27 (m, 3H), 2.81 (t, J = 7.0 Hz, 2H), 1.43 (d, J = 1.6 Hz, 12H). 
 
1-Tert-Butyl 4-ethyl 4-(phenylselanyl)piperidine-1,4-dicarboxylate (103). DIPA 
(2.49 mL, 17.49 mmol) was dissolved into anhydrous THF (10 mL) in dry glassware 
under N2, then chilled to -78 °C. Then, 2.5 M n-BuLi (5.60 mL, 13.99 mmol) was added 
dropwise, and the reaction was allowed to stir for 10 min. 1-Tert-butyl 4-ethyl piperidine-
1,4-dicarboxylate 102 (3.00 g, 11.66 mmol) – pre-dissolved in THF (10 mL) – was added 
dropwise to the reaction and the reaction was allowed to stir at -78 °C for 15 min. PhSeCl 
(2.68 g, 13.99 mmol) – pre-dissolved in anhydrous THF (10 mL) – was added dropwise 
to the reaction under the same conditions. The cooling bath was removed to allow for 
warming to RT, and the reaction was stirred for 3 h. After this time, the reaction was 
quenched by the addition of sat. aq. NH4Cl and extracted with 1:1 EtOAc:Et2O. The 
extract was subsequently washed with H2O (2X) and brine (1X), dried (MgSO4) and 
concentrated. The residue was purified by silica flash chromatography (80 g, 5% 
EtOAc:Hex) to give a clear, slightly yellow oil. Yield: 2.80 g, 6.78 mmol, 58%.  
1
H NMR 
(500 MHz, Chloroform-d) δ 7.56 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.30 (t, J = 
7.7 Hz, 2H), 4.10 (q, J = 7.1 Hz, 2H), 3.74 (s, 2H), 3.11 – 3.03 (m, 2H), 2.13 – 2.06 (m, 
2H), 1.84 (s, 2H), 1.44 (s, 9H), 1.18 (t, J = 7.1 Hz, 3H). 
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Ethyl 4-(phenylselanyl)piperidine-4-carboxylate hydrochloride (104). 1-tert-butyl 
4-ethyl 4-(phenylselanyl)piperidine-1,4-dicarboxylate (1.70 g, 4.12 mmol) was dissolved 
in Et2O (100 mL) at RT and 4 M HCl in 1,4-dioxane (15.46 mL, 61.80 mmol) was added 
dropwise. The reaction was stirred at RT for 4 d until complete by TLC. The solvent was 
removed in vacuo and Et2O was added and stripped off five times (5X) to remove excess 
HCl and solidify the salt. Further removal of solvent and HCl via rotovap and, lastly, high 
vacuum furnished the hydrochloride salt. Yield, 1.44, g, 4.12 mmol, 100%. TOF ES+ 
MS: (M + H) 314.1, (M + Na) 336.0. 
 
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-4-(phenylselanyl)piperidine-
4-carboxylate (105). Ethyl 4-(phenylselanyl)piperidine-4-carboxylate hydrochloride (200 
mg, 0.574 mmol) was dissolved in DCM (10 mL) and TEA (0.48 mL, 3.44 mmol), 
followed by 1-(4-chlorobenzyl)-1H-indole-2-carboxylic acid (164 mg, 0.574 mmol), 
EDCHCl (121 mg, 0.631 mmol), and HOBT (97 mg, 0.631 mmol), and the reaction was 
allowed to stir at RT for 15 h. After this time, the reaction was diluted with a 1:1 solution 
of EtOAc:Et2O and washed with 1M HCl (3X), H2O (3X), 10% Na2CO3 (3X), and brine 
(1X), then dried (MgSO4) and concentrated in vacuo. The resulting residue was purified 
via silica flash chromatography (12 g silica, 5% to 20% EtOAc:Hex) to yield an oil that 
may triturated to provide a fine white powder. Yield: 208 mg, 0.359 mmol, 63%. 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.64 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 7.9 Hz, 2H), 7.43 
– 7.36 (m, 2H), 7.30 (dt, J = 15.2, 7.8 Hz, 3H), 7.23 (d, J = 8.3 Hz, 2H), 7.16 (t, J = 7.5 
Hz, 1H), 7.04 (d, J = 8.2 Hz, 2H), 6.61 (s, 1H), 5.48 (s, 2H), 4.12 (q, J = 7.1 Hz, 3H), 
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3.84 (s, 1H), 3.33 – 3.20 (m, 2H), 2.12 (s, 1H), 1.81 (s, 2H), 1.45 (s, 1H), 1.19 (t, J = 7.1 
Hz, 3H). 
 
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-1,2,3,6-tetrahydropyridine-4-
carboxylate (106). Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-4-
(phenylselanyl)piperidine-4-carboxylate (160 mg, 0.276 mmol) was dissolved in DCM 
(10 mL) at RT then cooled to -78 °C. Suspended in DCM (10 mL), ~60% mCPBA (80 
mg, 0.276 mmol) was added to the solution dropwise and the reaction was allowed to stir 
for 30 min. Still at -78 °C, TEA (115 µL, 0.828 mmol) was added dropwise and the 
reaction was allowed to stir for another 30 min. At this time, the reaction was warmed to 
RT, then the reaction was then diluted with 2:1 EtOAc:Et2O and washed with 10% aq. 
Na2CO3 (3X), H2O (1X), 1 M HCl (2X), H2O (1X) again, and sat. aq. Na2CO3 (1X). The 
organic phase was dried with MgSO4 and concentrated. The resulting solid residue was 
taken up in Hex and the yellow supernatant was decanted off to remove selenoxides. 
Further purification was accomplished by silica flash chromatography (12 g silica, 5% to 
20% EtOAc:Hex) to provide the desired unsaturated ester as a white solid. Yield: 96 mg, 
0.227 mmol, 82%.  
1
H NMR (500 MHz, Chloroform-d) δ 7.66 (d, J = 7.9 Hz, 1H), 7.37 
(d, J = 8.3 Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 7.22 – 7.11 (m, 3H), 7.00 (d, J = 7.5 Hz, 
2H), 6.68 (s, 1H), 5.48 (s, 2H), 4.23 (q, J = 7.1 Hz, 4H), 3.68 (s, 2H), 2.32 (s, 2H), 1.31 
(t, J = 7.1 Hz, 3H). 
 
1-Tert-Butyl 4-ethyl 4-methylpiperidine-1,4-dicarboxylate (107). DIPA (0.62 mL, 
4.37 mmol) was dissolved into anhydrous THF (10 mL) in dry glassware under N2, then 
150 
 
chilled to -78 °C. Then, 2.5 M n-BuLi (1.40 mL, 3.50 mmol) was added dropwise, and 
the reaction was allowed to stir for 15 min. Boc-ethyl isonipecotate 102 (750 mg, 2.91 
mmol) – pre-dissolved in THF (5 mL) – was added dropwise to the reaction and the 
reaction was allowed to stir at -78 °C for 15 min. MeI (220 µL, 3.50 mmol) – pre-
dissolved in anhydrous THF (3 mL) – was added dropwise to the reaction under the same 
conditions. The cooling bath was removed to allow for warming to RT, and the reaction 
was stirred for 8 h. After this time, the reaction was quenched by the addition of sat. aq. 
NH4Cl and diluted with 1:1 EtOAc:Et2O, then washed with H2O (3X) and brine (1X), 
dried (MgSO4) and concentrated. The residue was purified by silica flash 
chromatography (40 g, 5 to 20% EtOAc:Hex) to give a clear colorless oil.  
1
H NMR (500 
MHz, Chloroform-d) δ 4.14 (q, J = 7.1 Hz, 2H), 3.74 (s, 2H), 2.96 (s, 2H), 2.04 (d, J = 
13.3 Hz, 2H), 1.42 (s, 9H), 1.32 (t, J = 12.5 Hz, 2H), 1.24 (t, J = 7.5 Hz, 3H), 1.17 (s, 
3H). 
 
Ethyl 4-methylpiperidine-1,4-dicarboxylate hydrochloride (108). The Boc-
protected amino ester 107 (500 mg, 1.84 mmol) was dissolved into 4M HCl dioxane (4 
mL) and stirred for 15 min. After this time, the dioxane was removed in vacuo and the 
material was sonicated in Et2O to give a tan solid. The Et2O was decanted off and the 
precipitate was dried via aspirator, then high vacuum, to afford the desired amine 
hydrochloride as a tan, hygroscopic solid. No further purification necessary. Yield: 350 
mg, 1.68 mmol, 100%. TOF ES+ MS: (M + H) 172.1, (M + Na) 194.1.  
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Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-4-methylpiperidine-4-
carboxylate (109). The amine hydrochloride 108 (240 mg, 1.16 mmol), indole carboxylic 
acid 4a (300 mg, 1.05 mmol), TEA (585 µL, 4.20 mmol), EDCHCl (242 mg, 1.26 
mmol), and HOBT (193 mg, 1.26 mmol) were dissolved in DCM (30 mL) and stirred at 
RT for 22 h. After this time, the reaction as diluted with EtOAc and washed with 1M HCl 
(3X), H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried 
(MgSO4) and concentrated, and the residue purified via silica flash chromatography (40 g 
silica, 30% to 90% EtOAc:Hex) to give a white solid. Yield: 281 mg, 0.64 mmol, 61%. 
 
1
H NMR (500 MHz, Chloroform-d) δ 7.65 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 
7.31 – 7.26 (m, 1H), 7.21 (d, J = 7.3 Hz, 2H), 7.16 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 7.8 
Hz, 2H), 6.61 (s, 1H), 5.48 (s, 2H), 4.29 (bs, 1H), 4.18 (q, J = 7.4, 7.0 Hz, 2H), 3.86 (bs, 
1H), 3.10 (bs, 1H), 2.98 (bs, 1H), 2.12 (bs, 1H), 1.85 (bs, 1H), 1.31 – 1.20 (m, 4H), 1.14 
(s, 3H), 0.77 (s, 2H). 
 
(1R,5S,6r)-Ethyl 3-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-3-
azabicyclo[3.1.0]hexane -6-carboxylate (113). The amine exo-112 (170 mg, 0.89 mmol) 
– prepared in a manner similar to that reported150, 151 – indole carboxylic acid 4a (304 mg, 
1.06 mmol), TEA (495 µL, 3.55 mmol), EDCHCl (204 mg, 1.06 mmol), and HOBT (163 
mg, 1.06 mmol) were dissolved in DCM (10 mL) and stirred at RT for 18 h. After this 
time, the reaction as diluted with EtOAc:Et2O (1:1) and washed with 1M HCl (1X), H2O 
(2X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) and 
concentrated, and the residue purified via silica flash chromatography (25 g silica, 5% to 
20% EtOAc:Hex) to give a white solid. Yield: 244 mg, 0.58 mmol, 78%. 
1
H NMR (500 
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MHz, Chloroform-d) δ 7.66 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.32 – 7.28 (m, 
1H), 7.26 – 7.22 (m, 2H), 7.17 (dd, J = 8.2, 6.7 Hz, 1H), 6.99 (d, J = 8.1 Hz, 2H), 6.74 (s, 
1H), 5.56 (d, J = 49.7 Hz, 2H), 4.22 (bd, J = 12.4 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.77 
(bd, J = 13.0 Hz, 2H), 3.52 (s, 1H), 2.18 – 2.04 (m, 2H), 1.29 (td, J = 7.1, 1.2 Hz, 3H), 
1.06 (t, J = 3.1 Hz, 1H). 
 
(1R,3s,5S)-Tert-Butyl 3-((2-(pyridin-4-yl)ethyl)carbamoyl)-8-
azabicyclo[3.2.1]octane-8-carboxylate (115). The Boc-protected amino ester 114 (175 
mg, 0.65 mmol) was dissolved in anhydrous THF (10 mL) with KOTMS (83 mg, 0.65 
mmol) and stirred under dry conditions under N2 for 18 h, at which time a precipitate was 
observed and the solvent was removed in vacuo to give the potassium salt as a white 
powder. No further purification necessary. Yield: 190 mg, 0.65 mmol, 100%. 
The potassium salt (191 mg, 0.65 mmol), amine 27 (93 µL, 0.78 mmol), 
EDCHCl (150 mg, 0.78 mmol), HOBT (119 mg, 0.78 mmol), and TEA (362 µL, 2.60 
mmol) were dissolved in DCM (10 mL) and stirred at RT for 24 h, at which time the 
DCM was removed in vacuo and the residue was taken up in EtOAc and washed with 
H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) 
and concentrated, and the residue purified via silica flash chromatography (25 g silica, 
1% to 20% methanolic ammonia:EtOAc) to give a tan powder. Yield: 41 mg, 0.083 
mmol, 57%. Yield: 146 mg, 0.41 mmol, 63%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.49 
(d, J = 5.8 Hz, 2H), 7.10 (d, J = 5.7 Hz, 2H), 5.66 (t, J = 5.9 Hz, 1H), 4.23 (d, J = 40.3 
Hz, 2H), 3.54 – 3.48 (m, 2H), 2.81 (t, J = 7.0 Hz, 2H), 2.58 (tt, J = 11.8, 5.3 Hz, 1H), 
1.97 – 1.84 (m, 5H), 1.61 – 1.56 (m, 3H), 1.46 (d, J = 1.1 Hz, 9H). 
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N-(2-(Pyridin-4-yl)ethyl)-2-tosyl-2-azaspiro[3.3]heptane-6-carboxamide (123). 
The tosyl amide carboxylic acid 122 (2.0 g, 6.77 mmol) – prepared in a manner similar to 
that reported
152, 153
 – amine 27 (0.97 mL, 8.13 mmol), HATU (309 g, 8.13 mmol), and 
TEA (2.83 mL, 20.31 mmol) were dissolved in DMF (10 mL) and stirred at RT for 18 h, 
at which time the reaction was diluted with EtOAc and washed with H2O (5X), 10% aq. 
Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) and concentrated, 
and the residue purified via silica flash chromatography (80 g silica, 1% to 20% 
methanolic ammonia:EtOAc) to give an extremely thick, clear, yellow-tinged oil. Yield: 
1.95 g, 4.88 mmol, 72%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.31 (d, J = 5.4 Hz, 2H), 
7.59 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.99 (d, J = 5.4 Hz, 2H), 6.30 (t, J = 
5.8 Hz, 1H), 3.61 (d, J = 5.5 Hz, 4H), 3.37 (q, J = 6.8 Hz, 2H), 2.69 (t, J = 7.1 Hz, 2H), 
2.62 (p, J = 7.8 Hz, 1H), 2.37 (s, 3H), 2.12 (dd, J = 11.1, 8.7 Hz, 2H), 2.05 – 1.98 (m, 
2H). TOF ES+ MS: (M + H) 400.1, (M + Na) 422.1.  
 
Methyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)azetidine-3-carboxylate 
(125). The following reagents were dissolved in DCM (10 mL) at RT: indole carboxylic 
acid 4a (150 mg, 0.53 mmol), methyl 4-azetidinecarboxylate hydrochloride (88 mg, 0.58 
mmol), TEA (366 µL, 2.26 mmol), EDCHCl (121 mg, 0.63 mmol), and HOBT (96 mg, 
0.63 mmol). The reaction was allowed to stir for 26 h at RT, after which time the solvent 
was remove in vacuo and the residue was dissolved in EtOAc and washed with 1M HCl 
(3X), H2O (2X), 10% aq. Na2CO3 (3X), and brine (1X), then dried (MgSO4) and 
concentrated. The residue was purified by silica flash chromatography (25 g silica, 5 to 
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40% EtOAc:Hex). Yield: 117 mg, 0.30 mmol, 58%. 
1
H NMR (500 MHz, Chloroform-d) 
δ 7.67 (d, J = 8.0 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.22 – 7.14 (m, 3H), 7.04 – 6.99 (m, 2H), 
6.83 (d, J = 1.2 Hz, 1H), 5.73 (s, 2H), 4.53 (bd, J = 36.9 Hz, 2H), 4.32 (bd, J = 26.0 Hz, 
2H), 3.78 (d, J = 1.4 Hz, 3H), 3.47 (p, J = 7.1 Hz, 1H). 
 
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)azepane-4-carboxylate (132). 
The carboxylic acid 4a (757 mg, 2.65 mmol), azapane ester hydrochloride 131 (550 mg, 
2.65 mmol) – prepared in a manner similar to that reported160 – EDCHCl (558 mg, 2.91 
mmol), HOBT (446 mg, 2.91 mmol), and TEA (1.48 mL, 10.59 mmol) were dissolved in 
DCM (20 mL) and stirred at RT for 18 h, at which time the DCM was removed in vacuo 
and the residue was taken up in EtOAc and washed with 1M HCl (2X), H2O (3X), 10% 
aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) and 
concentrated, and the residue purified via silica flash chromatography (45 g silica, 1% to 
20% methanolic ammonia:EtOAc) to give a colorless oil. Yield: 756 mg, 1.72 mmol, 
65%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.09 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 8.2 Hz, 
1H), 7.74 (d, J = 8.1 Hz, 0.5H), 7.66 (d, J = 8.0 Hz, 0.5H), 7.59 (ddd, J = 8.2, 7.0, 1.1 Hz, 
1H), 7.47 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.30 – 7.25 (m, 0.5H), 
7.23 – 7.16 (m, 1.5H), 7.04 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.1 Hz, 0.5H), 6.68 (d, J = 
11.9 Hz, 0.5H), 6.37 (d, J = 1.2 Hz, 2H), 5.59 – 5.42 (m, 1H), 4.16 (ddt, J = 19.2, 14.0, 
7.2 Hz, 2H), 3.98 – 3.60 (m, 2.5H), 3.51 (d, J = 12.2 Hz, 1H), 3.42 – 3.25 (m, 1H), 2.79 
(s, 0.5H), 2.53 (d, J = 47.4 Hz, 0.5H), 2.41 (s, 0.5H), 2.20 – 2.04 (m, 1H), 1.94 (bs, 
1.5H), 1.77 (bd, J = 12.1 Hz, 1H), 1.63 (m, 0.5H), 1.51 (bs, 0.5H), 1.38 (m, J = 10.0 Hz, 
0.5H), 1.33 – 1.01 (m, 3H). 
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Methyl 1-(4-chlorobenzyl)-4-fluoro-1H-pyrrole-2-carboxylate (138). Methyl 4-
fluoro-1H-pyrrole-2-carboxylate 137 (130 mg, 0.91 mmol) was dissolved in anhydrous 
DMF at room temperature, followed by the addition of potassium carbonate (151 mg, 
1.09 mmol) and 2a (0.14 mL, 1.09 mmol). The reaction was then stirred for 30 h at 60 
°C, after which time it was allowed to cool to room temperature. The reaction was diluted 
with a 1:1 solution of ethyl acetate/diethyl ether, washed with water (3×) and brine (1×), 
dried with magnesium sulfate, and concentrated in vacuo. The resulting brown residue 
was purified via flash chromatography (60 g silica, 10% ethyl acetate/hexanes) to afford 
methyl 1-(4-chlorobenzyl)-4-fluoro-1H-pyrrole-2-carboxylate as a light-yellow oil. 
Yield: 203 mg (83%). 
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.3 Hz, 2H), 7.03 (d, J 
= 8.3 Hz, 2H), 6.69−6.59 (m, 2H), 5.44 (s, 2H), 3.75 (s, 3H). 
 
1-(4-Chlorobenzyl)-4-fluoro-1H-pyrrole-2-carboxylic acid (139). Methyl 1-(4-
chlorobenzyl)-4-fluoro-1H-pyrrole-2-carboxylate 138 (150 mg, 0.56 mmol) was 
dissolved in ethanol (10 mL) at room temperature. Then 10% aqueous sodium hydroxide 
(2 mL) was added, and the reaction was stirred for 18 h at room temperature. At this time, 
solvent was stripped off in vacuo until material began to precipitate. Additional water 
was added (2 mL), and the solution was cooled in an ice bath, then acidified with 
concentrated HCl. The resulting precipitate was collected over a filter and washed with 
cold 1 M HCl, then dried under high vacuum to afford the desired carboxylic acid as a 
white powder. Yield: 111 mg (78%). 
1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.3 Hz, 
2H), 7.04 (d, J = 8.3 Hz, 2H), 6.79 (d, J = 2.0 Hz, 1H), 6.71−6.65 (m, 1H), 5.43 (s, 2H). 
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Ethyl 1-(4-chlorobenzyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylate (144). Ethyl 1-
(4-chlorobenzyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylate 143 (300 mg, 0.953 mmol) 
was dissolved into ethanol (8 mL) at RT, followed by the addition of 10% aqueous NaOH 
(8 mL), which initially caused precipitation, but homogeneity was achieved over time. 
The reaction was allowed to stir at RT for 12 h, at which time the solvent was removed in 
vacuo. The residue was taken up in a small amount of water (5 mL), the pH was adjusted 
to ∼4, and material was extracted with ethyl acetate (8×). The extracts were combined 
and the solvent removed again in vacuo to provide the title compound as a fine white 
powder. Yield: 226 mg, 83%. 
1
H NMR (400 MHz, DMSO-d6) δ 9.64 (s, 1H), 8.40 (d, J = 
6.3 Hz, 1H), 8.26 (d, J = 6.3 Hz, 1H), 7.61 (s, 1H), 7.35 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 
8.5 Hz, 2H), 6.06 (s, 2H). 
 
(4-(Cyclohexylmethyl)piperazin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-
yl)methanone (CCG-203941). The following reagents were dissolved in anhydrous DMF 
(1.5 mL) at RT: 1-(4-fluorobenzyl)-1H-indole-2-carboxylic acid 4b (50 mg, 0.186 
mmol), 1-(cyclohexylmethyl)piperazine (34 mg, 0.186 mmol), DIPEA (97 µL, 0.557 
mmol), EDCHCl (46 mg, 0.241 mmol), and HOBT (37 mg, 0.241 mmol). The reaction 
was allowed to stir for 24 h at RT, after which time it was diluted with 1:1 EtOAc:Et2O 
and washed with 10% aq. Na2CO3 (2X), then dried (MgSO4) and concentrated. The 
residue was purified by silica flash chromatography (20 g silica, 60% EtOAc:Hex). 
Yield: 45 mg, 0.10 mmol, 53%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J = 7.9 
Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.32 – 7.29 (m, 1H), 7.20 – 7.16 (m, 1H), 7.11 (dd, J = 
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8.6, 5.4 Hz, 2H), 6.95 (t, J = 8.7 Hz, 2H), 6.64 (s, 1H), 5.51 (s, 2H), 3.65 (bd, J = 74.0 
Hz, 4H), 2.36 (s, 2H), 2.11 – 1.95 (m, 4H), 1.79 – 1.67 (m, 5H), 1.31 – 1.16 (m, 4H), 0.89 
– 0.80 (m, 2H). HPLC tR = 6.65 min, >95% purity. 
 
(4-Benzylpiperazin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-yl)methanone (CCG-
203942). The following was added sequentially to anhydrous DMF: 1-(4-fluorobenzyl)-
1H-indole-2-carboxylic acid (50 mg, 0.186 mmol), DIPEA (65 µL, 0.371 mmol), 
EDCHCl (46 mg, 0.241 mmol), HOBT (37 mg, 0.241 mmol), and 1-benzylpiperazine 
(33 mg, 0.186 mmol). The solution was allowed to stir at room temperature for 22 h. At 
this time, a 1:1 solution of EtOAc:Et2O (5 mL) was added, and this was washed with 
aqueous 10% Na2CO3 (3X). The extract was then dried with anhydrous MgSO4, filtered, 
and the filtrate was concentrated in vacuo. The crude residue was purified by column 
chromatography (20 g silica, 80% EtOAC/Hexanes) to provide the title compound. Yield: 
57 mg, 0.13 mmol, 72 %. 
1
H NMR (500 MHz, Chloroform-d) δ 7.68 (d, J = 7.9 Hz, 1H), 
7.43 (d, J = 8.3 Hz, 1H), 7.39 – 7.31 (m, 6H), 7.20 (t, J = 7.5 Hz, 1H), 7.12 (dd, J = 7.8, 
5.6 Hz, 2H), 6.98 (t, J = 8.5 Hz, 2H), 6.66 (s, 1H), 5.53 (s, 2H), 3.68 (bd, J = 67.9 Hz, 
4H), 3.49 (s, 2H), 2.21 (bd, 4H). HPLC tR = 5.91 min, > 95%. 
 
(4-Benzoylpiperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-yl)methanone (CCG-
203943). The following reagents were dissolved in anhydrous DMF (2 mL) at RT: 1-(4-
fluorobenzyl)-1H-indole-2-carboxylic acid (50 mg, 0.186 mmol), phenyl(piperidine-4-
yl)methanone hydrochloride (42 mg, 0.186 mmol), DIPEA (72 µL, 0.557 mmol), 
EDCHCl (46 mg, 0.241 mmol), and HOBT (37 mg, 0.241 mmol). The reaction was 
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allowed to stir for 24 h at RT, after which time it was diluted with 1:1 EtOAc:Et2O and 
washed with 10% aq. Na2CO3 (3X), then dried (MgSO4) and concentrated. The residue 
was purified by silica flash chromatography (20 g silica, 80% EtOAc:Hex). Yield: 68 mg, 
0.154 mmol, 83%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.96 (dt, J = 8.4, 1.2 Hz, 2H), 
7.72 – 7.65 (m, 1H), 7.64 – 7.58 (m, 1H), 7.54 – 7.49 (m, 2H), 7.41 (d, J = 8.3 Hz, 1H), 
7.30 (ddd, J = 8.5, 7.1, 1.1 Hz, 1H), 7.19 (td, J = 7.4, 1.0 Hz, 1H), 7.16 – 7.11 (m, 2H), 
7.02 – 6.93 (m, 2H), 6.69 (d, J = 0.9 Hz, 1H), 5.52 (s, 2H), 4.63 (bs, 1H), 4.20 (bs, 1H), 
3.51 (tt, J = 10.7, 3.7 Hz, 1H), 3.06 (s, 2H), 2.05 – 1.48 (m, 4H). HPLC tR = 8.32 min, 
>95%. 
 
(4-(Benzyloxy)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-yl)methanone 
(CCG-203944). The following reagents were dissolved in anhydrous DMF (3 mL) at RT: 
1-(4-fluorobenzyl)-1H-indole-2-carboxylic acid (50 mg, 0.186 mmol), 4-
(benzyloxy)piperidine hydrochloride (42 mg, 0.186 mmol), DIPEA (72 µL, 0.557 mmol), 
EDCHCl (46 mg, 0.241 mmol), and HOBT (37 mg, 0.241 mmol). The reaction was 
allowed to stir for 24 h at RT, after which time it was diluted with 1:1 EtOAc:Et2O and 
washed with 10% aq. Na2CO3 (3X), then dried (MgSO4) and concentrated. The residue 
was purified by silica flash chromatography (20 g silica, 80% EtOAc:Hex). Yield: 29 mg, 
0.066 mmol, 35%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.70 (d, J = 7.9 Hz, 1H), 7.45 – 
7.37 (m, 5H), 7.36 – 7.28 (m, 2H), 7.21 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 7.16 – 7.11 (m, 
2H), 7.00 – 6.94 (m, 2H), 6.68 (d, J = 0.8 Hz, 1H), 5.53 (s, 2H), 4.58 (s, 2H), 3.92 (bd, J 
= 66.0 Hz, 2H), 3.66 (tt, J = 7.2, 3.5 Hz, 1H), 3.47 (bd, J = 48.5 Hz, 2H), 1.97 – 1.42 (m, 
4H). HPLC tR = 8.86 min, >95% purity. 
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(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(piperidine-1-carbonyl)piperidin-1-
yl)methanone (CCG-203945). The following was added sequentially to anhydrous DMF 
(2 mL): 1-(4-fluorobenzyl)-1H-indole-2-carboxylic acid (50 mg, 0.186 mmol), DIPEA 
(0.065 ml, 0.371 mmol), EDCHCl (46.3 mg, 0.241 mmol), HOBT (37.0 mg, 0.241 
mmol), and piperidin-1-yl(piperidin-4-yl)methanone (36.4 mg, 0.186 mmol). The 
solution was allowed to stir at RT for 24 h. At this time, a 1:1 solution of EtOAc:Et2O (5 
mL) was added, and this was washed with aqueous 10% Na2CO3 (3 x 2 mL). The extract 
was then dried with anhydrous MgSO4, filtered, and the filtrate was concentrated in 
vacuo. The crude residue was purified by column chromatography (20 g silica, 80% 
EtOAc/Hex) to provide the title compound. Yield: 35 mg, 0.065 mmol, 35%. 
1
H NMR 
(500 MHz, Chloroform-d) δ 7.70 – 7.64 (m, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.28 (dt, J = 
5.9, 1.3 Hz, 1H), 7.17 (td, J = 7.5, 7.0, 1.0 Hz, 1H), 7.12 (dd, J = 8.5, 5.4 Hz, 2H), 6.99 – 
6.93 (m, 2H), 6.67 (s, 1H), 5.49 (s, 2H), 4.61 (bs, 1H), 4.24 (bs, J = 8.8, 5.8 Hz, 1H), 3.58 
(t, J = 5.5 Hz, 2H), 3.49 – 3.37 (m, 2H), 2.93 (d, J = 12.7 Hz, 2H), 2.75 (dq, J = 14.3, 7.7, 
7.1 Hz, 1H), 1.77 – 1.58 (m, 8H), 1.31 – 1.25 (m, 1H), 0.94 – 0.81 (m, 1H). HPLC tR = 
7.55 min, >95% purity. 
 
(4-(Dibenzylamino)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-yl)methanone 
(CCG-204020). Tert-butyl 4-(dibenzylamino)piperidine-1-carboxylate (330 mg, 0.867 
mmol) was dissolved in DCM (5 mL), followed by the addition of trifluoroacetic acid 
(0.200 mL, 2.60 mmol). The reaction was allowed to stir for 18 h at RT, after which time 
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the solvent was removed in vacuo and the crude residue of N,N-dibenzylpiperidin-4-
amine bis(trifluoroacetate) was used directly in the subsequent reaction  
The following reagents were dissolved in anhydrous DMF (5 mL) at RT: 1-(4-
fluorobenzyl)-1H-indole-2-carboxylic acid (233 mg, 0.867 mmol), N,N-
dibenzylpiperidin-4-amine bis(trifluoroacetate) (243 mg, 0.867 mmol), DIPEA (757 µL, 
4.34 mmol), EDCHCl (183 mg, 0.954 mmol), and HOBT (146 mg, 0.954 mmol). The 
reaction was allowed to stir for 36 h at RT, after which time it was diluted with 1:1 
EtOAc:Et2O and washed with 10% aq. Na2CO3 (2X), then dried (MgSO4) and 
concentrated. The residue was triturated with Et2O to yield a light brown solid. Yield: 
380 mg, 0.715 mmol, 82%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.69 (dd, J = 8.0, 3.9 
Hz, 1H), 7.43 – 7.38 (m, 5H), 7.37 – 7.31 (m, 5H), 7.29 – 7.25 (m, 2H), 7.21 (t, J = 7.3, 
3.4 Hz, 1H), 7.11 – 7.07 (m, 2H), 6.94 (t, J = 11.1, 8.7, 2.0 Hz, 2H), 6.65 (s, 1H), 5.53 (s, 
2H), 4.78 (bs, 1H), 4.17 (bs, 1H), 3.59 (s, 4H), 2.85 – 2.67 (m, 2H), 2.58 (bs, 1H), 1.92 
(bs, 1H), 1.67 (bs, 1H), 1.49 (bs, 1H), 1.04 (bs, J = 30.5 Hz, 1H). HPLC tR = 6.48 min, 
>95%. 
 
N-Benzyl-1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-
carboxamide (CCG-204054). The following was dissolved in anhydrous DMF (3 mL): 1-
(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-carboxylic acid (115 mg, 0.332 
mmol), Hunig's Base (0.174 ml, 0.995 mmol), EDCHCl (76 mg, 0.398 mmol), HOBt 
(60.9 mg, 0.398 mmol), and benzylamine (0.040 ml, 0.365 mmol). This was stirred at 
room temperature for 1 day with 3Å molecular sieves. At this time, a 1:1 solution of 
EtOAc:Et2O (20 mL) was added and the organic layer was washed with 10% aq. 
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Na2CO3 (2 x 10 mL) and brine (1 x 10 mL). The organic solution was then dried 
(anhydrous MgSO4) and concentrated in vacuo. Trituration in Et2O provided 101 mg of 
the title compound as a fine, ruddy brown solid. 
1
H NMR (500 MHz, Chloroform-d) δ 
7.39 – 7.34 (m, 2H), 7.33 – 7.26 (m, 5H), 7.06 (dd, J = 8.9, 2.5 Hz, 2H), 6.82 (dd, J = 2.7, 
1.7 Hz, 1H), 6.35 (dd, J = 3.7, 1.6 Hz, 1H), 6.15 (dd, J = 3.7, 2.7 Hz, 1H), 5.76 (s, 1H), 
5.30 (s, 2H), 4.47 (d, J = 5.6 Hz, 2H), 4.39 (bd, J = 13.3 Hz, 2H), 2.86 (t, J = 12.7 Hz, 
2H), 2.33 (tt, J = 11.3, 3.8 Hz, 1H), 1.81 (d, J = 13.0 Hz, 2H), 1.51 (d, J = 12.9 Hz, 2H). 
HPLC tR = 7.06 min, > 95%. 
 
(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(piperidin-1-ylmethyl)piperidin-1-
yl)methanone (CCG-204055).  Tert-butyl 4-(piperidin-1-ylmethyl)piperidine-1-
carboxylate (100 mg, 0.469 mmol) was dissolved in DCM (5 mL), and TFA (1 mL) was 
added. The reaction was allowed to stir for 12 h, after which time the solvent was 
stripped off in vacuo, then thoroughly removed under high vacuum. The crude residue 
was then taken directly into the next step. 
The following was added to anhydrous DMF (2 mL) sequentially: 1-(4-
fluorobenzyl)-1H-indole-2-carboxylic acid (66.8 mg, 0.248 mmol), DIPEA (0.217 ml, 
1.240 mmol), EDCHCl (52.3 mg, 0.273 mmol), HOBT (41.8 mg, 0.273 mmol), and 1-
(piperidin-4-ylmethyl)piperidine trifluoroacetate (45.2 mg, 0.248 mmol). This was stirred 
at room temperature for 24 h with 3Å MS. At this time, a 1:1 solution of EtOAc:Et2O 
was added and the solution was washed with 10% aq. Na2CO3. The organic phase was 
dried with MgSO4 and concentrated in vacuo. The residue was then purified by silica gel 
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chromatography (20g silica, 80% EtOAc/Hexanes) to give an oil. Yield: 58 mg , 0.134 
mmol, 54%. HPLC tR = 5.36 min, > 95%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.66 (d, 
J = 7.9 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.29 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.18 (ddd, 
J = 8.0, 7.0, 0.9 Hz, 1H), 7.14 – 7.09 (m, 2H), 6.99 – 6.92 (m, 2H), 6.63 (d, J = 0.7 Hz, 
1H), 5.50 (s, 2H), 4.66 (bs, 1H), 4.10 (bs, 1H), 2.77 (d, J = 64.4 Hz, 2H), 2.41 – 2.27 (m, 
4H), 2.11 – 2.02 (m, 2H), 1.83 – 1.53 (m, 5H), 1.48 – 1.39 (m, 2H), 1.05 (bs, 1H), 0.66 
(bs, 1H). HPLC tR = 5.36 min, >95% purity. 
 
(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(hydroxy(phenyl)methyl)piperidin-1-
yl)methanone (CCG-204056). The following was added sequentially to anhydrous DMF 
(5 mL): 1-(4-fluorobenzyl)-1H-indole-2-carboxylic acid (0.119 g, 0.443 mmol), 
Hunig'sBase (0.232 ml, 1.329 mmol), EDCHCl (0.093 g, 0.487 mmol), HOBT (0.075 g, 
0.487 mmol), and phenyl(piperidin-4-yl)methanol (0.085 g, 0.443 mmol). The solution 
was stirred at room temperature for 30 h, at which time a 1:1 solution of EtOAc:Et2O 
was added and washed with 10% aq. Na2CO3. The organic solution was dried with 
MgSO4 and concentrated in vacuo to give a residue that was purified by silica gel 
chromatography (45 g silica, 80% EtOAc/Hex). Yield: 67 mg, . 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.66 (d, J = 7.9 Hz, 1H), 7.38 (dd, J = 14.5, 7.8 Hz, 3H), 7.32 – 7.26 (m, 
4H), 7.17 (t, J = 7.5 Hz, 1H), 7.09 (dd, J = 8.5, 5.3 Hz, 2H), 6.98 – 6.92 (m, 2H), 6.61 (s, 
1H), 5.48 (d, J = 6.5 Hz, 2H), 4.67 (d, J = 54.5 Hz, 1H), 4.30 – 4.23 (m, 1H), 4.22 – 3.93 
(m, 1H), 2.86 – 2.52 (m, 2H), 2.43 – 1.83 (m, 2H), 1.79 (dtd, J = 11.5, 7.7, 3.7 Hz, 1H), 
1.28 – 0.94 (m, 2H). HPLC tR = 7.85 min, > 95%. 
 
163 
 
(4-(Benzylamino)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-yl)methanone 
(CCG-205420). (4-(Dibenzylamino)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-
yl)methanone CCG-204020 was dissolved in EtOH (10 mL) and THF (10 mL), along 
with a few drops of conc. HCl. This solution was sparged with N2 and Pd(OH)2 was 
added. The reaction was then shaken on a hydrogenator at 45 psi H2 at RT for 1 h (longer 
reaction times cause rapid accumulation of complete debenzylation.) The reaction was 
filtered over celite and the filtrate was diluted with EtOAc and washed with sat. aq. 
Na2CO3 (1X), dried (MgSO4) and concentrated to give the desired compound as an oil. 
Yield: 77%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.70 – 7.65 (m, 1H), 7.41 – 7.32 (m, 
5H), 7.32 – 7.27 (m, 2H), 7.22 – 7.16 (m, 1H), 7.12 (dd, J = 8.3, 5.3 Hz, 2H), 6.96 (ddd, J 
= 9.7, 7.5, 1.1 Hz, 2H), 6.65 (s, 1H), 5.51 (s, 2H), 4.49 (bs, 1H), 4.07 (bs, 1H), 3.83 (s, 
2H), 3.00 (bs, 2H), 2.77 (tt, J = 9.9, 4.0 Hz, 1H), 2.04 – 1.64 (m, 2H), 1.32 (m, 2H). TOF 
ES+ MS: 442.1 (M + H), 464.1 (M + Na). HPLC tR = 5.83 min, > 90%. 
 
(4-(Cyclohexyl(hydroxy)methyl)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-
yl)methanone (CCG-205421).  Tert-butyl 4-(cyclohexyl(hydroxy)methyl)piperidine-1-
carboxylate (100 mg, 0.336 mmol) was dissolved in anhydrous THF (5 mL) and TFA (52 
µL, 0.672 mmol) and stirred at RT for 15 h. After this time, the solvent was removed in 
vacuo via rotovap, then thoroughly removed under high vacuum. The resulting residue 
was taken directly into the next step. 
4-(Cyclohexyl(hydroxy)methyl)piperidine trifluoroacetate (~105 mg, 0.336 
mmol) was dissolved in anhydrous DMF (3 mL), followed by 1-(4-fluorobenzyl)-1H-
indole-2-carboxylic acid (100 mg, 0.370 mmol), DIPEA (0.352 mL, 2.016 mmol), 
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EDCHCl (77 mg, 0.403 mmol), and HOBT (62 mg, 0.403 mmol). The reaction was 
allowed to stir at RT for 24 h, after which time the reaction was diluted with 1:1 
EtOAc:Et2O and washed with 10% aq. Na2CO3 (3X), dried (MgSO4), and concentrated. 
The resulting residue was purified by silica flash chromatography (20 g silica, 80% 
EtOAc:Hex). Yield: 90 mg, 0.202 mmol, 60%. 
1
H NMR (500 MHz, Chloroform-d) δ 
7.66 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.31 – 7.27 (m, 1H), 7.18 (ddd, J = 7.9, 
7.0, 1.0 Hz, 1H), 7.14 – 7.08 (m, 2H), 6.98 – 6.92 (m, 2H), 6.64 (d, J = 0.8 Hz, 1H), 5.51 
(s, 2H), 4.75 (bs, 1H), 4.15 (bs, 1H), 3.05 (d, J = 5.6 Hz, 1H), 2.83 (bs, 1H), 2.68 (bs, 
1H), 1.82 – 1.58 (m, 7H), 1.41 – 1.04 (m, 9H). ES+ TOF MS: 449.2 (M + H), 471.2 (M + 
Na). HPLC tR = 8.72 min, > 90%. 
 
N-Benzyl-1-(1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carbonyl)piperidine-4-
carboxamide (CCG-205431). Ethyl 1-(4-chlorobenzyl)-3-methyl-1H-indole-2-
carboxylate (310 mg, 0.946 mmol) was dissolved in THF (20 mL) and 5 M aq. NaOH (20 
mL) and stirred at 55 °C for 18 h. The reaction was then cooled to 0 °C and acidified to 
pH<1 with conc. HCl and material was extracted from the aqueous phase with 1:1 
EtOAc:Et2O. The extract was dried (MgSO4) and concentrated, giving 1-(4-
chlorobenzyl)-3-methyl-1H-indole-2-carboxylic acid as a yellow solid. Yield: 273 mg, 
0.911 mmol, 96%. 
The following reagents were dissolved in anhydrous DMF (3 mL) at RT: 1-(4-
chlorobenzyl)-3-methyl-1H-indole-2-carboxylic acid (90 mg, 0.315 mmol), N-
benzylpiperidine-4-carboxamide hydrochloride (70 mg, 0.315 mmol), DIPEA (170 µL, 
0.945 mmol), and HATU (144 mg, 0.378 mmol). The reaction was allowed to stir for 20 
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h at RT, after which time it was diluted with 1:1 EtOAc:Et2O and washed with 10% aq. 
Na2CO3 (3X), then dried (MgSO4) and concentrated. The residue was purified by silica 
flash chromatography (20 g silica, 50% EtOAc:Hex). Yield: 77 mg, 0.153 mmol, 51%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.59 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.3 Hz, 7H), 
7.18 (t, J = 7.8 Hz, 3H), 7.03 (t, J = 8.2 Hz, 2H), 5.73 (s, 1H), 5.57 (s, 1H), 5.38 (d, J = 
11.8 Hz, 2H), 4.77 (d, J = 10.9 Hz, 1H), 4.44 (d, J = 5.9 Hz, 2H), 3.76 (d, J = 14.8 Hz, 
1H), 3.08 (d, J = 17.3 Hz, 1H), 2.80 (s, 3H), 2.29 (d, J = 21.5 Hz, 3H), 1.96 (d, J = 11.2 
Hz, 1H), 1.76 (d, J = 17.2 Hz, 1H), 1.52 (s, 1H). ES+ TOF MS: 500.3 (M + H), 522.2 (M 
+ Na). HPLC tR = 7.95 min, > 95%. 
 
 (1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(isoindoline-2-carbonyl)piperidin-1-
yl)methanone. (CCG-205470) The following was added sequentially to DCM (2 mL): 1-
(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (50 mg, 0.126 
mmol), DIPEA (0.07 mL, 0.378 mmol), EDCHCl (30 mg, 0.151 mmol), HOBT (24 mg, 
0.151 mmol), and isoindoline (0.018 mL, 0.151 mmol). The mixture was stirred for 18 h 
at RT, at which time the solution diluted with a 1:1 solution of EtOAc:Et2O and washed 
with 1M HCl (1X), 10% aq. Na2CO3 (1X) and brine (1X). The organic phase was dried 
with magnesium sulfate and concentrated in vacuo. The resulting residue was dissolved 
in EtOAc and precipitated out with Hex, and then collected over a filter and washed with 
a 10:1 solution of Hex:EtOAc. Yield: 22 mg, 0.044 mmol, 35%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 7.65 (d, J = 7.9 Hz, 1H), 7.40 – 7.21 (m, 8H), 7.15 (t, J = 7.4 Hz, 1H), 
7.05 (d, J = 8.3 Hz, 2H), 6.68 (d, J = 1.6 Hz, 1H), 5.47 (s, 2H), 4.88 (s, 2H), 4.81 (s, 2H), 
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4.42 (bs, 4H), 2.97 (bs, 2H), 2.72 (td, J = 14.7, 12.7, 4.7 Hz, 1H), 1.78 (bs, 2H). ES+ 
TOF MS: 498.2 (M + H), 520.2 (M + Na). HPLC tR = 5.85 min, > 95%. 
 
 1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2,3-dihydro-1H-inden-2-yl)piperidine-
4-carboxamide. (CCG-205471) The following was added sequentially to DCM (2 mL): 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (50 mg, 0.126 
mmol), DIPEA (0.07 mL, 0.378 mmol), EDCHCl (30 mg, 0.151 mmol), HOBT (24 mg, 
0.151 mmol), and 2-aminoindane (0.020 mL, 0.151 mmol). The mixture was stirred for 
36 h at rt, at which time the solution diluted with a 1:1 solution of EtOAc:Et2O and 
washed with 1M HCl (1X), 10% aq. Na2CO3 (1X) and brine (1X), which resulted in a 
precipitate that failed to go into either phase. The precipitate was collected and washed 
with water and Et2O to afford the title compound as a white solid. Yield: 52 mg, 0.102 
mmol, 81%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.64 (d, J = 7.9 Hz, 1H), 7.35 – 7.29 
(m, 1H), 7.25 – 7.11 (m, 8H), 7.03 (d, J = 8.1 Hz, 2H), 6.64 (s, 1H), 5.62 (d, J = 7.6 Hz, 
1H), 5.46 (s, 2H), 4.83 – 4.69 (m, 1H), 4.32 (bs, 4H), 3.33 (dd, J = 16.3, 7.0 Hz, 2H), 
2.89 – 2.72 (m, 4H), 2.27 – 2.14 (m, 1H), 1.74 (bs, 2H). ES+ TOF MS: 512.2 (M + H), 
534.2 (M + Na). HPLC tR = 5.96 min, > 95%. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2,3-dihydro-1H-inden-1-
yl)piperidine-4-carboxamide (CCG-205472). The following was added sequentially to 
DCM (2 mL): 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid 
71 (50 mg, 0.13 mmol), DIPEA (0.07 mL, 0.38 mmol), EDCHCl (30 mg, 0.15 mmol), 
HOBT (24 mg, 0.15 mmol), and 1-aminoindane (20 µL, 0.15 mmol). The mixture was 
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stirred for 18 h at rt, at which time the solution diluted with a 2:1 solution of EtOAc:Et2O 
and washed with 1M HCl (2X), 10% aq. Na2CO3 (1X) and brine (1X). The organic phase 
was dried with MgSO4 and concentrated in vacuo. The resulting residue was dissolved in 
EtOAc and precipitated out Hex, and then collected over a filter and washed with Et2O to 
give the title compound as a white solid. Yield: 33 mg, 0.06 mmol, 51%. 
1
H NMR (500 
MHz, Chloroform-d) δ 7.66 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.29 – 7.20 (m, 
7H), 7.17 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 8.0 Hz, 2H), 6.66 (s, 1H), 5.66 (d, J = 8.4 Hz, 
1H), 5.47 (s, 2H), 4.49 (bs, 1H), 4.33 (bs, 1H), 3.04 – 2.95 (m, 1H), 2.89 (dt, J = 15.9, 8.0 
Hz, 3H), 2.62 (dtd, J = 12.2, 7.8, 3.8 Hz, 1H), 2.33 (tt, J = 11.1, 3.9 Hz, 1H), 1.94 – 1.54 
(m, 6H). ES+ TOF MS: 512.2 (M + H), 534.2 (M + Na). HPLC tR = 5.93 min, > 95%.  
 
(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(2-phenylpyrrolidine-1-carbonyl)piperidin-
1-yl)methanone. (CCG-205473) The following was added sequentially to DCM (2 mL): 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid 71 (50 mg, 
0.126 mmol), DIPEA (0.07 mL, 0.378 mmol), EDCHCl (30 mg, 0.151 mmol), HOBT 
(24 mg, 0.151 mmol), and 2-phenylpyrrolidine (0.023 mL, 0.151 mmol). The mixture 
was stirred for 18 h at rt, at which time the solution diluted with a 1:1 solution of 
EtOAc:Et2O and washed with 1M HCl (1X), 10% aq. sodium carbonate (1X) and brine 
(1X). The organic phase was dried with magnesium sulfate and concentrated in vacuo. 
The resulting residue was dissolved in EtOAc and precipitated out hexanes, and then 
collected over a filter and washed with diethyl ether to give the title compound as a white 
solid. Yield: 20 mg, 0.038 mmol, 30%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.66 – 7.57 
(m, 1H), 7.33 – 7.14 (m, 10H), 7.00 (d, J = 8.1 Hz, 2H), 6.58 (s, 1H), 5.41 (s, 2H), 4.34 
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(s, 4H), 3.73 (dd, J = 19.2, 11.3 Hz, 2H), 3.07 – 2.88 (m, 1H), 2.73 (s, 1H), 2.51 – 2.26 
(m, 3H), 2.04 – 1.44 (m, 5H). ES+ TOF MS: 526.2 (M + H), 548.2 (M + Na). HPLC tR = 
6.62 min, > 95%. 
 
(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(3-phenylpyrrolidine-1-carbonyl)piperidin-
1-yl)methanone. (CCG-205474) The following was added sequentially to DCM (2 mL): 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (50 mg, 0.126 
mmol), DIPEA (0.07 mL, 0.378 mmol), EDCHCl (30 mg, 0.151 mmol), HOBT (24 mg, 
0.151 mmol), and 3-phenylpyrrolidine (0.023 mL, 0.151 mmol). The mixture was stirred 
for 36 h at rt, at which time the solution diluted with a 1:1 solution of EtOAc:Et2O and 
washed with 1M HCl (1X), 10% aq. sodium carbonate (1X) and brine (1X). The organic 
phase was dried with magnesium sulfate and concentrated in vacuo. The resulting residue 
was dissolved in EtOAc and precipitated out hexanes, and then collected over a filter and 
washed with diethyl ether to give the title compound as a slightly yellow solid. Yield: 21 
mg, 0.040 mmol, 32%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.66 (dd, J = 7.8, 2.8 Hz, 
1H), 7.34 (dq, J = 14.5, 7.4 Hz, 3H), 7.29 – 7.20 (m, 6H), 7.16 (t, J = 7.8 Hz, 1H), 7.06 
(dd, J = 7.9, 5.4 Hz, 2H), 6.68 (d, J = 6.3 Hz, 1H), 5.48 (d, J = 5.0 Hz, 2H), 4.57 (s, 1H), 
4.33 (s, 1H), 4.03 (dd, J = 11.9, 7.5 Hz, 1H), 3.98 – 3.91 (m, 1H), 3.85 (ddd, J = 11.6, 
8.3, 2.4 Hz, 1H), 3.73 (td, J = 9.1, 8.3, 2.9 Hz, 1H), 3.60 (td, J = 9.6, 6.8 Hz, 1H), 3.49 
(ddd, J = 21.3, 9.6, 4.0 Hz, 2H), 3.38 (p, J = 7.9 Hz, 1H), 2.92 (s, 2H), 2.62 (dp, J = 21.4, 
7.5 Hz, 1H), 2.46 – 2.36 (m, 1H), 2.31 (dq, J = 13.1, 4.1, 2.6 Hz, 1H), 2.16 – 2.00 (m, 
2H). ES+ TOF MS: 526.3 (M + H), 548.2 (M + Na). HPLC tR = 6.37 min, > 95%. 
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(4-(Cyclohexanecarbonyl)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-yl)methanone 
(CCG-205475). 4-(Cyclohexyl(hydroxy)methyl)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-
indol-2-yl)methanone (85 mg, 0.189 mmol) was dissolved in DCM (4 mL) and cooled to 
-78 °C. Anhydrous DMSO (34 µL, 0.474 mmol) and (COCl)2 (34 µL, 0.379 mmol) were 
added, and the solution was stirred for 30 min, at which time TEA (130 µL, 0.947 mmol) 
was added dropwise and the reaction was allowed to stir for an additional 30 min, then 
the bath was removed and it was allowed to stir until it reached RT. The reaction was 
diluted with 1:1 EtOAc:Et2O and washed with H2O (2X) and brine (1X), dried (MgSO4), 
and concentrated in vacuo. The residue was purified via silica flash chromatography (50 
g silica, 10% EtOAc:Hex). Yield: 49 mg, 0.106 mmol, 58%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.64 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.29 – 7.24 (m, 1H), 
7.15 (t, J = 7.5 Hz, 1H), 7.08 (dd, J = 8.2, 5.5 Hz, 2H), 6.99 – 6.89 (m, 2H), 6.62 (s, 1H), 
5.47 (s, 2H), 4.54 (bs, 1H), 4.15 (bs, 1H), 2.94 – 2.81 (m, 2H), 2.68 (tt, J = 11.2, 3.6 Hz, 
1H), 2.46 (tt, J = 11.1, 2.9 Hz, 1H), 1.82 – 1.64 (m, 7H), 1.38 – 1.17 (m, 7H). TOF ES+ 
MS: (M + Na) 469.2. HPLC tR = 8.93 min, > 90%. 
 
(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(piperidin-1-ylmethyl)piperidin-1-
yl)methanone (CCG-205476).  Tert-Butyl 4-(piperidin-1-ylmethyl)piperidine-1-
carboxylate (238 mg, 0.843 mmol) was dissolved in DCM (10 mL), and TFA (2 mL) was 
added. The reaction was allowed to stir for 12 h, after which time the solvent was 
stripped off in vacuo, then thoroughly removed under high vacuum. The crude residue 
was then taken directly into the next step. 
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The following was added to DCM (6 mL): 1-(4-chlorobenzyl)-1H-indole-2-
carboxylic acid (110 mg, 0.380 mmol), DIPEA (0.50 mL, 2.95 mmol), EDCHCl (100 
mg, 0.506 mmol), HOBT (80 mg, 0.506 mmol), and 1-(piperidin-4-ylmethyl)piperidine 
(150 mg, 0.843 mmol). The solution was stirred at RT for 15 h, at which time the solution 
was diluted with a 1:1 solution of EtOAc:Et2O and washed with H2O (1X), 10% aq. 
Na2CO3 (1X), and brine (1X). The organic phase was then dried over MgSO4 and 
concentrated in vacuo. The resulting residue was purified via silica flash chromatography 
(40 g silica, 10% EtOAc:Hex) and triturated with EtOAc and Hex to afford the title 
compound as a white powder. Yield: 109 mg, 0.242 mmol, 63%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 7.63 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.28 – 7.11 (m, 4H), 
7.03 (d, J = 8.4 Hz, 2H), 6.59 (s, 1H), 5.46 (s, 2H), 4.59 (bs, 2H), 4.09 (bs, 2H), 2.73 (bs, 
2H), 2.34 (bs, 2H), 2.08 (d, J = 6.8 Hz, 2H), 1.67 (s, 6H), 1.44 – 1.32 (m, 2H), 0.95 (bs, 
1H), 0.56 (bs, 1H). ES+ TOF MS: 450.2 (M + H). HPLC tR = 6.18 min, > 95%. 
 
(4-Benzylpiperazin-1-yl)(1-(4-chlorobenzyl)-1H-indol-2-yl)methanone (CCG-
206327). The following was added to DCM (5 mL): 1-(4-chlorobenzyl)-1H-indole-2-
carboxylic acid (70 mg, 0.245 mmol), DIPEA (0.130 mL, 0.735 mmol), EDCHCl (57 
mg, 0.294 mmol), HOBT (45 mg, 0.294 mmol), and 1-benzylpiperazine (0.085 mL, 
0.490 mmol). The solution was stirred at RT for 16 h, at which time the solution was 
diluted with a 1:1 solution of EtOAc:Et2O and washed with H2O (1X), 10% aq. Na2CO3 
(1 x), and brine (1 x). The organic phase was then dried over MgSO4 and concentrated in 
vacuo. The resulting residue was purified via silica flash chromatography (30 g silica, 
10% EtOAc:Hex) and triturated with EtOAc and Hex to afford the title compound as a 
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white powder. Yield: 52 mg, 0.117 mmol, 48%. 
1
H NMR (400 MHz, Chloroform-d) δ 
7.62 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.32 – 7.19 (m, 8H), 7.14 (t, J = 7.5 
Hz, 1H), 7.02 (d, J = 8.2 Hz, 2H), 6.60 (s, 1H), 5.48 (s, 2H), 3.63 (bs, 4H), 3.42 (s, 2H), 
2.35 (bs, 2H), 2.04 (bs, J = 11.7 Hz, 2H). TOF ES+ MS: (M + H) 444.2, (M + Na) 466.2. 
HPLC tR = 6.12 min, > 95%. 
 
  (1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(indoline-1-carbonyl)piperidin-1-
yl)methanone. (CCG-206328) The following was added sequentially to DCM (5 mL): 1-
(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (100 mg, 0.252 
mmol), DIPEA (1.4 mL, 0.756 mmol), EDCHCl (60 mg, 0.302 mmol), HOBT (48 mg, 
0.302 mmol), and indoline (0.040 mL, 0.302 mmol). The mixture was stirred for 24 h at 
rt, at which time the solution diluted with EtOAc and washed with water (2X) and brine 
(1X). The organic phase was dried with magnesium sulfate and concentrated in vacuo. 
The resulting residue was dissolved in EtOAc and precipitated out hexanes, and then 
collected over a filter and washed with diethyl ether to give the title compound as a white 
solid. Yield: 
1
H NMR (400 MHz, Chloroform-d) δ 7.66 (d, J = 7.8 Hz, 1H), 7.33 (t, J = 
8.8 Hz, 1H), 7.30 – 7.13 (m, 8H), 7.04 (d, J = 8.2 Hz, 2H), 6.65 (s, 1H), 5.48 (s, 2H), 
4.36 (s, 2H), 3.39 (t, J = 5.8 Hz, 2H), 3.08 (q, J = 9.6, 9.1 Hz, 2H), 2.99 – 2.82 (m, 2H), 
2.71 – 2.64 (m, 2H), 2.26 (tt, J = 11.3, 3.9 Hz, 1H), 1.76 (s, 2H), 1.50 (s, 2H). TOF ES+ 
MS: (M + H) 498.2. HPLC tR = 8.58 min, >95% purity. 
 
1-(1-(4-Chlorobenzyl)-1H-pyrrole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-206381). The following was added 
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sequentially to DCM: 1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)piperidine-4-
carboxylic acid (600 mg, 1.73 mmol), TEA (0.725 mL, 5.19 mmol), EDCHCl (365 mg, 
1.903 mmol), and HOBt (291 mqg, 1.903 mmol). This was allowed to stir at rt for 30 
min, at which time pyridylethylamine ( 0.227 mL, 1.903 mmol) was added. Stirring 
continued for 18 h. At this time, the DCM and TEA were stripped off, and the residue 
was taken up in EtOAc and washed with 10% aqueous sodium carbonate (3X). The 
organic phase was collected, dried over magnesium sulfate, and concentrated in vacuo. 
The resulting solid/oil mixture was recrystallized from EtOAc to afford the title 
compound as small, white crystals. Yield: 586 mg, 1.29 mmol, 75%. 
1
HNMR (400 MHz, 
CDCl3) δ 8.50 (d, J = 5.7 Hz, 2H), 7.21 (d, J = 8.3 Hz, 2H), 7.09 (d, J = 5.6 Hz, 2H), 7.02 
(d, J = 8.2 Hz, 2H), 6.78 (s, 1H), 6.30 (dd, J = 3.6, 1.2 Hz, 1H), 6.13−6.09 (m, 1H), 5.48 
(t, J = 5.4 Hz, 1H), 5.26 (s, 2H), 4.32 (d, J = 12.7 Hz, 2H), 3.53 (q, J = 6.8 Hz, 2H), 2.82 
(t, J = 7.0 Hz, 4H), 2.19 (tt, J = 11.2, 3.6 Hz, 1H), 1.68 (d, J = 14.4 Hz, 2H), 1.35 (q, J = 
11.0, 9.8 Hz, 2H). Anal. Calcd for C25H27ClN4O2: C, 66.58%; H, 6.04%; N, 12.42%. 
Found: C, 66.68%; H, 6.32%; N, 12.38%. TOF ES+ MS: (M + H) 451.2, (M + Na) 473.2. 
HPLC tR = 5.03 min, >95% purity. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide (CCG-206382). The following was added 
sequentially to DCM (8 mL): 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carboxylic acid (180 mg, 0.454 mmol), DIPEA (0.317 mL, 1.814 mmol), EDCHCl (96 
mg, 0.499 mmol), HOBT (76 mg, 0.499 mmol), and crude (2,3-dihydro-1H-inden-2-
yl)methanamine (105 mg, 0.713 mmol). The mixture was stirred for 18 h at RT, at which 
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time the solution diluted with a 1:1 solution of EtOAc:Et2O and washed with 1 M HCl 
(1X), 10% aq. Na2CO3 (1X). The organic phase was dried with MgSO4 and concentrated 
in vacuo. Purification was accomplished via silica flash chromatography (60 g silica, 
50% EtOAc:Hex), followed by EtOAc/Hex tritutation to give the title compound as a 
white powder. Yield: 137 mg, 0.260 mmol, 57%. 
1
H NMR (400 MHz, Chloroform-d) δ 
7.66 (d, J = 7.8 Hz, 1H), 7.33 (t, J = 8.8 Hz, 1H), 7.30 – 7.13 (m, 8H), 7.04 (d, J = 8.2 
Hz, 2H), 6.65 (s, 1H), 5.48 (s, 2H), 4.36 (s, 2H), 3.39 (t, J = 5.8 Hz, 2H), 3.08 (q, J = 9.6, 
9.1 Hz, 2H), 2.99 – 2.82 (m, 2H), 2.71 – 2.64 (m, 2H), 2.26 (tt, J = 11.3, 3.9 Hz, 1H), 
1.76 (s, 2H), 1.50 (s, 2H). TOF ES+ MS: (M + H) 526.2, (M + Na) 548.2. HPLC tR = 
8.25 min, > 95%. 
 
N-Benzyl-1-(1-(4-chlorobenzyl)-7-methyl-1H-indole-2-carbonyl)piperidine-4-
carboxamide (CCG-206447). The following was added to sequentially to anhydrous 
DMF (2 mL): 1-(4-chlorobenzyl)-7-methyl-1H-indole-2-carboxylic acid (50 mg, 0.167 
mmol), DIPEA (0.10 mL, 0.584 mmol), EDCHCl (38 mg, 0.200 mmol), and HOBT (31 
mg, 0.200 mmol). This was allowed to stir for 30 min at RT, after which time the crude 
N-benzylpiperidine-4-carboxamide (36 mg, 0.20 mmol) was added. The reaction was 
stirred at RT for 18 h, at which time the reaction was diluted with 1:1 EtOAc:Et2O and 
washed with 10% aq. Na2CO3 (2x), dried over MgSO4, and concentrated. The residue 
was purified via silica flash chromatography (20 g silica, 50% EtOAc:Hex) to afford the 
title compound as a white powder. Yield: 39 mg, 0.078 mmol, 47%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.51 (d, J = 7.7 Hz, 1H), 7.37 – 7.33 (m, 2H), 7.31 – 7.26 (m, 3H), 7.19 
(dd, J = 10.0, 3.6 Hz, 2H), 7.08 – 6.99 (m, 2H), 6.82 (d, J = 8.2 Hz, 2H), 6.64 (s, 1H), 
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5.73 (s, 2H), 4.58 (bs, 1H), 4.45 (t, J = 5.9 Hz, 2H), 4.11 (bs, 1H), 2.83 (bs, 2H), 2.58 (s, 
3H), 2.34 – 2.27 (m, 1H), 1.80 (bs, 2H), 1.37 (bs, 2H). TOF ES+ MS: (M + H) 500.2, ( M 
+ Na) 522.2. HPLC tR = 8.01 min, > 95%. 
 
(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone 
(CCG-206462). The following was added sequentially to DMF (10 mL): 1-(4-
fluorobenzyl)-1H-indole-2-carboxylic acid (1.175 g, 4.36 mmol), DIPEA (2.29 mL, 
13.09 mmol), EDCHCl (1.00 g, 5.24 mmol), and HOBT (802 mg, 5.24 mmol). This 
solution was allowed to stir at RT for 1.5 h, at which time 4-piperidinemethanol (754 mg, 
6.55 mmol) was added. Stirring continued for 22 h at RT, at which time the solution was 
partitioned between H2O and 1:1 solution of EtOAc:Et2O. The organic extract was then 
washed with saturated aq. Na2CO3, dried with MgSO4, and concentrated in vacuo. 
Purification was accomplished via silica flash chromatography (100 g silica, 80% 
EtOAc/Hexanes.) Resulting residue was crystallized via Et2O:Hex trituration to give the 
title compound as a white solid. Yield: 1.51 g, 4.11 mmol, 94%.  
1
H NMR (400 MHz, 
Chloroform-d) δ 7.63 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.29 – 7.22 (m, 1H), 
7.14 (t, J = 7.5 Hz, 1H), 7.10 – 7.04 (m, 2H), 6.91 (t, J = 8.2 Hz, 2H), 6.60 (s, 1H), 5.46 
(s, 2H), 4.64 (bs, 1H), 4.14 (bs, 1H), 3.42 (t, J = 5.1 Hz, 2H), 2.76 (s, 2H), 1.44 (t, J = 5.0 
Hz, 1H), 1.05 (bs, 1H), 0.71 (bs, 1H). HPLC tR = 6.62 min, >95% purity. 
 
2-Benzyl-5-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)octahydro-1H-pyrrolo[3,4-
c]pyridin-1-one. (CCG-206485) 5-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)octahydro-
1H-pyrrolo[3,4-c]pyridin-1-one (64 mg, 0.245 mmol) was dissolved in anhydrous DMF 
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(5 mL). A 60% oil suspension of NaH (29 mg, 0.735 mmol) was added at RT under N2 
and stirred for 1 h. BnBr (0.035 mL, 0.294 mmol) was added and stirring continued for 
18 h under the same conditions. After this time, the solution was diluted with EtOAc and 
washed with 10% aq. Na2CO3 (2X), dried with MgSO4, and concentrated in vacuo. 
Purification was done via silica flash chromatography (25 g silica, 80% EtOAc:Hex.) The 
residue was dissolved in DCM, and rapid solvent removal afforded the title compound as 
a white powder. Yield: 56 mg, 0.112 mmol, 72%. 
1
H NMR (500 MHz, Chloroform-d) δ 
7.71 (d, J = 7.9 Hz, 1H), 7.37 – 7.26 (m, 5H), 7.26 – 7.20 (m, 5H), 7.15 (t, J = 7.4 Hz, 
1H), 7.10 (d, J = 8.2 Hz, 2H), 5.49 (d, J = 3.7 Hz, 2H), 4.55 (d, J = 14.6 Hz, 2H), 4.39 (d, 
J = 14.5 Hz, 1H), 4.12 (bs, 1H), 3.43 – 3.30 (m, 2H), 2.98 – 2.89 (m, 1H), 2.84 (d, J = 1.6 
Hz, 1H), 2.63 – 2.44 (m, 2H), 1.75 (bs, 1H), 1.41 (bs, J = 13.5 Hz, 1H). TOF ES+ MS: 
(M + H) 498.2, (M + Na) 520.2. HPLC tR = 8.23 min, >95% purity. 
 
(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(((4-methylphenethyl)amino)methyl)-
piperidin-1-yl)methanone (CCG-206486). 1-(1-(4-fluorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carbaldehyde (46 mg, 0.126 mmol) was dissolved in THF (2 mL) 
and 2-(p-tolyl)ethanamine (0.030 mL, 0.189 mmol) was added. The solution was stirred 
at rt for 10 h, at which time the THF was removed in vacuo and the residue dissolved in 
EtOH (5 mL), and sodium cyanoborohydride (24 mg, 0.349 mmol) and a catalytic drop 
of glacial acetic acid were added. Stirring was permitted for 14 h, at which time the 
solvent was removed in vacuo, the residue was taken up in EtOAc. The organic phase 
was washed with 10% aq. sodium carbonate, dried over magnesium sulfate, and 
concentrated. Purification was accomplished via silica gel flash chromatography (30 g 
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silica gel, 5:95 7M methanolic ammonia:ethyl acetate.) The title compound was obtained 
as a yellow oil. Yield: 26 mg, 0.054 mmol, 43%. 
1
H NMR (500 MHz, Chloroform-d) δ 
7.64 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.27 (t, J = 7.7 Hz, 2H), 7.18 – 7.13 
(m, 1H), 7.12 – 7.06 (m, 5H), 6.91 (t, J = 8.5 Hz, 2H), 6.60 (s, 1H), 5.47 (s, 2H), 4.62 (bs, 
1H), 4.09 (bs, 1H), 2.84 (t, J = 7.0 Hz, 2H), 2.76 (t, J = 7.0 Hz, 2H), 2.70 (bs, 2H), 2.44 
(d, J = 5.9 Hz, 2H), 2.32 (s, 3H), 1.79 – 1.62 (m, 5H). TOF ES+ MS: (M + H) 484.1, (M 
+ Na) 506.1. HPLC tR = 6.43 min, >95% purity. 
 
 (R)-(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(((1-phenylethyl)amino)methyl)-
piperidin-1-yl)methanone (CCG-206499). 1-(1-(4-fluorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carbaldehyde (91 mg, 0.250 mmol) was dissolved in THF (4 mL) 
and (R)-α-methylbenzylamine (0.048 mL, 0.375 mmol) was added. The solution was 
stirred at rt for 10 h, at which time the THF was removed in vacuo and the residue 
dissolved in EtOH (5 mL), and sodium cyanoborohydride (47 mg, 0.749 mmol) and a 
catalytic drop of glacial acetic acid were added. Stirring was permitted for 15 h, at which 
time the solvent was removed in vacuo, the residue was taken up in EtOAc. The organic 
phase was washed with 10% aq. sodium carbonate, dried over magnesium sulfate, and 
concentrated. Purification was accomplished via silica gel flash chromatography (30 g 
silica gel, 5:95 7M methanolic ammonia:ethyl acetate.) The title compound was obtained 
as a yellow oil. Yield: 52 mg, 0.111 mmol, 44%. 
1
H NMR (500 MHz, Chloroform-d) δ 
7.64 (d, J = 7.9 Hz, 1H), 7.45 – 7.25 (m, 7H), 7.16 (t, J = 7.5 Hz, 1H), 7.10 – 7.01 (m, 
2H), 6.91 – 6.80 (m, 2H), 6.60 (s, 1H), 5.46 (s, 2H), 4.60 (s, 1H), 4.05 (s, 1H), 3.80 (q, J 
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= 6.3 Hz, 1H), 2.80 (s, 2H), 2.38 (dd, J = 11.6, 6.0 Hz, 1H), 2.23 (dd, J = 16.5, 4.8 Hz, 
1H), 1.70 (d, J = 54.9 Hz, 4H), 1.42 (d, J = 6.6 Hz, 3H), 0.99 (s, 1H), 0.57 (s, 1H). TOF 
ES+ MS: (M + H) 470.3, (M + Na) 492.2. HPLC tR = 5.96 min, >95% purity. 
 
(4-((Benzylamino)methyl)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-
yl)methanone. (CCG-206500). 1-(1-(4-fluorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carbaldehyde (52 mg, 0.143 mmol) was dissolved in THF (2 mL) and benzylamine 
(0.025 mL, 0.285 mmol) was added. The solution was stirred at RT for 10 h, at which 
time the THF was removed in vacuo and the residue dissolved in EtOH (5 mL), and 
NaCNBH3 (18 mg, 0.285 mmol) and a catalytic drop of glacial AcOH were added. 
Stirring was permitted for 14 h, at which time the solvent was removed in vacuo, the 
residue was taken up in EtOAc. The organic phase was washed with 10% aq. Na2CO3, 
dried MgSO4, and concentrated. Purification was accomplished via silica flash 
chromatography (30 g silica gel, 5:95 7M methanolic ammonia:EtOAc.) The title 
compound was obtained as a yellow oil. Yield: 23 mg, 0.050 mmol, 40%. 
1
H NMR (500 
MHz, Chloroform-d) δ 7.65 (d, J = 7.9 Hz, 1H), 7.39 – 7.27 (m, 7H), 7.16 (t, J = 7.5 Hz, 
1H), 7.09 (dd, J = 8.2, 5.5 Hz, 2H), 6.91 (t, J = 8.6 Hz, 2H), 6.61 (s, 1H), 5.48 (s, 2H), 
4.65 (bs, 1H), 4.10 (bs, 1H), 3.78 (s, 2H), 2.77 (bd, J = 50.6 Hz, 2H), 2.46 (d, J = 6.4 Hz, 
2H), 1.79 – 1.61 (m, 3H), 1.09 (bs, 1H), 0.66 (bs, 1H). TOF ES+ MS: (M + H) 456.2, (M 
+ Na) 478.2. HPLC tR = 6.04 min, >90% purity. 
 
 (S)-(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(((1-phenylethyl)amino)methyl)-
piperidin-1-yl)methanone (CCG-206501). 1-(1-(4-fluorobenzyl)-1H-indole-2-
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carbonyl)piperidine-4-carbaldehyde (35 mg, 0.096 mmol) was dissolved in THF (2 mL) 
and (S)-α-methylbenzylamine (0.013 mL, 0.115 mmol) was added. The solution was 
stirred at RT for 10 h, at which time the THF was removed in vacuo and the residue 
dissolved in EtOH (5 mL), and sodium cyanoborohydride (13 mg, 0.192 mmol) and a 
catalytic drop of glacial AcOH were added. Stirring was permitted for 14 h, at which time 
the solvent was removed in vacuo, the residue was taken up in EtOAc. The organic phase 
was washed with 10% aq. Na2CO3, dried over MgSO4, and concentrated. Purification was 
accomplished via silica flash chromatography (30 g silica gel, 5:95 7M methanolic 
ammonia:EtOAc.) The title compound was obtained as a yellow oil. Yield: 21 mg, 0.045 
mmol, 47%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.64 (d, J = 8.0 Hz, 1H), 7.39 – 7.22 
(m, 7H), 7.16 (t, J = 7.5 Hz, 1H), 7.08 (dd, J = 8.1, 5.5 Hz, 2H), 6.88 (t, J = 7.9 Hz, 2H), 
6.59 (s, 1H), 5.47 (s, 2H), 4.61 (s, 1H), 4.05 (s, 1H), 3.74 – 3.69 (m, 1H), 2.75 (d, J = 
49.0 Hz, 2H), 2.41 – 2.33 (m, 1H), 2.22 (dd, J = 11.6, 7.1 Hz, 1H), 1.59 (d, J = 10.4 Hz, 
4H), 1.35 (d, J = 6.6 Hz, 3H), 1.01 (s, 1H), 0.63 (s, 1H). TOF ES+ MS: (M + H) 470.3, 
(M + Na) 492.2. HPLC tR = 5.98 min, > 95% purity. 
 
 (1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(morpholinomethyl)piperidin-1-
yl)methanone. (CCG-206502) 1-(1-(4-fluorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carbaldehyde (52 mg, 0.143 mmol) was dissolved in EtOH (5 mL) and morpholine (0.025 
mL, 0.285 mmol), sodium cyanoborohydride (18 mg, 0.285 mmol), and a catalytic drop 
of glacial acetic acid were added. Stirring was permitted for 13 h, at which time the 
solvent was removed in vacuo, the residue was taken up in EtOAc. The organic phase 
was washed with 10% aq. sodium carbonate, dried over magnesium sulfate, and 
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concentrated. Purification was accomplished via silica gel flash chromatography (30 g 
silica gel, 100% EtOAc.) The title compound was obtained as an oil. Yield: 15 mg, 0.034 
mmol, 24%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.65 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 
8.3 Hz, 1H), 7.30 – 7.27 (m, 1H), 7.17 (t, J = 8.3 Hz, 1H), 7.12 – 7.07 (m, 2H), 6.97 – 
6.89 (m, 2H), 6.63 – 6.59 (m, 1H), 5.49 (s, 2H), 4.65 (bs, 1H), 4.11 (bs, 1H), 3.69 (s, 4H), 
2.76 (bd, J = 43.7 Hz, 2H), 2.39 (s, 4H), 2.11 (s, 2H), 1.83 – 1.57 (m, 3H), 0.99 (bs, 1H), 
0.60 (bs, 1H). TOF ES+ MS: (M + H) 436.2, (M + Na) 458.2. HPLC tR = 5.38 min, 
>95% purity. 
 
 (4-((Benzyl(methyl)amino)methyl)piperidin-1-yl)(1-(4-fluorobenzyl)-1H-indol-2-
yl)methanone (CCG-206503). 1-(1-(4-fluorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carbaldehyde (86 mg, 0.236 mmol) was dissolved in EtOH (5 mL) and N-
methylbenzylamine (0.027 mL, 0.283 mmol), NaCNBH3 (30 mg, 0.472 mmol), and a 
catalytic drop of glacial AcOH were added. Stirring was permitted for 14 h, at which time 
the solvent was removed in vacuo, the residue was taken up in EtOAc. The organic phase 
was washed with 10% aq. Na2CO3, dried over MgSO4, and concentrated. Purification was 
accomplished via silica flash chromatography (30 g silica gel, 100% EtOAc.) The title 
compound was obtained as an oil. Yield: 23 mg, 0.049 mmol, 20%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.64 (t, J = 7.4 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 7.35 – 7.22 (m, 6H), 
7.16 (q, J = 7.3 Hz, 1H), 7.07 (td, J = 8.0, 5.4 Hz, 2H), 6.87 – 6.79 (m, 2H), 6.59 (d, J = 
7.0 Hz, 1H), 5.47 (s, 2H), 4.61 (bs, 1H), 4.06 (bs, 1H), 3.46 (s, 2H), 2.70 (bs, 2H), 2.18 
(d, J = 7.2 Hz, 3H), 2.10 – 1.60 (m, 5H), 0.95 (bs, 1H), 0.50 (bs, 1H). TOF ES+ MS: (M 
+ H) 470.2, (M + Na) 492.2. HPLC tR = 6.04 min, > 95% purity. 
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(1-(4-Fluorobenzyl)-1H-indol-2-yl)(4-(((2-(pyridin-4-yl)ethyl)amino)methyl)-
piperidin-1-yl)methanone (CCG-206504). 1-(1-(4-fluorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carbaldehyde (100 mg, 0.273 mmol) was dissolved in EtOH (5 
mL) and 4-(2-aminoethyl)pyridine (50 µL, 0.410 mmol), NaCNBH3 (51 mg, 0.819 
mmol), and a catalytic drop of glacial AcOH were added. Stirring was permitted for 10 h, 
at which time the solvent was removed in vacuo and the residue was taken up in EtOAc. 
The organic phase was washed with 10% aq. Na2CO3, dried over MgSO4, and 
concentrated. Purification was accomplished via silica flash chromatography (30 g silica 
gel, 100% EtOAc.) The title compound was obtained as an oil. Yield: 51 mg, 0.109 
mmol, 45%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.51 (d, J = 4.7 Hz, 2H), 7.64 (d, J = 
7.9 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.17 – 7.11 (m, 3H), 7.10 – 
7.06 (m, 2H), 6.97 – 6.89 (m, 3H), 6.60 (s, 1H), 5.47 (s, 2H), 4.65 (bs, 1H), 4.08 (bs, 1H), 
2.87 (t, J = 7.1 Hz, 2H), 2.78 (t, J = 7.0 Hz, 2H), 2.70 (bs, 2H), 2.43 (s, 2H), 1.72 – 1.54 
(m, 5H). TOF ES+ MS: (M + H) 471.3, (M + Na) 493.2. HPLC tR = 5.51 min, >95% 
purity. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(1-(2,3-dihydro-1H-inden-2-
yl)ethyl)piperidine-4-carboxamide (CCG-206549). The following was added 
sequentially to DCM (5 mL): 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carboxylic acid (109 mg, 0.275 mmol), DIPEA (0.144 mL, 0.825 mmol), EDCHCl (63 
mg, 0.330 mmol), HOBT (51 mg, 0.330 mmol), and crude 2-(1-aminoethyl)indane (~44 
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mg, 0.275 mmol). The mixture was stirred for 16 h at rt, at which time the solution 
diluted with a 1:1 solution of ethyl acetate:diethyl ether and washed with 1M HCl (1X), 
10% aq. sodium carbonate (1X) and brine (1X). The organic phase was dried with 
magnesium sulfate and concentrated in vacuo. The resulting residue was dissolved in 
EtOAc and precipitated out hexanes, and then collected over a filter and washed with 
diethyl ether to give the title compound as a white solid. Yield: 59 mg, 0.109 mmol, 40%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.66 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.3 Hz, 1H), 
7.29 – 7.13 (m, 8H), 7.04 (d, J = 8.2 Hz, 2H), 6.65 (s, 1H), 5.48 (s, 2H), 5.30 (d, J = 8.9 
Hz, 1H), 4.45 (s, 1H), 4.25 – 4.14 (m, 1H), 3.02 (td, J = 16.7, 8.3 Hz, 2H), 2.91 – 2.65 
(m, 4H), 2.51 (h, J = 8.1 Hz, 1H), 2.22 (tq, J = 10.8, 4.1 Hz, 1H), 1.63 (d, J = 95.6 Hz, 
5H), 1.21 (d, J = 6.7 Hz, 3H). TOF ES+ MS: (M + H) 540.2. HPLC tR = 8.55 min, >95% 
purity. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-((2,3-dihydro-1H-inden-1-
yl)methyl)piperidine-4-carboxamide. (CCG-206550) The following was added 
sequentially to DCM (6 mL): 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carboxylic acid (134 mg, 0.340 mmol), DIPEA (0.178 mL, 1.019 mmol), EDCHCl (78 
mg, 0.408 mmol), HOBT (62.4 mg, 0.408 mmol), and 2-indanmethanamine 
hydrochloride (62 mg, 0.340 mmol). The mixture was stirred for 18 h at rt, at which time 
the solution diluted with a 1:1 solution of ethyl acetate:diethyl ether and washed with 1M 
HCl (1X), 10% aq. sodium carbonate (1X) and brine (1X). The organic phase was dried 
with magnesium sulfate and concentrated in vacuo. The resulting residue was dissolved 
in EtOAc and precipitated out hexanes, and then collected over a filter and washed with 
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diethyl ether to give the title compound as a white solid. Yield: 72 mg, 0.137 mmol, 41%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.63 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 
7.27 – 7.22 (m, 3H), 7.21 – 7.13 (m, 5H), 7.01 (d, J = 8.2 Hz, 2H), 6.62 (s, 1H), 5.45 (s, 
2H), 5.38 (t, J = 5.3 Hz, 1H), 4.36 (s, 2H), 3.62 (dt, J = 12.2, 5.8 Hz, 1H), 3.50 – 3.34 (m, 
2H), 2.88 (tt, J = 15.8, 8.2 Hz, 4H), 2.23 (ddd, J = 13.3, 9.5, 5.8 Hz, 2H), 1.78 (ddd, J = 
13.3, 8.2, 6.4 Hz, 3H), 1.49 (s, 2H). TOF ES+ MS: (M + H) 526.2. HPLC tR = 8.35 min, 
>95% purity. 
 
N-Benzyl-1-(1-(4-chlorobenzyl)-1H-imidazole-2-carbonyl)piperidine-4-
carboxamide (CCG-206586). Ethyl 1-(4-chlorobenzyl)-1H-imidazole-2-carboxylate 
(7.28 g, 27.5 mmol), was dissolved in EtOH (10 mL) and 10% aq. NaOH (20 mL) and 
stirred at rt for 15 h. The solvent was then stripped off, water was added, and the solution 
acidified with HCl. The resulting precipitate was collected over a filter and washed with 
1M HCl and dried to afford the carboxylic acid as a white powder which was taken 
directly into the next step. Yield: 6.506 g, 27.5 mmol, 100%.  
The following was added sequentially to DMF: 1-(4-chlorobenzyl)-1H-imidazole-
2-carboxylic acid (71 mg, 0.298 mmol), DIPEA (0.16 mL, 0.894 mmol), EDCHCl (69 
mg, 0.358 mmol), and HOBT (55 mg, 0.358 mmol). This was allowed to stir at rt for 30 
min, at which time N-benzylpiperidine-4-carboxamide (~ 65 mg, 0.298 mmol) was added 
and syirring continued at rt for 14 h. Addition of water caused precipitation, which was 
collected over a filter and washed with water and small amount of diethyl ether and 
EtOAc to give the title compound as a white solid. Yield: 37 mg, 0.085 mmol, 28%. 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.34 – 7.22 (m, 7H), 7.12 (d, J = 8.3 Hz, 2H), 7.04 (s, 
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1H), 6.93 (s, 1H), 5.72 (t, J = 5.1 Hz, 1H), 5.36 (d, J = 5.1 Hz, 2H), 4.63 (t, J = 15.1 Hz, 
2H), 4.43 (d, J = 5.6 Hz, 2H), 3.14 (t, J = 12.6 Hz, 1H), 2.82 (t, J = 12.8 Hz, 1H), 2.38 (tt, 
J = 11.3, 3.9 Hz, 1H), 1.95 (d, J = 13.4 Hz, 1H), 1.83 (d, J = 13.3 Hz, 1H), 1.72 – 1.55 
(m, 2H). TOF ES+ MS: (M + H) 437.2, (M + Na) 459.2. HPLC tR = 5.59 min, >95% 
purity. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(3-phenylpropyl)piperidine-4-
carboxamide (CCG-206587). The following were added sequentially to DCM (10 
mL): 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (100 mg, 
0.252 mmol), DIPEA (132 µL, 0.756 mmol), EDCHCl (58 mg, 0.302 mmol), HOBt (46 
mg, 0.302 mmol), and then 3-phenylpropylamine (43 µL, 0.302 mmol). The reaction was 
allowed to stir at RT for 13 h, at which time it was diluted with EtOAc, washed with 1 M 
HCl (3X), H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), dried over MgSO4, and 
concentrated in vacuo. The residue was the purified by silica flash chromatography (20 g 
silica, 70% EtOAc:Hex) to provide the desired material as a colorless oil. Yield: 101 mg, 
0.197 mmol, 78%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.65 (d, J = 7.9 Hz, 1H), 7.37 – 
7.23 (m, 5H), 7.24 – 7.12 (m, 6H), 6.64 (s, 1H), 5.45 (s, 2H), 5.39 (t, J = 5.4 Hz, 1H), 
4.50 (bs, 1H), 4.21 (bs, 1H), 3.29 (q, J = 6.5 Hz, 2H), 2.84 (bs, 2H), 2.65 (t, J = 7.5 Hz, 
2H), 2.20 (tt, J = 11.0, 3.5 Hz, 1H), 1.85 (p, J = 7.5 Hz, 2H), 1.72 (bs, 2H), 1.44 (bs, 2H). 
TOF ES+ MS: (M + H) 515.1, (M + Na) 537.0. HPLC tR = 8.16 min, > 90%. 
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1-(1-(4-Chlorobenzyl)-1H-pyrrole-2-carbonyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)azetidine-3-carboxamide (CCG-208793). Methyl 1-(1-(4-chlorobenzyl)-1H-
pyrrole-2-carbonyl)azetidine-3-carboxylate 29 (300 mg, 0.90 mmol) was dissolved in 200 
proof EtOH (10 mL) and 10% aq. NaOH (10 mL) was added. The reaction was allowed 
to stir at RT for 24 h, at which time the solvent was stripped off in vacuo and the residue 
was taken up in H2O and acidified to pH 1 by addition of conc. HCl at 0°C. The resulting 
precipitate was collected over a filter and dried by aspirator then high vacuum to afford 
the desired carboxylic acid as a white powder.  Yield: 250 mg, 0.78 mmol, 87%. 
1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)azetidine-3-carboxylic acid (50 mg, 
0.16 mmol) was added to DCM (5 mL), followed by indanyl amine 75 (29 mg, 0.17 
mmol), TEA (66 µL, 0.47 mmol), EDCHCl (33 mg, 0.17 mmol), and HOBT (26 mg, 
0.17 mmol). The reaction was allowed to stir at RT for 21 h, at which time the reaction 
was concentrated and the residue taken up in EtOAc. This solution was then washed with 
1M HCl (2X), H2O (3X) and 10% aq. Na2CO3 (3X), and brine (1X), dried (MgSO4), and 
concentrated. The residue was purified by silica flash chromatography (4 g silica, 10% to 
60% EtOAc:Hex) to provide the final compound as a white powder. Yield: 39 mg, 0.09 
mmol, 56%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.28 – 7.24 (m, 3H), 7.21 – 7.18 (m, 
2H), 7.16 – 7.13 (m, 2H), 7.09 – 7.04 (m, 2H), 6.81 (dd, J = 2.6, 1.6 Hz, 1H), 6.52 (dd, J 
= 4.0, 1.5 Hz, 1H), 6.19 – 6.16 (m, 1H), 5.56 (d, J = 9.0 Hz, 3H), 4.30 (bs, 4H), 3.42 (t, J 
= 6.0 Hz, 2H), 3.22 (p, J = 7.4 Hz, 1H), 3.09 (q, J = 10.0, 9.3 Hz, 2H), 2.75 – 2.65 (m, 
3H). TOF ES+ MS: (M + H) 448.2, (M + Na) 470.2. HPLC tR = 7.56 min, > 95%. 
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N
1
-(4-Chlorobenzyl)-N4-(2-(pyridin-4-yl)ethyl)piperidine-1,4-dicarboxamide 
(208825). Ethyl 1-((4-chlorobenzyl)carbamoyl)piperidine-4-carboxylate 31a (810 mg, 
2.50 mmol) was dissolved in 200 proof EtOH (20 mL) at RT, followed by the addition of 
10% aq. NaOH, which elicited precipitation. The mixture was then stirred at 50 °C for 2 
h over which time it became a solution. The reaction was then allowed to cool to RT and 
the solvent was then removed in vacuo. The residue was taken up in H2O and acidified to 
pH 1 with conc. HCl  at 0 °C and the resulting precipitate was collected over a filter, 
washed with cold 1 M aq. HCl, and dried over the filter then under high vacuum to give 
the desired compound as a white powder. No further purification as necessary. Yield: 675 
mg, 2.27 mmol, 91%.  
1-((4-chlorobenzyl)carbamoyl)piperidine-4-carboxylic acid (60 mg, 0.20 mmol) 
and TEA (93 µL, 0.61 mmol) were dissolved in DCM (5 mL), followed by EDCHCl (47 
mg, 0.22 mmol), HOBT (37 mg, 0.22 mmol), and amine 27 (30 µL, 0.20 mmol). The 
reaction was allowed to stir at RT for 15 h. After this time, the reaction was diluted with 
EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried 
with MgSO4 and concentrated. The residue was then crystallized from EtOAc and 
washed with Et2O to provide an off-white, slightly tanned solid. Yield: 42 mg, 0.11 
mmol, 52%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.52 (d, J = 4.4 Hz, 2H), 7.32 – 7.20 
(m, 4H), 7.11 (d, J = 4.4 Hz, 2H), 5.56 (s, 1H), 4.79 (d, J = 5.9 Hz, 1H), 4.37 (d, J = 5.2 
Hz, 2H), 3.96 (d, J = 13.2 Hz, 2H), 3.55 (q, J = 6.4, 5.8 Hz, 2H), 2.85 – 2.78 (m, 4H), 
2.19 (t, J = 11.5 Hz, 1H), 1.77 (d, J = 13.0 Hz, 2H), 1.63 (dd, J = 18.8, 5.5 Hz, 2H). TOF 
ES+ MS: (M + H) 401.2, (M + Na) 423.2. HPLC tR = 4.61 min, > 95% purity. 
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N
1
-(4-Chlorobenzyl)-N
4
-((2,3-dihydro-1H-inden-2-yl)methyl)piperidine-1,4-
dicarboxamide (CCG-208826). Ethyl 1-((4-chlorobenzyl)carbamoyl)piperidine-4-
carboxylate 31a (810 mg, 2.50 mmol) was dissolved in 200 proof EtOH (20 mL) at RT, 
followed by the addition of 10% aq. NaOH, which elicited precipitation. The mixture was 
then stirred at 50 °C for 2 h over which time it became a solution. The reaction was then 
allowed to cool to RT and the solvent was then removed in vacuo. The residue was taken 
up in H2O and acidified to pH 1 with conc. HCl  at 0 °C and the resulting precipitate was 
collected over a filter, washed with cold 1 M aq. HCl, and dried over the filter then under 
high vacuum to give the desired compound as a white powder. No further purification as 
necessary. Yield: 675 mg, 2.27 mmol, 91%.  
1-((4-chlorobenzyl)carbamoyl)piperidine-4-carboxylic acid (60 mg, 0.20 mmol) 
and TEA (93 µL, 0.61 mmol) were dissolved in DCM (5 mL), followed by EDCHCl (47 
mg, 0.22 mmol), HOBT (37 mg, 0.22 mmol), and amine 27 (30 µL, 0.20 mmol). The 
reaction was allowed to stir at RT for 16 h. After this time, the reaction was diluted with 
EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried 
with MgSO4 and concentrated. The residue was then crystallized from EtOAc and 
washed with Et2O to provide a tan solid. Yield: 47 mg, 0.11 mmol, 54%. 
1
H NMR (500 
MHz, Chloroform-d) δ 7.32 – 7.28 (m, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.21 – 7.18 (m, 
2H), 7.16 – 7.13 (m, 2H), 5.57 (s, 1H), 4.39 (s, 2H), 3.98 (dt, J = 13.4, 3.7 Hz, 2H), 3.38 
(t, J = 6.0 Hz, 2H), 3.08 (q, J = 10.3, 9.4 Hz, 2H), 2.85 (ddd, J = 13.3, 11.8, 2.8 Hz, 2H), 
2.70 – 2.64 (m, 3H), 2.23 (ddt, J = 11.4, 7.7, 3.8 Hz, 1H), 1.83 – 1.58 (m, 4H). TOF ES+ 
MS: (M + H) 426.2. HPLC tR = 6.69 min, > 95%. 
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N
1
-(4-Chlorophenethyl)-N
4
-(2-(pyridin-4-yl)ethyl)piperidine-1,4-dicarboxamide 
(CCG-208827). Ethyl 1-((4-chlorophenethyl)carbamoyl)-piperidine-4-carboxylate 31b 
(807 mg, 2.382 mmol) was dissolved in EtOH (20 mL), and 10% aq NaOH (15 mL) was 
added. The resulting mixture was warmed to 50 °C and stirred for 2 h. The now 
homogeneous solution was then concentrated in vacuo, a small amount of water was 
added back, and the solution chilled in an ice bath. The solution was then acidified with 
concentrated HCl, and the resulting precipitate was collected over a filter, washed with 1 
M HCl and ice-cold water, filter-dried, then further dried under high vacuum to afford 1-
((4-chlorophenethyl)carbamoyl)piperidine-4-carboxylic acid as a white powder. Yield: 
631 mg (85%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 7.30 (d, J = 8.4 Hz, 2H), 
7.18 (d, J = 8.4 Hz, 2H), 6.54 (t, J = 5.4 Hz, 1H), 3.80 (d, J = 13.3 Hz, 2H), 3.18 (q, J = 
7.0 Hz, 2H), 2.76−2.62 (m, 4H), 2.36 (ddt, J = 11.0, 7.6, 3.9 Hz, 1H), 1.75−1.64 (m, 2H), 
1.40−1.25 (m, 2H).  
The carboxylic acid (60 mg, 0.193 mmol), TEA (81 μL, 0.579 mmol), EDCHCl 
(41 mg, 0.212 mmol), HOBT (33 mg, 0.212 mmol), and 4-(2-aminoethyl)pyridine 27 (25 
μL, 0.212 mmol) were all added sequentially to DCM (5 mL) at RT. This solution was 
allowed to stir for 16 h at RT, after which time the reaction was diluted with ethyl acetate 
and washed with water (3×), 10% aq sodium carbonate (3×), and brine (1×), then dried 
(magnesium sulfate) and concentrated in vacuo. The resulting residue was then 
crystallized from ethyl acetate and washed with diethyl ether to provide the title 
compound as a tan solid. Yield: 46 mg (57%). 
1HNMR (400 MHz, CDCl3) δ 8.61−8.26 
(m, 2H), 7.30−7.19 (m, 2H), 7.17−7.01 (m, 4H), 5.91−5.66 (m, 1H), 4.59 (dd, J = 13.4, 
5.6 Hz, 1H), 3.86 (d, J = 13.2 Hz, 2H), 3.53 (q, J = 6.7 Hz, 2H), 3.42 (q, J = 6.8 Hz, 2H), 
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2.82 (t, J = 6.8 Hz, 2H), 2.79−2.61 (m, 4H), 2.17 (t, J = 9.6 Hz, 1H), 1.73 (d, J = 12.9 Hz, 
2H), 1.57 (qd, J = 12.9, 12.5, 3.8 Hz, 2H). TOF ES+ MS: (M + H) 415.2, (M + Na) 
437.2. HPLC tR = 4.70 min, > 95%. 
 
N
1
-(4-Chlorophenethyl)-N4-((2,3-dihydro-1H-inden-2-yl)methyl)piperidine-1,4-
dicarboxamide (CCG-208828). Ethyl 1-((4-chlorophenethyl)carbamoyl)-piperidine-4-
carboxylate 31b (807 mg, 2.382 mmol) was dissolved in EtOH (20 mL), and 10% aq 
NaOH (15 mL) was added. The resulting mixture was warmed to 50 °C and stirred for 2 
h. The now homogeneous solution was then concentrated in vacuo, a small amount of 
water was added back, and the solution chilled in an ice bath. The solution was then 
acidified with concentrated HCl, and the resulting precipitate was collected over a filter, 
washed with 1 M HCl and ice-cold water, filter-dried, then further dried under high 
vacuum to afford 1-((4-chlorophenethyl)carbamoyl)piperidine-4-carboxylic acid as a 
white powder. Yield: 631 mg (85%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 
7.30 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.54 (t, J = 5.4 Hz, 1H), 3.80 (d, J = 
13.3 Hz, 2H), 3.18 (q, J = 7.0 Hz, 2H), 2.76−2.62 (m, 4H), 2.36 (ddt, J = 11.0, 7.6, 3.9 
Hz, 1H), 1.75−1.64 (m, 2H), 1.40−1.25 (m, 2H).  
The carboxylic acid (60 mg, 0.19 mmol), TEA (81 μL, 0.58 mmol), EDCHCl (41 
mg, 0.21 mmol), HOBT (33 mg, 0.21 mmol), and indanyl amine 75 (39 mg, 0.21 mmol) 
were all added sequentially to DCM (5 mL) at RT. This solution was allowed to stir for 
15 h at RT, after which time the reaction was diluted with EtOAc and washed with 05M 
HCl (3X), H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried (magnesium 
sulfate) and concentrated in vacuo. The resulting residue was then crystallized from 
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EtOAc to give tan crystals. Yield: 55 mg, 0.12 mmol, 64%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.28 – 7.27 (m, 2H), 7.21 – 7.18 (m, 2H), 7.16 – 7.12 (m, 4H), 5.54 (s, 
1H), 4.45 (s, 1H), 3.88 (d, J = 9.9 Hz, 1H), 3.46 (q, J = 6.7 Hz, 2H), 3.38 (t, J = 6.0 Hz, 
2H), 3.08 (q, J = 7.3, 6.5 Hz, 2H), 2.83 – 2.75 (m, 3H), 2.72 – 2.65 (m, 3H), 2.21 (tt, J = 
11.5, 3.9 Hz, 1H), 1.79 (dd, J = 13.0, 3.2 Hz, 2H), 1.62 (td, J = 12.7, 12.2, 4.4 Hz, 4H). 
TOF ES+ MS: (M + H) 440.2, (M + Na) 462.2. HPLC tR = 7.32 min, > 95%. 
 
N-Benzyl-1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)azetidine-3-carboxamide 
(CCG-208829). Methyl 1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)azetidine-3-
carboxylate 29 (300 mg, 0.90 mmol) was dissolved in 200 proof EtOH (10 mL) and 10% 
aq. NaOH (10 mL) was added. The reaction was allowed to stir at RT for 24 h, at which 
time the solvent was stripped off in vacuo and the residue was taken up in H2O and 
acidified to pH 1 by addition of conc. HCl at 0°C. The resulting precipitate was collected 
over a filter and dried by aspirator then high vacuum to afford the desired carboxylic acid 
as a white powder.  Yield: 250 mg, 0.78 mmol, 87%. 
1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)azetidine-3-carboxylic acid (50 mg, 
0.16 mmol) was added to DCM (5 mL), followed by benzylamine (19 µL, 0.17 mmol), 
TEA (66 µL, 0.47 mmol), EDCHCl (33 mg, 0.17 mmol), and HOBT (26 mg, 0.17 
mmol). The reaction was allowed to stir at RT for 15 h, at which time the reaction was 
concentrated and the residue taken up in EtOAc. This solution was then washed with 
0.5M HCl (2X), H2O (3X) and 10% aq. Na2CO3 (3X), and brine (1X), dried (MgSO4), 
and concentrated. The residue was purified by silica flash chromatography (4 g silica, 
30% to 60% EtOAc:Hex) to provide the final compound as a white powder. Yield: 29 
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mg, 0.07 mmol, 45%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.38 – 7.23 (m, 7H), 7.06 (d, 
J = 8.2 Hz, 2H), 6.80 (s, 1H), 6.53 (d, J = 3.5 Hz, 1H), 6.19 – 6.16 (m, 1H), 5.82 (s, 1H), 
5.54 (s, 2H), 4.57 (s, 1H), 4.48 (d, J = 5.7 Hz, 2H), 4.32 (s, 2H), 3.28 (p, J = 7.4 Hz, 1H). 
TOF ES+ MS: (M + H) 408.1, (M + Na) 430.1. HPLC tR = 7.06 min, > 95%. 
 
1-(3-(4-Chlorophenyl)propanoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-208846). Ethyl 1-(3-(4-chlorophenyl)propanoyl)piperidine-4-
carboxylate 33b (850 mg, 2.62 mmol) was dissolved in EtOH (10 mL), followed by the 
addition of 10% aq. NaOH (10 mL). This was stirred 11 h at RT, after which time a 
majority of the solvent was stripped off in vacuo. The remaining concentrated aq. 
solution was chilled to 0 °C and acidified to pH<1 with conc. HCl. The aq. solution was 
decanted off of the resulting gummy residue. H2O was then added, sonicated, and 
decanted. The residue was then dried under high vacuum, and the thick viscous residue 
was sonicated in Et2O to afford the carboxylic acid as a white solid that was collected 
over a filter. Yield: 730 mg, 2.47 mmol, 94%.  
1-(3-(4-chlorophenyl)propanoyl)piperidine-4-carboxylic acid (50 mg, 0.17 mmol) 
was added to DCM (2 mL) at RT followed by TEA (71 µL, 0.51 mmol), EDC HCl (36 
mg, 0.19 mmol), HOBT (28 mg, 0.19 mmol), and amine 27 (22 µL, 0.19 mmol). The 
reaction was allowed to stir at RT for 14 h, after which time the DCM was removed in 
vacuo and the residue taken up in EtOAc, which was subsequently washed with 0.5 M aq. 
HCl (1X), H2O (2X), 10% aq. Na2CO3 (2X), and brine (1X), then dried (MgSO4) and 
decanted. The material was crystallized from the dropwise addition of EtOAc to boiling 
hexanes, then cooling of the solution. Yield: 42 mg, 0.11 mmol, 62%. 
1
H NMR (500 
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MHz, Chloroform-d) δ 8.52 – 8.48 (m, 2H), 7.29 – 7.20 (m, 2H), 7.17 – 7.07 (m, 4H), 
5.66 (s, 1H), 4.57 (d, J = 12.9 Hz, 1H), 3.81 (d, J = 13.2 Hz, 1H), 3.54 (q, J = 5.9 Hz, 
2H), 2.96 – 2.89 (m, 3H), 2.82 (t, J = 6.1 Hz, 2H), 2.63 – 2.54 (m, 3H), 2.22 (dt, J = 11.2, 
5.8 Hz, 1H), 1.79 – 1.69 (m, 2H), 1.60 – 1.46 (m, 2H). TOF ES+ MS: 400.2 (M + H), 
422.2 (M + Na). HPLC tR = 4.89 min, > 95% purity. 
 
1-(3-(4-Chlorophenyl)propanoyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide (CCG-208847). Ethyl 1-(3-(4-
chlorophenyl)propanoyl)piperidine-4-carboxylate 33b (850 mg, 2.62 mmol) was 
dissolved in EtOH (10 mL), followed by the addition of 10% aq. NaOH (10 mL). This 
was stirred 11 h at RT, after which time a majority of the solvent was stripped off in 
vacuo. The remaining concentrated aq. solution was chilled to 0 °C and acidified to pH<1 
with conc. HCl. The aq. solution was decanted off of the resulting gummy residue. H2O 
was then added, sonicated, and decanted. The residue was then dried under high vacuum, 
and the thick viscous residue was sonicated in Et2O to afford the carboxylic acid as a 
white solid that was collected over a filter. Yield: 730 mg, 2.47 mmol, 94%. 
The following were added sequentially to DCM (2 mL) at RT: 1-(2-(4-
chlorophenyl)acetyl)piperidine-4-carboxylic acid (50 mg, 0.17 mmol), TEA (71 µL, 0.51 
mmol), EDCHCl (36 mg, 0.19 mmol), HOBT (29 mg, 0.19 mmol), and indanyl amine 75 
(34 mg, 0.19 mmol). This solution was stirred a RT for 15 h, at which time the DCM was 
removed in vacuo and the residue was diluted with EtOAc and washed with 1M HCl 
(3X), H2O (2X), 10% aq. Na2CO3 (2X), and brine (1X), then dried (MgSO4) and 
concentrated. The crude residue was purified by crystallization from boiling EtOAc to 
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give crystals. Yield: 44 mg, 0.10 mmol, 61%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.26 
(d, J = 8.7 Hz, 2H), 7.21 – 7.18 (m, 2H), 7.17 – 7.12 (m, 4H), 5.54 (t, J = 5.9 Hz, 1H), 
4.58 (dd, J = 13.6, 3.6 Hz, 1H), 3.83 (dt, J = 14.4, 3.9 Hz, 1H), 3.38 (t, J = 5.7 Hz, 2H), 
3.08 (q, J = 7.5, 6.6 Hz, 2H), 3.00 – 2.89 (m, 3H), 2.74 – 2.65 (m, 3H), 2.60 (dd, J = 8.6, 
6.3 Hz, 2H), 2.26 (tt, J = 11.4, 3.9 Hz, 1H), 1.83 – 1.74 (m, 2H), 1.60 – 1.47 (m, 2H). 
TOF ES+ MS: (M + H) 425.2, (M + Na) 447.2. HPLC tR = 7.14 min, > 95%. 
 
1-(2-(4-Chlorophenyl)acetyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
(CCG-208848). Ethyl 1-(2-(4-chlorophenyl)acetyl)piperidine-4-carboxylate 3a (811 mg, 
2.62 mmol) was added to EtOH (15 mL) and 10% aq. NaOH (5 mL). This mixture was 
heated to 50 °C and stirred for 5 h, then allowed to cool to RT. Solvent was removed in 
vacuo until precipitation began to occur, at which point the material was cooled to 0 °C 
and acidified to pH<1 by the dropwise addition of conc. HCl. The solution was decanted 
off the resulting gum, and the residue was air dried, then dried under high vacuum to 
afford a highly gummy material that could be solidified by sonication in Et2O to provide 
the carboxylic acid as a white powder without further purification. Yield: 723 mg, 2.57 
mmol, 98%.  
The following were added sequentially to DCM (5 mL) at RT: 1-(2-(4-
chlorophenyl)acetyl)piperidine-4-carboxylic acid (60 mg, 0.22 mmol), TEA (93 µL, 0.67 
mmol), EDCHCl (47 mg, 0.25 mmol), HOBT (37 mg, 0.25 mmol), and amine 27 (29 
µL, 0.25 mmol). This solution was stirred a RT for 18 h, at which time the reaction was 
diluted with EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), 
then dried (MgSO4) and concentrated. The crude residue was purified by crystallization 
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from the dropwise addition of EtOAc to boiling hexanes, then cooling of the solution, to 
give crystals. Yield: 40 mg, 0.105 mmol, 54%. 
1
H NMR (500 MHz, Chloroform-d) δ 
8.52 (d, J = 4.7 Hz, 2H), 7.29 (d, J = 7.8 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 
4.8 Hz, 2H), 5.50 (bs, 1H), 4.57 (d, J = 13.3 Hz, 1H), 3.86 (d, J = 13.5 Hz, 1H), 3.68 (s, 
2H), 3.54 (q, J = 6.6 Hz, 2H), 3.03 – 2.96 (m, 1H), 2.82 (t, J = 6.9 Hz, 2H), 2.70 – 2.62 
(m, 1H), 2.21 (tt, J = 11.1, 3.6 Hz, 1H), 1.77 (d, J = 12.3 Hz, 2H), 1.57 (qd, J = 12.2, 4.1 
Hz, 1H), 1.46 (qd, J = 12.3, 3.9 Hz, 1H). TOF ES+ MS: 386.2 (M + H), 408.2 (M + Na). 
HPLC tR = 6.87 min, > 95% purity. 
 
1-(2-(4-Chlorophenyl)acetyl)-N-((2,3-dihydro-1H-inden-2-yl)methyl)piperidine-
4-carboxamide (CCG-208849). Ethyl 1-(2-(4-chlorophenyl)acetyl)piperidine-4-
carboxylate (811 mg, 2.62 mmol) was added to EtOH (15 mL) and 10% aq. NaOH (5 
mL). This mixture was heated to 50 °C and stirred for 5 h, then allowed to cool to RT. 
Solvent was removed in vacuo until precipitation began to occur, at which point the 
material was cooled to 0 °C and acidified to pH<1 by the dropwise addition of conc. HCl. 
The solution was decanted off the resulting gum, and the residue was air dried, then dried 
under high vacuum to afford a highly gummy material that could be solidified by 
sonication in Et2O to provide the carboxylic acid as a white powder without further 
purification. Yield: 723 mg, 2.57 mmol, 98%.  
The following were added sequentially to DCM (2 mL) at RT: 1-(2-(4-
chlorophenyl)acetyl)piperidine-4-carboxylic acid (50 mg, 0.18 mmol), TEA (74 µL, 0.53 
mmol), EDCHCl (37 mg, 0.20 mmol), HOBT (30 mg, 0.20 mmol), and indanyl amine 75 
(36 mg, 0.20 mmol). This solution was stirred a RT for 10 h, at which time the DCM was 
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removed in vacuo and the residue was diluted with EtOAc and washed with 0.5M HCl 
(2X), H2O (2X), 10% aq. Na2CO3 (2X), and brine (1X), then dried (MgSO4) and 
concentrated. The crude residue was purified by crystallization from boiling EtOAc to 
give crystals. Yield: 43 mg, 0.11 mmol, 59%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.32 
– 7.24 (m, 2H), 7.23 – 7.02 (m, 6H), 5.52 (t, J = 6.0 Hz, 1H), 4.63 – 4.53 (m, 1H), 3.95 – 
3.82 (m, 1H), 3.69 (s, 2H), 3.37 (td, J = 6.0, 1.8 Hz, 2H), 3.13 – 2.97 (m, 3H), 2.70 – 2.57 
(m, 4H), 2.24 (tt, J = 11.2, 3.9 Hz, 1H), 1.83 – 1.70 (m, 2H), 1.61 – 1.45 (m, 2H). TOF 
ES+ MS: (M + H) 411.2. HPLC tR = 6.87 min, > 95%. 
 
1-(1-(4-Chlorobenzyl)-1H-imidazole-2-carbonyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide (CCG-208913). Ethyl 1-(4-chlorobenzyl)-1H-
imidazole-2-carboxylate 23b (7.28 g, 27.5 mmol), was dissolved in EtOH (10 mL) and 
10% aq. NaOH (20 mL) and stirred at rt for 15 h. The solvent was then stripped off, 
water was added, and the solution acidified with HCl. The resulting precipitate was 
collected over a filter and washed with 1M HCl and dried to afford the carboxylic acid as 
a white powder which was taken directly into the next step. Yield: 6.506 g, 27.5 mmol, 
100%. 
1-(4-chlorobenzyl)-1H-imidazole-2-carboxylic acid (50 mg, 0.21 mmol) was 
added to DCM (5 mL), followed by N-((2,3-dihydro-1H-inden-2-yl)methyl)piperidine-4-
carboxamide (69 mg, 0.23 mmol), TEA (88 µL, 0.63 mmol), EDCHCl (45 mg, 0.23 
mmol), and HOBT (36 mg, 0.23 mmol). The reaction was allowed to stir at RT for 20 h, 
at which time the reaction was concentrated and the residue taken up in EtOAc. This 
solution was then washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), dried 
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(MgSO4), and concentrated. The residue was purified by silica flash chromatography (10 
g silica, 60 to 100% EtOAc:Hex) to provide the final compound as a white powder. 
Yield: 48 mg, 0.10 mmol, 47%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.31 (d, J = 8.3 
Hz, 2H), 7.21 – 7.12 (m, 6H), 7.07 (s, 1H), 6.96 (s, 1H), 5.67 – 5.61 (m, 1H), 5.38 (d, J = 
5.6 Hz, 2H), 4.62 (t, J = 14.0 Hz, 2H), 3.37 (t, J = 5.8 Hz, 2H), 3.15 (t, J = 12.1 Hz, 1H), 
3.07 (q, J = 9.6, 8.8 Hz, 2H), 2.87 – 2.79 (m, 1H), 2.71 – 2.65 (m, 3H), 2.34 (tt, J = 11.4, 
4.0 Hz, 1H), 1.89 (d, J = 13.4 Hz, 1H), 1.82 – 1.75 (m, 1H), 1.61 (dtd, J = 36.5, 12.2, 3.5 
Hz, 2H). TOF ES+ MS: (M + H) 477.2, (M + Na) 499.2. HPLC tR = 6.07 min, > 95%. 
 
1-(1-(4-Chlorobenzyl)-1H-pyrrole-2-carbonyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide (CCG-208914). 1-(1-(4-chlorobenzyl)-1H-pyrrole-
2-carbonyl)piperidine-4-carboxylic acid 25a (50 mg, 0.14 mmol) was added to DCM (5 
mL), followed by indanyl amine 75 (29 mg, 0.16 mmol), TEA (60 µL, 0.43 mmol), 
EDCHCl (30 mg, 0.16 mmol), and HOBT (24 mg, 0.16 mmol). The reaction was 
allowed to stir at RT for 20 h, at which time the reaction was concentrated and the residue 
taken up in EtOAc. This solution was then washed with 1M HCl (3X), H2O (3X) and 
10% aq. Na2CO3 (3X), and brine (1X), dried (MgSO4), and concentrated. The residue 
was purified by silica flash chromatography (10 g silica, 60% EtOAc:Hex) to provide the 
final compound as a white powder. Yield: 42 mg, 0.09 mmol, 61%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.29 – 7.25 (m, 2H), 7.23 – 7.17 (m, 2H), 7.17 – 7.13 (m, 2H), 7.05 (d, J 
= 8.4 Hz, 2H), 6.81 – 6.80 (m, 1H), 6.34 (dd, J = 3.7, 1.6 Hz, 1H), 6.14 (d, J = 6.4 Hz, 
1H), 5.52 (t, J = 5.0 Hz, 1H), 5.29 (s, 2H), 4.36 (d, J = 11.7 Hz, 2H), 3.38 (t, J = 6.0 Hz, 
2H), 3.08 (q, J = 9.4, 8.9 Hz, 2H), 2.84 (t, J = 11.9 Hz, 2H), 2.73 – 2.65 (m, 3H), 2.25 (tq, 
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J = 11.2, 3.8 Hz, 1H), 1.77 – 1.68 (m, 2H), 1.43 (d, J = 11.7 Hz, 2H).  TOF ES+ MS: (M 
+ H) 476.2, (M + Na) 498.2. HPLC tR = 7.60 min, > 95%.  
 
1-(1-(4-Chlorobenzyl)-1H-pyrrole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)azetidine-
3-carboxamide (CCG-208915). Methyl 1-(1-(4-chlorobenzyl)-1H-pyrrole-2-
carbonyl)azetidine-3-carboxylate 29 (300 mg, 0.90 mmol) was dissolved in 200 proof 
EtOH (10 mL) and 10% aq. NaOH (10 mL) was added. The reaction was allowed to stir 
at RT for 24 h, at which time the solvent was stripped off in vacuo and the residue was 
taken up in H2O and acidified to pH 1 by addition of conc. HCl at 0°C. The resulting 
precipitate was collected over a filter and dried by aspirator then high vacuum to afford 
the desired carboxylic acid as a white powder.  Yield: 250 mg, 0.78 mmol, 87%. 
1-(1-(4-chlorobenzyl)-1H-pyrrole-2-carbonyl)azetidine-3-carboxylic acid (50 mg, 
0.16 mmol) was added to DCM (5 mL), followed by 4-(2-aminoethyl)pyridine (20 µL, 
0.17 mmol), TEA (66 µL, 0.47 mmol), EDCHCl (33 mg, 0.17 mmol), and HOBT (26 
mg, 0.17 mmol). The reaction was allowed to stir at RT for 17 h, at which time the 
reaction was concentrated and the residue taken up in EtOAc. This solution was then 
washed with H2O (3X) and 10% aq. Na2CO3 (3X), and brine (1X), dried (MgSO4), and 
concentrated. The residue was purified by silica flash chromatography (4 g silica, 1% to 
30% 7 M methanolic ammonia/EtOAc) to provide the final compound as a white powder. 
Yield: 32 mg, 0.076 mmol, 48%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.48 (s, 2H), 7.25 
(d, J = 8.3 Hz, 2H), 7.10 (d, J = 4.1 Hz, 2H), 7.04 (d, J = 8.2 Hz, 2H), 6.80 (s, 1H), 6.50 
(d, J = 3.9 Hz, 1H), 6.17 (t, J = 3.2 Hz, 1H), 5.97 (t, J = 5.2 Hz, 1H), 5.52 (s, 2H), 4.25 
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(bs, 4H), 3.58 (q, J = 6.6 Hz, 2H), 3.20 (p, J = 7.4 Hz, 1H), 2.84 (t, J = 6.9 Hz, 2H). TOF 
ES+ MS: (M + H) 423.1, (M + Na) 445.1. HPLC rt = 5.09 min, >95% purity. 
 
1-(1-(4-Chlorobenzyl)-1H-imidazole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-208916). Ethyl 1-(4-chlorobenzyl)-1H-
imidazole-2-carboxylate 23b (7.28 g, 27.5 mmol), was dissolved in EtOH (10 mL) and 
10% aq. NaOH (20 mL) and stirred at rt for 15 h. The solvent was then stripped off, 
water was added, and the solution acidified with HCl. The resulting precipitate was 
collected over a filter and washed with 1M HCl and dried to afford the carboxylic acid as 
a white powder which was taken directly into the next step. Yield: 6.506 g, 27.5 mmol, 
100%. 
The following were added sequentially to DCM (5 mL): 1-(4-chlorobenzyl)-1H-
imidazole-2-carboxylic acid (73 mg, 0.309 mmol), N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide dihydrochloride (100 mg, 0.371 mmol), DIPEA (162 μL, 0.927 mmol), 
EDCHCl (65 mg, 0.340 mmol), and HOBt (52 mg, 0.340 mmol). The solution was 
allowed to stir at RT for 24 h, after which time the DCM was stripped off in vacuo and 
the resulting residue was taken up on 10% aq. Na2CO3. Material was then extracted with 
EtOAc. The extract was dried (MgSO4) and concentrated in vacuo. The residue was then 
triturated with EtOAc:Hex and collected over a filter. The impure yellow powder was 
then recrystallized from EtOAc to provide the title compound as off-white crystals. 
Yield: 89 mg (64%). 
1
H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 5.2 Hz, 2H), 7.28 (d, J = 
8.3 Hz, 2H), 7.15–7.07 (m, 4H), 7.05 (s, 1H), 6.95 (s, 1H), 5.59 (t, J = 5.7 Hz, 1H), 5.35 
(d,J = 8.9 Hz, 2H), 4.58 (d, J = 13.4 Hz, 2H), 3.53 (q, J = 6.7 Hz, 2H), 3.10 (t, J = 13.7 
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Hz, 1H), 2.87–2.71 (m, 3H), 2.29 (tt, J = 11.0, 3.4 Hz, 1H), 2.00–1.41 (m, 4H). TOF ES+ 
MS: (M + H) 452.2, (M + Na) 474.2. HPLC rt = 4.24 min, >90% purity. 
 
1-(1-(4-Chlorobenzyl)-4-fluoro-1H-pyrrole-2-carbonyl)-N-((2,3-dihydro-1H-
inden-2-yl)methyl)piperidine-4-carboxamide (CCG-209020). The following reagents 
were dissolved in DCM (3 mL) at RT: 1-(4-chlorobenzyl)-4-fluoro-1H-pyrrole-2-
carboxylic acid 136 (50 mg, 0.197 mmol), N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide dihydrochloride (70 mg, 0.237 mmol), TEA (110 
µL, 0.788 mmol), EDCHCl (45 mg, 0.237 mmol), and HOBT (36 mg, 0.237 mmol). The 
reaction was allowed to stir for 16 h, after which time it was diluted with EtOAc and 
washed with HCl (3X), H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried 
(MgSO4) and concentrated. The residue was purified by silica flash chromatography (10 
g silica, 5% to 50% EtOAc:Hex) to give the desired product as a white solid. Yield: 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.26 (d, J = 8.0 Hz, 2H), 7.21 – 7.09 (m, 4H), 7.05 (d, 
J = 8.2 Hz, 2H), 6.56 – 6.50 (m, 1H), 6.05 (s, 1H), 5.54 (t, J = 5.1 Hz, 1H), 5.15 (s, 2H), 
4.28 (d, J = 13.2 Hz, 2H), 3.36 (t, J = 5.7 Hz, 2H), 3.05 (q, J = 9.2 Hz, 2H), 2.82 (t, J = 
11.7 Hz, 2H), 2.71 – 2.61 (m, 3H), 2.22 (tt, J = 11.1, 3.7 Hz, 1H), 1.71 (d, J = 12.0 Hz, 
2H), 1.42 (d, J = 11.4 Hz, 2H). TOF ES+ MS: (M + H) 494.2. HPLC rt = 7.75 min, >95% 
purity. 
 
1-(1-(4-Chlorobenzyl)-4-fluoro-1H-pyrrole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-209021). The following were added 
sequentially to DCM (3 mL): 1-(4-chlorobenzyl)-4-fluoro-1H-pyrrole-2-carboxylic 
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acid 139 (50 mg, 0.20 mmol), TEA (0.11 mL, 0.79 mmol), EDCHCl (45 mg, 0.24 
mmol), HOBT (36 mg, 0.24 mmol), and then amine dihydrochloride 36 (64 mg, 0.24 
mmol). The reaction was allowed to stir at RT for 14 h, at which time it was diluted with 
EtOAc, washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), dried with 
MgSO4, and concentrated in vacuo. The residue was the purified by silica flash 
chromatography (10 g silica, 1% 7 M methanolic ammonia/EtOAc) to provide the desired 
material as a white powder. Yield: 48 mg (52%). 
1
H NMR (400 MHz, CDCl3) δ 8.54 
(d, J = 4.3 Hz, 2H), 7.25–7.20 (m, 2H), 7.14 (d, J = 4.4 Hz, 2H), 7.06 (d, J = 6.9 Hz, 2H), 
6.58–6.54 (m, 1H), 6.05 (s, 1H), 5.46–5.38 (m, 1H), 5.17 (s, 2H), 4.29 (d, J = 6.7 Hz, 
2H), 3.55 (q, J = 7.3 Hz, 2H), 2.83 (dt, J = 17.9, 9.0 Hz, 4H), 2.27–2.15 (m, 1H), 1.77–
1.63 (m, 2H), 1.38 (d, J = 13.4 Hz, 2H). TOF ES+ MS: (M + H) 469.2, (M + Na) 491.2. 
HPLC rt = 5.18 min, >95% purity. 
 
1-(1-(4-Chlorobenzyl)-1H-pyrrolo[2,3-c]pyridine-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-211751). Azaindole ethyl ester 144 (300 mg, 
0.953 mmol) was dissolved into ethanol (8 mL) at RT, followed by the addition of 10% 
aqueous NaOH (8 mL), which initially caused precipitation, but homogeneity was 
achieved over time. The reaction was allowed to stir at RT for 12 h, at which time the 
solvent was removed in vacuo. The residue was taken up in a small amount of water (5 
mL), the pH was adjusted to ∼4, and material was extracted with ethyl acetate (8×). The 
extracts were combined and the solvent removed again in vacuo to provide the title 
compound as a fine white powder. Yield: 226 mg (83%). 
1
H NMR (400 MHz, DMSO-
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d6) δ 9.64 (s, 1H), 8.40 (d, J = 6.3 Hz, 1H), 8.26 (d, J = 6.3 Hz, 1H), 7.61 (s, 1H), 7.35 (d, 
J = 8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H), 6.06 (s, 2H).  
The azaindole carboxylic acid (50 mg, 0.174 mmol) was dissolved into DCM (2 
mL) at RT, followed by amine dihydrochloride 36 (59 mg, 0.192 mmol) and TEA (122 
μL, 0.872 mmol). Once all material was in solution, EDCHCl (37 mg, 0.192 mmol) and 
HOBT (29 mg, 0.192 mmol) were added and the reaction was allowed to stir for 18 h at 
RT. At this time, the reaction was diluted with a solution of ethyl acetate/diethyl ether 
(1:1) and washed with water (3×), 10% aq sodium carbonate (3×), and brine (1×), then 
dried (magnesium sulfate) and concentrated in vacuo. The resulting residue was then 
purified by flash chromatography (50 g silica, 5% 7.0 M methanolic ammonia/95% ethyl 
acetate) to give the title compound as white solid. Yield: 53 mg (61%). 
1
H NMR (400 
MHz, CDCl3) δ 8.78 (s, 1H), 8.49 (d, J = 5.4 Hz, 2H), 8.27 (d, J = 5.5 Hz, 1H), 7.51 (d, J 
= 5.5 Hz, 1H), 7.21 (d, J = 8.2 Hz, 2H), 7.09 (d, J = 5.3 Hz, 2H), 7.05 (d, J = 8.2 Hz, 2H), 
6.56 (s, 1H), 5.67 (t, J = 5.6 Hz, 1H), 5.48 (s, 2H), 4.57 (s, 1H), 3.91 (s, 1H), 3.53 (q, J = 
6.6 Hz, 2H), 2.96−2.69 (m, 4H), 2.21 (tt, J =11.1, 7.5, 3.7 Hz, 1H), 1.88−1.69 (m, 1H), 
1.67−1.46 (m, 2H), 1.33−1.22 (m, 1H). TOF ES+ MS: (M + H) 502.2. HPLC tR = 4.01 
min, > 95%. 
 
(R)-1-(1-(4-Chlorobenzoyl)pyrrolidine-2-carbonyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide (CCG-211753). (R)-Ethyl 1-(1-(4-
chlorobenzoyl)pyrrolidine-2-carbonyl)piperidine-4-carboxylate (R)-40 (300 mg, 0.76 
mmol) was dissolved in a 9:1 DCM:MeOH solution (20 mL), and a solution of 
methanolic NaOH (92 mg NaOH/2mL MeOH) was added. This was stirred at RT for 2 h, 
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after which time the solvent was stripped off in vacuo to give a white solid that was 
dissolved in a small amount of H2O and acidified by the addition of conc. HCl, and the 
material was extracted with EtOAc (3X). The combined organic extracts were dried 
(MgSO4) and concentrated. The clear oily residue was then dissolved in minimum EtOAc 
and precipitated with Hex to afford a white powder. No further purification necessary. 
Yield: 260 mg, 0.71 mmol, 93%. 
(R)-1-(4-chlorobenzoyl)pyrrolidine-2-carboxylic acid (50 mg, 0.14 mmol) was 
added to DCM (5 mL), followed by the sequential addition of TEA (76 µL, 0.55 mmol), 
HATU (63 mg, 0.16 mmol), and indanyl amine 75 (24 mg, 0.16 mmol).  The reaction 
was stirred for 22 h at RT, after which time the reaction was diluted in sat. aq. NH4Cl and 
extracted with EtOAc. The organic extract was then washed with 1M HCl (3X), H2O 
(3X), 10% aq. Na2CO3 (3X), and sat. aq. Na2CO3 (1X), then dried with MgSO4 and 
concentrated. The residue was purified via silica flash chromatography (4 g silica, 5% to 
20% 7 M methanolic ammonia:EtOAc) to give the desired compound as a white powder. 
Yield: 37 mg, 0.08 mmol, 57%.  
1
H NMR (400 MHz, Chloroform-d) δ 7.52 (d, J = 8.1 
Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.18 – 7.11 (m, 4H), 6.04 (s, 0.5H), 5.75 – 5.67 (m, 
0.5H), 5.03 (m, 1H), 4.60 (d, J = 13.3 Hz, 0.5H), 4.47 (d, J = 13.6 Hz, 0.5H), 4.07 (dd, J 
= 30.7, 13.8 Hz, 1H), 3.80 (m, 0.5H), 3.68 (m, 1.5H), 3.51 (m, 1H), 3.32 (m, 2H), 3.04 
(m, 2H), 2.85 – 2.74 (m, 1H), 2.72 – 2.56 (m, 3H), 2.43 (m, 0.5H), 2.36 – 2.14 (m, 1.5H), 
2.14 – 2.00 (m, 2H), 2.02 – 1.76 (m, 5H), 1.65 (dd, J = 29.2, 12.8 Hz, 2H). TOF ES+ MS: 
(M + H) 494.2. HPLC tR = 6.37 min, > 95% purity. 
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(S)-1-(1-(4-Chlorobenzoyl)pyrrolidine-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-211751). (S)-Ethyl 1-(1-(4-
chlorobenzoyl)pyrrolidine-2-carbonyl)piperidine-4-carboxylate (S)-40 (300 mg, 0.76 
mmol) was dissolved in a 9:1 DCM:MeOH solution (20 mL), and a solution of 
methanolic NaOH (92 mg NaOH/2mL MeOH) was added. This was stirred at RT for 2 h, 
after which time the solvent was stripped off in vacuo to give a white solid that was 
dissolved in a small amount of H2O and acidified by the addition of conc. HCl, and the 
material was extracted with EtOAc (3X). The combined organic extracts were dried 
(MgSO4) and concentrated. The clear oily residue was then dissolved in minimum EtOAc 
ad precipitated with Hex to afford a white powder. No further purification necessary. 
Yield: 265 mg, 0.73 mmol, 95%. 
(S)-1-(4-chlorobenzoyl)pyrrolidine-2-carboxylic acid (50 mg, 0.14 mmol) was 
added to DCM (5 mL), followed by the sequential addition of TEA (76 µL, 0.55 mmol), 
HATU (63 mg, 0.16 mmol), and amine 27 (20 µL, 0.16 mmol).  The reaction was stirred 
for 17 h at RT, after which time the reaction was diluted in sat. aq. NH4Cl and extracted 
with EtOAc. The organic extract was then washed with 10% aq. NH4Cl (2X), 10% aq. 
Na2CO3 (3X), and sat. aq. Na2CO3 (1X), then dried with MgSO4 and concentrated. The 
residue was purified via silica flash chromatography (4 g silica, 5% to 20% 7 M 
methanolic ammonia:EtOAc) to give the desired compound as a white powder. Yield: 42 
mg, 0.09 mmol, 65%.  
1
H NMR (500 MHz, Chloroform-d) δ 8.52 (m, 2H), 7.53 (d, J = 
8.0 Hz, 2H), 7.37 (t, J = 7.0 Hz, 2H), 7.16 – 7.09 (m, 2H), 5.91 (d, J = 2.1 Hz, 0.5H), 
5.58 – 5.49 (m, 0.5H), 5.07 – 4.97 (m, 1H), 4.63 (d, J = 14.5 Hz, 0.5H), 4.48 (d, J = 13.9 
Hz, 1H), 4.09 (dd, J = 41.8, 14.7 Hz, 2H), 3.68 (t, J = 9.9 Hz, 1H), 3.54 (m, 3H), 3.32 – 
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3.21 (m, 0.5H), 3.12 (t, J = 12.8 Hz, 0.5H), 2.83 (dt, J = 14.6, 6.8 Hz, 3H), 2.64 (t, J = 
12.6 Hz, 0.5H), 2.47 –1.15 (m, 7H). TOF ES+ MS: (M + H) 469.3, (M + Na) 491.2. 
HPLC tR = 4.36 min, > 95% purity. 
 
(S)-1-(1-(4-Chlorobenzoyl)pyrrolidine-2-carbonyl)-N-((2,3-dihydro-1H-inden-2-
yl)methyl)piperidine-4-carboxamide (CCG-211755). (S)-Ethyl 1-(1-(4-
chlorobenzoyl)pyrrolidine-2-carbonyl)piperidine-4-carboxylate (S)-40 (300 mg, 0.76 
mmol) was dissolved in a 9:1 DCM:MeOH solution (20 mL), and a solution of 
methanolic NaOH (92 mg NaOH/2mL MeOH) was added. This was stirred at RT for 2 h, 
after which time the solvent was stripped off in vacuo to give a white solid that was 
dissolved in a small amount of H2O and acidified by the addition of conc. HCl, and the 
material was extracted with EtOAc (3X). The combined organic extracts were dried 
(MgSO4) and concentrated. The clear oily residue was then dissolved in minimum EtOAc 
ad precipitated with Hex to afford a white powder. No further purification necessary. 
Yield: 265 mg, 0.73 mmol, 95%.  
(S)-1-(4-chlorobenzoyl)pyrrolidine-2-carboxylic acid (50 mg, 0.14 mmol) was 
added to DCM (5 mL), followed by the sequential addition of TEA (76 µL, 0.55 mmol), 
HATU (63 mg, 0.16 mmol), and indanyl amine 75 (24 mg, 0.16 mmol).  The reaction 
was stirred for 19 h at RT, after which time the reaction was diluted in sat. aq. NH4Cl and 
extracted with EtOAc. The organic extract was then washed with 1M HCl (3X), H2O 
(3X), 10% aq. Na2CO3 (3X), and sat. aq. Na2CO3 (1X), then dried with MgSO4 and 
concentrated. The residue was purified via silica flash chromatography (4 g silica, 5% to 
20% 7 M methanolic ammonia:EtOAc) to give the desired compound as a white powder. 
204 
 
Yield: 44 mg, 0.09 mmol, 68%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.61 – 7.54 (m, 
1H), 7.54 – 7.49 (m, 1H), 7.44 – 7.37 (m, 1H), 7.37 – 7.28 (m, 2H), 7.25 – 7.06 (m, 4H), 
6.14 – 6.02 (m, 0.5H), 5.81 – 5.70 (m, 0.5H), 5.19 – 4.96 (m, 1H), 4.60 (d, J = 13.6 Hz, 
0.5H), 4.47 (d, J = 13.7 Hz, 0.5H), 4.06 (dd, J = 30.8, 14.3 Hz, 1H), 3.73 – 3.61 (m, 1H), 
3.59 – 3.43 (m, 1H), 3.42 – 3.21 (m, 2H), 3.19 – 2.94 (m, 3H), 2.76 – 2.53 (m, 3H), 2.35 
– 2.14 (m, 2H), 2.11 – 1.77 (m, 5H), 1.77 – 1.51 (m, 2H). TOF ES+ MS: (M + H) 494.2. 
HPLC tR = 6.37 min, > 95% purity. 
 
(R)-1-(1-(4-Chlorobenzoyl)pyrrolidine-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-211756). (R)-Ethyl 1-(1-(4-
chlorobenzoyl)pyrrolidine-2-carbonyl)piperidine-4-carboxylate (R)-40 (300 mg, 0.76 
mmol) was dissolved in a 9:1 DCM:MeOH solution (20 mL), and a solution of 
methanolic NaOH (92 mg NaOH/2mL MeOH) was added. This was stirred at RT for 2 h, 
after which time the solvent was stripped off in vacuo to give a white solid that was 
dissolved in a small amount of H2O and acidified by the addition of conc. HCl, and the 
material was extracted with EtOAc (3X). The combined organic extracts were dried 
(MgSO4) and concentrated. The clear oily residue was then dissolved in minimum EtOAc 
and precipitated with Hex to afford a white powder. No further purification necessary. 
Yield: 260 mg, 0.71 mmol, 93%.  
(R)-1-(4-chlorobenzoyl)pyrrolidine-2-carboxylic acid (50 mg, 0.14 mmol) was 
added to DCM (5 mL), followed by the sequential addition of TEA (76 µL, 0.55 mmol), 
HATU (63 mg, 0.16 mmol), and amine 27 (20 µL, 0.16 mmol).  The reaction was stirred 
for 18 h at RT, after which time the reaction was diluted in sat. aq. NH4Cl and extracted 
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with EtOAc. The organic extract was then washed with 10% aq. NH4Cl (2X), 10% aq. 
Na2CO3 (3X), and sat. aq. Na2CO3 (1X), then dried with MgSO4 and concentrated. The 
residue was purified via silica flash chromatography (4 g silica, 5% to 20% 7 M 
methanolic ammonia:EtOAc) to give the desired compound as a white powder. Yield: 41 
mg, 0.09 mmol, 62%.  
1
H NMR (500 MHz, Chloroform-d) δ 8.59 – 8.47 (m, 2H), 7.53 
(d, J = 8.1 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.12 (dd, J = 9.5, 4.8 Hz, 2H), 5.90 (s, 0.5H), 
5.50 (s, 0.5H), 5.10 – 4.99 (m, 1H), 4.63 (d, J = 13.3 Hz, 0.5H), 4.48 (d, J = 13.2 Hz, 
1H), 4.09 (dd, J = 40.4, 14.2 Hz, 2H), 3.70 (t, J = 8.6 Hz, 1H), 3.54 (m, 3H), 3.29 (t, J = 
12.8 Hz, 0.5H), 3.12 (t, J = 12.7 Hz, 0.5H), 2.83 (dt, J = 14.7, 6.6 Hz, 3H), 2.64 (t, J = 
12.6 Hz, 0.5H), 2.40-1.20 (m, 7H). TOF ES+ MS: (M + H) 469.3, (M + Na) 491.3. HPLC 
tR = 4.26 min, > 95% purity. 
 
(S)-1-(1-(4-Chlorobenzyl)pyrrolidine-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-211757). (S)-1-(4-chlorobenzyl)pyrrolidine-2-
carboxylic acid (S)-38 (63 mg, 0.27 mmol) was added to DCM (2 mL), followed by the 
sequential addition of TEA (150 µL, 1.06 mmol), HATU (111 mg, 0.29 mmol), and 
amine dihydrochloride 36 (75 mg, 0.28 mmol).  The reaction was stirred for 24 h at RT, 
after which time the reaction was diluted in sat. aq. NH4Cl and extracted with EtOAc. 
The organic extract was then washed with 10% aq. NH4Cl (2X), 10% aq. Na2CO3 (3X), 
and sat. aq. Na2CO3 (1X), then dried with MgSO4 and concentrated. The residue was 
purified via silica flash chromatography (4 g silica, 5% to 20% 7 M methanolic 
ammonia/EtOAc) to give a slightly yellow oil that was triturated from Et2O/Hex to 
provide a white powder. Yield: 64 mg, 0.14 mmol, 53%. 
1
H NMR (500 MHz, 
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Chloroform-d) δ 8.48 (d, J = 4.6 Hz, 2H), 7.31 – 7.22 (m, 4H), 7.11 (bs, 2H), 5.82 (bs, 
1H), 4.52 (bs, 1H), 4.13 (d, J = 11.9 Hz, 1H), 3.89 (dd, J = 18.3, 13.1 Hz, 1H), 3.58 – 
3.49 (m, 2H), 3.46 – 3.34 (m, 2H), 3.10 – 3.00 (m, 1H), 2.94 (d, J = 9.3 Hz, 1H), 2.87 – 
2.79 (m, 2H), 2.63 – 2.52 (m, 1H), 2.33 – 2.26 (m, 2H), 2.18 – 2.08 (m, 1H), 1.89 – 1.75 
(m, 4H), 1.60 – 1.50 (m, 2H). TOF ES+ MS: (M + H) 455.2, (M + Na) 477.2.  HPLC tR = 
3.39 min, > 90% purity. 
 
(R)-1-(1-(4-Chlorobenzyl)pyrrolidine-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-211758). (R)-1-(4-chlorobenzyl)pyrrolidine-2-
carboxylic acid (R)-38 (64 mg, 0.27 mmol) was added to DCM (2 mL), followed by the 
sequential addition of TEA (150 µL, 1.06 mmol), HATU (111 mg, 0.29 mmol), and 
amine dihydrochloride 36 (75 mg, 0.28 mmol).  The reaction was stirred for 20 h at RT, 
after which time the reaction was diluted in sat. aq. NH4Cl and extracted with EtOAc. 
The organic extract was then washed with 10% aq. NH4Cl (2X), 10% aq. Na2CO3 (3X), 
and sat. aq. Na2CO3 (1X), then dried with MgSO4 and concentrated. The residue was 
purified via silica flash chromatography (4 g silica, 5% to 20% 7 M methanolic 
ammonia:EtOAc) to give a slightly yellow oil that was triturated from Et2O/Hex to 
provide a white powder. Yield: 75 mg, 0.17 mmol, 62%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.52 (d, J = 5.1 Hz, 2H), 7.26 (s, 4H), 7.12 (s, 2H), 5.57 (s, 1H), 4.55 (d, 
J = 11.7 Hz, 1H), 4.15 (bs, 1H), 3.90 (dd, J = 18.8, 13.1 Hz, 1H), 3.61 – 3.50 (m, 2H), 
3.39 (d, J = 12.0 Hz, 2H), 3.06 (d, J = 7.0 Hz, 1H), 2.98 – 2.91 (m, 1H), 2.84 (q, J = 6.2 
Hz, 2H), 2.59 (q, J = 13.9, 13.3 Hz, 1H), 2.33 – 2.21 (m, 2H), 2.14 (s, 1H), 1.80 – 1.77 
207 
 
(m, 2H), 1.59 – 1.48 (m, 2H). TOF ES+ MS: (M + H) 455.2, (M + Na) 477.2. HPLC tR = 
3.44 min, > 90% purity. 
 
(E)-(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(4-(pyridin-4-yl)but-1-en-1-
yl)piperidin-1-yl)methanone  (CCG-211822). (E)-tert-butyl 4-(4-(pyridin-4-yl)but-1-en-
1-yl)piperidine-1-carboxylate 99b (100 mg, 0.316 mmol) was dissolved in anhydrous 
1,4-dioxane (1 mL) and 4 M HCl in 1,4-dioxane (0.55 mL, 2.21 mmol) was added. The 
reaction was allowed to stir for 1 h, at which time the solvent was stripped off and 
replaced with Et2O. The oily residue was solidified with sonication, washed (decantation) 
with Et2O (3X) and then dried under high vacuum to give the dihydrochloride as a white 
powder. Yield: 91 mg, 0.316 mmol, 100%. 
 (E)-4-(4-(pyridin-4-yl)but-1-en-1-yl)piperidine dihydrochloride (75 mg, 0.259 
mmol) was dissolved in DCM (10 mL) and TEA (217 µL, 1.56 mmol), followed by the 
indole carboxylic acid 4a (89 mg, 0.311 mmol), EDCHCl (60 mg, 0.311 mmol), and 
HOBT (48 mg, 0.311 mmol), and the reaction was allowed to stir at RT for 18 h. After 
this time, the reaction was diluted with EtOAc and washed with H2O (3X), 10% Na2CO3 
(3X), and brine (1X), then dried (Na2SO4) and concentrated in vacuo. The resulting 
residue was purified via silica flash chromatography (10 g silica, 1% to 20% methanolic 
ammonia:EtOAc) to provide a clear, colorless oil. Yield: 72 mg, 0.148 mmol, 57%. 
1
H 
NMR (400 MHz, Chloroform-d) δ 8.54 – 8.39 (m, 2H), 7.63 (d, J = 7.8 Hz, 1H), 7.35 (d, 
J = 8.2 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.21 – 7.10 (m, 3H), 7.08 (s, 2H), 7.01 (d, J = 
8.0 Hz, 2H), 6.59 (s, 1H), 5.46 (s, 2H), 5.37 – 5.31 (m, 1H), 5.26 (d, J = 11 Hz, 1H), 4.57 
(bs, 1H), 4.04 (bs, 1H), 2.85 (bs, 2H), 2.65 (t, J = 7.3 Hz, 2H), 2.39 – 2.23 (m, 2H), 2.07 
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(s, 1H), 1.64 (bs, 1H), 1.41 (bs, 1H), 1.08 (bs, 1H), 0.64 (bs, 1H). TOF ES+ MS: (M + H) 
484.2. HPLC tR = 6.24 min, > 95% purity. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)-1,2,3,6-
tetrahydropyridine-4-carboxamide (CCG-211823). Ethyl 1-(1-(4-chlorobenzyl)-1H-
indole-2-carbonyl)-1,2,3,6-tetrahydropyridine-4-carboxylate (53 mg, 0.125 mmol) was 
dissolved in EtOH (5 mL), followed by the addition of 10% aq. NaOH (2 mL). This 
reaction was allowed to stir for 4 h, at which time the solvent was removed in vacuo. The 
residue was dissolved in H2O and acidified with conc. HCl at 0 °C. The resulting 
precipitate was collected over a filter and dried under high vacuum to give a white 
powder. Yield: 46 mg, 0.116 mmol, 93%.  
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)-1,2,3,6-
tetrahydropyridine-4-carboxylic acid (33 mg, 0.084 mmol) was dissolved in DCM (5 mL) 
and TEA (35 µL, 0.251 mmol), followed by EDCHCl (18 mg, 0.092 mmol), and HOBT 
(14 mg, 0.092 mmol), and the reaction was allowed to stir at RT for 21 h. After this time, 
the reaction was diluted with EtOAc:Et2O and washed with H2O (2X), 10% Na2CO3 
(3X), and brine (1X), then dried (Na2SO4) and concentrated in vacuo. The resulting 
residue was purified via silica flash chromatography (4 g silica, 80% to 100% 
EtOAc:Hex) to provide a fine white powder. Yield: 38 mg, 0.076 mmol, 91%. 
1
H NMR 
(400 MHz, Chloroform-d) δ 8.51 (d, J = 4.1 Hz, 2H), 7.66 (d, J = 7.9 Hz, 1H), 7.30 – 
7.05 (m, 8H), 6.97 (d, J = 8.1 Hz, 2H), 6.78 (s, 1H), 5.77 (s, 1H), 5.51 (s, 2H), 4.83 (bs, 
1H), 3.89 (bs, 1H), 3.61 – 3.43 (m, 3H), 2.99 (s, 1H), 2.84 (t, J = 6.9 Hz, 2H), 2.16 (bs, 
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1H), 1.94 (bs, 1H). TOF ES+ MS: (M + H) 499.2, (M + Na) 521.2. HPLC tR = 5.46 min, 
> 95%. 
 
1-(2-((4-Chlorophenyl)amino)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-211824). Ethyl 1-(2-((4-chlorophenyl)amino)benzoyl)piperidine-4-
carboxylate (72 mg, 0.19 mmol) was dissolved in EtOH (5 mL), followed by the addition 
of 10% aq. NaOH (2 mL). This reaction was allowed to stir at RT for 24 h, after which 
time the solvent was stripped off in vacuo and the residue was taken up in H2O and 
acidified to pH<1 with conc. HCl at 0 °C. The resulting white precipitate was collected 
over a filter, dried via aspirator then high vacuum to afford the carboxylic acid as a white 
powder requiring no further purification. Yield: 47 mg, 0.13 mmol, 70%.  
1-(2-((4-chlorophenyl)amino)benzoyl)piperidine-4-carboxylic acid (36 mg, 0.10 
mmol), 4-(2-aminoethyl)pyridine (13 µL, 0.11 mmol), TEA (42 µL, 0.30 mmol), 
EDCHCl (21 mg, 0.11 mmol), and HOBT (17 mg, 0.11 mmol) were all added to DCM 
(5 mL) in the listed order and stirred at RT for 20 h, at which time the reaction was 
diluted with 1:1 EtOAc:Et2O and washed with 0.5 M aq. HCl (1X), H2O (1X), 10% aq. 
Na2CO3 (3X), and brine (1X). The organic phase was then dried (MgSO4) and 
concentrated, and the residue was purified via silica flash chromatography (4 g silica, 
80% to 100% EtOAc:Hex gradient) to give the title compound as a clear, colorless oil. 
Yield: 36 mg, 0.078 mmol, 78%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.51 (d, J = 4.9 
Hz, 2H), 7.32 (d, J = 8.3 Hz, 1H), 7.26 – 7.19 (m, 3H), 7.17 (d, J = 7.6 Hz, 1H), 7.13 – 
7.09 (m, 2H), 7.00 (d, J = 8.6 Hz, 2H), 6.89 (t, J = 7.4 Hz, 1H), 5.56 (s, 1H), 4.23 (bs, 
2H), 3.53 (q, J = 6.6 Hz, 2H), 2.93 (s, 2H), 2.82 (t, J = 6.9 Hz, 2H), 2.28 (tt, J = 11.2, 3.7 
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Hz, 1H), 1.80 – 1.66 (m, 4H). TOF ES+ MS: (M + H) 463.2, (M + Na) 485.2. HPLC tR = 
5.23 min, > 95%. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-4-methyl-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-211825).  1-(1-(4-chlorobenzyl)-1H-indole-2-
carbonyl)-4-methylpiperidine-4-carboxylic acid (100 mg, 0.243 mmol), 4-(2-
aminoethyl)pyridine (32 µL, 0.268 mmol), TEA (100 µL, 0.730 mmol), EDCHCl (51 
mg, 0.268 mmol), and HOBT (41 mg, 0.268 mmol) were dissolved in DCM (5 mL) and 
stirred at RT for 16 h. After this time, the reaction was diluted with a 2:1 solution of 
EtOAc:Et2O and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then 
dried (MgSO4) and concentrated. The residue was purified by silica flash 
chromatography (4 g silica, 1% to 5% methanolic ammonia:EtOAc) to give a clear 
colorless oil. Yield: 113 mg, 0.219 mmol, 90%. 
1
H NMR (500 MHz, Chloroform-d) δ 
8.46 (d, J = 4.7 Hz, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.26 (t, J = 
7.7 Hz, 1H), 7.19 – 7.12 (m, 3H), 7.08 (d, J = 4.8 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 6.58 
(s, 1H), 5.95 (t, J = 5.6 Hz, 1H), 5.44 (s, 2H), 4.02 (s, 1H), 3.68 (s, 1H), 3.52 (q, J = 6.5 
Hz, 2H), 3.22 (s, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.22 (s, 1H), 1.86 (s, 1H), 1.67 (s, 1H), 
1.28 (s, 1H), 1.05 (s, 3H), 0.77 (s, 1H). TOF ES+ MS: (M + H) 515.0. HPLC tR = 5.49 
min, > 95%. 
 
(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(3-(pyridin-4-yl)propyl)piperazin-1-
yl)methanone (CCG-211826). t-Butyl 4-(3-(pyridin-4-yl)propyl)piperazine-1-carboxylate 
(160 mg, 0.524 mmol) was dissolved in 1,4-dioxane (2 mL) at RT, and a 4 M HCl in 1,4-
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dioxane solution (1.31 mL, 5.24 mmol) was added. The reaction was allowed to stir for 
15 min, over which time precipitation occurred. The solvent was removed in vacuo and 
dried under high vacuum to give the trishydrochloride salt as a tan powder. Yield: 168 
mg, 0.524 mmol, 100%.  
 1-(4-Chlorobenzyl)-1H-indole-2-carboxylic acid (91 mg, 0.318 mmol), 4-(3-
(pyridin-4-yl)propyl)piperazine trishydrochloride (100 mg, 0.318 mmol), TEA (266 µL, 
1.907 mmol), EDCHCl (67 mg, 0.350 mmol), and HOBT (54 mg, 0.350 mmol) were 
dissolved in DCM (5 mL) and stirred at RT for 14 h. After this time, the reaction was 
diluted with a 2:1 solution of EtOAc:Et2O and washed with H2O (3X), 10% aq. Na2CO3 
(3X), and brine (1X), then dried (MgSO4) and concentrated. The residue was purified by 
silica flash chromatography (4 g silica, 1% to 5% MeOH:EtOAc) to give a clear colorless 
oil. Yield: 94 mg, 0.199 mmol, 63%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.49 (d, J = 
5.2 Hz, 2H), 7.65 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.31 – 7.26 (m, 1H), 7.19 
(dd, J = 13.2, 7.9 Hz, 3H), 7.11 (d, J = 5.2 Hz, 2H), 7.03 (d, J = 8.2 Hz, 2H), 6.62 (s, 1H), 
5.49 (s, 2H), 3.64 (bs, 4H), 2.64 (t, J = 7.6 Hz, 2H), 2.36 – 2.26 (m, 4H), 2.00 (bs, 2H), 
1.79 (p, J = 7.5 Hz, 2H). TOF ES+ MS: (M + H) 473.2, (M + Na) 495.2. HPLC tR = 4.78 
min, > 95%. 
 
(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-phenethylpiperazin-1-yl)methanone (CCG-
211827). 1-(4-Chlorobenzyl)-1H-indole-2-carboxylic acid (100 mg, 0.350 mmol), N-(2-
phenylethyl)piperazine (73 µL, 0.385 mmol), TEA (146 µL, 1.050 mmol), EDCHCl (74 
mg, 0.385 mmol), and HOBT (59 mg, 0.385 mmol) were dissolved in DCM (6 mL) and 
stirred at RT for 14 h. After this time, the reaction was diluted with a 2:1 solution of 
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EtOAc:Et2O and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then 
dried (MgSO4) and concentrated. The residue was purified by silica flash 
chromatography (4 g silica, 60% EtOAc:Hex) to give a clear colorless oil. Yield: 109 mg, 
0.238 mmol, 68%.  
1
H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J = 7.9 Hz, 1H), 7.39 
(d, J = 8.4 Hz, 1H), 7.33 – 7.26 (m, 3H), 7.20 (dt, J = 19.0, 7.8 Hz, 6H), 7.05 (d, J = 8.3 
Hz, 2H), 6.65 (s, 1H), 5.50 (s, 2H), 3.68 (s, 4H), 2.77 (dd, J = 9.6, 6.5 Hz, 2H), 2.57 (dd, 
J = 9.7, 6.5 Hz, 2H), 2.28 (d, J = 147.4 Hz, 5H). TOF ES+ MS: (M + H) 458.2. HPLC tR 
= 5.76 min, > 95%. 
 
(Z)-(1-(4-Chlorobenzyl)-1H-indol-2-yl)(4-(4-(pyridin-4-yl)but-1-en-1-
yl)piperidin-1-yl)methanone (CCG-211829). (Z)-tert-butyl 4-(4-(pyridin-4-yl)but-1-en-1-
yl)piperidine-1-carboxylate 99a (100 mg, 0.316 mmol) was dissolved in anhydrous 1,4-
dioxane (1 mL) and 4 M HCl in 1,4-dioxane (0.55 mL, 2.21 mmol) was added. The 
reaction was allowed to stir for 1 h, at which time the solvent was stripped off and 
replaced with Et2O. The oily residue was solidified with sonication, washed (decantation) 
with Et2O (3X) and then dried under high vacuum to give the dihydrochloride as a white 
powder. Yield: 90 mg, 0.316 mmol, 100%. 
 (Z)-4-(4-(pyridin-4-yl)but-1-en-1-yl)piperidine dihydrochloride (75 mg, 0.259 
mmol) was dissolved in DCM (10 mL) and TEA (217 µL, 1.56 mmol), followed by the 
indole carboxylic acid 4a (89 mg, 0.311 mmol), EDCHCl (60 mg, 0.311 mmol), and 
HOBT (48 mg, 0.311 mmol), and the reaction was allowed to stir at RT for 16 h. After 
this time, the reaction was diluted with EtOAc and washed with H2O (3X), 10% Na2CO3 
(3X), and brine (1X), then dried (Na2SO4) and concentrated in vacuo. The resulting 
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residue was purified via silica flash chromatography (10 g silica, 1% to 20% methanolic 
ammonia:EtOAc) to provide a clear, colorless oil. Yield: 54 mg, 0.111 mmol, 43%. 
1
H 
NMR (400 MHz, Chloroform-d) δ 8.47 (d, J = 5.5 Hz, 2H), 7.62 (d, J = 7.9 Hz, 1H), 7.35 
(d, J = 8.3 Hz, 1H), 7.28 – 7.22 (m, 1H), 7.17 (dd, J = 15.8, 7.9 Hz, 3H), 7.09 (d, J = 5.5 
Hz, 2H), 7.01 (d, J = 8.3 Hz, 2H), 6.58 (s, 1H), 5.46 (s, 2H), 5.32 (dt, J = 8.1, 7.4 Hz, 
1H), 5.11 (t, J = 8.1 Hz, 1H), 4.54 (bs, 1H), 4.05 (bs, 1H), 2.78 (bs, 2H), 2.64 (t, J = 7.2 
Hz, 2H), 2.36 (q, J = 7.4 Hz, 2H), 2.31 – 2.19 (m, 1H), 1.43 (bs, 1H), 1.12 (bs, 2H), 0.64 
(bs, 1H). TOF ES+ MS: (M + H) 484.2. HPLC tR = 6.29 min, > 95%. 
 
N-(1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)piperidin-4-yl)-3-(pyridin-4-
yl)propanamide (CCG-212052). t-Butyl 4-(3-(pyridin-4-yl)propanamido)piperidine-1-
carboxylate (250 mg, 0.750 mmol) was dissolved in 1,4-dioxane (1 mL) and 4 M HCl 
(1.0 mL, 4.12 mmol) in 1,4-dioxane was added. The reaction was allowed to stir for 1 h, 
then the solvent was removed and replaced with Et2O and the oily material was solidified 
with sonication. Washing with Et2O and thorough drying under high vacuum afforded the 
desired dihydrochloride salt. Yield: 230 mg, 0.750 mmol, 100%. 
4-(3-(pyridin-4-yl)propanamido)piperidine dihydrochloride (100 mg, 0.327 
mmol), 1-(4-chlorobenzyl)-1H-indole-2-carboxylic acid 4a (112 mg, 0.392 mmol), TEA 
(273 µL, 1.959 mmol), EDCHCl (75 mg, 0.392 mmol), and HOBT (60 mg, 0.392 mmol) 
were all dissolved in DCM (10 mL) and stirred at RT for 22 h, after which time the DCM 
was removed in vacuo and the residue was taken up in EtOAc and washed with H2O 
(2X), 10% Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. The 
resulting residue was purified via silica flash chromatography (10 g silica, 1% to 20%  
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methanolic ammonia:EtOAc) to provide a white solid. Yield: 100 mg, 0.20 mmol, 61%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.50 (d, J = 4.3 Hz, 2H), 7.65 (d, J = 7.9 Hz, 1H), 
7.41 (d, J = 8.4 Hz, 1H), 7.30 (t, J = 7.7 Hz, 1H), 7.22 – 7.17 (m, 3H), 7.14 – 7.11 (m, 
2H), 7.07 – 7.03 (m, 2H), 6.59 (d, J = 1.8 Hz, 1H), 5.48 (s, 2H), 5.30 (d, J = 8.0 Hz, 1H), 
4.50 (s, 1H), 4.09 (s, 1H), 3.89 (d, J = 7.1 Hz, 1H), 2.95 (t, J = 7.3 Hz, 2H), 2.82 (s, 2H), 
2.45 (t, J = 7.1 Hz, 2H), 1.83 (bs, 1H), 1.62 (bs, 1H), 1.02 (bs, 1H), 0.36 (bs, 1H). TOF 
ES+ MS: (M + H) 501.2, (M + Na) 523.2. 
 
4-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)-
piperazine-1-carboxamide (CCG-212390). t-Butyl 4-((2-(pyridin-4-
yl)ethyl)carbamoyl)piperazine-1-carboxylate (233 mg, 0.70 mmol) was dissolved in 
anhydrous 1,4-dioxane (1 mL), and 4 M HCl in 1,4-dioxane (1.0 mL, 4.18 mmol) was 
added. The reaction was allowed to stir for 2 h, after which time the solvent was removed 
and the residue was solidified via sonication in Et2O. The solid was washed with Et2O 
then thoroughly dried under high vacuum to give the dihydrochloride salt as a tan 
powder. Yield: 214 mg, 0.70 mmol, 100%. 
4-((2-(pyridin-4-yl)ethyl)carbamoyl)piperazine dihydrochloride (214 mg, 0.70 
mmol), 1-(4-chlorobenzyl)-1H-indole-2-carboxylic acid (200 mg, 0.70 mmol), TEA 
(0.388 mL, 2.79 mmol), EDCHCl (147 mg, 0.766 mmol), and HOBT (117 mg, 0.766 
mmol) were dissolved in DCM (10 mL) and stirred for 16 h at RT. After this time, the 
reaction was diluted with EtOAc and washed with H2O (3X), 10% Na2CO3 (3X), and 
brine (1X), then dried (MgSO4) and concentrated. The resulting residue was purified via 
silica flash chromatography (25 g silica, 1% to 20% methanolic ammonia:EtOAc) to 
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provide a white solid. Yield: 224 mg, 0.446 mmol, 64%. 
1
H NMR (400 MHz, 
Chloroform-d) δ 8.47 (d, J = 5.4 Hz, 2H), 7.64 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.4 Hz, 
1H), 7.31 – 7.26 (m, 1H), 7.17 (dd, J = 12.9, 7.8 Hz, 3H), 7.11 (d, J = 5.4 Hz, 2H), 6.99 
(d, J = 8.2 Hz, 2H), 6.63 (s, 1H), 5.47 (s, 2H), 4.72 (t, J = 5.4 Hz, 1H), 3.60 (s, 4H), 3.49 
(q, J = 6.6 Hz, 2H), 3.16 (bs, 4H), 2.82 (t, J = 6.9 Hz, 2H). TOF ES+ MS: (M + H) 502.2, 
(M + Na) 524.2. HPLC tR = 5.40 min, > 95%. 
 
1-(2-(4-Chlorobenzoyl)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-212391). 2-(4-chlorobenzoyl)benzoic acid (366 mg, 1.404 mmol) 
was added to DCM (20 mL), followed by amine dihydrochloride 36 (473 mg, 1.544 
mmol), TEA (978 µL, 7.02 mmol), EDCHCl (296 mg, 1.544 mmol), and HOBT (237 
mg, 1.544 mmol.) The reaction was allowed to stir at RT for 20 h, at which time the 
solvent was removed in vacuo. The residue was taken up in EtOAc and washed with H2O 
(1X), 10% aq. Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. The 
residue was then purified by silica flash chromatography (25 g silica, 1% to 20% 7 M 
methanolic ammonia:EtOAc.) 
1
H NMR (400 MHz, Chloroform-d) δ 8.47 (d, J = 5.5 Hz, 
2H), 7.72 (d, J = 8.4 Hz, 2H), 7.61 – 7.53 (m, 1H), 7.52 – 7.24 (m, 5H), 7.10 (d, J = 5.4 
Hz, 2H), 5.98 (t, J = 5.5 Hz, 1H), 4.47 (d, J = 12.9 Hz, 1H), 3.62 (d, J = 13.5 Hz, 1H), 
3.51 (q, J = 6.6 Hz, 2H), 3.02 (t, J = 11.6 Hz, 1H), 2.81 (t, J = 6.9 Hz, 2H), 2.71 (t, J = 
11.9 Hz, 1H), 2.28 (ddd, J = 14.9, 11.1, 3.9 Hz, 1H), 1.91 – 1.52 (m, 4H). TOF ES+ MS: 
(M + H) 476.2, (M + Na) 498.2. HPLC tR = 4.83 min, > 95%. 
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1-(2-(4-chlorophenoxy)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-212392). Methyl 2-(4-chlorophenoxy)benzoate 41 was dissolved in 
EtOH (5 mL), followed by the addition of 10% aq. NaOH (2 mL). The reaction was 
allowed to stir for 14 h, after which time the solvent was stripped off in vacuo and the 
residue re-dissolved in H2O. This aqueous solution was then cooled to 0 °C and acidified 
to pH<1 with conc. HCl, and the resulting precipitate was collected over a filter, then 
dried via aspirator and high vacuum to provide the desired carboxylic acid as a white 
powder. No further purification necessary. Yield: 92 mg, 0.37 mmol, 97%. 
All of the previously prepared carboxylic acid (92 mg, 0.37 mmol) was added to 
DCM (5 mL), followed by amine dihydrochloride 36 (136 mg, 0.44 mmol), TEA (310 
µL, 2.22 mmol), EDCHCl (85 mg, 0.44 mmol), and HOBT (68 mg, 0.44 mmol). The 
solution was allowed to stir at RT for 18 h, after which time the reaction was 
concentrated in vacuo and the resulting residue was taken up in EtOAc and washed with 
H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. 
The resulting residue was purified by silica flash chromatography (10 g silica, 1% to 20% 
methanolic ammonia:EtOAc) to give the desired compound as a thick oil. 
1
H NMR (500 
MHz, Chloroform-d) δ 8.43 (d, J = 4.7 Hz, 2H), 7.28 (dt, J = 29.2, 7.9 Hz, 4H), 7.14 (t, J 
= 7.4 Hz, 1H), 7.06 (d, J = 4.8 Hz, 2H), 6.97 – 6.76 (m, 3H), 6.15 (d, J = 47.8 Hz, 1H), 
4.57 (d, J = 12.6 Hz, 1H), 3.63 (bs, 1H), 3.48 (q, J = 6.5 Hz, 2H), 3.04 – 2.88 (m, 1H), 
2.77 (t, J = 6.9 Hz, 2H), 2.75 – 2.62 (m, 1H), 2.24 (t, J = 11.0 Hz, 1H), 1.81 – 1.73 (m, 
1H), 1.72 – 1.61 (m, 2H), 1.61 – 1.51 (m, 1H). TOF ES+ MS: (M + H) 464.1, (M + Na) 
486.1. HPLC tR = 4.79 min, > 90%. 
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1-(2-((4-Chlorophenyl)(methyl)amino)benzoyl)-N-(2-(pyridin-4-yl)ethyl)-
piperidine-4-carboxamide (CCG-212393). Methyl 2-((4-
chlorophenyl)(methyl)amino)benzoate 45 (120 mg, 0.44 mmol) was dissolved in EtOH (8 
mL), followed by the addition of 10% aq. NaOH (3 mL). The reaction was allowed to stir 
at RT for 6 h, after which time the solvent was removed and the residue was taken up in 
H2O, cooled to 0 °C, and acidified to pH<1. The resulting white precipitate was collected 
over a filter, dried under high vacuum, and used without further purification. Yield: 108 
mg, 0.41 mmol, 95%. 
1
H NMR (400 MHz, Chloroform-d) δ 9.44 (s, 1H), 7.96 (dd, J = 
8.0, 1.5 Hz, 1H), 7.35 – 7.24 (m, 3H), 7.17 (t, J = 9.0 Hz, 3H), 6.79 – 6.72 (m, 1H), 3.89 
(s, 3H). 
2-((4-chlorophenyl)(methyl)amino)benzoic acid (85 mg, 0.33 mmol), amine 
dihydrochloride 36 (119 mg, 0.39 mmol), TEA (270 µL, 1.95 mmol), EDCHCl (75 mg, 
0.39 mmol), and HOBT (60 mg, 0.39 mmol) were added to DCM (5 mL) sequentially, 
and the solution was allowed to stir at RT for 20 h. After this time, the solvent was 
removed in vacuo and the residue was dissolved in EtOAc and washed with H2O (3X), 
10% aq. Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. The residue 
was then purified via silica flash chromatography (10 g silica, 1% to 20% methanolic 
ammonia:EtOAc) to provide the desired compound as a thick colorless oil. Yield: 90 mg, 
0.19 mmol, 58%. 
1
H NMR (400 MHz, Chloroform-d, mixture of rotamers) δ 8.48 (m, 
2H), 7.39 (t, J = 8.1 Hz, 1H), 7.34 – 7.19 (m, 3H), 7.09 (d, J = 7.9 Hz, 4H), 6.63 (t, J = 
9.6 Hz, 2H), 5.75 (t, J = 5.4 Hz, 0.5H), 5.41 (t, J = 5.4 Hz, 0.5H), 4.64 – 4.44 (m, 1H), 
3.61 – 3.39 (m, 3H), 3.22 (s, 1.5H), 3.17 (s, 1.5H), 2.93 – 2.84 (m, 0.5H), 2.83 – 2.74 (m, 
2H), 2.74 – 2.63 (m, 1H), 2.53 – 2.44 (m, 0.5H), 2.22 – 2.09 (m, 1H), 1.82 (bd, J = 13.1 
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Hz, 0.5H), 1.78 – 1.51 (m, 3.5H), 1.41 (bd, J = 13.2 Hz, 0.5H), 1.30 (qd, J = 12.9, 4.2 Hz, 
0.5H). TOF ES+ MS: (M + H) 477.2, 499.1. HPLC tR = 5.13 min, > 90% purity.  
 
(3aS,7aR)-5-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-2-(2-(pyridin-4-
yl)ethyl)octahydro-1H-pyrrolo[3,4-c]pyridin-1-one (CCG-212394). 5-(1-(4-
chlorobenzyl)-1H-indole-2-carbonyl)octahydro-1H-pyrrolo[3,4-c]pyridin-1-one 91 (35 
mg, 0.09 mmol) was dissolved in anhydrous DMF (5 mL). A 60% oil suspension of NaH 
(17 mg, 0.43 mmol) was added at RT under N2 and stirred for 1 h. 4-(2-
Bromoethyl)pyridine (19 mg, 0.10 mmol) was added and stirring continued for 22 h 
under the same conditions. After this time, the solution was diluted with EtOAc and 
washed with H2O (1X), 10% aq. Na2CO3 (2X), and brine (1X), dried with MgSO4, and 
concentrated in vacuo. Purification was done via silica flash chromatography (10 g silica, 
1 to 20% methanolic ammonia:EtOAc.) The residue was dissolved in DCM, and rapid 
solvent removal afforded the title compound as a white powder. Yield: 36 mg, 0.07 
mmol, 82%. 
1
H NMR (400 MHz, Chloroform-d) δ 8.51 (d, J = 4.8 Hz, 2H), 7.68 (d, J = 
7.9 Hz, 1H), 7.29 – 7.23 (m, 2H), 7.23 – 7.17 (m, 3H), 7.17 – 7.11 (m, 3H), 7.05 (d, J = 
8.0 Hz, 2H), 5.45 (d, J = 7.0 Hz, 2H), 4.43 (d, J = 13.7 Hz, 1H), 4.10 (d, J = 3.8 Hz, 1H), 
3.66 – 3.49 (m, 2H), 3.41 – 3.34 (m, 1H), 3.32 – 3.25 (m, 1H), 2.92 – 2.77 (m, 4H), 2.42 
(bs, 2H), 2.10 (bs, 1H), 1.75 (bs, 1H), 1.31 (bs, 1H). TOF ES+ MS: (M + H) 513.2, (M + 
Na) 535.2. HPLC tR = 5.53 min, > 95% purity. 
 
1-(2-((4-Chlorobenzyl)amino)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-222660). Methyl 2-((4-chlorobenzyl)amino)benzoate 47a (80 mg, 
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0.29 mmol) was dissolved in MeOH (8 mL) and 10% aq. NaOH (4 mL) was added and 
the reaction was stirred at RT for 24 h. At this time, the solvent was removed in vacuo 
and the residue was dissolved in H2O and acidified with conc. HCl to pH<1 at 0 °C. The 
resulting precipitate was collected over a filter and dried via aspirator then high vacuum 
to afford the desired carboxylic acid as a white powder. No further purification necessary. 
Yield: 75 mg, 0.29 mmol, 99%. 
2-((4-chlorobenzyl)amino)benzoic acid (75 mg, 0.29 mmol) was dissolved in 
DCM (12 mL) along with TEA (325 µL, 2.32 mmol), EDCHCl (67 mg, 0.35 mmol), 
HOBT (53 mg, 0.35 mmol), and N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
dihydrochloride (133 mg, 0.44 mmol). The solution was stirred at RT for 20 h, after 
which time the DCM was stripped off in vacuo and the resulting residue was taken up in 
EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried 
(MgSO4) and concentrated. The residue was then purified via silica flash chromatography 
(10 g silica, 1% to 30% methanolic ammonia:EtOAc) to give the desired compound. 
Yield: 63 mg, 0.132 mmol, 46%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.60 – 8.51 (m, 
2H), 7.30 – 7.25 (m, 4H), 7.22 – 7.15 (m, 1H), 7.14 – 7.10 (m, 2H), 7.08 (dd, J = 7.6, 1.6 
Hz, 1H), 6.67 (t, J = 7.4 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H), 5.58 (t, J = 5.2 Hz, 1H), 5.53 
(t, J = 5.7 Hz, 1H), 4.33 (m, 4H), 3.57 (q, J = 6.7 Hz, 2H), 2.95 (t, J = 12.8 Hz, 2H), 2.85 
(t, J = 6.9 Hz, 2H), 2.30 (tt, J = 11.1, 3.8 Hz, 1H), 1.82 (m, 2H), 1.74 (dt, J = 15.9, 7.9 
Hz, 2H). TOF ES+ MS: (M + H) 477.2, (M + Na) 499.2. HPLC tR = 5.33 min, > 90%.  
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)azepane-4-
carboxamide (CCG-222661). The ethyl ester 132 (160 mg, 0.37 mmol) was dissolved in 
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EtOH (6 mL) and 10% aq. NaOH (4 mL) was added and the reaction was stirred at RT 
for 24 h. At this time, the solvent was removed in vacuo and the white residue was 
dissolved in H2O and acidified with conc. HCl to pH<1 at 0 °C. The resulting precipitate 
was collected over a filter and dried via aspirator then high vacuum to afford the desired 
carboxylic acid as a white powder. No further purification necessary. Yield: 144 mg, 0.35 
mmol, 96%. 
The carboxylic acid (60 mg, 0.15 mmol), amine 27 (21 µL, 0.18 mmol), 
EDCHCl (34 mg, 0.18 mmol), HOBT (27 mg, 0.18 mmol), and TEA (61 µL, 0.44 
mmol) were dissolved in DCM (10 mL) and stirred at RT for 29 h, at which time the 
DCM was removed in vacuo and the residue was taken up in EtOAc and washed with 
H2O (1X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) 
and concentrated, and the residue purified via silica flash chromatography (10 g silica, 
1% to 20% methanolic ammonia:EtOAc) to give a colorless oil. Yield: 40 mg, 0.76 
mmol, 52%. HPLC tR = 5.53 min, > 95%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.51 (bs, 
2H), 7.65 (d, J = 7.6 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.28 (s, 1H), 7.16 (d, J = 7.4 Hz, 3H), 
7.12 (bs, 2H), 7.02 (d, J = 8.0 Hz, 2H), 6.65 (d, J = 6.3 Hz, 1H), 5.48 (d, J = 9.4 Hz, 2H), 
3.77 – 3.64 (m, 2H), 3.60 – 3.36 (m, 4H), 3.31 – 3.15 (m, 1H), 2.86 – 2.77 (m, 2H), 2.08 
– 1.97 (m, 2H), 1.91 – 1.69 (m, 3H), 1.56 – 1.48 (m, 1H), 1.43 – 1.34 (m, 1H). TOF ES+ 
MS: (M + H) 515.2, (M + Na) 537.2. HPLC tR = 5.52 min, > 95%. 
 
1-(2-(4-Chlorobenzyl)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
(CCG-222821). 2-(4-chlorobenzyl)benzoic acid (40 mg, 0.16 mmol), N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide dihydrochloride (55 mg, 0.18 mmol), TEA (225 µL, 
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1.62 mmol), EDCHCl (37 mg, 0.20 mmol), and HOBT (30 mg, 0.20 mmol) were 
dissolved in DCM (10 mL) and stirred at RT for 24 h. The DCM was then removed in 
vacuo and the residue was taken up in EtOAc, then washed with H2O (3X), 10% aq. 
Na2CO3 (3X), and brine (1X), then dried (MgSO4) and concentrated. Purification via 
silica flash chromatography (4 g silica, 1% to 20% methanolic ammonia:EtOAc) 
provided the desired compound as white microcrystals upon concentration. 
1
H NMR (500 
MHz, Chloroform-d, 3:2 mixture of rotamers) δ 8.51 (bs, 2H), 7.33 (t, J = 7.3 Hz, 1H), 
7.27 – 7.18 (m, 4H), 7.17 – 7.05 (m, 5H), 5.61 – 5.42 (m, 1H), 4.73 – 4.59 (m, 1H), 4.18 
– 4.03 (m, 1H), 3.93 – 3.80 (m, 1H), 3.53 (q, J = 6.5 Hz, 2H), 3.37 – 3.15 (m, 1H), 2.86 – 
2.81 (m, 2H), 2.50 (td, J = 12.7, 3.1 Hz, 1H), 2.23 – 1.99 (m, 2H), 1.90 – 1.75 (m, 2H), 
1.73 – 1.49 (m, 2H). TOF ES+ MS: (M + H) 462.2, (M + Na) 484.2. HPLC tR = 4.90 
min, > 90%.  
 
1-(1-(4-Chlorobenzyl)-2-oxo-1,2-dihydroquinolin-4-yl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-222822). Ethyl 1-(1-(4-chlorobenzyl)-2-oxo-
1,2-dihydroquinolin-4-yl)piperidine-4-carboxylate (75 mg, 0.18 mmol) was dissolved 
into a mixture of EtOH (4 mL), THF (4 mL), and 10% aq. NaOH (2 mL) and stirred at 
RT for 18 h. After this time, the reaction was concentrated and the residue dissolved in 
H2O, chilled to 0 °C, and acidified to pH<1 with conc. HCl. The resulting precipitate was 
collected over a filter and washed with cold 1M HCl, air dried via aspirator, then dried 
under high vacuum to give 1-(1-(4-chlorobenzyl)-2-oxo-1,2-dihydroquinolin-4-
yl)piperidine-4-carboxylic acid as a white solid. No further purification necessary. Yield: 
67 mg, 0.17 mmol, 95%.  
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1-(1-(4-chlorobenzyl)-2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-carboxylic 
acid (48 mg, 0.12 mmol), 4-(2-aminoethyl)pyridine (17 µL, 0.15 mmol), TEA (51 µL, 
0.36 mmol), EDCHCl (28 mg, 0.15 mmol), and HOBT (22 mg, 0.15 mmol) were 
dissolved in DCM (5 mL) and stirred at RT for 20 h. DCM was then removed in vacuo 
and the residue taken up in EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), 
and brine (1X), then dried (MgSO4) and concentrated. The residue was purified by silica 
flash chromatography (10 g silica, 1% to 20% methanolic ammonia:EtOAc). Yield: 45 
mg, 0.05 mmol, 45%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.54 (s, 2H), 7.78 (d, J = 8.1 
Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.21 – 7.00 (m, 6H), 6.22 (s, 
1H), 5.81 (t, J = 5.4 Hz, 1H), 5.46 (s, 2H), 3.58 (dt, J = 16.9, 8.7 Hz, 4H), 2.87 (t, J = 6.9 
Hz, 2H), 2.74 (t, J = 11.6 Hz, 2H), 2.28 (tt, J = 11.4, 3.7 Hz, 1H), 2.05 (qd, J = 12.5, 
12.0, 3.5 Hz, 2H), 1.94 (d, J = 11.2 Hz, 2H). TOF ES+ MS: (M + H) 501.2, (M + Na) 
523.2. HPLC tR = 5.25 min, >95% purity. 
 
1-(1-(4-Chlorophenyl)-2-oxo-1,2-dihydroquinolin-4-yl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG-222823). Ethyl 1-(1-(4-chlorophenyl)-2-oxo-
1,2-dihydroquinolin-4-yl)piperidine-4-carboxylate 58 (150 mg, 0.37 mmol) was 
dissolved in THF (10 mL) followed by the addition of 10% aq. NaOH (5 mL). This 
biphasic reaction was stirred at RT for 20 h. The solvent was then stripped off in vacuo 
and the resulting residue was dissolved in H2O, chilled to 0°C, then acidified to pH < 1. 
The resulting precipitate was collected over a filter, air dried, then high vacuum dried to 
provide 1-(1-(4-chlorophenyl)-2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-carboxylic 
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acid as a white powder. No further purification necessary. Yield: 130 mg, 0.33 mmol, 
91%. 
1-(1-(4-Chlorophenyl)-2-oxo-1,2-dihydroquinolin-4-yl)piperidine-4-carboxylic 
acid (66 mg, 0.17 mmol), 4-(2-aminoethyl)pyridine (25 µL, 0.21 mmol), TEA (72 µL, 
0.52 mmol), ED C (40 mg, 0.21 mmol), and HOBT (32 mg, 0.21 mmol) were dissolved 
in DCM (5 mL) and stirred at RT for 19 h. The reaction was then diluted with EtOAc and 
washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), then dried (MgSO4) and 
concentrated. The residue was purified via silica flash chromatography (10 g silica, 1 to 
17% methanolic ammonia/EtOAc) to give the title compound as an off-white powder. 
Yield: 47 mg, 0.10 mmol, 56%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.55 (d, J = 5.1 
Hz, 2H), 7.79 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 8.2 Hz, 2H), 7.32 (t, J = 7.5 Hz, 1H), 7.25 
– 7.18 (m, 3H), 7.15 (d, J = 4.9 Hz, 2H), 6.66 (d, J = 8.4 Hz, 1H), 6.20 (s, 1H), 5.78 (t, J 
= 6.0 Hz, 1H), 5.30 (s, 1H), 3.58 (q, J = 9.6, 6.8 Hz, 4H), 2.85 (t, J = 6.8 Hz, 2H), 2.77 (t, 
J = 11.9 Hz, 2H), 2.34 – 2.21 (m, 2H), 2.07 (q, J = 13.3 Hz, 2H), 1.95 (d, J = 13.5 Hz, 
2H). TOF ES+ MS: (M + H) 487.2, (M + Na) 509.2. HPLC tR = 5.09 min, >95% purity. 
 
1-(9H-Carbazole-1-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
(CCG-222824). 9H-carbazole-1-carboxylic acid was prepared according to Journal of 
Organic Chemistry, Vol. 53, No. 4, 1988, 794-799. 
9H-Carbazole-1-carboxylic acid (120 mg, 0.57 mmol), N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide dihydrochloride (190 mg, 0.63 mmol), TEA (475 µL, 
3.41 mmol), EDCHCl (120 mg, 0.63 mmol) and HOBT (96 mg, 0.63 mmol) were 
dissolved in DCM (10 mL) and stirred at RT for 14 h. At this time, the reaction was 
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diluted with EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X), 
then dried (MgSO4) and concentrated. The residue was purified via silica flash 
chromatography (10 g silica, 10% to 30% methanolic ammonia/EtOAc) to give a tan 
powder. Yield: 170 mg, 0.40 mmol, 70%. 
1
H NMR (500 MHz, Chloroform-d) δ 9.13 (s, 
1H), 8.53 (d, J = 5.6 Hz, 2H), 8.14 (d, J = 7.7 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.50 – 
7.42 (m, 2H), 7.41 (d, J = 7.5 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.11 
(d, J = 5.3 Hz, 2H), 5.59 (t, J = 5.5 Hz, 1H), 4.46 (s, 2H), 3.56 (q, J = 6.6 Hz, 2H), 3.04 
(t, J = 12.3 Hz, 2H), 2.84 (t, J = 6.9 Hz, 2H), 2.32 (ddd, J = 15.0, 10.9, 4.1 Hz, 1H), 1.91 
– 1.72 (m, 4H). TOF ES+ MS: (M + H) 427.2, (M + Na) 449.2. HPLC tR = 4.80 min, 
>95% purity. 
 
1-(6-Chloro-9H-carbazole-1-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-222825). Methyl 6-chloro-9H-carbazole-1-carboxylate (54 mg, 0.21 
mmol) was dissolved in EtOH (4 mL) and THF (5 mL), then 10% aq. NaOH (2 mL) was 
added. The reaction was allowed to stir at RT for 22 h, after which time the solvent was 
stripped off in vacuo. The residue was taken up in H2O and acidified to pH<1 with conc. 
HCl, and the resulting white precipitate was collected over a filter, air dried, then high 
vacuum dried to give 6-chloro-9H-carbazole-1-carboxylic acid as a white powder with no 
further purification. Yield: 51 mg, 0.21 mmol, 100%.  
6-Chloro-9H-carbazole-1-carboxylic acid (51 mg, 0.21 mmol) was added to DCM 
(5 mL), followed by N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide dihydrochloride 
(76 mg, 0.25 mmol), TEA (145 µL, 1.04 mmol), EDCHCl (48 mg, 0.25 mmol) and 
HOBT (38 mg, 0.25 mmol). This solution was stirred at RT for 16 h, at which time the 
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solvent was removed in vacuo and the residue taken up in EtOAc and washed with H2O 
(3X), 10% aq. Na2CO3 (3X), and brined (1X). The extract was dried (MgSO4) and 
concentrated, and the residue purified via silica flash chromatography (10 g silica, 1% to 
20% methanolic ammonia: EtOAc). Yield: 48 mg, 0.10 mmol, 50%. 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.53 (d, J = 4.7 Hz, 2H), 8.10 – 8.06 (m, 1H), 8.04 – 7.98 (m, 1H), 7.48 
– 7.36 (m, 3H), 7.22 (ddd, J = 7.6, 5.9, 1.0 Hz, 1H), 7.13 (d, J = 5.1 Hz, 2H), 5.61 – 5.52 
(m, 1H), 4.45 (bs, 2H), 3.57 (q, J = 6.6 Hz, 2H), 3.06 (s, 2H), 2.85 (t, J = 6.9 Hz, 2H), 
2.34 (tt, J = 10.9, 4.6 Hz, 1H), 1.91 – 1.69 (m, 4H). TOF ES+ MS: (M + H) 461.2, (M + 
Na) 483.2. HPLC tR = 5.23 min, > 90% purity. 
 
Exo-(1R,5S,6r)-3-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide (CCG-222980). The ethyl ester 113 
(206 mg, 0.49 mmol) was dissolved in anhydrous THF (10 mL), followed by the addition 
of KOTMS (66 mg, 0.51 mmol). The reaction stirred at RT for 48 h, solvent was 
removed in vacuo, the residue was dried under high vacuum overnight, leaving the 
potassium salt residue that was taken directly into the next step. Yield: 213 mg, 0.49 
mmol, 100%. 
The potassium salt (211 mg, 0.49 mmol), amine 27 (64 µL, 0.54 mmol), HATU 
(204 mg, 0.54 mmol), and DIPEA (170 µL, 0.97 mmol) were dissolved in DCM (10 mL) 
and stirred at RT for 24 h, at which time the DCM was removed in vacuo and the residue 
was diluted in EtOAc and washed with H2O (2X), 10% aq. Na2CO3 (3X), and brine (1X). 
The organic extract was dried (MgSO4) and concentrated, and the residue purified via 
silica flash chromatography (25 g silica, 1% to 20% methanolic ammonia:EtOAc) to give 
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an off-white powder. Yield: 134 mg, 0.27 mmol, 55%. 
1
H NMR (500 MHz, Chloroform-
d) δ 8.44 (d, J = 5.0 Hz, 2H), 7.61 (d, J = 7.9 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.17 – 7.10 
(m, 3H), 7.06 (d, J = 5.0 Hz, 2H), 6.88 (d, J = 8.1 Hz, 2H), 6.66 (s, 1H), 6.07 (t, J = 5.9 
Hz, 1H), 5.55 – 5.34 (m, 2H), 4.02 (d, J = 12.3 Hz, 1H), 3.72 – 3.58 (m, 2H), 3.53 – 3.32 
(m, 4H), 2.75 (t, J = 7.0 Hz, 2H), 1.99 (d, J = 9.4 Hz, 2H). TOF ES+ MS: (M + H) 499.2, 
(M + Na) 521.2. HPLC tR = 5.36 min, > 95%. 
 
1-(2-(Phenylamino)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
(CCG-222981). Methyl 2-(phenylamino)benzoate (74 mg, 0.33 mmol) was dissolved in 
10% aq. NaOH (1 mL), THF (5 mL), and EtOH (2 mL), and stirred at RT for 5 h. At this 
time, the solvent was stripped off in vacuo and the residue was dissolved in H2O and 
acidified with conc. HCl to pH < 1. Material was collected over a filter and air-dried then 
dried under high vacuum to give 2-(phenylamino)benzoic acid as a white powder. No 
further purification necessary. Yield: 62 mg, 0.29 mmol, 89%. 
2-(Phenylamino)benzoic acid (56 mg, 0.26 mmol), N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide dihydrochloride (97 mg, 0.32 mmol), EDCHCl (60 
mg, 0.32 mmol), HOBT (48 mg, 0.32 mmol), and TEA (220 µL, 1.58 mmol) were 
dissolved in DCM (10 mL) and stirred at RT for 17 h. After this time, the DCM was 
removed in vacuo. The residue was taken up in EtOAc and washed with H2O (3X), 10% 
aq. Na2CO3 (3X), and brine (1X), and dried (MgSO4) and concentrated. The residue was 
purified via silica flash chromatography (10 g silica, 1% to 20% methanolic NH3/EtOAc) 
to give the desired compound as a colorless oil. Yield: 53 mg, 0.12 mmol, 47%. 
1
H NMR 
(500 MHz, Chloroform-d) δ 8.47 (d, J = 5.0 Hz, 2H), 7.37 (d, J = 8.3 Hz, 1H), 7.28 – 
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7.21 (m, 3H), 7.15 (d, J = 7.6 Hz, 1H), 7.10 – 7.02 (m, 4H), 6.93 (t, J = 7.8 Hz, 1H), 6.86 
(t, J = 7.4 Hz, 1H), 5.78 (s, 1H), 4.26 (s, 2H), 3.50 (q, J = 6.5 Hz, 2H), 2.92 (bs, 2H), 2.80 
(t, J = 6.9 Hz, 2H), 2.28 (ddd, J = 14.7, 11.0, 3.4 Hz, 1H), 1.77 (bs, 2H), 1.70 – 1.57 (m, 
2H). TOF ES+ MS: (M + H) 429.2, (M + Na) 451.2. HPLC tR = 5.05 min, > 95%.  
 
1-(2-(Benzylamino)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
(CCG-222982). Methyl 2-(benzylamino)benzoate (50 mg, 0.21 mmol) was dissolved in 
EtOH (2 mL) and THF (5 mL), then 10% aq. NaOH (2 mL) was added and the reaction 
was stirred at RT for 15 h. At this time, the solvent was removed in vacuo and the residue 
was dissolved in H2O and acidified with conc. HCl to pH<1. The resulting precipitate 
was collected over a filter and dried via aspirator then high vacuum to afford the desired 
2-(benzylamino)benzoic acid as a white powder. No further purification necessary. Yield: 
41 mg, 0.18 mmol, 88%. 
Ethyl 2-(benzylamino)benzoate (30 mg, 0.13 mmol) was dissolved in DCM (5 
mL), followed by N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide dihydrochloride (45 
mg, 0.15 mmol), TEA (0.11 mL, 0.79 mmol), EDCHCl (30 mg, 0.16 mmol), and HOBT 
(24 mg, 0.16 mmol). The reaction was then stirred at RT for 16 h, at which time the 
reaction was diluted with EtOAc and washed with H2O (2X), 10% aq. Na2CO3 (2X), and 
brine (1X), then dried (MgSO4) and concentrated in vacuo. The resulting residue was 
then purified by silica flash chromatography (10 g silica, 1% to 20% methanolic 
ammonia:EtOAc) to provide the desired product as a colorless oil. Yield: 26 mg, 0.06 
mmol, 48%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.48 (d, J = 5.7 Hz, 2H), 7.32 (d, J = 
6.7 Hz, 4H), 7.26 – 7.21 (m, 1H), 7.17 (t, J = 7.8 Hz, 1H), 7.10 (d, J = 5.7 Hz, 2H), 7.07 
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– 7.02 (m, 1H), 6.63 (dd, J = 7.8, 3.8 Hz, 2H), 5.92 (t, J = 5.6 Hz, 1H), 5.44 (t, J = 5.4 
Hz, 1H), 4.33 (d, J = 5.3 Hz, 2H), 4.26 (bs, 2H), 3.52 (q, J = 6.7 Hz, 2H), 2.90 (t, J = 11.7 
Hz, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.28 (tt, J = 11.2, 3.5 Hz, 1H), 1.78 (d, J = 12.1 Hz, 
2H), 1.69 (qd, J = 12.9, 12.4, 4.0 Hz, 2H). TOF ES+ MS: (M + H) 443.2, (M + Na) 
465.2. HPLC tR = 4.92 min, > 95%.  
 
1-(2-((4-Chlorophenethyl)amino)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG-222983). 2-((4-chlorophenethyl)amino)benzoic acid (40 mg, 0.15 
mmol), N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide dihydrochloride (53 mg, 0.17 
mmol), EDCHCl (33 mg, 0.17 mmol), HOBT (26 mg, 0.17 mmol), and TEA (0.12 mL, 
0.87 mmol) were dissolved in DCM (10 mL) and stirred at RT for 24 h, at which time the 
DCM was removed in vacuo and the residue was taken up in EtOAc and washed with 
H2O (2X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) 
and concentrated, and the residue purified via silica flash chromatography (10 g silica, 
1% to 20% methanolic ammonia:EtOAc) to give a colorless oil. Yield: 41 mg, 0.083 
mmol, 57%. HPLC tR = 5.55 min, > 95%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.52 (d, 
J = 5.2 Hz, 2H), 7.30 – 7.21 (m, 3H), 7.16 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 5.2 Hz, 2H), 
7.05 (d, J = 7.5 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.65 (d, J = 7.4 Hz, 1H), 5.57 (t, J = 
5.6 Hz, 1H), 4.97 (bs, 1H), 4.21 (bs, 2H), 3.56 (q, J = 6.5 Hz, 2H), 3.34 (t, J = 7.2 Hz, 
2H), 2.89 (t, J = 7.2 Hz, 2H), 2.83 (q, J = 12.6, 9.7 Hz, 4H), 2.24 (tt, J = 11.2, 3.7 Hz, 
1H), 1.77 – 1.62 (m, 7H). TOF ES+ MS: (M + H) 491.2, (M + Na) 513.2. HPLC tR = 
5.44 min, >95% purity. 
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(1R,3s,5S)-8-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)-8-azabicyclo[3.2.1]octane-3-carboxamide (CCG-224000). The Boc-protected 
right-hand half 115 (100 mg, 0.35 mmol) was dissolved into 4M HCl (5 mL) and stirred 
for 15 min at RT. After this time, Et2O (15 mL) was added to precipitate the material and 
the reaction was sonicated for 15 min. The resulting residue did not solidify, so the liquid 
phase was decanted off and the residue was dried under aspirator vacuum, then high 
vacuum, for 48 h. The resulting solid aminde dihydrochloride 116 was then taken directly 
into the subsequent reaction. Yield: 115 mg, 0.35 mmol, 99%. 
The indole carboxylic acid 4a (52 mg, 0.18 mmol), amine dihydrochloride 116 
(60 mg, 0.18 mmol), EDCHCl (45 mg, 0.24 mmol), HOBT (36 mg, 0.24 mmol), and 
TEA (252 µL, 0.24 mmol) were dissolved in DCM (3 mL) and stirred at RT for 20 h, at 
which time the DCM was removed in vacuo and the residue was diluted in EtOAc and 
washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was 
dried (MgSO4) and concentrated, and the residue purified via silica flash chromatography 
(10 g silica, 1% to 20% methanolic ammonia:EtOAc) to give an off-white powder. Yield: 
59 mg, 0.11 mmol, 61%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.44 (d, J = 4.8 Hz, 2H), 
7.63 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.19 – 7.12 
(m, 3H), 7.07 (d, J = 5.0 Hz, 2H), 6.98 (d, J = 8.1 Hz, 2H), 6.74 (s, 1H), 6.11 (t, J = 5.7 
Hz, 1H), 5.51 (d, J = 9.8 Hz, 2H), 4.82 (bs, 1H), 4.39 (bs, 1H), 3.48 (q, J = 6.6 Hz, 2H), 
2.78 (t, J = 7.0 Hz, 2H), 2.60 (tt, J = 11.5, 5.2 Hz, 1H), 2.30 (bs, 2H), 1.76 (dd, J = 143.8, 
60.1 Hz, 7H). TOF ES+ MS: (M + H) 527.2, (M + Na) 549.2. HPLC tR = 5.55 min, 
>95%. 
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2-(1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)piperidin-4-yl)-N-(pyridin-4-
ylmethyl)acetamide (CCG-224001). The ethyl ester 96 (350 mg, 0.80 mmol) was 
dissolved in EtOH (10 mL), THF (10 mL), and 10% aq. KOH (3.22 mL) was added and 
the reaction was stirred at RT for 13 h. At this time, the solvent was removed in vacuo 
and the thick white residue was diluted in H2O, sonicated, and acidified with conc. HCl to 
pH<1 at 0 °C. The resulting precipitate was collected over a filter and dried via aspirator 
then high vacuum to afford the desired carboxylic acid as a white powder. No further 
purification necessary. Yield: 311 mg, 0.76 mmol, 95%. 
The carboxylic acid (62 mg, 0.15 mmol), amine 27 (18 µL, 0.18 mmol), 
EDCHCl (35 mg, 0.18 mmol), HOBT (28 mg, 0.18 mmol), and TEA (84 µL, 0.60 
mmol) were dissolved in DCM (5 mL) and stirred at RT for 18 h, at which time the DCM 
was removed in vacuo and the residue was taken up in EtOAc and washed with H2O 
(3X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) and 
concentrated, and the residue purified via silica flash chromatography (10 g silica, 1% to 
20% methanolic ammonia:EtOAc) to give a colorless oil. Yield: 42 mg, 0.08 mmol, 54%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.51 (d, J = 5.6 Hz, 2H), 7.64 (d, J = 7.9 Hz, 1H), 
7.39 (d, J = 8.3 Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 7.20 – 7.14 (m, 3H), 7.13 (d, J = 5.3 
Hz, 2H), 7.02 (d, J = 8.2 Hz, 2H), 6.59 (s, 1H), 6.34 (t, J = 5.7 Hz, 1H), 5.45 (s, 2H), 4.59 
(bs, 1H), 4.39 (s, 2H), 4.06 (bs, 1H), 2.88 (bs, 1H), 2.67 (bs, 1H), 2.13 – 2.02 (m, 3H), 
1.71 (bs, 1H), 1.45 (bs, 1H), 0.97 (bs, 1H), 0.32 (bs, 1H). TOF ES+ MS: (M + H) 501.2, 
(M + Na) 523.2. HPLC tR = 5.49 min, > 95%. 
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1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)azetidine-
3-carboxamide (CCG-224002). The methyl ester 125 (100 mg, 0.26 mmol) was 
dissolved in EtOH (5 mL) and 10% aq. NaOH (3 mL) was added and the reaction was 
stirred at RT for 24 h. At this time, the solvent was removed in vacuo and the white 
residue was dissolved in H2O and acidified with conc. HCl to pH<1 at 0 °C. The resulting 
precipitate was collected over a filter and dried via aspirator then high vacuum to afford 
the desired carboxylic acid as a white powder. No further purification necessary. Yield: 
95 mg, 0.26 mmol, 99%. 
The carboxylic acid (50 mg, 0.14 mmol), amine 27 (100 µL, 0.16 mmol), 
EDCHCl (31 mg, 0.16 mmol), HOBT (25 mg, 0.16 mmol), and TEA (76 µL, 0.54 
mmol) were dissolved in DCM (5 mL) and stirred at RT for 15 h, at which time the DCM 
was removed in vacuo and the residue was taken up in EtOAc and washed with H2O 
(3X), 10% aq. Na2CO3 (3X), and brine (1X). The organic extract was dried (MgSO4) and 
concentrated, and the residue purified via silica flash chromatography (10 g silica, 1% to 
20% methanolic ammonia:EtOAc) to give a colorless oil. Yield: 42 mg, 0.09 mmol, 65%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.53 (d, J = 5.2 Hz, 2H), 7.67 (d, J = 8.0 Hz, 1H), 
7.34 – 7.28 (m, 2H), 7.22 (d, J = 8.4 Hz, 2H), 7.19 – 7.15 (m, 1H), 7.13 (s, 2H), 7.03 (d, J 
= 8.4 Hz, 2H), 6.83 (s, 1H), 5.73 (s, 2H), 5.67 (s, 1H), 4.62 (s, 1H), 4.31 (d, J = 71.6 Hz, 
3H), 3.61 (q, J = 6.6 Hz, 2H), 3.22 (p, J = 7.4 Hz, 2H), 2.87 (t, J = 7.0 Hz, 2H). TOF ES+ 
MS: (M + H) 473.2, (M + Na) 495.2. HPLC tR = 5.60 min, >95% purity. 
 
2-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)-2-
azaspiro[3.3]heptane-6-carboxamide (CCG-224220). In a dry round bottom flask under 
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argon at RT, naphthalene (220 mg, 1.74 mmol) was dissolved in anhydrous THF (10 mL) 
containing hexane-washed sodium (100 mg, 4.35 mmol). The mixture was sonicated until 
the reaction became a dark green homogenous solution and no solid material was visible. 
This entire solution was then added dropwise to tosyl amide 123 (41 mg, 0.10 mmol), 
dissolved in anhydrous THF (1 mL), which caused the reaction to turn turbid brown. This 
was allowed to stir for 5 min. After this time, the reaction was diluted with EtOAc and a 
few drops of MeOH and washed with H2O (1X), 10% Na2CO3 (3X), and brine (1X), then 
dried (MgSO4) and concentrated. The residue of amine 124 was used directly in the 
subsequent reaction.  
The indole carboxylic acid 4a (29 mg, 0.10 mmol), spiro amine 124 (approx. 30 
mg, 0.10 mmol), HATU (49 mg, 0.12 mmol), and TEA (42 µL, 0.30 mmol) were 
dissolved in DMF (2 mL) and stirred at RT for 18 h, at which time the reaction was 
diluted with EtOAc and washed with H2O (3X), 10% aq. Na2CO3 (3X), and brine (1X). 
The organic extract was dried (MgSO4) and concentrated, and the residue purified via 
silica flash chromatography (4 g silica, 1% to 20% methanolic ammonia:EtOAc) to give a 
colorless oil. Yield: 18 mg, 0.04 mmol, 35%. 
1
H NMR (500 MHz, Chloroform-d) δ 8.50 
(d, J = 4.5 Hz, 2H), 7.65 (d, J = 7.7 Hz, 1H), 7.28 (d, J = 16.1 Hz, 3H), 7.19 – 7.13 (m, 
2H), 7.11 (d, J = 5.2 Hz, 2H), 6.99 (d, J = 7.6 Hz, 2H), 6.80 (s, 1H), 5.71 (s, 2H), 5.58 
(bs, 1H), 4.28 (bd, J = 32.5 Hz, 2H), 4.06 (s, 2H), 3.52 (q, J = 6.7 Hz, 2H), 2.82 (t, J = 
7.0 Hz, 2H), 2.74 (bs, 1H), 2.49 – 2.29 (m, 4H). TOF ES+ MS: (M + H) 513.2, (M + Na) 
535.2. HPLC tR = 5.65 min, > 95%. 
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